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 GENETICS AND GENOMICS OF COMPLEX DISEASES: MOUSE 
ATHEROSCLEROSIS MODIFIER GENES AND HUMAN GENE EXPRESSION 
AFTER BARIATRIC SURGERY  
 
STELA Z. BERISHA 
 ABSTRACT 
 
     The overall goal of our research was to study and identify genes involved in the 
development of complex diseases in mice and humans through integrative 
genetic/genomic approaches.  Two complex diseases were the focus of research, 
atherosclerosis and type 2 diabetes.  
    Mouse models of atherosclerosis, in which the genetic background and the 
environment can be controlled for, were used to identify and validate atherosclerosis 
modifier genes.  We studied an atherosclerosis quantitative trait locus (QTL) on the distal 
end of chromosome 5, called Ath24, and generated interval-specific congenic mice on the 
atherosclerosis resistant AKR and susceptible DBA/2 apoE-deficient strains.  To date we 
have not validated this locus.  Because the congenic mice were on pure parental 
backgrounds we cannot account for strain dependent gene-gene interactions present in the 
F2 cohort used to identify Ath24; and thus, we are currently generating congenic mice for 
the Ath24 QTL on the F1 background. 
     A major goal of this research was to confirm or exclude Pan3 as the atherosclerosis 
modifier gene responsible for the Ath24 QTL, and/or identify new candidate genes.  
Strain differences in Pan3 sequence and splicing were characterized.  Pan3 hemizygous 
 
 
vi 
mice on the DBA/2 apoE-deficient background were generated but we observed no 
significant differences in lesion size when compare to wild type mice.  We are currently 
assessing the effect of Pan3 partial deficiency on the F1 background.     
     We studied the in vitro effect of cholesterol loading on the transcriptome of AKR and 
DBA/2 macrophages.  265 acetylated-LDL regulated transcripts with significant strain 
interaction effects were identified.  Three transcripts, Alox5ap, Hmgb1 and Por, map to 
the Ath24 locus and were identified as plausible candidates for this QTL.  
     Also, a pilot study was performed to investigate the effects of bariatric surgery on 
whole blood gene expression profiles in obese subjects with type 2 diabetes.  The 
expression levels of 200 unique genes were significantly altered after bariatric surgery, 
and seven of these transcripts were strongly correlated with the changes in body weight 
and fasting plasma glucose.  Our preliminary data suggest that whole blood expression 
levels of specific transcripts may be useful as biomarkers for type 2 diabetes and/or 
therapeutic response. 
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CHAPTER I 
INTRODUCTION 
 
 
I.1. Complex Traits and Diseases 
     By definition, any trait that does not exhibit the Mendelian mode of inheritance 
attributable to a single gene locus is considered a complex trait 1.  Accumulating evidence 
provides a better understanding and to date has proven that complex traits are influenced 
by the involvement of multiple genes (variations in two or more genes participating in the 
same biological pathway), interactions between two or more genes (intergenic 
interactions) and/or interactions between genes and environmental factors.  Complex 
traits can be discreet or quantitative and the difference between the two is that while 
discreet traits are measured by a specific outcome (for example, disease versus no 
disease), quantitative traits vary continuously in a population 1.  Hundreds of rare human 
diseases of Mendelian inheritance have been discovered and genetically mapped to the 
human genome 2.   However, many medically important traits do not follow simple 
monogenic Mendelian inheritance, including but not limited to atherosclerosis, 
hypertension, atrial fibrillation, type 1 and type 2 diabetes, asthma, cancer, multiple 
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sclerosis and Alzheimer’s disease.  Thus, genetic characterization of complex traits and 
diseases continues to be a significant challenge for geneticists.    
 
I.2. Genetic Studies of Human Complex Diseases 
     Genetic mapping was proposed as a necessary method to achieve the goal of 
identifying the genes responsible for the complex diseases.  It relies on the principle that 
a causative gene can be identified without prior knowledge to its function simply by 
comparing the inheritance pattern of the trait with the inheritance pattern of a 
chromosomal region 1.  To enable this type of analysis a linkage map of the human 
genome was needed.  Initially, restriction fragment length polymorphisms (RFLPs) were 
used as molecular markers for the construction of linkage maps for the human genome, 
which were later replaced by microsatellites 3.  Nowadays, genetic studies take advantage 
of sophisticated genetic maps achieved by the complete sequencing of the human genome 
and accumulating information on single nucleotide polymorphisms (SNPs), which are 
used extensively in association studies of DNA variation with the phenotype of complex 
diseases/traits 4. 
 
I.2.1. Family-based genetic linkage analysis  
     This kind of study was performed by using families and it represents a model that tries 
to explain the inheritance pattern of phenotypes and genotypes observed in a pedigree 1, 5.  
Studies applying linkage analysis were especially predominant in the 1990’s due to the 
available technology.  Several disease genes were discovered and their physical position 
in the genome was determined.  Goldstein and Brown 6 discovered mutations in the low 
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density lipoprotein (LDL) – receptor gene that causes familial hypercholesterolemia and 
leads to premature atherosclerosis.  Nonetheless, the above example represents a single-
gene defect, or monogenic forms of coronary artery disease (CAD), and overall, 
monogenic forms of CAD or other complex diseases account for a very small proportion 
of the subjects affected by it.  With time it became evident that genetic linkage analysis 
worked perfectly well for the Mendelian mode of inheritance, but it was harder to 
characterize the genetic components of complex traits by pedigree linkage analysis 1.     
     At this point allele-sharing methods gained interest and became especially prevalent.  
Lander and Botstein were the first to address the complexity of many human traits and 
diseases and to recognize that affected individuals of common descent will share the 
causative mutation(s) as well as the surrounding alleles at the nearby loci 3.  The studies 
applying the allele-sharing method did not assume a model of inheritance for the trait 1.  
They include sibling pairs, twin studies involving monozygotic and/or dizygotic twins, as 
well as adoptee studies, the later conducted to separate the effect of the genetic from that 
of the environmental component on the disease outcome.  The method was used 
successfully to identify the myocyte enhancer factor 2A (MEF2A) gene as the causative 
gene for an autosomal dominant form of myocardial infarction 7, 8.  The MEF2A gene 
encodes a DNA-binding transcription factor that activates muscle-specific, growth-factor 
induced, and stress-induced genes.  
 
I.2.2. Genome wide association studies  
     Family linkage analyses are very powerful in detecting rare high-risk monogenic 
disease alleles 9.  However, from the public health perspective, the population attributable 
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fraction (PAF, which refers to the fraction of the disease that could be eliminated had the 
risk factor been removed) for rare alleles in common diseases is less than 10% 10.  
Currently, two views are being debated in the field of human genetics 11.  One viewpoint 
is based on the hypothesis that common complex traits result from the sum of the effects 
caused by rare high risk alleles; and, the second hypothesizes that complex traits are 
mainly due to multiple common variants with small or modest effect sizes, referred to as 
common disease/common variant (CDCV) hypothesis.  Genetic association studies were 
introduced as a new and a more powerful approach in identifying common variants 
responsible for the phenotype of complex traits. 
      Genetic wide associations are large case-control studies based on the comparison of 
unrelated affected versus unaffected individuals from a population.  One of the 
advantages of the genome wide association studies (GWAS) is that the familial 
inheritance pattern is not included in the analysis 1, 9.  Consequently, it is much easier to 
recruit a large number of unrelated individuals than it is to collect families with affected 
individuals, an advantage that is particularly important when studying diseases of old age.  
However, an obstacle to consider is the fact the genomic region shared by the unrelated 
affected individual is much smaller than the region shared by related individuals, and to 
overcome it a much denser map of molecular markers is needed.  Single nucleotide 
polymorphisms (SNPs) represent the most common form of the variation in the human 
DNA; therefore SNPs are the molecular marker of choice in constructing whole genome 
association maps.  Genome wide association (GWA) studies are designed to assay 
thousands of single nucleotide polymorphisms (SNPs) throughout the genome.   
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     Another advantage of the GWAS is their “easy” statistics, which provides us with the 
information whether an allele A located at a given genomic region  is significantly 
associated with the trait (at a higher frequency) in cases versus control cohorts 7.  
However, one of the most challenging problems associated with GWA studies is the large 
number of test performed which result in a high number of false positives and 
consequently nonreplicable findings 12.  Several methods have been proposed to correct 
for multiple testing hypotheses including Bonferroni correction which is the most 
commonly used correction approach in GWA studies 12-14, false discovery rate 56, 
Bayesian approach 15, permutation method 16, etc.  Until these methods are validated, 
there are certain guidelines and recommendations in place for researches that wish to 
conduct GWA studies in order to reduce bias 12.  The guidelines recommend a very 
careful study design including appropriate quality controls, using the stringent threshold 
of 5x10E-8 for the p-values 13, 14 (calculated based on the Bonferroni correction for 
genome-wide significance of 0.05), and validating the data in independent cohort 12.  
     GWA studies have identified significant statistical associations between the genetic 
variations and different complex traits over the past few years.  By June 2010, about 
2,865 genome-wide significant associations were identified between common SNPs and 
different phenotypes 17.  Among other complex diseases, GWA studies have been 
successfully used to identify genetic variation associated with CAD and type 2 diabetes 
(T2D).  The first GWA study for CAD was performed by Ozaki et al., who found 1400 
SNPs associated with myocardial infarction (MI) in 94 MI case and 658 control subjects.  
A replication study of over 1000 case and control subjects validated one of the previously 
reported SNPs, leading to the identification of a significant SNP in the LTA gene which 
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encodes for lymphotoxin-α, a cytokine produced by lymphocytes that mediates 
inflammatory, immunostimulatory and antiviral responses.  Multiple GWA studies have 
identified a locus on chromosome 9 (9p21) associated with MI/CAD 18-20.  GWA studies 
have identified several loci harboring SNPs which are highly associated with differences 
in low density lipoprotein (LDL), high density lipoprotein (HDL) or triglyceride levels 9, 
some of which carry previously known rare variants of Mendelian inheritance.     
     Also, GWA studies have identified about 18 genomic regions associated with 
increased risk of T2D in Caucasians 11, four of which contain candidate genes for T2D 
with rare mutations (Mendelian monogenic inheritance).  A great success story of GWA 
studies was the discovery of a common variant in the fat mass and obesity associated 
(FTO) gene which was found to be associated with body mass index, and is believed to 
predispose the individuals affected by it to childhood and adult obesity 21.     
     One of the most interesting findings of the GWA studies is the fact that about 15 loci 
have been identified as strongly associated with more than one complex disease 11; and, 
to add another level of complexity, an allele that is protective for one particular disease 
increases the susceptible of the subjects affected by it to another complex disease.  A 
nonsynonymous SNP in PTPN22 gene (coding for protein tyrosine phosphatase, non- 
receptor type 22) was found to protect against Crohn’s disease but also predisposes the 
carriers of the mutation to other types of autoimmune diseases 11.  
     GWA studies have greatly advanced our knowledge and understanding of human 
diseases.  To illustrate this point, the SNP on chromosome 9 (9p21) was found to be 
associated with three different phenotypes, myocardial infarction, abdominal aortic 
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aneurysm and intracranial aneurysm, conditions that were not thought to have a common 
genetic/pathogenic basis 22. 
     As mentioned previously, GWA studies have the power to overcome the linkage 
studies in detecting genes with modest effects on the disease, but they have some 
limitations as well.  Geneticists admit that the power of GWAS to detect associations has 
been low 9, 11, and to increase the power means to increase the sample size for case 
cohorts (achieving 90% power to detect an allele with 20% frequency has been calculated 
to require 8600 samples involved) 9.  These numbers make the GWA approach difficult 
to perform due to the need for a large number of well-matched case and control subjects, 
the high cost of genotyping hundreds of thousands of SNPs, and the need for independent 
replication cohorts.  One of the major drawbacks from GWA studies is the modest effect 
of the identified common variants.  Cumulatively, genetic variants identified through 
GWAS for each of the different complex traits explain no more than 10% of the 
phenotype 11, 23, leaving the bulk of heritability unexplained.  There are several possible 
explanations for this: 1) SNPs are tested independently of each other for association with 
the trait, thus GWAS are missing gene-gene interactions that most likely involve several 
loci at once 24, 2) environmental effects are not being addressed properly, 3) less common 
SNPs are responsible for most of the genetic risk, and 4) other forms of DNA variation 
such as copy number variation (CNV) should be considered, a problem that is currently 
being addressed by development of hybrid SNP/CNV microarrays to simultaneously 
assess these structural variants in genome-wide association studies 25.  Another 
substantial limitation to the GWAS has been the inability to explain the biology and/or 
molecular mechanisms behind the significant associations discovered between genomic 
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loci and the complex trait studied.  One of the reasons might be that the SNP tested for 
the association does not cause the trait but is in linkage disequilibrium with the causative 
SNPs.  Also, a population’ s history plays a very important role, and  due to the 
population’s stratification, which refers to cases and controls having different ethnic 
population structures leading to different allele frequencies at many loci independent of 
disease status, in certain occasions has been difficult to replicate the findings 7.  However, 
the confounding effects of population stratification are a concern for all types of genetic 
association studies and can now be corrected for or adjusted for in GWA studies.   
     Overall, a great amount of research has been done to identify the underlying genes for 
complex diseases.  New genome-wide approaches have been developed and have 
revolutionized the study of complex diseases, with the hope that the knowledge of the 
genes involved will help improve the diagnosis and treatment of these complex diseases.  
 
I.3. Advantages of Using Mouse Models to Study Genetics of Complex Diseases 
     Studying genetic component(s) and defining the underlying mechanism(s) for 
complex diseases in humans is a very difficult task due to the complexity of the disease 
itself and other complications.  One of the major problems is the difficulty to characterize 
the trait in living humans and the inability to control for other factors that affect the 
complex diseases such as diet, lifestyle, environmental factors and/or other coexisting 
morbidities 26, 27over a long period of time.  In general, complex diseases in humans 
develop in the span of several years and the individual may undergo through many 
different developing stages of the disease without obvious signs of being affected.  One 
example is atherosclerosis, which starts with migration of monocytes in the intima layer, 
9 
 
induced by high concentrations of LDL cholesterol, where they differentiate into 
macrophages.  Macrophages take up modified lipoproteins, transform into foam cells and 
become “fatty streak” lesions.  With time, fatty streak lesions advance to “fibrous” 
lesions which have a fibrous cap that encloses foam cells and the lipid-rich necrotic 
debris called the “necrotic core”.  The fibrous cap itself is mainly composed of smooth 
muscle cells and extracellular matrix 28.        
     As mentioned previously, it is also difficult to collect enough case-control subjects 
that are needed for well-powered whole genome association studies.  Also, due to the 
effects of environment, diet, lifestyle, and other co-variables complex disease may 
display an incomplete penetrance with the phenotype, meaning that individuals carrying 
the affected allele might not develop the disease or vice-versa. 
     Therefore the use of other mammalian organisms as models to study complex disease 
can be very helpful.  And of all the available organisms, mice are unique for experimental 
research.  First of all, approximately 99% of mouse genes have their homologues in the 
human genome, 96% of which lie within a similar conserved syntenic interval in the 
human genome 29.  Also, evidence from previous studies shows that in many cases 
humans and mice share common inherited Mendelian or polygenic diseases 30.  About 
100 years of efforts in generating inbred strains and collecting strain information gives 
this species a tremendous advantage.  There are many resources available that offer so 
many possibilities to the scientist, starting with hundreds of inbred mice of diverse 
genotypes and phenotypes.  There are also many recent developments which have 
provided the opportunity to take mouse genetics to an unprecedented level.  Inbred strains 
with spontaneous as well as induced mutations for many genes are available.  
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Furthermore, a collection of congenic strains, which are particularly useful in controlling 
for phenotypic differences due to the strain backgrounds, and variations such as consomic 
strains (created when an entire chromosome has been transferred onto another genetic 
background) and genome tagged mice (GTM, with large overlapping segments of each 
chromosome transferred on a different genetic background and breed to homozygosity) 
are being generated and maintained 30-32.  Another advantage working with mice models 
is the possibility to create transgenic, knock-out, and knock-in mice for the gene(s) of 
interest.  Development of techniques that create temporal/conditional and/or tissue 
specific manipulations has been an immense contribution to the field of creating 
genetically engineered mice.  There are now several large-scale projects and established 
mouse clinics around the world that will use standardized protocols to measure the 
phenotypes from different strains of mice and make the data available for the scientific 
community 31, 33. 
     Economically speaking, it is cost-effective and easier to maintain mouse colonies as 
most of the strains breed fairly well, they have a short gestation period (~ 19 to 21 days) 
and their lifespan is about 2 years.  Compared to humans, it is much quicker to study and 
get information on the development of complex diseases when using mouse models. 
     Although there are many different mouse models available for diverse complex 
diseases, a thorough introduction on the mouse models of atherosclerosis will be given; 
and, the reason for choosing to do so is that an existing atherosclerosis model 
[apolipoprotein E (APOE) deficient mice] was used extensively in the search for 
atherosclerosis modifier gene(s) in the course of this project.  
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     Four genetically engineered mouse models have been created to study atherosclerosis, 
apoE deficient mice, LDL receptor deficient mice, human apoB transgenic mice and 
apoE*3-Leiden transgenic mice 26, 27, 34.  Normally mice do not develop aortic lesions as 
most of their plasma cholesterol is found in the form of HDL, also named “the good 
cholesterol” because high density lipoproteins pick up the excess cholesterol from blood 
and transfer it to liver tissue for excretion or reuse.  However, mice made deficient of 
APOE or LDLR protein, by knocking out both copies of their respective gene, have 
higher plasma cholesterol levels and develop severe atherosclerosis lesions in the aortic 
root.  Human apoB transgenic mice synthesize the human APOB protein in livers and 
when compared to the wild type mice they have increased LDL and total cholesterol 
levels.  The human apoB transgenic and LDL receptor deficient models are responsive to 
the diet, and they develop large aortic lesions when fed with the western type of diet 
(which contains high percentage of fat and cholesterol) but modest size lesions when fed 
with chow diet 26, 27.  ApoE*3-Leiden transgenic mice were generated by introducing a 
gene construct containing a rare mutation of the human apoE3 gene into C57Bl/6 mice 
which results in impaired clearance of apoE-containing lipoproteins but less so than in 
the Apoe-/- mice 34.  What these mouse models of atherosclerosis have in common is that 
they develop aortic lesions that progress like human lesions going from a fatty streak 
stage to an intermediate stage, to fibroproliferative lesions including atherosclerotic 
features such as a thick fibrous cap, necrotic cores, cholesterol clefs and calcifications 27; 
and, their aortic lesions contain the same type of cells seen in human lesions.  ApoE 
deficient model differs from the other genetically engineered models in respect of these 
characteristics: 1) it is the only model that develops broad aortic lesions when fed with a 
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chow diet, and, 2) their plasma cholesterol is composed mostly of βVLDL composed of 
cholesterol ester-enriched chylomicron remnants VLDL particles 27.   
     These mouse models of atherosclerosis have proven to be very useful in testing the 
effect that different candidate genes have on atherosclerosis.  The transgenic or knocked 
out newly identified candidate genes can be bred onto the Apoe-/- or Ldlr-/- backgrounds 
and the atherosclerosis burden can be estimated in these mice by quantifying the stained 
cross-sections taken from the lesion area in the aortic root 35 or other regions.  
     In recent years, mouse models of atherosclerosis and other complex diseases have 
been a powerful tool not only in testing the function of newly identified candidate genes, 
but also in helping to identify new candidates through quantitative trait locus analysis 
(QTL).   
 
I.4. Quantitative Trait Locus (QTL) Analysis 
     Mouse models can be used to identify new modifier genes for complex diseases 
through unbiased genetic methods, such as quantitative trait locus mapping.  The QTL 
method is very useful in identifying and mapping the chromosomal regions that harbor 
one or several genes that affect a trait/disease.  When the QTL method is combined with 
other genetic, genomic or proteomic approaches it can succeed in identifying the modifier 
gene(s) 36, 37.  One of the major advantages it offers is that one can identify the modifier 
genes without prior knowledge of their location in the genome and/or biological function, 
which often results in the discovery of new biological pathways and mechanisms 
underlying a complex phenotype.  
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I.4.1. QTL mapping 
     QTL mapping relies on the existence of inbred mouse strains with genetic and 
phenotypic differences 36, 38.  Since it is a very laborious and time-consuming technique it 
requires very careful planning.  Usually the first step in undertaking the QTL analysis 
challenge is to select for the right pair of inbred parental strains by performing 
phenotypic analysis of the trait of interest; and, assessing the mode of inheritance by 
comparing the phenotypic data from each of the parental strains and the F1 progeny (all 
individuals of the F1 progeny contain one copy from each of the parental alleles and are 
genetically identical).   
     Once the parental strains with significant phenotypic differences have been identified 
and the mode of inheritance has been determined, a strain intercross is performed to 
generate a cohort of recombinant mice.  If the quantitative trait measured in F1 progeny 
exhibits intermediate values compared to the parental strains, an F2 cohort is generated 
where each individual in this progeny has a unique distribution of parental alleles. If the 
F1 behaves like the one of the parental strains then a N2 cohort is generated by 
backcrossing F1 hybrids to the recessive parental strain.  The genetic diversity in the F2 or 
N2 progeny results from the recombination events that occur during the first meiotic 
division in the process of gametogenesis.  Then, two assays are performed in each of the 
F2 or N2 cohort mice: 1) the phenotypic trait of interest is quantitatively measured and 2) 
strain-specific polymorphic genetic markers (SNPs) or microsatellites, distributed over 
the genome are genotyped.  The data obtained are analyzed using J/QTL or other types of 
software designed to perform correlations and to detect regions in the genome, or loci, in 
which the inheritance of particular parental alleles is correlated with the phenotype.  The 
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resulting map uses genetic chromosomal location in centimorgans (cM) or physical 
chromosomal location in Mb on the X-axis, and the LOD score on the Y-axis, which 
generates a series of peaks.  The LOD score is the logarithm of the odds ratio for the 
association of each marker with the phenotype.  To determine the significance of the 
LOD peak one can either use the criteria defined by Lander and Kruglyak for genome-
wide significance of the QTLs after correcting for multiple testing 2 or perform 
permutation analysis 39, the later being especially helpful in providing valid significance 
thresholds in situations when the phenotype or trait is not normally distributed 40.  Each 
significant peak represents a locus, where one or several genes reside, that affects the 
phenotype 36.  To assist in mapping and comparing the newly identified QTL with other 
QTLs that control for related traits, a 1 or 1.5 LOD drop-off confidence interval is 
estimated 40.  On average, the QTL interval represents a chromosomal region of 10-30 
cM.  Altogether, hundreds of QTLs have been identified for complex diseases in mice 
and the data, including the respective published articles, are collected and stored in a 
QTL Archive database accessible through the website http://churchill.jax.org/datasets/ 
qtlarchive.shtml maintained by The Churchill Group at Jackson Laboratory.  
 
I.4.2. QTL confirmation.  
     One possible method to confirm a newly identified significant linkage before 
proceeding to fine mapping of the QTL interval is by carrying out further independent 
crosses 40 and repeating the QTL analysis explained in detail above.  Srivastava and 
colleagues 41, 42 identified three QTLs significantly linked to the regulation of HDL and 
cholesterol levels in an NZBxRF strain intercross (F2 mice), two novel QTLs and a third 
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one located in chromosome 5.  They found that the location and the peak for the QTL on 
chromosome 5 were concordant with other QTLs identified previously in both chow-fed 
and atherogenic-fed F2 cohorts from two other intercrosses, NZBxSM and B6xCast/Ei.   
     Comparative genetics is another helpful strategy in increasing the confidence towards 
finding the QTL gene.  This strategy relies on the fact that QTLs for some traits may map 
to homologous genomic regions in different species, known also as regions with shared 
synteny.  Sugiyama and colleagues 43 identified six QTLs significantly linked with salt-
induced blood pressure in mice; and, using comparative genetics they found that five of 
the loci were concordant with hypertension loci identified in rats, and four were 
concordant with hypertension loci previously identified in humans.  A study comparing 
atherosclerosis QTLs in mice with atherosclerosis QTLs in humans found that more than 
half (~62%) of identified QTLs were concordant with each other, suggesting that these 
atherosclerosis QTLs have the same underlying genes 44.  
     The traditional method of confirming the QTL interval is by breeding interval specific 
congenic mice in which the region of interest is maintained from the donor strain, while 
the rest of the genome is derived from the recipient strain.  To create congenic strains an 
F1 mouse is backcrossed to each of the inbred parental strains, and the progeny at each 
backcross generation is repeatedly bred to the host parental strain.  For further 
backcrossing, specific strain-specific markers located within the QTL interval are used to 
select for the progeny that are heterozygous for the QTL interval of interest.  Backcross 
breeding after 10 or more generations results in creation of congenic mice that are 
heterozygous for the locus of interest (retaining one copy of the allele from the donor 
strain) and have the rest of the genome (approximately 99.9%) derived from the recipient 
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strain.  A speed congenic breeding procedure 45 was developed and is widely used now to 
speed up the process of generating congenic strains.  It uses additional markers positioned 
throughout the mouse genome to identify individuals with the highest degree of similarity 
with the recipient strain background after each backcrossing.  Instead of ten, one needs 
only 4-6 cycles of backcrossing to obtain the congenic strains.   
     The final step in confirming the QTL interval is “progeny testing”.  The interval 
specific congenic mice are brother-sister matted to generate a cohort of mice that contain 
0, 1 or 2 copies of the donor allele.  The QTL interval is validated if a significant 
difference is observed in the phenotypic trait in the three genetically different groups of 
the brother-sister matting progeny (QTLAQTLA, QTLAQTLB and QTLBQTLB, where A 
and B are the respective QTL interval alleles inherited from each of the parental strains).   
     As mentioned previously, the initial QTL interval is typically ~10-30 cM in size (or 
roughly 20-60 Mb) and contains many genes (sometimes more than 100-200).  Finding 
the causative gene(s) is a daunting task, however there are several approaches that 
someone can follow to identify plausible candidates and test their function/effect on the 
development of the phenotypic trait.  The classical approach is to fine map the interval 
which serves to narrow down the region of interest.  There are also alternative approaches 
to the fine mapping, which have been successfully implemented in several studies.   
 
I.4.3. Fine mapping of a confirmed QTL interval.   
     Fine mapping of a QTL interval is achieved through further backcrossing of the 
congenic mice to the parental strain and selecting the progeny in which the recombination 
occurred within the interval.  By further backcrossing the recombinants to the parental 
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strain one generates subcongenic strains with partially overlapping genomic regions 
within the QTL interval.  Progeny testing is performed on each of the subcongenic lines 
and the data are analyzed to determine the genomic region shared by the subcongenic 
lines that confirms the phenotype.  Thus, fine mapping helps narrowing down the QTL 
interval to 1-2 Mb (~0.5-1 cM) which, depending on the density of the genes located in 
the region, may contain 1 to 20 or more genes that may all be considered as candidates 
for the causative gene.  Fine mapping might be very time-consuming and there are 
several alternative approaches that can be followed to identify candidate genes in a 
shorter timeframe and without prior knowledge of their function and role in the biological 
processes.    
 
I.4.4. Alternative approaches to  identifying causative genes  
    Whole genome gene expression analysis is a very useful approach that may lead to the 
identification of candidate genes within QTLs.  The gene expression data obtained from 
microarray analysis are analyzed to find which transcript’s expression is correlated to the 
phenotype, and the ones with the best correlations are examined to find whether they map 
to a complex trait QTL.  An expression array study led to the identification of the CD36 
gene as responsible for a QTL associated with insulin resistance and fatty acid 
metabolism in isolated adipocytes from rat 46.  Also, three major candidate genes were 
identified for inflammatory bowel-like (IBD) disease in mice by combining QTL and 
microarray analysis 47.  The candidate genes, Cd14, Gbp1 and Plag2a2, were located 
within IBD QTLs and were found to be differentially expressed between B6- and C3-
Il10-/- mice.   
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     Human studies 48 have demonstrated that the variability in gene expression, which was 
observed within the same cell type and development stages in several tested individuals, 
is heritable.  There is less variability in gene expression among related individuals when 
compared to unrelated individuals 49, 50.  In other words, transcript abundance might be 
considered as a quantitative trait and as such can be measured and mapped the same way 
we do for other quantitative traits.  Several studies in human, mice or other organisms 
have performed linear regression analysis to identify DNA variants that correlate with the 
expression levels of the transcripts, and have mapped the so called expression QTLs 
(eQTLs).  A key advantage of this analysis is that it identifies genomic variants that 
regulate mRNA levels without prior knowledge of the regulatory mechanisms involved.  
A second advantage is that it allows parallel investigation of many gene expression 
phenotypes 49.      
     Once identified the expression QTLs (eQTLs) can be classified as cis-eQTL or trans-
eQTL.  A cis-eQTL results from DNA variation that directly influences either its own 
transcript level 48, 50 or the transcript level of other closely located genes.  Practically, one 
can characterize as cis-eQTL those in which the eQTL maps on the same chromosome 
and within a certain distance from the transcript’s location.  Trans-eQTL results from 
DNA variation at one locus that influences the expression of a gene found at a different 
locus 48, 50, for example on a different chromosome.  In other words, trans-eQTL 
represents an eQTL that maps to a different locus from the locus that contains the 
transcript whose level is being tested.  Integrating QTL analysis and expression QTL 
approach, Meng and colleagues identified ATP-binding cassette, subfamily C member 6 
(Abcc6) as a strong candidate gene for Dyscalc1, a QTL linked to dystrophic cardiac 
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calcification 51.  They examined expression data from two intercrosses and in both 
scenarios found a strong cis-eQTL for the Abcc6 transcript, and its expression level in 
liver significantly correlated with myocardial calcification and aortic medial calcification.  
Phenotypic studies in transgenic mice confirmed that Abcc6 gene is the causative gene 
for Dyscalc1 QTL.  
     While whole genome gene expression has contributed enormously to the discovery of 
causative genes, many biological changes that underlie various QTLs might not be 
detected at mRNA level.  Therefore, one needs to pursue other venues, such as searching 
for polymorphisms in the coding or regulatory regions of genes located within QTL or 
analyzing the proteins’ abundance.  Searching for polymorphism differences between the 
strains of choice is very easy based on the accumulating amount of online sequencing 
data and development of tools that make the information accessible to the scientific 
community and public.  Several inbred mouse strains have been sequenced by academic 
institutions, research centers and biotech industries, and the data are available in different 
websites.  Using public SNP information, Stylianou and colleagues identified in total 336 
candidate genes, located within 9 QTLs for different complex diseases, with 
nonsynonymous coding mutations that might affect the protein structure and function 52.  
Also, Petryshen et al., searched for polymorphism differences and identified Drd3, 
Lsamp, Gap43, Zbtb20, Btg3, etc., as candidate genes for the QTLs contributing to the 
prepulse inhibition of acoustic startle (PPI), a genetically complex phenotype impaired in 
psychiatric disorders 53.    
     Furthermore, Stylianou and colleagues combined three different approaches; detection 
of polymorphism, mRNA expression levels and protein abundance/concentration, to find 
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candidate genes for previously identified QTLs linked to HDL levels, gallstone presence 
and obesity/body weight 52.  Protein abundance was measured in livers of NZB and SM 
strains and differences were found in five proteins (ACADS, FH1, HSD11B1, NDUFA9 
and APOA2) located within the selected QTLs.  The 4-fold increase for APOA2 protein 
in NZB strain relative to SM strain was not observed at the mRNA level. 
     Overall, the combination and use of these powerful genetic-genomic-proteomic 
methods have been proven to be successful for the identification of candidate genes and 
metabolic pathways involved in complex traits, as well as in shortening the time-length of 
these studies.   
 
I.4.5. Applying the knowledge gained from mouse studies to human diseases  
     After a QTL gene is identified in mouse studies, its role in human disease can be 
tested by performing a candidate gene association study.  For example, the Tnfsf4 gene 
was identified as a modifier of atherosclerosis in mice, and subsequently a polymorphism 
found in the human Tnfsf4 gene was found to be associated with CAD 54.  In addition, the 
identification of modifier genes for complex diseases in mice may reveal new pathways, 
and consequently all of the human genes in these pathways can then be investigated for 
genetic association with the disease.  Thus, the identification of the modifier genes for 
complex diseases in mice should greatly facilitate the identification of modifier genes in 
humans.  These discoveries may lead to the development of new diagnostics and/or 
therapeutics for the prevention and/or treatment of complex diseases. 
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I.5. Dissertation Research Goals 
     The overall goal in our laboratory is to study and identify genes, mechanisms and 
pathways involved in the development of complex diseases in mice and humans through 
integrative genetics/genomics approaches.  Two complex diseases were the focus of 
research for this dissertation, atherosclerosis and type 2 diabetes.  
     Prior genetics studies performed in our laboratory have identified loci linked to 
atherosclerosis susceptibility in a strain intercross between AKR and DBA/2 Apoe-/- mice 
55.  The atherosclerosis 24 (Ath24) QTL, which was found to be significantly associated 
with the aortic lesion size in the female F2 cohort, is located at the distal end of the 
chromosome 5.  Correlation analysis of the phenotype with the whole genome gene 
expression in bone marrow macrophages of the female F2 cohort revealed polyA specific 
ribonuclease subunit 3 (Pan3), a gene located at the peak of the Ath24 QTL as the top 
candidate gene (details regarding identification of Ath24 QTL and Pan3 gene are given in 
the chapters  and III).     
     Based on these findings, the first research goal was to generate congenic mice for the 
Ath24 QTL on the AKR and DBA/2 parental strain backgrounds and perform phenotypic 
studies to validate the QTL.  We tested the hypothesis that by introgressing the Ath24 
QTL allele from the atherosclerosis susceptible DBA/2 strain into the genome of the 
AKR resistant strain, the congenic mice would develop larger aortic lesions and vice 
versa, mice susceptible to atherosclerosis would become more resistant and develop 
smaller atherosclerotic lesions.   
     The second goal was to search for differences between AKR and DBA/2 Pan3 allele 
and evaluate the effect of Pan3 transcript’s partial or total deficiency on atherosclerosis.  
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Hence, in chapter III we tested the hypothesis that structural or mRNA level differences 
of the Pan3 allele between the two parental strains results in differences in protein 
structure or abundance which play a significant role in the development or protection 
from atherosclerosis. 
     A third goal was to evaluate the effect of cholesterol loading on the AKR and DBA/2 
bone marrow derived macrophages which could also lead to the identification of alternate 
candidate genes for the previously identified atherosclerosis QTL.      
 
     In chapter V, we present the study conducted on type 2 diabetes in human subjects.  
Type 2 diabetes is a complex disease that affects millions of people worldwide and 
bariatric surgery is considered the best treatment as it has been shown to provide 
sustainable improvement in weight loss, fasting plasma glucose, glycated hemoglobin 
A1C (HbA1C) and other clinical characteristics related to the disease.  Aiming to identify 
genes or molecular pathways implicated in type 2 diabetes, we used the genomic 
approach and compared the expression of genes before and after treatment in subjects 
who underwent bariatric surgery which cures T2D often before substantial weight loss.     
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CHAPTER II 
PHENOTYPIC STUDIES IN ATH24 QTL CONGENIC MICE 
 
 
INTRODUCTION 
     Atherosclerosis and the diseases caused by it such as coronary artery disease (CAD), 
cerebrovascular disease, peripheral arterial disease, and myocardial infarction (MI) 
represent the leading cause of illness and death in United States and worldwide.  
Atherosclerosis is a complex disease that progresses from the earliest lesions (called 
“fatty streaks”) consisting mainly of subendothelial accumulations of foam cells 
(cholesterol engorged macrophages) to more advanced lesions characterized by a necrotic 
core rich in lipids and dead macrophages and smooth muscles cells (SMCs) surrounded 
by a fibrous cap build of SMCs and extracellular matrix 1, 2.  There are two types of 
plaque that are usually formed in the large arteries; the hard and stable plaque which 
causes the artery walls to thicken and harden, and the soft and unstable plaque which 
most likely ruptures or fissures 3.  Plaque formation and the lesion buildup in the arterial 
intima and media layers result in the restriction of blood flow.  Positive remodeling 
occurs in early atherosclerosis which results in an enlargement of the outer wall of the 
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vessel and the lumen 4.  The modification helps preserve the blood flow until it can no 
longer compensate (usually when the atherosclerotic plaque occupies 40% or more of the 
lumen area) 4.  The most severe implication in atherosclerosis development occurs when 
the plaque ruptures exposing the blood to a pro thrombotic environment leading to the 
formation of a thrombus or blood clot which can occlude the artery and cause ischemia in 
the myocardium 2, 5.  This event is called a myocardial infarction (MI) and leads to the 
rapid development of myocardial necrosis 6.   
     Atherosclerosis and CAD are complex multi-factorial disorders caused by various 
combinations of genetic and environmental factors.  Many environmental and other 
complex disease risk factors are well known, e.g. hyperlipidemia, smoking, high fat diet, 
stress, high blood pressure, diabetes, obesity, physical inactivity, etc.  Atherosclerosis 
also has a genetic component because family history is a significant predictor, with 
family and twin genetic studies showing that the genetic component accounts for ~50% 
of ones risk 7.  Several genes and mechanisms involved in the development of 
atherosclerosis have been discovered; however, the fact that the most effective 
atherosclerosis treatment (statin drugs) reduces coronary events by only one third 8 points 
to the necessity of searching for new atherosclerosis susceptibility related genetic factors 
and molecular mechanisms which will eventually lead to better treatment and therapies.   
     Due to its complexity and inability to separate genetic factors’ contribution in the 
development of atherosclerosis from that of environmental factors, it has been difficult to 
study the genetics of the disease in human populations.  For these reasons, mouse models 
of atherosclerosis have proven to be very useful in: 1) identifying new candidate genes 
through application of QTL analysis and, 2) testing the role of newly identified 
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candidates on the atherosclerosis in vivo.  Two atherosclerosis modifying genes have 
been found in unbiased genetic studies performed with mouse models, arachidonate 5-
lipoxygenase (Alox5) and Tnfsf4 also known as Ox40l 9-11.  Both genes were shown to be 
associated with the risk of MI in genetic association studies performed in human 
populations 8, 11.  Also, the angiopoietin-like 3 (Angptl3) gene which is located within an 
atherosclerosis regulating QTL (Ath8) identified previously in a strain intercross in mice 
may also modify atherosclerosis susceptibility in humans 12.  This study found that 
polymorphisms in the ANGPTL3 gene are associated with the size of coronary 
atherosclerosis plaque in a human case-control cohort.  These findings support the idea 
that QTL analyses in mouse models are very helpful in identifying causative genes for 
human disease.         
     It has been shown that the genetic background plays an important role in determining 
the degree to which atherosclerosis develops in apolipoprotein E (apoE) deficient mice 13.  
Smith et al., measured the aortic root lesions in several inbred apoE deficient mice strains 
and found that atherosclerosis susceptible DBA/2 mice develop ~10-fold larger lesions 
compared to atherosclerosis resistance AKR mice 14.  These two strains were further used 
to map regions in the mouse genome that were best associated with the aortic root lesion 
area by performing a strain intercross and generating an F2 cohort of 95 females and 114 
males.  Genotypic and phenotypic data collected from the F2 cohort were analyzed to 
identify regions in the mouse genome that were associated with atherosclerosis 
susceptibility 15.  Based on the evidence that cardiovascular disease is a classic example 
of complex disease with gender-specific differences 16, the QTL analyses were performed 
in combined as well as in female and male only F2 cohorts. Several atherosclerosis 
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susceptibility associated loci were identified.  The strongest atherosclerosis associated 
locus identified in the female F2 cohort is Ath24 QTL with a LOD score of 3.35 (when 
using aortic root lesion area as phenotype, unadjusted P value 8.6E-5, permutation based 
genome-wide p-value < 0.20) meeting the generally accepted criteria for marginal 
genome wide significance 15.  The locus is stronger and meets the criteria for genome 
wide significance when using non-log transformed lesion area values 15.  Ath24 QTL is 
located at the distal end of the chromosome 5 (peak located at 84 cM) and maps near to 
previously identified QTLs for body weight QTL 13 (Bw13; 81 cM) 17, liver weight QTL 
2 ( Lwq2; 81 cM) 17, blood pressure QTL 4 (Bpq4; 78 cM) 18 and other more distant loci 
associated with hypercholesterolemia (Hypch; 72 cM) 19and high density lipoproteins 
level (HDLq1; 70 cM) 20, all identified in different strain intercrosses.   
     Furthermore, linear regression analysis for the Ath24 QTL revealed that 15% of the 
variation observed in aortic lesion size in the female F2 cohort is associated with the 
inheritance of the marker located at this LOD peak 15.   
     A QTL is classically validated by creating and studying interval specific congenic 
mice on the parental backgrounds.  Many studies made use of this strategy and   
succeeded in confirming different QTL, such as an atherosclerosis susceptibility QTL 
(Athsq1) 21 on chromosome 1, a complex QTL for carbohydrate (Mnic1) and total energy 
(Kcal2) intake 22 on chromosome 17 and a HDL cholesterol-related QTL mapping to 
chromosome 6 23.  
     The study presented in this chapter aimed at confirming Ath24 QTL as a locus 
harboring the gene(s) responsible for modifying atherosclerosis susceptibility in AKR 
and DBA/2 strains.  We hypothesized that by introgressing the Ath24 QTL interval from 
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one parental strain into the genome of the other parental strain the aortic lesion area size 
in congenic mice with either one or two copies of the donor strain would be significantly 
different from the aortic lesion size of their respective parental strains.  Thus, we expect 
Ath24 QTL congenic mice with the DBA/2 locus bred onto the atherosclerosis resistant 
AKR background to become susceptible and develop larger lesions than the parental 
AKR inbred strain and vice versa.  Because the effect of Ath24 locus was found to be 
specific for females 15 we present the data for female mice only.  Furthermore, generation 
of congenic mice for the Ath24 locus on both parental strains is very useful in fine 
mapping the interval, a process that can lead to the positional cloning of the 
atherosclerosis modifying candidate genes.  This classical approach was followed by Clee 
et al., and helped identify Sorcs1, a gene that encodes for sortilin-related VPS10 domain 
containing receptor 1, as the underlying causative gene for a type 2 diabetes associated 
locus (T2dm2) 24.       
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MATERIALS AND METHODS 
Isolation of DNA from mouse ear, liver and/or tail for genotyping  
     A piece from mouse ear, liver or tail was placed in a 1.5 ml microcentrifuge tube 
containing 0.5 ml lysis buffer consisting of 4 M urea, 10 mM EDTA, 0.5% w/v N-
laurylsarcosine, 0.1 M Tris (pH, 8.0) and 0.2 M NaCl.  Proteinase K (Catalog # 
03115879001, Roche Diagnostics, Indianapolis, IN) was added to a final concentration of 
1 mg/ml prior to digestion.  The samples were incubated at 55oC overnight, with constant 
rocking.  The next day, the samples were centrifuged in a microcentrifuge at 15,000 rpm 
at RT for 5-6 minutes, to pellet hair and the undigested debris.  The supernatant was 
transferred in a new 1.5 ml tube containing 0.5 ml isopropanol.  The tubes were mixed 
thoroughly by inversion and centrifuged in a microcentrifuge at 15,000 rpm at RT for 5 
minutes.  The supernatant was discharged very carefully to prevent from losing the DNA 
pellet.  Next, DNA pellet was washed once with 0.5 ml 70% ethanol, centrifuged at 
15,000 rpm at RT for 3-4 minutes, and the supernatant was aspirated off the tube.  DNA 
pellet was air dried for 1-2 minutes and dissolved in 0.2 ml of 0.1X TE buffer, consisting 
of 1 mM Tris (pH, 8.0) and 0.1 mM EDTA 25.  DNA samples were incubated in a 37oC 
incubator for 1-2 days and its concentration was measured by using a nanodrop 
(Nanodrop Technologies, Wilmington, DE) and stored at 4oC.  
 
Generation of Ath24 QTL interval specific congenic mice by marker assisted 
backcrossing 
    To create interval specific congenic mice onto each of the parental backgrounds, we 
started by backcrossing F1 mice from the AKR x DBA/2 intercross to each of the parental 
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strains.  The new progeny was genotyped for 3 SNPs (rs4225536, rs3023062 and 
rs13478595) located within the Ath24 QTL (at 138.8, 145.6 and 151.1 Mb, respectively).  
SNP genotyping was performed by using pre-designed TaqMan SNP genotyping assays 
developed by Applied Biosystems for the abovementioned SNPs (Table 2.1), following 
the manufacturer’s guidelines.  The amplification reactions were prepared in a total 
volume of 5 μl, in triplicates for each sample, including the controls (2 parental strains’ 
DNA, F1 DNA, and no template).  Genotypes were determined by calculating the ratio of 
the signals contributed by each allele and comparing each sample’s ratio with the 
controls.  
     DNA from mice that were found to be heterozygous for Ath24 QTL interval were 
further genotyped by using Illumina GoldenGate genotyping assay (performed at the LRI 
Genomic Core) to identify among them, the mice with the highest similarity to the 
parental strain genome (or with the least contamination from the donor strain).  In total, 
598 SNPs of the 1450 genotyped were polymorphic between AKR and DBA/2 strains.  
The selected mice were used for subsequent backcrossing with respective parental strain 
mice and the same procedure was followed up to N12 generation for AKR parental strain 
and N8 generation for DBA/2 parental strain.  Official nomenclature for the congenic 
strains is: DBA/2.AKR-Ath24 (host strain.donor strain-atherosclerosis QTL introgressed 
into the DBA/2 background) and AKR.DBA/2-Ath24. 
 
Phenotypic studies: measuring heart and body weight, and aortic root lesion size   
     The congenic mice that were heterozygous for Ath24 QTL were brother – sister 
mated.  The progeny from this breeding were genotyped for 9 SNPs for congenic mice on 
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the AKR apoE deficient background and 6 SNPs for those on the DBA/2 apoE deficient 
background (Ath24 QTL interval on AKR apoE deficient background is longer than the 
congenic Ath24 interval on the DBA/2 parental strain).  Detailed information regarding 
the SNP IDs, their location and the pre-designed Applied Biosystems TaqMan 
genotyping assays are given in (Table 2.1).  The genotyping assay for rs13462610 SNP 
was custom-designed by using FileBuilder 3.1 software and manufactured by Applied 
Biosystems.  The genomic sequence and the position of rs13462610 SNP are given in 
Appendix 2A.   
 
Table 2.1: List of TaqMan genotyping assays used to genotype the mice for Ath24 QTL 
interval.      
SNP ID Chr. 5 Position/Build 37.1 AKR DBA/2 Gene symbol Type of assay Assay ID 
Rs6202530 117 543 691 G A Suds3  Pre-designed M__23796483_10 
Rs13478490 120 880 737 T C Lhx5  Pre-designed M__25013752_10 
Rs13478521 128 826 064 T C Tmem132d  Pre-designed M__25141194_10 
Rs29632776 131 389 527 A C Wbscr17  Pre-designed M__25307043_10 
Rs13478540 134 520 937 G A - Pre-designed M__24718489_10 
Rs4225536 138 898 368 A G Zfp157  Pre-designed M__45281656_20 
Rs6298689 140 240 607 C T Ints1  Pre-designed M__24567869_10 
Rs3023062 145 631 811 G A Smurf1  Pre-designed M__25007558_20 
Rs4138683 148 159 603 G A Flt3  Pre-designed M__23832330_10 
Rs13462610 152 450 057 T G Rfc3 Custom-made -  
 
     Progeny testing was performed with mice fed with a chow diet (2018 Teklad Global 
18% Protein Rodent Diet, Harlan Laboratories) and sacrificed at 14 and 16 weeks of age 
by CO2 inhalation (N12 and N7 generation for AKR.DBA/2-Ath24 and DBA/2.AKR-
Ath24 congenics, respectively).  Body weight was measured and blood samples were 
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collected from the retro-orbital plexus into heparinized capillary tubes.  Then a midline 
incision of the skin was made and the peritoneal membrane was cut to expose the 
diaphragm.  Diaphragm and ribs were cut to expose the heart and the right atrium was 
clipped to drain the blood into the chest cavity.  A 10 ml saline perfusion (with PBS) was 
performed with a 26 gauge 3/8” needle inserted into the left ventricle.  The heart was 
removed, weighted, and placed into a glass vial containing 10% buffered formalin 
solution (Catalog # SF100-4, Fisher Scientific), and the samples were stored at 4oC for 
subsequent histological analysis.  Thereafter, hearts were sectioned and lesions were 
stained and quantified as it is previously described 26.   
 
Phenotypic studies: measuring total and HDL cholesterol levels 
     Blood samples were spun in a microcentrifuge for 20 minutes at 15,000 rpm (RT) and 
the plasma, separated from blood cells, was transferred to a new 1.5 ml tube.  A few 
microliters of plasma (5 to 10 μl) were diluted 10 times with PBS prior to quantifying the 
total cholesterol.  Also, 30 μl of plasma from each sample were transferred to Beckman 
centrifuge tubes (Catalog # 343775, Beckman Coulter, Brea, CA) and layered on top with 
30 μl PBS (creating two distinct layers).  The samples were spun for 3 hours at 70,000 
rpm at 4oC in an ultracentrifuge.  Then, the bottom layer (30 μl) was transferred to new 
1.5 ml tubes to which were added 3 μl of HDL precipitating reagent (Stanbio, Catalog # 
0599).  HDL precipitating reagent contains dextran sulfate and magnesium ions that 
precipitate the LDL and VLDL cholesterol fractions, leaving the HDL cholesterol 
fraction in solution.  
37 
 
.    After adding the HDL precipitating reagent, the samples were mixed well by 
vortexing and allowed to sit at RT for 5 minutes.  Then, the samples were spun down for 
5 minutes at 13,200 rpm (RT).  The supernatant was used to quantify HDL levels in 
duplicates (10 μl per each well).  Samples and standards were loaded in duplicates in a 
96-wells transparent plate; and, 250 μl enzymatic cholesterol reagent (Stanbio 
Cholesterol LiquiColor®, Catalog # 1010-430, STANBIO, Boerne, Texas) were added to 
each well.  The plate was put on a shaker for 1-2 minutes at RT and then incubated for 18 
minutes in a 37oC incubator.  The optical density (OD) for the samples and standards was 
read at a 505 wavelength in a plate spectrophotometer and the mean value for each 
sample’s total and HDL cholesterol reading was adjusted to account for the appropriate 
dilution.   
 
Statistical analysis  
Kolmogorov-Smirnov (KS) tests were performed to assess whether the phenotype values 
exhibited normal Gaussian distributions.  For normally distributed phenotypes, 
parametric unpaired t-test was performed to compare the values between two groups of 
mice and one-way ANOVA was performed when comparing 3 groups of mice; and, 
Mann-Whitney (2 groups) and Kruskal-Wallis (3 groups) nonparametric tests were 
performed when the data failed to show normal distribution of the phenotypes.  Statistical 
analyses were done using GraphPad Prism software, version 4.0 for Windows (GraphPad 
Software, San Diego, California, www.graphpad.com).  
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RESULTS 
Atherosclerosis in Ath24 QTL congenic mice 
Ath24 locus was identified by Smith et al., 15 and is located at the distal end of the 
chromosome 5 (Figure 2.1).  The LOD peak maps to 147.39 Mb (Genome Build 37.1) 
and the one LOD drop-off confidence interval extends from about 137 to 149 Mb  
(chromosome 5 is ~152. Mb) 15. 
 
     To confirm the role of Ath24 QTL in modifying atherosclerosis susceptibility we 
generated congenic mice for the Ath24 QTL interval onto the AKR and DBA/2 Apoe-/- 
parental backgrounds.  For this purpose we backcrossed F1 mice from the AKR x DBA/2 
intercross to each of the parental strains for several generations.  Fully congenic mice on 
the AKR Apoe-/- background were obtained by N12 generation.  Ath24 QTL interval in the 
congenic mice on AKR Apoe-/- background extends from 117.3 Mb to the end of 
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Figure 2.1: Presentation of Ath24 QTL in a genetic map for the chromosome 5.  The 
map is constructed by plotting the physical chromosomal location in Mb for each 
chromosome 5 genotyped marker on the X axis against LOD score on the Y axis.  LOD 
score is the log of the odds ratio for the association of each marker with the phenotype.  
The peak at the distal end of chromosome 5 represents Ath24 QTL together with its 1 
LOD drop-off confidence interval shown by the red line. 
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chromosome 5 (152.5 Mb) and no other contamination with DBA/2 markers was detected 
by Illumina Golden Gate SNP genotyping assay (Figure 2.2, AKR congenic line 5.0). 
     Congenic mice on the DBA/2 Apoe-/- parental background were obtained by N7 
generation.  The Ath24 QTL interval extends from 138.8 to 152.4 Mb (end of 
chromosome, as shown in Figure 2.2, DBA/2 congenic line 5.0) and the congenic mice 
contain no other contamination with AKR markers throughout the rest of the genome. 
 
  
    
    In the process of testing atherosclerosis development in congenic mice we identified 
different recombinants within Ath24 QTL in either of the parental backgrounds.  The best 
recombinants for the interval were selected to be the founders of subcongenic lines 
(shown in Figure 2.2).  At present, these overlapping subcongenic lines are maintained by 
breeding the Ath24 QTL subcongenics, homozygous for the donor strain, with each other.   
115 120 125 130 135 140 145 150
DBA/2.AKR-Ath24 (line 5.0)
1-LOD interval
DBA/2.AKR-Ath24 (line 5.1)
DBA/2.AKR-Ath24 (line 5.2)
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AKR.DBA/2-Ath24 (line 5.4)
AKR.DBA/2-Ath24 (line 5.2)
Chromosome 5 Mb  
 
Figure 2.2: Schematic representation of Ath24 QTL congenic and subcongenic lines 
generated on the AKR Apoe-/- background (shown in blue) and DBA Apoe-/- background 
(shown in green).  1 LOD drop-off confidence interval is shown in red.  Grey areas represent 
genomic regions between two neighboring genotyped SNPs (positioned about 3.5 Mb apart), one 
homozygous for the parental background and the second heterozygous, where due to the 
recombination events that might have occurred we remain uncertain of the genotype. 
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Atherosclerosis in Ath24 locus congenic mice on the AKR Apoe-/- background 
     We hypothesized that introgressing the Ath24 locus interval from atherosclerosis 
susceptible DBA/2 strain onto the resistant strain (AKR) background would render the 
congenic mice prone to developing larger aortic lesions.  Smith et al.,15 found that 15% of 
the variation observed in aortic lesion size in the female F2 cohort is associated with the 
inheritance of the DBA/2 allele for the marker at the peak of Ath24 QTL.   
     As explained above, fully congenic mice on the AKR Apoe-/- background were 
obtained by N12 generation.  In order to generate a testing progeny to asses the 
atherosclerosis burden we brother-sister mated the congenic mice heterozygous for the 
Ath24 QTL.  One problem we faced following this breeding strategy was the high 
number of recombinants with diverse genotypes for the Ath24 interval which most likely 
resulted from the interval’s length on this background (~35 or more Mb) and the presence 
of recombination hot spots.  To troubleshoot the problem, we undertook two different 
approaches.   
     The first approach was to perform separate statistical significance tests of the 
phenotypic traits for each individually genotyped strain-specific SNP within the Ath24 
interval (SNPs were positioned at about 3.5 Mb apart from each-other).  As phenotypic 
traits we quantified the aortic root lesion size, total and HDL cholesterol levels.  Body 
and heart weight were also measured in each of the individual mice at 14 weeks.  No 
significant differences were observed in aortic lesion size, total and HDL cholesterol, 
body weight, heart weight, heart to body weight ratio among the three genotypes, 
AKR.DBA/2 Apoe-/--Ath24AKR/AKR AKR.DBA/2 Apoe-/--Ath24AKR/DBA and AKR.DBA/2 
Apoe-/--Ath24DBA/DBA at 14 weeks of age.  Of the nine Ath24 QTL interval genotyped and 
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tested SNPs we are showing the data and statistical tests results for rs4225536 SNP 
located on chromosome 5 at 138.8 Mb (presented in Table 2.2 and Figure 2.3A).   
 
Table 2.2A:  Phenotypic data collected from Ath24 QTL congenic mice on AKR Apoe-/- 
background at 14 weeks.  Samples were separates into groups and analyzed based on the 
genotype of rs4225536 SNP.  
 Rs4225536 
AKR/AKR 
Rs4225536 
AKR/DBA 
Rs4225536 
DBA/DBA 
P-value 
Number of mice 12 11 5  
Aortic lesion  3,142 ± 2,858 5,639 ± 4,886 5,575 ± 2,766 0.2504 
Total cholesterol (TC) 361.4 ± 41.6  342.1 ± 28.4  381.6 ± 39.7 0.2565 
HDL cholesterol 39.35 ± 10.51 35.33 ± 4.11 47.45 ± 19.55 0.4158 
Body weight 30.18 ± 3.81 33.46 ± 4.02 31.64 ± 3.79 0.1520 
Coefficient of variation# 90.96% 86.65% 49.61%  
# applies to aortic lesions only; Data are presented in mean ± SD (standard deviation). 
42 
 
 
The second approach was to pursue a different strategy in generating the progeny testing 
that was by breeding mice homozygous for the AKR or DBA/2 Ath24 QTL allele 
(Ath24AKR/AKR or Ath24DBA/DBA) with mice of the same genotype to obtain a considerable 
number of homozygous mice for each group.      
     Preliminary analysis revealed a high degree of variation in the aortic lesion size within 
each genetically different group.  A high coefficient of variation means that one needs a 
considerable higher number of mice to be tested in order to gain statistical power to 
detect real differences of the trait.  Based on the preliminary data at 16 weeks of age with 
a coefficient of variation of ~0.4, we calculated that a sample size of 20 female mice per 
group has a 80 % power to detect a 36% or more difference in mean lesion size among 
the groups with when using aortic lesion area as phenotype.  One solution to this problem 
was to sacrifice the congenic mice at 16 weeks of age, a time when the aortic lesions are 
expected to be more advanced.  The strategy helped reduce the coefficient of variation in 
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Figure 2.3:  Effect on the aortic lesion area size of the Ath24 QTL interval on AKR Apoe-/- 
parental background at: A) 14 weeks, and B) 16 weeks of age.  The QTL is located at the distal end 
of the chromosome 5.  The bar graphs represent atherosclerotic lesion size (mean ± SD) at the aortic 
root in female mice.  Numbers next to the genotype represent the number of mice used in the individual 
groups. 
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the group of mice homozygous for the parental allele (down from 91% to 50%) but quite 
the opposite occurred in the group of mice homozygous for the donor Ath24 QTL interval 
allele for which the coefficient of variation increased from 50% to 105%.  Nevertheless, 
sacrificing mice at 16 weeks provided (on average) a ~17% reduction in the coefficient of 
variation for aortic lesions in Ath24 QTL congenic mice on the DBA/2 Apoe-/- 
background (shown in Table 2.3).   
     Although at a preliminary stage, the data obtained thus far show no significant 
difference in lesion size (Figure 2.3A and B).  Also, no significant differences were 
observed for total and HDL cholesterol levels, body weight, heart weight and heart to 
body weight ratio at 16 weeks of age (Table 2.2B), which was expected as none of this 
traits was found to be associated with markers located within the Ath24 QTL interval, as 
previously reported 15.  
 
Table 2.2B:  Phenotypic data collected from Ath24 QTL congenic mice on AKR Apoe-/- 
background at 16 weeks.  Samples were separated into groups and analyzed based on the 
Ath24 QTL genotype.  
 Nornally 
distributed 
AKR.DBA/2 - 
Ath24AKR/AKR 
AKR.DBA/2 - 
Ath24DBA/DBA 
P-value 
Number of mice#  8 6  
Aortic lesion  No 8,201 ± 4,103 5,533 ± 5,856 0.2824 
Total cholesterol (TC) Yes 373.2 ± 57.31 386.3 ± 72.01 0.6740 
HDL cholesterol Yes 34.62 ± 7.78 30.72 ± 4.82 0.2435 
Body weight Yes 32.58 ± 3.63 33.09 ± 5.96 0.8115 
Coefficient of variation#  50.02% 105.83%  
# applies to aortic lesions only; Data are presented in mean ± SD (standard deviation). 
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Atherosclerosis in Ath24 locus congenic mice on the DBA Apoe-/- background 
     We also tested the effect of the Ath24 QTL interval on the DBA/2 Apoe-/- background.  
DBA/2 Apoe-/- parental strain mice develop large lesions (Figure 2.4A and B).  
Hypothetically, based on the chromosome 5 Ath24 QTL, we would expect a reduction in 
lesion size of DBA/2.AKR Apoe-/--Ath24AKR/DBA and DBA/2.AKR Apoe-/--Ath24AKR/AKR  
mice as the congenic mice which retain one or two copies of AKR-Ath24 QTL allele 
become more resistant to atherosclerosis.  However, this was not observed (at either 14 or 
16 weeks of age, Figure 2.4A and B); and, therefore the atherosclerosis susceptibility 
QTL on the distal end of the chromosome 5 has not yet been validated on the DBA/2 
Apoe-/- background in female mice.  In fact we observed the opposite of what we were 
expecting, with congenic mice homozygous for the donor allele (from atherosclerosis 
resistant strain) developing bigger aortic lesions than the congenic mice homozygous for 
the parental Ath24 QTL allele on the atherosclerosis susceptible DBA Apoe-/- strain 
background.  The difference in aortic lesions size, although opposite to our expectations, 
was observed to be statistically significant at 14 weeks (Table 2.3).  No significant 
changes were observed in body weight, total and HDL cholesterol between the groups 
studied (Table 2.3). 
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Figure 2.4:  Effect on the aortic lesion area size of the Ath24 QTL interval on DBA/2 Apoe-/- 
parental background at: A) 14 weeks, and B) 16 weeks of age.  The bar graphs represent 
atherosclerotic lesion size (mean ± SD) at the aortic root in female mice.  Numbers next to the genotype 
represent the number of mice used in the individual groups. 
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Table 2.3:  Phenotypic data collected from Ath24 QTL congenic mice on DBA/2 Apoe-/- 
background at 14 and 16 weeks.  Samples were separated into groups and analyzed based 
on the Ath24 QTL genotype (138.8 – 152.4 Mb). 
14 WEEKS 
 Normally 
distributed 
DBA/2.AKR - 
Ath24AKR/AKR 
DBA/2.AKR - 
Ath24DBA/DBA 
P-value 
Number of mice  11 13  
Aortic lesion  No 104,500 ± 45,281 64,140 ± 37,306 0.0128* 
Total cholesterol (TC) No 917.4 ± 99.23 892.3 ± 149.5 0.4120 
HDL cholesterol Yes 24.80 ± 4.81 23.41 ± 5.63 0.5045 
Body weight Yes 21.29 ± 2.48 21.57 ± 2.191 0.7760 
Coefficient of variation#  43.33% 58.16%  
16 WEEKS 
 Normally 
distributed 
DBA/2.AKR - 
Ath24AKR/AKR 
DBA/2.AKR - 
Ath24DBA/DBA 
P-value 
Number of mice#  16 5  
Aortic lesion  Yes 316,390 ± 110,190 222,523 ± 109,146 0.1121 
Total cholesterol (TC) Yes 887.9 ± 139.90 869.7 ± 78.85 0.7642 
HDL cholesterol No 24.81 ± 6.57 25.65 ± 6.70 0.7264 
Body weight Yes 21.96 ± 1.78 22.16 ± 2.25 0.8222 
Coefficient of variation#  34.83% 49.05%  
# applies to aortic lesions only; Data are presented in mean ± SD (standard deviation) 
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DISCUSSION 
     The aim of this study was to use congenic strains to confirm a previously identified 
atherosclerosis QTL15 located on the distal end of chromosome 5 in female mice.  To 
achieve our goal, we firstly generated congenic mice for the Ath24 QTL on AKR and 
DBA/2 Apoe-/- parental strains and then performed progeny testing by brother-sister 
mating and, quantifying aortic root lesion area and other atherosclerosis related traits 
such as total and HDL cholesterol at 14 and 16 weeks of age.  In the process, several 
recombinants within the Ath24 QTL interval were detected and some of them were used 
as founders of overlapping subcongenic lines that are currently maintained in the animal 
facility at LRI, Cleveland Clinic. 
     The atherosclerosis assays are ongoing, however we have not been able to validate the 
Ath24 QTL interval on either of the parental strains background up to date.  One of the 
reasons might be that the new genetic background of the congenic strain suppresses the 
full expression of the quantitative trait 27.  This phenomenon (genetic background 
affecting a given phenotype to the point that it becomes undetectable) has been 
previously illustrated in cystic fibrosis (CF), a Mendelian inherited trait 28.  The study 
showed that the same CF mutation had different impacts on the BALB/c and C57BL/6 
backgrounds with the former developing minimal histopathology and the later developing 
a lung disease consisting of fibrosis.   
     Also, the genetic background of the congenic mice is quite different from the genetic 
background of the F2 cohort that was used to identify the QTL.  By putting the 
atherosclerosis QTL interval on the parental backgrounds we might have eliminated 
important interactions with other regions of the genome; and, given that atherosclerosis 
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represents a complex disease, gene-gene interactions is one of the major mechanisms 
altering the disease outcome.  A hypothetical example is that a polymorphism located 
within Ath24 QTL might affect the expression of another gene located outside of the 
atherosclerosis QTL (trans-eQTL).  Teupser et al., faced the same problem when they 
could not validate an atherosclerosis QTL on proximal end of chromosome 10 which was 
previously identified in FVB and C57 BL/6 mice on the Apoe-/- and Ldlr-/- backgrounds 
29.  They successfully validated the atherosclerosis QTL on the chromosome 10 by 
following a novel strategy, designed to bring out genetic interactions and consequently 
the desired phenotype modified by the responsible modifier gene.  The advantage of this 
strategy is that instead of using congenic mice and testing the phenotype on an 
uncontaminated background of either parental strain, it uses interval specific congenic 
strains on the F1 background, generated by breeding the “classically” obtained congenic 
mice on one parental background with the other parental strain.   
     At present, we are breeding congenic lines on both of the parental backgrounds (AKR 
and DBA/2) with the opposite parental strains to generate F1.Apoe-/--Ath24AKR/AKR and 
F1.Apoe-/--Ath24DBA/DBA mice and test atherosclerosis by quantifying aortic root lesion 
area in female animals hoping the strategy will prove to be very useful in confirming 
atherosclerosis QTL (Ath24) on chromosome 5.  
     Another possibility is that the Ath24 QTL might be a false positive, and therefore not 
verifiable in congenic strains.  To validate the Ath24 QTL, a new (AKRxDBA/2)F2 
cohort was recently generated in our laboratory.  The collection of data and analysis are 
ongoing and being performed by other members of the lab.  
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CHAPTER III 
STRUCTURAL STUDIES OF PAN3 GENE IN AKR AND DBA/2 INBRED MOUSE 
STRAINS AND THE ASSESSMENT OF PAN3 PARTIAL DEFICIENCY EFFECT ON 
DEVELOPMENT OF ATHEROSCLEROSIS IN FEMALE MICE 
 
 
 
INTRODUCTION 
     In an effort to identify genes that affect development of atherosclerosis Smith et al., 1 
mapped quantitative trait loci for the disease in a strain intercross between atherosclerosis 
resistant strain (AKR Apoe-/-) and atherosclerosis susceptible strain (DBA/2 Apoe-/-).  
This unbiased genetic approach identified a locus on the distal end of the chromosome 5, 
called atherosclerosis 24 QTL (Ath24), as significantly associated with the aortic root 
lesion area in a female (AKRxDBA/2)F2 cohort.  By definition, each one of the genes 
residing within the Ath24 QTL confidence interval (137 to 149 Mb) is considered a 
candidate for the trait.  The question that arises is which one of the 292 genes located 
within the Ath24 QTL interval is the “culprit” gene?  To answer this question one can 
follow the classical approach of fine mapping the QTL interval which helps reduce the 
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number of candidate genes.  However, fine mapping suffers of two major drawbacks: 1) 
it is time-consuming, and 2) even after fine mapping one can be left with a considerably 
large number of candidate genes to pursue further studies of their role in modifying the 
outcome of the disease for validation purposes 2.   
    Advancements in microarray technology brought the concept of “genetical genomics”3, 
a new alternative to identifying candidate genes for QTLs.  Based on the assumption that 
the interplay of genetic and environmental factors results in quantitative changes of the 
genes’ products in the cell lines or tissues most closely related to the disease in question 
3, combining QTL mapping for a phenotype of interest with whole genome gene 
expression may help identify candidate genes associated with the phenotype.  The 
strategy has been broadly used in studies of diverse complex traits in different organisms 
and several strong candidate genes exhibiting differences in expression levels and 
mapping to previously identified QTLs have been identified 4-13. 
     To identify candidate genes for the previously identified atherosclerosis susceptibility 
QTLs, our lab took advantage of the genetical genomics approach (Smith, JD, 
unpublished data) and assessed the whole genome gene expression (~17,000 transcripts) 
in bone marrow macrophages of F2 female cohort.  The transcript whose expression was 
best correlated (r2 = 0.20) with aortic lesion size maps to chromosome 5 at 148.2 Mb 
(Genome Build 37.1), which corresponds to the location of the Ath24 LOD peak (~147.4 
Mb).  The transcript encodes for a protein called Pan3 [polyA specific ribonuclease 
subunit homolog (S. cerevisiae)], and its expression was positively correlated with lesion 
area in the F2 cohort. 
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     Association analyses of genome variations (SNPs) and gene expression levels (as 
quantitative traits) identified a cis-eQTL as strongly correlated with changes in 
expression level of Pan3 gene in F2 female cohort (LOD = 7.86).  Also, 30% of Pan3 
expression variance was found to be associated with the inheritance of the DBA/2 versus 
AKR allele for the cis-eQTL marker with the AKR allele associated with decreased 
expression, and the DBA/2 allele associated with increased expression in a co-dominant 
mode of inheritance.  The cis-eQTLs that map to the same location with a clinical trait 
QTL are very important and represent strong positional candidate genes 14, 15.  Thus, the 
Pan3 transcript represents our prime candidate responsible for the Ath24 QTL, with the 
AKR allele associated with lower expression levels and smaller aortic lesion areas. 
     The correlation between Pan3 expression and atherosclerosis was examined in more 
detail and it was revealed that the correlation between the transcript’s expression and the 
lesion area is allele dependent.  In mice that inherited two copies of the AKR Pan3 allele, 
there was no correlation between Pan3 expression and lesion area, whereas mice that 
inherited one AKR and one DBA/2 Pan3 alleles showed a modest degree of correlation  
between Pan3 expression and the phenotype (r2 = 0.08).  A very strong correlation 
between Pan3 expression and lesion area was observed in mice that inherited two copies 
of the DBA/2 Pan3 allele, r2=0.42.  Thus expression of the AKR allele had no apparent 
effect on atherosclerosis, but in mice homozygous for the DBA/2 allele Pan3 expression 
is associated with 42% of lesion variance. 
     The Pan3 gene encodes a protein fully named: polyA specific ribonuclease subunit 
homolog (homolog to the gene originally identified in yeast) 16.  Pan3 protein is one of 
the two subunits of the poly(A) specific ribonuclease complex (PAN) 17 which is 
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involved in the first phase of mRNA deadenylation.  The catalytic subunit Pan2 shortens 
the poly(A) tails of mRNA to ~110 nucleotides in association with its regulatory subunit, 
Pan3, marking the beginning of the mRNA turnover.  Then the PAN complex is replaced 
by Ccr4/Caf1 complex which catalyzes further shortening of the poly(A) tail.  In contrast 
to yeast, where PAN complex functions in both nucleus and cytoplasm, the mammalian 
PAN complex is found only in the cytoplasm 18, 19.   
     Studies indicate that the Pan2 subunit contains a 3’- 5’ poly(A) nuclease activity, 
while Pan3 is the regulatory subunit which binds directly to poly(A) binding proteins 
(PABPs).  When bound together PABP and Pan3 proteins act as positive regulators of the 
Pan2 activity in yeast 20.  A distinct feature of the human Pan3 (hPan3) protein is the 
presence of a kinase domain, identified by computational methods in residues 302-549; 
however, the functional significance of this domain in the regulation of PAN complex is 
not clear yet 16.   
     Shyu and colleagues 21 studied the role of Pan3 in mRNA deadenylation and decay in 
mammalian cells and demonstrated that it helps recruit Pan2, Ccr4 and Caf1 proteins to 
the processing bodies (P-bodies), which represent cytoplasmic foci containing proteins 
involved in mRNA metabolism 22.  This study demonstrated that knockdown of Pan3 
gene in NIH3T3 cells using siRNAs was associated with a reduction in P-bodies with 
little or no effect on the first phase of deadenylation.  Another important observation was 
that Pan3 knockdown has a differential effect on the mRNA decay and resulted in: 1) 
increased overall stability of the premature termination codon-containing mRNAs which 
are degraded through nonsense mediated decay (NMD), and in 2) accelerated decay of 
AU-rich elements (AREs)-containing mRNAs and stable β-globin message 21.  The two 
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later transcripts are usually degraded through two major paths of mRNA decay 
recognized in mammalian cells, mRNA decay directed by AU-rich elements and decay of 
stable transcripts respectively. 
     Based on the findings from the genetical-genomics approach we decided to further 
investigate the role of Pan3 gene in atherosclerosis as a plausible candidate gene for 
Ath24 QTL.  Our hypothesis is that the proteins encoded by the AKR and DBA/2 Pan3 
alleles differ from each other either at structural or expression level.  Structurally, it 
might be possible that the protein encoded by the AKR Pan3 allele has a loss of function, 
or that the DBA/2 isoform has a detrimental gain of function.  In both scenarios, 
differences between Pan3 gene/transcript/protein in AKR versus DBA/2 strains might 
result in changes in the rate of decay for transcript(s) playing a role in atherosclerosis.   
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MATERIALS AND METHODS 
General Methods 
Plating and culturing bone marrow-derived macrophages  
     Bone marrow-derived macrophages from parental strains, AKR and DBA/2, as well as 
Pan3 wild type (wt, Pan3 +/+) and/or hemizygous mice (Pan3 -/+) were frequently used to 
isolate DNA or RNA, prepare protein lysates and/or other purposes.  Mice were 
sacrificed by CO2 inhalation, femoral and humeral bones were removed from each mouse 
and placed in a sterile culture cell dish (Catalog # 353001, BD, Franklin Lakes, NJ), and 
put on ice.  Monocytes were flashed out of the bones into a 50 ml sterile conical tube 
(Catalog # 352098, BD Franklin Lakes, NJ) by using a 10 ml syringe (Catalog # 309604, 
BD, Franklin Lakes, NJ) with a 26 gauge 3/8" needle (Catalog # 305110, BD, Franklin 
Lakes, NJ) filled with sterile Dulbecco’s modified Eagles’s medium (DMEM, ordered 
from the media core at Lerner Research Institute) with no additional compounds added to 
it.  This and subsequent steps of the protocol, except centrifugations, were performed in a 
sterile hood.  Upon collection, cells were centrifuged for 5-6 minutes at 1,200 rotations 
per minute (rpm) at 4oC temperature.  Media was aspirated off the tube and cells were 
washed twice with 10 ml sterile phosphate buffered saline (PBS) solution at room 
temperature (RT).  After washing steps, the cells were resuspended in sterile filtered 
DMEM with 0.2% weight/volume (w/v) bovine serum albumin (BSA) (Sigma-Aldrich, 
St. Louis, MO).  Even aliquots of cells’ suspension were plated into three to six 100-mm 
tissue culture dishes (Catalog # 0875712, Fisher, Pittsburgh, PA) and allowed to adhere 
for two to four hours at 37oC in a culture cell incubator.  Media and non-adherent cells 
were aspirated off and the remaining cells were cultured in sterile-filtered bone marrow 
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macrophages growth media consisting of DMEM, 7.6% fetal bovine serum (FBS) 
(Catalog # BS 3031, Valley Biomedical, Winchester, VA), 15% L-cell conditioned 
media* (which serves as a source of macrophage colony stimulating factor, MCSF) and 
0.76% penicillin/streptomycin mixture (5000U/ml pen-G and 5000 μg/ml strep sulfate) 
for two weeks.  Cell media was replaced every two-three days and after two weeks cells 
had proliferated, grown and differentiated into confluent bone marrow-derived 
macrophages (BMM). 
*L-cell conditioned media is prepared in our lab by incubating L-cells with DMEM, 10% FBS and ~1% 
Pen/Strep mixture (5 ml) at 37oC in a cell culture incubator.  The media is collected and replaced with new 
one every 2-3 days.  The collected media is sterile filtered, aliquoted in 100 ml and stored in -20oC       
 
Harvesting cells 
     At two weeks time (14 days), the media was removed and the BMM cells were 
washed twice with ice-cold PBS.  Then, cells were scrapped in 1 ml ice-cold PBS and 
transferred to 1.5 ml microcentrifuge tubes.  Cell pellets were obtained by centrifugation 
in a microcentrifuge at 5,000 rpm for 2 minutes at RT.  After aspirating PBS the cell 
pellets were kept on ice for subsequent use or stored in -80oC.   
 
Isolation of DNA from cell pellets 
     DNA from BMM cell pellets was isolated by using DNeasy Blood and Tissue kit 
(Catalog # 69504, Qiagen, Valencia, CA) following the manufacturer’s instructions.  
Isolation of DNA from mouse ear, liver and/or tail for genotyping  
     The protocol followed for DNA isolation from mouse tissue is explained in details in 
Chapter 2, Materials and Methods section.  
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Isolation of RNA from animal cell pellets or tissue 
     In the course of this project, total RNA was frequently isolated from BMM cell pellet 
and liver tissue by using RNeasy Mini Kit (Catalog # 74104, Qiagen, Valencia, CA), 
following the manufacturer’s guidelines.  On-column digestion was performed to remove 
the genomic DNA by using RNase-free DNase (Catalog # 79254, Qiagen, Valencia, CA).  
The DNase itself is removed in the subsequent washing steps.  Total RNA was eluted in 
50 μl RNase-free water and quantified.  RNA purity was tested by incubating 200-500 ng 
of total RNA at 37oC (total volume brought to 10 μl with RNase-free water).  After 
incubation RNA samples were run on a 1.2% agarose/Ethidium bromide gel and the 
presence of intact 18S and 28S ribosomal RNA bands verifies that total RNA is intact 
from RNases.  Total RNA samples were stored in -80oC. 
     To isolate total RNA from liver tissue, the selected mouse was euthanized by CO2 
inhalation. Then a midline incision of the skin was made and the peritoneal membrane is 
cut to expose the diaphragm and internal organs, including liver.  A 10 ml saline 
perfusion (with PBS) was performed with a 26 gauge 3/8” needle inserted at the left 
ventricle of the heart; the right atrium clipped to drain the blood into the chest cavity.  
After perfusion a few 3-mm-cube (or up to 30 mg) liver pieces were cut and put in 2 ml 
cryogenic vials (Catalog # 430659, Corning Incorporated, Corning, NY).  The vials were 
put immediately in liquid nitrogen to flash freeze the tissues and preserve RNA.  To 
disrupt the tissue and homogenize the lysate one of the frozen liver pieces was put in 650 
μl of RLT buffer mixed with β-mercaptoethanol (10 μl for 1 ml RLT buffer).  
Homogenization and subsequent steps, including on-column DNA digestion, were 
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performed following the manufacturer’s instructions.  Total RNA concentration was 
measured and its purity was tested as explained above. 
  
Genotyping of the Pan3 gene coding sequence and its upstream promoter region 
     Twenty-eight primer pairs (Appendix 3A) were designed to amplify the Mus musculus 
Pan3 gene coding region, including a 2.5 kilobases (Kb) sequence upstream the 5’ end of 
Pan3 gene, using Primer Select from LASERGENE software package (DNASTAR, 
Madison, WI).  The primers were designed to amplify the entire exonic sequence for each 
of the 17 exons (number 2 to 18), including their flanking intronic sequences (50-100 
nucleotides on the 5’ and 3’ ends of each exon).  Several primer pairs were designed to 
amplify overlapping fragments of 400-600 bp in size for the longest sequences at the 
promoter region/exon 1 and exon 19, (2,620 and 2,132 base pairs, respectively) of Pan3 
gene.  Primers were synthesized by IDT (Integrated DNA Technologies, Coralville, IA) 
and diluted with sterile H2O to 100 pmol/µl stock solution.  Liver DNA from F1 mice 
(which contains one copy from each of the parental alleles), AKR and DBA/2 apoE-
deficient mice was isolated as explained above and used as a template for PCR reactions.  
PCR reactions for each primer pair and DNA template were prepared in sterile 0.2 ml  
PCR tubes (Catalog # C18000, Denville Scientific, Metuchen, NJ) in a total volume of 25 
μl by combining 2.5 μl of 10X reaction buffer, 1 μl of 25 mM magnesium chloride 
(MgCl2), 2 μl of 2.5 mM dNTPs mixture, 0.25 μl of 100 pmol/ μl forward primer 
solution, 0.25 μl of 100 pmol/ μl reverse primer solution, 0.25 μl of JumpStart Taq 
Polymerase (Catalog # D4184, Sigma-Aldrich, St. Louis, MO), 17.25 μl sterile PCR-
grade water and 1 μl DNA template (concentration ranged from 10 to 250 ng/μl).  A 
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control reaction with no template DNA was included for each primer pair.  The tubes 
were put in a thermal cycler preheated to 94oC and PCR reactions were run under the 
following conditions: initial denaturation at 94oC for 1 minute; 35 cycles of: denaturation 
at 94oC for 30 seconds, annealing at primer pair’s specific annealing temperature 
(Appendix 3A) for 45 seconds and elongation at 72oC for 45-60 seconds (depending on 
the expected size of the PCR product); and a final elongation step at 72oC for 7 minutes.  
After amplification 10 μl of the PCR reaction were mixed well with 2.5 μl of 6X 
bromophenol blue DNA loading dye (0.25% w/v bromophenol blue and 30% v/v 
glycerol) and run on a 1.2% agarose/EthBr gel for 50 minutes at 145 V.  PCR products 
were column purified using QIAquick PCR purification kit (Catalog # 28104, Qiagen, 
Valencia, CA) and submitted to the Genomic Core of Lerner Research Institute for 
sequencing as an 11 μl premix consisting of 10 ng PCR product/100 bp, 10 pmol forward 
or reverse primer and sterile H2O.  The sequencing data were aligned with the original 
Mus musculus Pan3 genomic sequence*, retrieved from Entrez Gene of National Center 
for Biotechnology Information (NCBI) 23 website, using SeqMan program from 
LASERGENE software package to detect the presence of SNPs which appear as 
overlapping peaks in the sequence trace plots (made visible by using FinchTV software, 
Geospiza, Seattle, WA).  
*Current NCBI Reference Sequence ID and position on the chromosome 5: NC_000071, 148,242,465-
148,360,072.  
Analysis of sequencing data from Perlegen and other online sources  
     Meanwhile, Perlegen Sciences conducted a study 24 of genome-wide DNA variation in 
15 commonly used, genetically diverse strains of inbred laboratory mice including AKR 
and DBA/2 strains.  The data were downloaded from the website (http://mouse.perlegen. 
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com/mouse/download.html) and the SNPs reported in the region that covers the Pan3 
gene including 5 Kb upstream and downstream flanking regions were compared between 
AKR and DBA/2 strains. 
     The list of SNPs identified as different between the two strains was constantly updated 
using SNP query in Mouse Phenome Database website (http://www.jax.org/phenome) 
which includes sequencing data from multiple projects 25. 
 
Northern blotting with non-radioactive PCR-amplified probes 
     Probe preparation:   Three different biotinylated probes were prepared to hybridize 
with Mus musculus Pan3 mRNA; two single-stranded DNA probes synthesized through 
asymmetric PCR (antisense primer to sense primer ratio was equal to 100 to 1) and one 
double-stranded DNA probe synthesized through regular PCR (antisense to sense, 1:1).  
The first strand cDNA was used as template which was synthesized from BMM total 
RNA by using StrataScript first-strand synthesis system (Catalog # 200420, Stratagene, 
La Jolla, CA) following the manufacturer’s guidelines. 
     Pan3 mRNA sequence was blasted (NCBI Blast) 23 prior to designing the probes in 
order to determine the regions that would be specific to Pan3 transcript only.  The first 
probe, a 341 bp long-ssDNA, was designed to recognize the beginning of Pan3 transcript 
and hybridize with exons 2, 3, 4 and 5 sequence (forward primer: 5’-ATGGAGGTGCT-
TTAACTGATG-3’, reverse primer: 5’-AGAGAAGGCAGACATATTTGACT-3’).  The 
second northern blotting probe, a 346 bp long-ssDNA, was designed to recognize and 
hybridize to the 5’ end of Pan3 transcript’s last exon (exon 19, forward primer: 5’-
GATGCTTTGCGGCCTGACTCTG-3’, reverse primer: 5’-TCCCCACATTTCTTCCC-
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AGGTATG-3’); and, the third probe, a 288 bp long-dsDNA, was designed to hybridize to 
the 3’ end of the exon 19 (forward primer: 5’-TGAGAGTATCGAATGAAGGATGTG-
3’, reverse primer: 5’-AACAGGGTTAAAGATGAGCAACAG-3’).  To optimize the 
hybridization conditions the ratio of dCTP to biotin-11-dCTP (Catalog # NEL 538/NEL 
538A, PerkinElmer, Boston, MA) in the PCR reactions was maintained at 2/3 to 1/3.  The 
asymmetric PCR reactions were prepared as follows: 2 μl of 10X reaction buffer, 0.8 μl 
of 25 mM MgCl2, 2 μl of  1 mM dATP, 2 μl of 1 mM dTTP, 2 μl of 1 mM dGTP, 1.3 μl 
of 1 mM dCTP, 0.7 μl of 1 mM biotin-11-dCTP, 1 μl of 0.1 μM/μl sense strand primer, 1 
μl of 10 μM/μl antisense strand primer, 0.25 μl of JumpStart Taq Polymerase (2.5 U/μl), 
5.95 μl sterile PCR-grade water and 1 μl cDNA template (synthesized from either AKR 
or DBA/2 BMM total RNA, as explained above).  To amplify the dsDNA northern probe 
3 the PCR reactions were prepared as explained above for asymmetric PCR with the 
difference that antisense and sense strand primers were of equal concentrations (10 μM/μl 
each primer).  PCR reactions were run at the following conditions: initial denaturation at 
94oC for 1 minute; 40 cycles of: denaturation at 94oC for 30 seconds, annealing at primer 
pair’s specific annealing temperature (56.5oC for northern probes 1 and 2, and 54oC for 
northern probe 3) for 45 seconds and elongation at 72oC for 45 seconds; and a final 
elongation step at 72oC for 7 minutes.  After amplification, 5 μl of the PCR reaction 
mixed with 1 μl of 6X bromophenol blue DNA loading dye, were run and visualized on a 
1.2% agarose/EthBr gel.  The remaining volume of the PCR products were column 
purified using QIAquick PCR purification kit, quantified and used directly for 
hybridization and/or stored at -20oC for future use. 
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     Gel electrophoresis, transfer, hybridization and signal detection:  Total RNA was 
isolated from BMM cells of AKR and DBA/2 apoE-deficient strains (including both 
genders, cultured and collected as explained above) using miRNeasy Mini Kit (Catalog # 
217004, Qiagen, Valencia, CA) following the manufacturer’s instructions.  The 
advantage of using this kit is that besides longer RNA transcripts it isolates RNAs shorter 
than 200 nucleotides in length.  RNA concentration for each sample was measured using 
the nanodrop and its purity from contamination with RNases was tested.  Aliquots of total 
RNA (5 to 8 ng/lane) were used for the northern blotting.  The gel and samples for the 
Northern blotting were prepared following the detailed instructions included in the 
NorthernMax® Kit (Catalog # 1940, Ambion, Austin, TX).  RNA samples were mixed 
with the loading dye and heated at 65oC for 5 minutes before loading them on the 
denaturing gel and run for three hours at 85 V.  After gel electrophoresis, total RNA was 
transferred downwardly on a positively charged nylon membrane, BrightStar-Plus 
membrane (Catalog # AM10100, Ambion, Austin, TX), following manufacturer’s 
guidelines.  To covalently link the RNA molecules to the amine groups on the surface of 
the membrane, the damp membrane was wrapped in a transparent plastic sheet (Saran 
wrap) and exposed to approximately 120 millijoules/cm2 UV light (the optimal option on 
a calibrated UV-crosslinker).  The membrane was prehybridized with ULTRAhyb buffer 
for 30 minutes at 48oC, then 10-15 ng of probe were added to each northern blot and left 
to hybridize overnight at 48oC. 
     After hybridization, the northern blots were removed from the hybridization buffer 
and washed twice for 5 minutes each at RT with low stringency wash solution 
(NorthernMax® Kit), followed by two 15 minutes washings at 55oC with high stringency 
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buffer solution.  BrightStar® BioDetect™ nonisotopic detection kit (Catalog # AM1930, 
Ambion, Austin TX) was used to detect the hybridized biotinylated probes following the 
manufacturer’s instructions.  The film was exposed to the membrane for approximately 2 
hours before developing it.  
 
Exon skipping and/or intron retention 
     Nine primer pairs were designed to PCR amplify and sequence the exons 2 to 18 of 
the Pan3 mRNA, including a few base pairs from the first exon’s 3’ end and ~130 bp at 
the exon 19’s 5’ end.  The primer pairs were designed so that each of the pairs (except the 
ones that include exons 1 and 19) would amplify the entire sequence of 3 consecutive 
exons (for example: exons 2, 3 and 4) and, the following primer pair would amplify the 
entire sequence of 3 consecutive exons, including the last exon amplified by the previous 
pair (for example: exons 4, 5 and 6).  A schematic view of the design is shown in Figure 
3.1.  To increase the specificity of PCR products each primer was blasted towards the 
mouse genome 23, and only the primers that did not align to other regions of the genome 
were selected to be synthesized and used for PCR amplifications.  Complementary DNA 
(cDNA) synthesized by BMM total RNA of AKR and DBA/2 strains as explained above, 
was used as a template for PCR reactions.  The names, sequences and the optimal 
annealing temperate for each designed primer pair are given in Appendix 3B. 
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       PCR reactions for each 
primer pair and DNA template were prepared in sterile 0.2 ml  PCR tubes in a total 
volume of 50 μl by combining 5 μl of 10X Easy-A reaction buffer, 4 μl of 2.5 mM 
dNTPs mixture, 1 μl of 100 ng/ μl forward primer, 1 μl of 100 ng/ μl reverse primer, 0.5 
μl of 5U/μl Easy-A High-Fidelity cloning enzyme (Catalog # 600402, Stratagene), 37 μl 
sterile PCR-grade water and 1.5 μl cDNA template.  A control reaction with no template 
DNA was included for each primer pair.  The tubes were put in a thermal cycler 
preheated at 95oC and PCR reactions were run under the following conditions: initial 
denaturation at 95oC for 2 minutes; 40 cycles of: denaturation at 95oC for 40 seconds, 
annealing at primer pair’s specific annealing temperature for 30 seconds and elongation 
at 72oC for 3 minutes; and a final elongation step at 72oC for 7 minutes.  After 
amplification 10 μl of the PCR reaction, mixed with 2.5 μl of 6X bromophenol blue DNA 
loading dye were run on a 1.2% agarose/EthBr gel for 50 minutes at 145 V.  PCR 
products were column purified using QIAquick PCR purification kit or QIAEX II Gel 
Extraction kit (Catalog # 20021, Qiagen) and submitted to the Genomic Core of Lerner 
Research Institute for sequencing.  The sequencing data were analyzed and the sequences 
Exons 2, 3 & 4
Exons 4, 5 & 6
Exons  1     2  3      4     5     6    7       8      9
 
 
Figure 3.1: Schematic diagram representing the experiment 
designed to detect exon skipping and/or intron retention.  
Consecutive exons of a hypothetical mRNA/cDNA are shown in 
different colors (purple and black) 
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obtained from AKR and DBA/2 were compared with each-other and with the reference 
Pan3 mRNA sequence (NM_028291.2). 
 
Identification of possible alternative 5’ and 3’ ends for Pan3 transcript(s) 
     Total RNA was isolated from bone marrow macrophages cells of the female 
individuals from AKR and DBA/2 strains using RNAse Easy Kit (Qiagen), as explained 
above. 
Primer design:  Three anti-sense and three sense gene specific primers (GSP) were 
designed for 5’ rapid amplification of cDNA ends (RACE) and 3’ ends, respectively.  For 
best amplification results, GSP primers were designed to be 23-28 nucleotides long, have 
a high GC content (50% and above), a melting temperature (Tm.) of equal or greater than 
64oC.  To increase the specificity of PCR products the primers were blasted towards the 
mouse genome (NCBI Blast) 23 and the ones that did not align to other regions in the 
genome were selected to be synthesized and used for PCR amplification of 5’- race and 
3’- race cDNA samples (except for MmPan3-5’race primer no. 4, which partially aligns 
to other genomic regions).  An additional Pan3 gene specific sense primer, designed for 
other purposes/experiments, was also used for amplification of 3’ ends (MmPan3-5’race 
primer no. 3a).  RACE gene specific primers’ names, sequences and their respective Tm 
are provided in Table 3.1.   
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Table 3.1:  Gene specific primers for 5’ and 3’ RACE  
Primer’s name Direction Sequence Annealing 
temperature 
MmPan3-3’race no. 1 Sense 5’-CACTCCTGCCAATAACCCTGCTCCTCA-3’ 65.1oC 
MmPan3-3’race no. 2 Sense 5’-TTCTTCATGGCCGACGAGCTCCGACAGG-3’ 66.8oC 
MmPan3-3’race no. 3 Sense 5’-CGAGAAGAGCGTGCTGGTGGTGACATAC-3’ 64.0oC 
MmPan3-5’race no. 3a Sense 5’-TGGGAACAATCAACGAGAGG-3’ 54.2oC 
MmPan3-5’race no. 4 Antisense 5’-TGTCGGAGCTCGTCGGCCATGAAGAAGG-3’ 66.8oC 
MmPan3-5’race no. 5 Antisense 5’-CCGGTTGGGAGGTGGCAGTGGTTC-3’ 66.1oC 
MmPan3-5’race no. 6 Antisense 5’-TGGCCTTCTCAGATGACCGACCCTACAG-3’ 64.4oC 
 
     Rapid amplification of cDNA ends (RACE). SMART™ Race cDNA Amplification kit 
(Catalog # 634914, Clontech, Mountain View, CA) was used to determine if there are 
alternative 5’ and/or 3’ ends to the Pan3 transcript(s) in BMM.  Separate 5’ and 3’ first-
strand cDNA synthesis reactions were prepared as described in the manufacturer’s 
manual starting with 1 μg BMM total RNA from AKR or DBA/2 strains, including a 
positive control with the provided human placental total RNA.  The reactions were 
prepared in 0.2 ml sterile PCR tubes, mixed well, spun down and incubated at 42oC for 
1.5 hours in a thermal cycler.  Then each of the first-strand reactions were diluted with 15 
μl of Tricine-EDTA buffer (provided with the kit) and the tubes were heated to 72oC for 
7 minutes to stop the reaction.  Synthesized 5’- or 3’-RACE cDNA was purified by using 
QIAquick PCR purification kit following manufacturer’s instructions.  At this point the 
5’- and 3’-RACE cDNA samples were either kept on ice for subsequent use or stored at -
20oC. 
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    Reactions for PCR amplification of cDNA ends were prepared as specified in the 
manufacturer’s instructions, using Clontech’s Advantage 2 PCR kit (Catalog # 630296).  
PCR reactions were run at the following conditions: initial denaturation at 94oC for 1 
minute; 35 cycles of: denaturation at 94oC for 30 seconds, annealing at GSP’s melting 
temperature for 30 seconds and elongation at 72oC for 3 minutes (elongation time for 
amplification with MmPan3-3’race primer no. 1 was adjusted to 4 minutes because the 
PCR product’s expected length was higher than 3 Kb (1 minute per Kb); and a final 
elongation step at 72oC for 7 minutes. 
     Characterization of RACE products.  PCR amplified products were run on a 1.2% 
agarose/EthBr gel for 55 minutes at 135 V, and the bands of interest were gel purified 
using QIAEX II Gel Extraction kit (Catalog # 20021, Qiagen).  The isolated and purified 
DNA products were then cloned directly into a T/A PCR cloning vector, using pGEM®-T 
Easy vector system ( Catalog # TM042, Promega, Madison, WI) following the 
manufacturer’ guidelines.  The ligation reactions were incubated overnight at 16oC in a 
thermal cycler.  The next day, 2μl of ligation reaction were used to transform DH5α 
competent cells (Catalog # 18265-017, Invitrogen, Carlsbad, CA), including the 
appropriate controls, a DNA insert provided with the ligation kit and a vector self-ligation 
reaction.  After transformation the cells were incubated with 500-600 μl Miller’s LB 
Broth (LRI Media Core) for 1.5 hours in a 37oC water bath.  At this point, 100 μl of each 
transformation culture were plated onto LB/ampicillin/IPTG/X-Gal plates and incubated 
in a 37oC incubator for 16-18 hours.  White colonies were cultured overnight in 3 ml LB 
broth media with ampicillin in a 37oC shaking incubator.  DNA was isolated from each 
selected colony’s miniprep using QIAprep Spin Miniprep kit (Catalog # 27106, Qiagen) 
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following the manufacturer’s guidelines. DNA samples were screened to identify the 
ones with the insert of interest, which were then submitted for sequencing with T7 (5’-
TAATACGACTCACTATAGGG-3’) and SP6 (5’-ATTTAGGTGACACTATAGAA-3’) 
primers to the LRI Genomic Core.  The sequencing data were analyzed and compared to 
the reference sequence of Pan3 mRNA (4,314 bp long, NCBI reference sequence ID: 
NM_028291.2).  This record is currently updated (December, 2009) to NM_028291.4 
representing a new mRNA for Pan3 gene that includes 314 additional base pairs (4628 
bp) at the 5’ end.  
 
RNA sequencing 
     Total RNA was isolated from AKR and DBA/2 BMM and 10 μg aliquot per sample 
were submitted to the Genomic Core, Lerner Research Institute to build the libraries for 
ultra-high throughput sequencing of cDNA.  Briefly, total RNA was subjected to two 
rounds of hybridization with Sera-Mag magnetic oligo(dT) beads (Illumina) to isolate the 
poly(A) containing mRNA molecules.  Then the poly(A)-containing mRNA molecules 
were fragmented by treatment with divalent cations (5X fragmentation buffer) under 
elevated temperatures (94oC for 5 minutes).  The treatment was stopped by adding 2 μl of 
fragmentation stop solution (included in the Illumina mRNA-Seq sample preparation Kit, 
Catalog # RS-930-1001).  After the treatment the samples were centrifuged at 14,000 rpm 
for 25 minutes at 4oC to pellet the RNA fragments and washed afterwards with 70% 
ethanol.  The cleaved RNA fragments were reverse transcribed using SuperScript II and 
random primers to synthesize first strand cDNA.  This step was followed by the removal 
of RNA template using RNaseH and the cDNA second strand synthesis using DNA 
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Polymerase I.  The cDNA fragments were ligated to the adapters, purified and enriched 
by PCR amplification to create the final cDNA library which was then submitted to the 
Ohio State University for sequencing.  The libraries were sequenced as single ends 51-
mers, and the reads were aligned and mapped to the mouse genome on UCSC Genome 
Browser by using TopHat files and mapping software.  The software maps the short 
RNA-Seq reads to the mouse genome using the ultra high-throughput short reader aligner 
“Bowtie” 26 and identifies splice junctions between exons 27.         
 
Generation of Pan3 allele hemizygous/knockout mice  
     BayGenomics created the Pan3 knockout allele by random insertion of the gene 
trapping pGT1Lxf vector, a splice-acceptor-β-geo vector 28, 29,  in a 129 strain (agouti coat 
color) derived embryonic stem cell (ES) line (BGB533 Cell line, BayGenomics).  The 
cells with one disrupted Pan3 allele (Pan3-/+) were injected into the C57BL/6 (black coat 
color) host blastocysts and implanted in female mice to yield chimeric progeny 
(performed as a fee for service at UC Davis).  The degree of chimerism is estimated by 
the percentage of the agouti coat color.  Highly chimeric males were bred to C57BL/6 
females and coat color was used to detect germline transmission.  Agouti pups are the 
progeny where the germline transmission occurred, and black pups are the pups where no 
germline transmission occurred.  The progeny selected (agouti coat color) for germline 
transmission (Pan3-/+ genotype) were shipped to the Cleveland Clinic, Biological 
Research Unit (BRU).   
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Development of a PCR-based screening for the different Pan3 genotypes (Pan3+/+, 
Pan3-/+ and Pan3-/-)  
     Once the precise insertion site of the trapping vector was determined (explained in 
details in the Results section), a multiplex genotyping PCR was developed to identify the 
Pan3 genotypes; wild type (+/+), hemizygous (-/+) and knockout (-/-).  The names and 
sequences of the three primers used for this purpose are: Pan3-Int5-wt forward, 5’-
CTGCTCATTTGGCTATTAAAGGATTT-3’; Pan3-Int582 forward primer, 5’-
GGTGCGGGCCTCTTCGCTATTA-3’; Pan3-Int582 reverse primer, 5’-ACTTGCCGA-
GCAGAAGGTAAGGTCCTA-3’.  Genotyping PCR reactions for each DNA sample 
isolated from a piece of ear (punched when mice are weaned at 21 days after birth) were 
prepared in 0.2 ml PCR tube in a total volume of 12.5 μl by mixing: 1.25 μl of 10X 
reaction buffer, 0.5 μl of 25 mM MgCl2, 1 μl of 2.5 mM dNTPs mixture, 0.125 μl of 100 
pmol/ μl Pan3-Int5-wt forward primer, 0.125 μl of 100 pmol/ μl Pan3-Int582 reverse 
primer, 0.10 μl of 100 pmol/ μl Pan3-Int582 forward primer 0.15 μl of JumpStart Taq 
Polymerase, 8.75 μl sterile PCR-grade water and 0.5 μl DNA template (concentration 
ranged from 10 to 250 ng/μl).  Two positive control reactions, one that amplifies the wild 
type and the second that amplifies the hemizygous genotype bands; together, with one 
negative control reaction with no template DNA were included each time the genotyping 
PCR was run.  The tubes were put in a thermal cycler preheated to 94oC and PCR 
reactions were run under the following conditions: initial denaturation at 94oC for 1 
minute; 30 cycles of: denaturation at 94oC for 30 seconds, annealing at 57.7oC for 45 
seconds and elongation at 72oC for 45 seconds; and a final elongation step at 72oC for 7 
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minutes.  After amplification the PCR reaction were run on a 1.2% agarose/EthBr gel for 
50 minutes at 145 V.      
 
Backcrossing of Pan3-/+ onto the DBA/2 inbred apoE-deficient mice  
     To generate Pan3-/+ mice on the inbred DBA/2 apoE-deficient background, Pan3-/+ 
mice were bred to DBA/2 apoE-deficient mice for several generations (currently, we are 
at N9 generation).  First, each new progeny was PCR genotyped (as explained in the 
previous experiment) to identify hemizygous (Pan3-/+) mice.  To speed the process and 
obtain Pan3-/+ mice on DBA/2 apoE-deficient background by the N5 or N6 generation, 
DNA from identified Pan3 hemizygous mice was submitted to the Genomic Core for 
Illumina Golgen Gate mouse genotyping assay, which genotypes 1,450 SNP for each 
sample in one experiment.  Genotyping data from each sample, made available through 
BeadStudio Illumina software (Illumina, San Diego, CA) were analyzed and compared to 
the controls (2 DNA samples from inbred DBA/2 apoE-deficient mice).  The mice with 
the highest degree of similarity with inbred DBA/2 apoE-deficient strain genotype were 
used for further backcrossing. 
 
Quantification of Pan3 gene expression in Pan3+/+, Pan3-/+ and Pan3-/- mice 
     Bone marrow macrophages were cultured from eight wild type and eight Pan3 
hemizygous mice (4 females and 4 males for each genotype) bred onto the DBA/2 apoE-
deficient background (N8 generation).  The mice were sacrificed at 14 weeks of age by 
CO2 inhalation.  BMM cell pellets were used to isolate total RNA as explained above.  In 
addition, the expression of Pan3 gene by quantitative Real-Time PCR (qPCR) was tested 
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in four samples from each of the parental strains and 15 samples from the F2 female 
cohort; 5 for each of the three genotypes for the closest marker to the Pan3 gene 
(rs13478585, located at 147.39 Mb in the exon 2 of G-couples protein receptor 12 gene) 
for which BMM total RNA was available.  Total BMM RNA (1 μg) from each of the 
samples included was used to synthesize first –strand cDNA with random primers, using 
SuperScript® VILO cDNA synthesis kit (Catalog # 11754, Invitrogen) following the 
manufacturers’ instructions.  Synthesized cDNA was purified by using QIAquick PCR 
Purification kit and used as a template in quantitative PCR (qPCR).  Two different gene 
expression TaqMan assays were used to quantify the expression level of Pan3 transcript 
in BMM, one pre-designed (Mm00511574_m1, Applied Biosystems, Foster City, CA) 
which amplifies the junction between exons 18 and 19 and a custom made assay that 
amplifies the junction between exons 2 and 3 (sequences of primers and probes designed 
for this assay are given in Appendix 3C.  Pan3 gene expression was measured relative to 
the beta-actin endogenous control in all the samples as previously described 30.  
 
Phenotypic studies  
     To quantify the lesion size and determine total and HDL cholesterol levels, Pan3 wild 
type and hemizygous mice on the DBA/2 apoE-deficient background were fed with a 
chow diet (2018 Teklad Global 18% Protein Rodent Diet, Harlan Laboratories) and 
sacrificed at 14 weeks (N6 and N7 generation combined) and 16 weeks (N9 generation) of 
age by CO2 inhalation.  A detailed description of the protocol followed in sampling 
blood, hearts and/or other data such as body weight, heart weight, etc., as well as 
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quantifying lesion size, total and HDL cholesterol is provided in Chapter 2, Materials and 
Methods sections. 
     Liver tissues were collected and flash-frozen in liquid nitrogen, and femoral and 
humeral bones were removed to harvest bone marrow monocytes (as explained above) 
from a selected subgroup of mice (8 Pan3+/+ and 8 Pan3-/+ mice, four of each gender). 
Statistical analysis 
     Kolmogorov-Smirnov (KS) tests were performed to assess whether the phenotype 
values exhibited normal Gaussian distributions.  For normally distributed phenotypes, 
parametric unpaired t-test was performed to compare the values between two groups of 
mice; and, Mann-Whitney nonparametric test was performed when the data failed to 
show normal distribution of the phenotypes.  Statistical analyses were performed using 
GraphPad Prism software, version 4.0 for Windows (GraphPad Software, San Diego, 
California, www.graphpad.com).  
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RESULTS 
Part 1: Detection of Pan3 mRNA Differences between AKR and DBA/2 apoE-deficient 
Strains in Bone Marrow Macrophages 
     The Smith laboratory identified Pan3 as the transcript whose expression was best 
correlated (r2 = 0.20) with the aortic lesion size (unpublished data).  Pan3 gene maps to 
chromosome 5 at 148.2 Mb at the peak of Ath24 QTL (~147.4 Mb, Figure 3.2) and it 
represents our prime candidate gene. 
 
     Our study was based on the hypothesis that the proteins encoded by the AKR and 
DBA/2 Pan3 alleles differ from each other either at structural or expression level.  To test 
the hypothesis and detect any structural DNA or mRNA variants that differ between 
AKR and DBA/2 strains we performed several experiments, the results of which are 
presented in this section.  Most of the experiments were performed by using bone marrow 
0 10 20 30 40 50 60 70 80 90 10
0
11
0
12
0
13
0
14
0
15
0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0 1 LOD interval  (137-149 Mb)
Pan3 gene
Chr 5 (Mb position)
LO
D
 s
co
re
 
 
Figure 3.2: Genetic map of the chromosome 5 and Pan3 gene location within Ath24 QTL.  
The graph represents a genetic map for the association of aortic lesion area size with the 
chromosome 5 markers. The peak at the distal end of chromosome 5 represents Ath24 QTL 
together with its 1- LOD drop-off confidence interval shown by the red line. As illustrated Pan3 
gene is located at the peak of Ath24 QTL interval. 
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macrophages as they represent a crucial cell type involved in the pathophysiology of 
atherosclerosis.    
 
Identification of SNP differences between AKR and DBA/2 Pan3 alleles  
     Two coding synonymous SNPs were identified by direct sequencing, one in exon 7 
(GAT to GAC) coding for aspartic acid (ASP) and the second mutation in exon 17 (TTG 
to CTG) coding for leucine (LEU), both shown in Figure 3.3.   
  
     These two coding region SNPs were also found in the Perlegen database together with 
other SNPs located in the non-coding regions (introns) of the Pan3 gene (Appendix 3D).  
In total, there are 56 SNPs identified as different between AKR and DBA/2 strains in the 
A 
 
B 
 
 
Figure 3.3: Mus musculus Pan3 gene coding SNP differences found between AKR and 
DBA/2 strain; A) coding synonymous SNP located on exon 7 (C/T; aspartic acid); B) coding 
synonymous SNP located on exon 17 (C/T, leucine).  These results were generated by direct 
sequencing of F1 mice DNA. 
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Pan3 genomic sequence (including 5Kb upstream and downstream of Pan3 gene); 2 
coding synonymous, 48 intronic and 6 SNPs in the region downstream exon 19, which is 
the last exon of Pan3 gene).   
     The SNP in exon 7 is located 12 base pairs before the 3’ end of the exonic sequence, 
in proximity to a splice site.  To find other possible changes in the splicing regions or in 
the target binding sequences of the splicing complex factors, a search for SNPs located 
within 50 bp upstream and/or downstream the intron-exon junctions was performed.  
There were no other different SNPs located within 50 bp upstream or downstream intron-
exon junctions between the two strains.  Thus, the exon 7 SNP near the junction is the 
most likely SNP to play a role in splicing, although other SNPs can not be ruled out. 
     In addition, we identified two novel SNPs that were different between AKR and 
DBA/2 strain (Figure 3.4), located respectively at -1,145 and -1,423 bp upstream the 
Pan3 gene.  Analysis of the sequence upstream Pan3 gene containing the novel SNPs in 
JASPAR (http://jaspar.genereg.net), an open-access website which predicts transcription 
factors binding sites based on current information of experimentally demonstrated 
transcription binding site sequences 31, revealed that both SNPs were located in predicted 
transcription factor binding sites.  The SNP closest to the Pan3 gene was found to be 
located within a predicted binding site sequence for CCCTC-binding factor (Ctcf), a 
transcriptional regulator protein (Figure 3.4).  After comparing the sequencing data 
between the two strains we found that AKR strain carries the consensus A allele for the 
SNP while DBA/2 carries the C allele [gctcc(A/C)tcttttgacaa].  Ctcf is a nuclear protein 
that binds to different DNA target sequences and proteins, mostly known for its role as a 
transcription silencer.  However, recent studies have found that depending upon the 
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context of the site and the specific combination of the zinc finger proteins 32, Ctcf can act 
as an activator of transcription by binding to a complex containing the histone 
acetyltransferase (HAT) enzyme or can act as a transcription repressor by binding to a 
complex containing the histone deacetylase (HDAC) enzyme 23.  The second SNP was 
found to be located within a predicted binding site for runt-related transcription factor 1 
(Runx1).  DBA/2 strain carries the consensus C allele while AKR strain carries the T 
allele [cactg(C/T)ggttc].  Runx1 is involved in the development of normal hematopoiesis 
and act as an activator for the expression of a number of important regulator genes 
participating in this process 33. 
 
 
Searching for alternatively spliced variants 
     Several expressed sequence tags (EST) were found on the NCBI and University of 
California Santa Cruz (UCSC) Genome browser websites, providing preliminary 
…cactgCggttc….gctccAtcttttgacaa….tttcctc
-1,423 bp -1,145 bp +1 bp (exon 1)
Runx1 Ctcf
 
Figure 3.4: Two novel SNPs identified upstream Pan3 gene that are different between AKR and 
DBA/2 strains.  The first SNP is located at -1,423 bp upstream Pan3 gene [cactg(T/C)ggttc] and the 
second one is located at -1,145 bp upstream Pan3 gene [gctcc(A/C)tcttttgacaa].  Both SNPs were found to 
be located in predicted binding sites for Runx1 and Ctcf transcription factors.  Screen-shot of the Pan3 
gene and its genomic location was generated by UCSC Genome browser at http://genome.ucsc.edu/ 
 
 
80 
 
evidence that there may be alternatively spliced variants of the Pan3 gene.  Currently, 
there are reported 19 different ESTs for the Pan3 gene in C57BL/6 mouse strain, five of 
which are predicted to be translatable into proteins; AK012409 EST (NCBI protein 
ID/size, BAB28221/ 251 amino acids), AK028869 EST (BAC26161/ 107aa), AK153632 
EST (BAE32127/ 147aa), BC082547 EST (AAH82547/ 560aa) and BC082321 EST 
(AAH86321, 408aa) (information available at http://genome.ucsc.edu/ website 34).  No 
data were available for the AKR and DBA/2 strains, therefore experiments were 
performed to determine if there are alternatively spliced variants of Pan3 gene in bone 
marrow macrophages and identify any possible structural differences between the two 
strains. 
 
Determination of Pan3 transcript(s) size in bone marrow macrophages of AKR and 
DBA/2 apoE-deficient strains 
Northern blotting 35, 36 was performed to: 1) identify the canonical and possible new 
alternative transcripts of the Pan3 gene expressed in BMM of AKR and DBA/2 strains, 2) 
determine their respective molecular size, and 3) observe if there were differences in 
Pan3 transcript(s) between the two strains.  Three different Pan3 transcript specific 
probes were synthesized and used for hybridization and detection, one of which did not 
hybridize well with the transcript.  Of the two probes that hybridized well, the first probe 
was designed to recognize the beginning of Pan3 transcript while the second northern 
blotting probe would recognize and hybridize to the 5’ end of Pan3 transcript’s last exon 
(exon 19).   
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     There were two distinct bands identified by the probes (Figure 3.5) in both strains, 
female and male gender samples, one of ~5.07 Kb and a second band of ~ 5.63 Kb in 
size.  The smaller 5.07 Kb band might be the canonical Pan3 transcript.  Its size is 
predicted to be 4,314 base pairs and the difference observed might be explained either by 
the fact that Pan3 transcript migrates very close to the robustly expressed 28S ribosomal 
RNA (~ 4.7 Kb in size) and consequently the Pan3 band’s detection signal is slightly 
shifted or Pan3 canonical transcript is longer than what is predicted and reported in 
databases.  NCBI records have recently posted an updated version of the Pan3 transcript 
(NM_028291.4, updated on December 2009) that is ~4.6 Kb in size.  
     Interestingly, the ~5.6 Kb band was recognized by all the probes and it might 
represent a new Pan3 specific transcript expressed in BMM of AKR and DBA/2 strains.  
There were no gender differences regarding the number of detected bands and their 
respective sizes.  What remains unknown is the specific sequence of these two transcripts 
in both strains and whether there are other alternatively spliced transcripts of Pan3 gene 
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Figure 3.5: Results from Northern blotting of Pan3 transcript in AKR and DBA/2 strains 
BMM total RNA in males and females.  Black arrow points to the 28S ribosomal band, while 
blue arrows point to the Pan3 specific transcripts.  Images of the northern blotting with the third 
probe are not shown due to the detection signal’s weak intensity. 
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in BMM or other tissues of specific interest for the disease under study such as aortic 
endothelial cells and liver.      
     Based on this new evidence and the results from the database searches, we performed 
the following experiments to provide us with detailed information regarding the base pair 
content and structure of the newly identified and other possible Pan3 alternative 
transcripts in both strains.   
 
Exon skipping and/or intron retention 
     Messenger RNA splicing is an important post-transcriptional modification.  There are 
several types of common alternative splicing events and this experiment was designed to 
detect two of these, exon skipping and/or intron retention.  A detailed description of the 
experiment’s design is given in Materials and Methods section of this chapter.   
     Two new Pan3 specific bands were identified from PCR amplification of cDNA; both 
shown in Figure 3.6 (red arrows).  Sequencing data and blast analysis revealed that the 
first band, amplified with primers in exons  14 and 18, is longer than the expected size 
because it retains 74 base pairs from intron 14 (positioned between exons 14 and 15) of 
the Pan3 gene.  Theoretically, the new alternatively spliced Pan3 transcript (variant 1) 
might be translated into a truncated protein composed of 532 amino acids (Appendix 3E).  
Compared to the canonical Pan3 protein (NP_082567) it is 159 amino acids shorter, but 
the difference results from: 1) adding two novel amino acids at the end of the C-terminus 
(phenylalanine and glutamine, FQ) before the new stop codon, 2) modifying the 530th 
amino acid from lysine (L) to phenylalanine (F) and, 3) excluding last 161 amino acids 
from the C-terminus of the canonical Pan3 protein.      
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    The second band (~ 1 Kb), amplified by primers in exon 16 and 19, was found to be 
longer than the expected size because it retains intron 18 (positioned between exons 18 
and 19) of the Pan3 gene, which by itself is about 630 bps long.  It is very likely that the 
alternatively spliced Pan3 variant 2 represents the novel ~5.63 Kb Pan3 transcript 
identified also by Northern blotting as explained in the previous experiment.  Retention 
of the last intron introduces a premature stop codon and the corresponding alternative 
transcript was predicted to translate into a truncated protein composed of 687 amino 
acids.  Theoretically, the differences from the canonical Pan3 protein include exclusion of 
NDRNSN amino acids and introduction of two novel amino acids, glutamine (Q) and 
leucine (L) at the C-terminus.  Newly identified transcripts’ sequences and their 
respective protein’s amino acids content are given in Appendix 3E.  The band shown by 
green arrow was sequenced but turned out to be a nonspecific product whereas the rest of 
the bands have not been sequenced, yet.     
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          The only structural difference found between AKR and DBA/2 strains was 
rs32387906 SNP located in intron 18 (part of the alternatively spliced variant 2 
sequence); although, apparently with no direct effect on the protein’s composition of 
amino acids as the stop codon is located about 464 base pairs upstream of the 
abovementioned SNP.  
 
Identification of possible alternative 5’ and 3’ ends for Pan3 transcript(s) 
     Another direction in the search for alternative transcripts of any gene of interest is the 
detection of possible alternate 5’ and 3’ ends.  The purpose of this experiment was to 
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Figure 3.6: Newly identified alternatively spliced variants of the Pan3 gene in BMM of AKR and 
DBA/2 strains.  A) Amplification of Pan3 exons from cDNA, blue arrows point to the bands of the 
expected size, the red arrows point to unexpected Pan3 specific bands that were sequenced while the 
green arrow points to a nonspecific product; B) Pan3 canonical messenger RNA; C) Pan3 alternatively 
spliced variant 1; D) Pan3 alternatively spliced variant 2. 
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search for and identify alternative 5’ and 3’ ends of the Pan3 mRNA and if there were 
differences found between the AKR and DBA/2 strains, to determine the possible 
changes in the structure of the protein and possible implications in its function.  
Rapid amplification of cDNA ends (RACE) method was used to synthesize and amplify 
Pan3 transcript(s) 5’- and 3’- cDNA ends, as shown in Figure 3.7.   
     5’-RACE: Pan3 transcript (s) 5’-ends were amplified by using two different gene 
specific primers, positioned ~100 bp apart from each other, in order to identify Pan3 gene 
specific bands only and differentiate them from non-specific products.  The major 5’-
ends of Pan3 transript(s) that were PCR amplified with universal primer mix and gene 
specific primers 4 and 5 were of the expected size, ~854 and ~ 985 base pairs 
respectively (Figure 3.7A).  Although the bands have not been sequenced yet, these 
results suggest that the primary 5’-end agrees with the canonical sequence for the Pan3 
transcripts (NM_028291.2) in BMM cells of AKR and DBA/2 strains.     
     3’-RACE: two Pan3 specific bands were identified and sequenced from 3’-RACE 
experiments.  Sequencing data revealed a new alternative end for Pan3 gene, represented 
by the 0.5 Kb band in Figure 3.7B (green arrow).  The canonical Pan3 transcript is 
represented by the 2.1 Kb band in Figure 3.7B.  The other bands present in the gel were 
sequenced but were found to be nonspecific products.  Further analysis of sequencing 
data from the 0.5 Kb band revealed that the alternatively spliced variant 3 (Figure 3.7E) 
skips most of the exon 19, which is the longest exon for the Pan3 gene (2,132 base pairs), 
retaining only the last 289 base pairs.  Although the new transcript (variant 3) is shorter 
than the canonical Pan3 transcript (2,472 bp versus 4,314 bp), it was calculated to 
translate into a longer protein as the original stop codon is removed due to splicing 
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(Appendix 3E).  While the canonical Pan3 transcript translates into a 691 amino-acids 
long protein, the alternatively spliced variant 3 was calculated to translate into a 746 
amino acids long protein.  It is different from the canonical form because it leaves the last 
7 amino acids out of the sequence (GNDRNSN) and adds 62 novel amino acids to the C-
terminus of the protein (DTTRKGQPLKSCRVAHFSCVPISSPVSVFTSLQIPLRVPLCS 
ALTLVLSLDSNIVSRKHQYV).  No structural differences were observed between the 
AKR and DBA/2 strains.   
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Figure 3.7: Rapid Amplification of 5’ and 3’ Pan3 cDNA ends in AKR and DBA/2 strains.  A) Rapid 
amplification of Pan3 5’-cDNA ends amplified with Universal Primer Mix and Pan3 gene specific 
antisense primers no. 4 (lanes 2 & 3) and 5 (lanes 5 & 6); lane 1, 1KB DNA ladder (Invitrogen).  B) Rapid 
amplification of Pan3 3’-cDNA ends amplified with Universal Primer Mix and Pan3 gene specific sense 
primer no. 3a (Table 3.1); lane 1, 1KB DNA ladder; lane 2, AKR Pan3-3’end; lane 3, DBA/2 Pan3-3’ end. 
Blue arrows point to the Pan3 gene specific bands. C) RACE products for control human transferrin 
receptor (TFR); lane 1, 1KB DNA ladder; lane 2, 5’-RACE product; lane 3, 3’-RACE product; lane 4, 5’-
RACE internal control and lane 5, 3’RACE internal control.  D). Pan3 canonical messenger RNA; black 
areas represents the coding region; gray areas represents untranslated regions.  E) Pan3 alternatively 
spliced variant 3.  Green arrows point to the Pan3 specific bands (sequenced); blue arrows point to the 
Pan3 bands (not sequenced yet), and red arrows point to sequenced no specific products. 
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Mapping and quantifying the Pan3 exons in AKR and DBA/2 bone marrow 
macrophages 
     RNA sequencing is a relatively new method of mapping and quantifying mammalian 
transcriptomes 37.  It provides a means to measure transcriptome composition and 
discover possible new exons or genes by deep sequencing of cDNA, and determining 
their abundance by recording how frequently each gene is sequenced/present in the 
sample 37.   
     To identify possible new spliced variants for the Pan3 gene, we used ultra-high 
throughput RNA-sequencing method to sequence the transcriptome of bone marrow 
macrophages from female AKR and DBA/2 strains.  We used a cut-off of 2 or more 
different splice reads to call a locus “alternatively sliced”.  Overall we did not observe 
any significant difference regarding the number and location of identified Pan3 gene 
 
 
 
Figure 3.8: RNA sequencing.  The graphs present the splice junctions identified for Pan3 gene in AKR 
(first graph) and DBA/2 (second graph) from analyses of individually mapped reads generated from RNA 
sequencing in bone marrow macrophages.  The peaks in the graphs represent the number and density of 
reads corresponding to each known exon. 
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splice junctions between AKR and DBA/2 strains (Figure 3.8).  Some differences were 
observed in the frequency of reads spanning certain Pan3 exons between the two strains, 
for example exons 2-3, 7-8, 12-13, 16-17 were read more often in AKR sample compared 
to the DBA/2 sample, while exons 6-7, 10-11 and 18-19 were read more often in DBA/2 
versus AKR sample.  However, we should be very cautious in interpreting these findings 
because this was a preliminary analysis of RNA sequencing data performed without 
normalizing the data prior to running the analysis, and multiple biases and artifacts might 
have been introduced in the process of converting RNA to complementary cDNA 38.  A 
new open access software has been introduced very recently 39 that overcomes the 
restrictions imposed by prior gene annotations in identifying alternative transcription and 
splicing from analysis of RNA sequencing data.  The next step in the analysis of our data 
would be to normalize them to a housekeeping gene and rerun the analysis using the 
newly developed software program called Cufflinks 39. 
     In conclusion, we identified three new splice variants with alternative C-terminal ends 
for the Pan3 protein in bone marrow macrophages of AKR and DBA/2 strains.  We did 
not find any structural difference in the Pan3 canonical and the alternatively spliced 
transcripts between AKR and DBA/2 strains, but we identified two novel strain specific 
polymorphisms located upstream Pan3 gene.  These SNPs were found to be located 
within predicted binding sites for transcription factors Runx1 and Ctcf.  It would be 
worthwhile studying the effect (if any) that these SNPs have on the expression of Pan3 
gene in particular and/or other nearby genes.    
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Part 2: Characterization of the Effects of Pan3 Partial Deficiency on Atherosclerosis 
     Based on the positive correlation between Pan3 gene expression levels and the lesion 
area size we hypothesized that partial or total deficiency of Pan3 gene in the DBA/2 
apoE-deficient mice, the atherosclerosis susceptible strain with the large lesions, will be 
associated with reduced lesion area.  To test the hypothesis we decided to use a knockout 
mouse model for our gene of interest.  The experiments included in this section describe 
the results obtained from studying the effects of the reduced Pan3 mRNA expression 
levels on atherosclerosis  
 
Generation of Pan3 knockout mice and identification of the precise trapping vector 
insertion site    
     BayGenomics created the Pan3 knockout allele by random insertion of the gene 
trapping pGT1Lxf vector, a splice-acceptor-β-geo vector 28, in a 129 strain (agouti coat 
color) derived embryonic stem cell (ES) line.  5’ RACE sequences generated by Bay 
genomics from embryonic stem cells indicated that the trapping vector was inserted in the 
intron lying between exon 5 and 6 (intron’s length is about 32 Kb, Figure 3.9).  The cells 
with one disrupted Pan3 allele (Pan3-/+) were injected into the C57BL/6 (black coat color) 
host blastocysts and implanted in female mice to yield chimeric progeny.  The degree of 
chimerism is estimated by the percentage of the agouti coat color.  Highly chimeric males 
were bred to C57BL/6 females and coat color was used to detect germline transmission.  
Agouti pups are the progeny where the germline transmission occurred, and black pups 
are the pups where no germline transmission occurred.   
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     To identify the exact insertion site for the trapping vector we developed a PCR 
genotyping assay.  Primer pairs were designed at regular 2 Kb intervals throughout the 
intron (in both directions) with one of the primers positioned in the intron and one in the 
vector (Figure 3.9).    
     The designed primers were used to amplify genomic DNA from wild type and Pan3-/+ 
mice which were previously identified by the absence or presence of the trapping vector 
through PCR amplification of a ~ 0.5 Kb product with internal vector primers.  PCR 
amplified bands of interest were sequenced, and analysis of the sequencing data revealed 
that the insertion site of the trapping vector is located at position 7,984 bp of the intron 
(number 1 is considered the first base of the intron sequence).   
     The information on the precise position of the insertion site helped us to develop a 
multiplex PCR amplification-based genotyping assay to distinguish the Pan3 genotypes; 
wild type (+/+), heterozygous (+/-) and knockout (-/-) (Figure 3.10).  The genotyping 
assay was designed to amplify two bands: a 499 bp fragment from the wild type genomic 
DNA, flanking the insertion site, which does not amplify when genomic Pan3-/- DNA is 
used as template because the trapping vector’s length is about 8.6 Kb.  The second 
product, designed to recognize the insertion site, results from amplification of a 359 bp 
fragment with 180 bases lying in the 3’ end of the trapping vector and 179 bases in the 
intron sequence adjacent to it (Figure 3.10).  Both products will by amplified from the 
 
 
Figure 3.9: Schematic presentation of the assay designed to detect the precise insertion 
site of the trapping vector in the intron 5 of Pan3 gene. 
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Pan3-/+ mice, because their DNA contains one copy of the wild type allele and one copy 
of the trapped allele (Figure 3.10).   
 
 
Viability studies 
     To test the effect of Pan3 total deficiency on the viability of Pan3 knockout (-/-) mice, 
the hemizygous Pan3-/+ received from UC Davis were bred with each other.  The 
expected ratio of Pan3+/+, Pan3-/+ and Pan3-/- mice in the F1 generation is 1:2:1.  Of the 32 
mice born from Pan3-/+ x Pan3-/+ breeding, only 24 mice survived, 6 died immediately 
after birth and 2 died a few days after they were weaned.  Genomic DNA could be 
extracted and genotyped for all of them except for 3 mice who died neonataly.  Of the 29 
genotyped F1 mice 7 were wild type (Pan3+/+), 21 were hmizygous (Pan3-/+) and only one 
mouse was found deficient in Pan3 (Pan3-/-, the mouse died soon after birth).  Chi-
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Figure 3.10: Multiplex PCR amplification based genotyping assay to 
identify the Pan3 genotypes; wild type (Pan3+/+), heterozygous  
(Pan3-/+) and knockout (Pan3-/-). 
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squared test was used to determine if the observed ratio among the three genotypes was 
different from what is expected and Pan3-/- mice seem to have reduced viability (p-value 
= 0.0007).  Only one Pan3 knockout mouse from the F2 generation progeny (born from 
breeding of hemizygous Pan3-/+ mice of F1 generation with each other) survived for about 
one year. 
     Also, a second viability study was performed with Pan3 hemizygous mice bred onto 
the DBA/2 Apoe-/- inbred background (explained in details in the following experiment).  
Pan3-/+DBA/2 apoE-deficient mice were bred with each other and of the 38 mice born, 14 
were wildtype (Pan3+/+) and 24 hemizygous (Pan3-/+).  Thus, Pan3-/- mice on the DBA/2 
apoE-deficient background are not viable (Chi square test p-value = 0.005).  
 
Generation of Pan3-/+ mice on the DBA/2 apoE-deficient background and 
quantification of Pan3 gene expression in BMM of Pan3-/+ and Pan3+/+ mice 
     To test the effect of Pan3 partial or total deficiency on atherosclerosis we used marker 
selected backcrossing to obtain Pan3 hemizygous mice onto the DBA/2 Apoe-/- 
background.  By N6 generation Pan3-/+ congenic mice were completely inbred on the 
DBA/2 background, as ascertained by the Illumina Golden Gate genotyping assay of 
~1440 mouse SNPs spread throughout mouse genome.  The Pan3 deficient allele carries 
~81 Kb from 129 strain genome sequence upstream 5’end of the Pan3 gene.  In this way, 
all the differences in the genetic background were eliminated as a variable in the 
experiment and the only essential difference maintained is the one related to the Pan3 
allele region.  To date, backcrossing of the Pan3-/+ on the DBA/2 apoE-deficient mice has 
progressed to the N9 generation.  
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     Theoretically, progeny testing requires brother-sister mating of the Pan3 hemizygous 
mice in order to obtain DBA/2 apoE-deficient mice with 0, 1, or 2 copies of the Pan3 
gene.  However, based on the results of viability studies which revealed that Pan3-/- mice 
are not viable on the DBA/2 Apoe-/- inbred background, we followed a slightly different 
strategy to generate the progeny testing.  We backcrossed Pan3 hemizygous mice to the 
DBA/2 Apoe-/- in order to generate an equal number of wild type and hemizygous mice, 
as the expected ratio of the two genotypes from this breeding scheme is 1:1.   
     To verify that the insertion of the trapping vector in the Pan3 gene resulted in a 
reduction of its expression level we quantified the Pan3 mRNA expression in bone 
marrow macrophages of Pan3 wild type and hemizygous mice using two different real 
time PCR assays (Figure 3.11).  The first quantification assay measured the expression of 
Pan3 gene at exons 2-3 junction relative to the beta actin gene expression.  The purpose 
to quantify this part of the Pan3 transcript was to control for the differences in expression 
level of the Pan3 transcript in wild type mice with the combined expression level of Pan3 
and the fused Pan3 exons 1-5/β-galactosidase transcripts in hemizygous mice.  Thus, 
since the assay amplifies and quantifies a region of the transcript which remains intact by 
the insertion of the trapping vector, no significant difference is expected in the Pan3 
transcript expression level between the two groups; and, actually no significant 
differences were observed.  Whereas, a significant 64% reduction  in relative Pan3 
expression level was observed in the hemizygous versus wild type mice with the second 
quantification assay, which measured the expression of the transcript at exons 18-19 
junction located after the trapping vector’s insertion site (p-value = 0.0039, Figure 3.11).  
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Atherosclerosis in Pan3-/+ mice on the DBA apoE-deficient background 
     Pan3 hemizygous mice were backcrossed onto the DBA/2.Apoe-/- background, the 
atherosclerosis susceptible parental strain, as described above.  Based on the positive 
correlation observed between Pan3 gene expression and the aortic lesion size in the 
female F2 cohort (Smith JD., unpublished data), we hypothesized that a reduction in Pan3 
mRNA level will be associated with smaller lesion size.  Because the knockout Pan3 
mice (-/-) on the DBA/2 Apoe-/- background are not viable, we could not study the effect 
of Pan3 total deficiency on atherosclerosis.  Therefore we were able to compare only the 
Pan3 wild type with hemizygous mice.   
     In the first study, Pan3+/+ and Pan3-/+ mice on the DBA/2.Apoe-/- background were fed 
with chow diet and sacrificed at 14 weeks for assays of body weight, heart weight, total 
and HDL cholesterol, and aortic root lesion area (Table 3.2).  In a second study, in order 
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Figure 3.11:  Relative expression of Pan3 gene in bone marrow macrophages of female 
Pan3 wild type and hemizygous mice. 
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to reduce the variation for the aortic lesion phenotype, we decided to sacrifice mice at a 
later time point in atherosclerosis development at 16 weeks.  The strategy helped 
minimize the coefficient of variation, mostly for the Pan3-/+ mice (Table 3.2), from 
69.33% to 25.88%.  
Table 3.2: Phenotypic data collected from Pan3+/+ and Pan3-/+ mice on the DBA/2.Apoe-/- 
background at 14 and 16 weeks.    
14 WEEKS 
 Normally 
distributed 
DBA/2.Apoe-/- - 
Pan3wild type (+/+) 
DBA/2.Apoe-/- - 
Pan3hemizygous (-/+) 
P-value 
Number of mice  16 17  
Aortic lesion  No 71,225 ± 35,478 92,574 ± 64,180 0.5766 
Total cholesterol (TC) Yes 883.9 ± 124.2  957.4 ± 119.2 0.0878 
HDL cholesterol No 26.42 ± 5.95 23.74 ± 4.92 0.1258 
Body weight No 20.28 ± 1.98 20.26 ± 1.96 0.7431 
Aortic lesion CV#   49.81% 69.33%  
16 WEEKS 
 Normally 
distributed 
DBA/2.Apoe-/- - 
Pan3wild type (+/+) 
DBA/2.Apoe-/- - 
Pan3hemizygous (-/+) 
P-value 
Number of mice&  5 7  
Aortic lesion  Yes 222,523 ± 109,146 224,468 ± 58,102 0.9686 
Total cholesterol (TC) Yes 853.8 ± 81.77 989.6 ± 118.6 0.0094* 
HDL cholesterol Yes 25.92 ± 5.42 22.54 ± 5.23 0.2301 
Body weight Yes 21.43 ± 2.54 22.33 ± 2.64 0.4519 
Aortic lesion CV#   49.05% 25.88%  
*, represent significant P-values; #, Coefficient of variation; &, the numbers apply to aortic lesions 
only. Data are presented in mean ± SD (standard deviation). 
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     No significant differences were observed in body weight, heart weight and HDL 
cholesterol level between Pan3+/+ and Pan3-/+ mice on the DBA/2.Apoe-/- background 
(Table 3.2) either at 14 or 16 weeks.   
     Mean aortic lesion size in all mice increased by 2-fold or more in just two weeks time 
period (from 14 to 16 weeks).  However, contrary to our expectations, we did not observe 
significant differences in the means/medians of aortic lesion size between the Pan3 wild 
type and hemizygous mice (Figure 3.12, Table 3.2).    
 
    
 
      
     Surprisingly, the plasma levels of total cholesterol were found to be significantly 
different at 16 weeks (parametric t-test p-value = 0.0094) where mice with reduced Pan3 
expression level appear to have a higher plasma total cholesterol level (Figure 3.13, Table 
3.2).  Although, these are preliminary data and a bigger number of animals is needed to 
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Figure 3.12: Effect of Pan3 partial deficiency on aortic lesion size in 14 and 16 week old female 
mice on the atherosclerosis susceptible DBA/2 Apoe-/- background.   The bar graphs represent 
atherosclerotic lesion size (mean ± SD) at the aortic root in female mice.  Numbers next to the 
genotypes represent the number of mice used in the individual groups. 
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Figure 3.13: Effect of the Pan3 partial deficiency on plasma total cholesterol 
levels in 16 weeks old female mice on the DBA/2.Apoe-/- background. 
validate the finding, the increase in total cholesterol level seems to be attributable to 
increases in the level of LDL and other forms of plasma cholesterol, but not to the HDL 
cholesterol whose levels were not affected by the Pan3 gene’s partial deficiency.  
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DISCUSSION 
     Integrating QTL mapping and whole genome gene expression in bone marrow 
macrophages in an F2 female cohort, Smith and colleagues identified Pan3 gene as a 
prime candidate gene for the atherosclerosis (Ath24) QTL.  The goal of the studies 
presented in this chapter was to: 1) identify any structural or splice variant differences 
between the AKR and DBA/2 Pan3 allele; 2) test whether hemizygous mice with 
decreased Pan3 transcript expression level have reduced atherosclerosis,  a result that 
could also explain the positive association/correlation observed between Pan3 gene and 
the aortic root lesion size .   
     Structural studies.  Regarding splice variants, we identified three alternatively spliced 
variants for the Pan3 gene in bone marrow macrophages.  None of the newly identified 
transcripts had alternate 5’ ends when compared with the canonical Pan3 transcript, but 
all three of them differed in the 3’ends.  The alternatively spliced variant 1, which retains 
~74 base pairs from the intron 14, has a premature termination codon (PTC) inserted 
more than 50 base pairs upstream of the final exon junction.  In mammalian cells this 
event targets the PTC-carrying transcripts for degradation through nonsense mediated 
mRNA decay pathway 40, 41, therefore the alternatively spliced variant 1 is most likely 
degraded through the above mentioned pathway.  Theoretically, the two other identified 
alternatively spliced transcripts seem to be translatable into proteins, as the new stop 
codon is inserted either in less than 50-55 nucleotides upstream of the 3’-most  exon-exon 
junction (variant 2) or downstream this junction (variant 3) and therefore are not targeted 
for nonsense mediated degradation 41.  The predicted protein sequences differ from the 
canonical 691aa Pan3 protein at the C-terminus; and, while the alternatively spliced 
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variant 2 is predicted to translate into a truncated protein of 687aa, the third Pan3 
alternative variant is predicted to translate into a 746aa protein with a longer C-terminus.  
C-termini are well known for their ability to serve as subcellular targeting signal for their 
proteins, among other roles 42.  They are also known to interact with proteins, lipids 
and/or other molecules.  Although, we did not identify structural differences in these two 
Pan3 alternatively spliced variants between AKR and DBA/2, it would be worthwhile to 
determine their expression levels in the two strains and identify their presence and/or the 
presence of other possible alternatively spliced variants in tissues such as endothelial 
cells and liver that are known to be implicated in atherosclerosis.    
     Additionally, we searched for single nucleotide polymorphisms in the Pan3 gene and 
its upstream promoter region by sequencing the Pan3 gene’s coding and promoter region 
in AKR, DBA/2 or F1 mice and searching public sequencing data.  We identified two 
novel mutations that were different between AKR and DBA/2 strains.  The two SNPs are 
located upstream of the Pan3 exon 1 and each of them is positioned in predicted 
transcription factor binding sites for Runx1 and CTCF.  Runx1 is mainly associated with 
several types of leukemia, while CTCF has a dual role, depending upon the context of the 
DNA site it binds to, might act as activator or repressor of the transcription.  Recently, it 
was found to play an essential role in controlling the APOA1/C3/A4/A5 gene cluster 43. 
     In conclusion, we identified three new splice variants with alternative C-termini for 
the Pan3 protein in bone marrow macrophages of AKR and DBA/2 strains.  We did not 
find any structural difference in the Pan3 canonical and the alternatively spliced 
transcripts between AKR and DBA/2 strains, but we identified two novel strain specific 
polymorphisms located upstream Pan3 gene.  Because both SNPs were found to be 
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located within predicted binding sites for transcription factors, it would be useful to study 
the effect (if any) that these SNPs have on the expression of Pan3 gene in particular 
and/or other nearby genes.    
     Gene expression studies:  To study the effect of Pan3 gene deficiency on 
atherosclerosis, we used a knockout mouse model.  As explained earlier in the results 
section we were unable to study the effect of Pan3 total deficiency on atherosclerosis as 
Pan3 knockout (-/-) mice on the DBA/2 apoE-deficient background were not viable.  
However, we observed a 64% reduction in Pan3 gene expression level in bone marrow 
macrophage of female hemizygous (-/+) mice when compared to Pan3 wild type (+/+) 
mice.  Initially, the atherosclerosis assays were performed with 14 weeks old mice, but 
because we encountered a high coefficient of variation for the aortic lesion phenotype at 
this time point we decided to perform the assays at 16 weeks, when the lesions are 
expected to be as a more advanced stage of development.  Indeed, lesions were found to 
be more than 2-fold larger in size at 16 weeks, accompanied with an overall reduced 
coefficient of variation.   
     By reducing the expression of Pan3 gene in atherosclerosis susceptible DBA/2 apoE-
deficient mice we were expecting to see smaller aortic lesions in comparison with the 
parental DBA/2 apoE-deficient strain.  However, we did not observe a significant 
difference in aortic lesion size in Pan3 hemyzygous versus wild type mice, at either 14 or 
16 weeks of age.   
     The Pan3 gene was identified as a candidate gene for the Ath24 QTL by whole 
genome gene expression analysis; however, microarray technology has some limitations 
that affect the discovery of genes by introducing false positives.  We sequenced the Pan3 
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transcript region that hybridizes with the Affymetrix Pan3 probe in both AKR and 
DBA/2 strains and found no difference in base pair composition.  Also, we quantified the 
Pan3 transcript in a subset of BMM RNA samples from the F2 female cohort by using 
real-time PCR.  The real-time PCR results validated the microarray findings, and showed 
that female F2 mice with bigger aortic lesions have a higher expression of the Pan3 gene 
when compared with female F2 samples characterized by smaller aortic lesions (data not 
shown).  In addition, we measured the expression of Pan3 gene in the parental strains, but 
unexpectedly we found no difference between AKR and DBA/2 Apoe-/-.   
     Taking all these findings together it is possible that we may not observe an effect of 
the Pan3 gene partial deficiency when bred onto a pure parental background.  It is 
possible that we are missing important interactions among Pan3 and other genetic factors 
from both parental strains located in other regions of the genome, interactions which were 
made evident in the F2 cohort with each mouse carrying a unique distribution and 
combination of the parental alleles.  Therefore we decided to adopt a strategy developed 
by Teupser et al.,44 which consist in studying the effect of genetic variation on 
atherosclerosis in the F1 background.  The presence of both parental alleles in F1 
background mice will help bring back some of these gene-gene interactions and it might 
help validate the Pan3 gene as the causative gene for the Ath24 QTL.   
     Another explanation, however, is that the positive correlation observed between the 
phenotype and Pan3 gene expression is not genetic but results from effect of 
environmental or stochastic factors.  In this case, generation of a new replication female 
F2 cohort is necessary and this strategy is currently being pursued in our lab, by other 
members.  
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     An interesting result obtained from atherosclerosis assay performed at 16 weeks is the 
significant difference in plasma total cholesterol levels between Pan3 hemizygous and 
wild type mice.  Mice with lower Pan3 expression level appear to have a significantly 
higher plasma total cholesterol level compared to the Pan3 wild type mice.  At present, 
we can not conclude that the difference in total cholesterol is due to the Pan3 partial 
deficiency and the reason is that Pan3 hemizygous mice carry an interval of the 129 strain 
genome. This interval includes the rs4138683 SNP that differs between the 129 and 
DBA/2 strain.  This mouse SNP is a coding nonsynonymous variant located in exon 18 of 
the FMS-like tyrosine kinase 3 (Flt3) gene, which is positioned upstream the Pan3 gene.  
The Flt3 gene encodes a class 3 receptor tyrosine kinase that is involved in the regulation 
of hematopoiesis (NCBI, Entrez Gene) 45.   
     Relevant to atherosclerosis, the human SNP rs2153000, which is located in an intron 
of the FLT3 gene, was found to be associated with coronary artery disease in a 46 GWAS 
study (p-value = 2.9E-04).  Based on these findings we think that Flt3, a Pan3 
neighboring gene represent a strong alternate candidate gene for Ath24 QTL. 
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CHAPTER IV 
CHARACTERIZATION OF CHOLESTEROL (AcLDL) LOADING EFFECT ON THE 
GENE EXPRESSION IN BONE MARROW DERIVED MACROPHAGES OF AKR 
AND DBA/2 ApoE-DEFICIENT MICE 
 
 
 
INTRODUCTION 
     A complex sequence and interaction of events occur during atherosclerosis 
development.  A critical point in atherogenesis is the accumulation and entrapment of a 
large amount of lipids and lipoproteins in the extracellular matrix of the sub-endothelial 
intima layer 1, 2.  Monocytes migrate across the monolayer of endothelial cells and arrest 
in the intima layer where they differentiate in macrophages and start taking up modified 
low density lipoproteins by scavenger receptors 3, 4.  Once inside the cells modified LDL 
is degraded leaving cholesterol in the lysosomes which is transported to the 
endoplasmatic reticulum for conversion into cholesterol esters ans stored as lipid droplets 
5, 6.  Cholesterol esters inside the foam cells can be hydrolyzed back into free cholesterol 
and exported out of the cells through two principal mechanisms: 1) passive diffusion, 
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and/or 2) protein mediated efflux via ATP-binding cassette transporters Abca1 and 
Abcg1 and scavenger receptor SR-BI 7-11.  Macrophages can not limit the uptake of 
cholesterol 12 as the expression of scavenger receptors is not subject to feedback control 
by cellular cholesterol content 13, which makes them dependent on the cholesterol efflux 
in order to prevent their transformation into foam cells.  The imbalance between 
cholesterol influx and cholesterol efflux will lead to excessive accumulation of 
cholesterol in macrophages, which will eventually be stored in lipid droplets leading to 
the transformation of macrophages into cholesterol-engorged foam cells characteristic of 
fatty streaks 14-16. 
     The concept of macrophages as merely cells that accumulate, metabolize and transport 
cholesterol and/or store excess cholesterol in lipid droplets has been challenged in the 
past few years.  The use of drugs that lower plasma LDL-cholesterol levels have proven 
to be beneficial for about one-third of affected patients; however, atherosclerosis remains 
one of the main causes of mortality 17.  Inflammation is emerging as a mediator of several 
stages in atherogenesis and atherosclerosis is being viewed as a disease caused by a 
combination of elevated cholesterol and inflammation 18, 19.  Monocyte-derived 
macrophages besides being one of the major cellular components of lesions are emerging 
as key players in determining the balance between pro- and anti-inflammatory cytokines 
which in turn affects the activation and migration of other cell types to the atherosclerosis 
plaque impacting its stability 19.       
     To gain more knowledge on the contribution of macrophages to the development of 
atherosclerosis we aimed at studying the response of monocyte-derived macrophages 
from atherosclerosis resistant (AKR) and atherosclerosis susceptible (DBA/2) strains to 
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cholesterol loading.  When incubated with acetylated low density lipoprotein (Ac-LDL), 
M-CSF differentiated macrophages of the two strains showed significant differences in 
their cellular content of total cholesterol and cholesterol esters, as well as in the efflux of 
cholesterol outside the cells to HDL cholesterol (Figures 4.1 and 4.2, data courtesy of Dr. 
Peggy Robinet).  Atherosclerosis susceptible DBA/2 strain macrophages were 
characterized by significantly higher levels of total cholesterol (p-value < 0.001) and 
cholesterol esters (p-values <0.001) inside the cells when compared to atherosclerosis 
resistant AKR strain macrophages (Figure 4.1).   
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Figure 4.1: Cell total cholesterol, free cholesterol and cholesterol esters mass in AKR and DBA/2 
macrophages unloaded and acetylated-LDL loaded.  All data are mean ± SD, p-values calculated by 
one-way analysis of variance (ANOVA) with Newman-Keuls posttest. 
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     Also DBA/2 macrophages were found to have significantly lower levels of free 
cholesterol (p-value < 0.001).  Meanwhile, significant differences were observed in 
cholesterol efflux to apoA1 and HDL acceptors between the two strains revealed that 
DBA/2 macrophages efflux less cholesterol than AKR macrophages.   
 
     The studies presented in this chapter aimed at investigating the effect of cholesterol 
loading on the transcriptome of AKR and DBA/2 macrophages and detect possible 
transcripts and/or mechanisms that could explain the differences observed in the 
physiological response to loading with acetylated-LDL.  Furthermore, we sought to 
identify new alternate candidate genes for the previously identified Ath24 QTL.    
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Figure 4.2: Cell cholesterol efflux to apoA1 and/or HDL acceptor. 
All data are mean ± SD, p-values calculated by unpaired t-test. 
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MATERIALS AND METHODS 
Loading of macrophages with acetylated LDL 
     Bone marrow derived macrophages (BMM) from female AKR and DBA/2 Apoe-/- 
strains were cultured in p100 cell culture dishes for 14 days (as explained in detail in 
Chapter 3, Materials and Methods section).  The cells were incubated for 24 hours in the 
presence or absence of 100 μg/ml acetylated LDL (four p100 plates each for control and 
AcLDL cholesterol loaded macrophages from AKR and DBA/2 strains).  After the 
incubation, the media and cholesterol were aspirated off and cells were washed twice 
with 10 ml ice cold PBS.  Then, the cells were scrapped in 1ml ice-cold PBS and 
transferred to 1.5 ml microcentrifuge tubes.  Cell pellets were obtained by centrifugation 
in a microcentrifuge at 5,000 rpm for 2 minutes at RT.  After aspirating PBS the cell 
pellets were kept on ice for subsequent use or stored in -80oC.   
 
Isolation of total RNA from BMM cell pellets       
     Total RNA was isolated from cell pellets by using RNeasy Mini Kit (Catalog # 74104, 
Qiagen, Valencia, CA), following the manufacturer’s guidelines.  On-column digestion 
was performed to remove the genomic DNA with RNase-free DNase (Catalog # 79254, 
Qiagen, Valencia, CA).  The DNase itself is removed in the subsequent washing steps.  
Total RNA was eluted in 50 μl RNase-free water and quantified.  RNA purity was tested 
by incubating 200-500 ng of total RNA at 37oC (total volume brought to 10 μl with 
RNase-free water).  After incubation RNA samples were run on a 1.2% agarose/Ethidium 
bromide gel and the presence of intact 18S and 28S ribosomal RNA bands verifies that 
total RNA is intact. 
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Hybridization and detection of gene transcripts 
     An aliquot of total RNA for each sample (~ 2 μg) was submitted to the Genomic Core 
at Lerner Research Institute.  Total RNA was used as template to synthesize single 
stranded cDNA following the manufacturer’s protocol.  Single stranded cDNA is then 
converted into double stranded cDNA, purified and in vitro transcribed (in the presence 
of biotinylated UTP and CTP) to produce biotin-labeled cRNA.  Purified labeled cRNA 
was hybridized to MouseRef–8_v1_1 microarrays (Illumina) for 16 hours at 58oC, 
according to the manufacturer’s instructions.  Eight samples were profiled on one chip 
with 24,613 transcript probes per sample.  To reduce the chip-to-chip variability two 
control and two cholesterol loaded samples from each strain were put on each microarray 
chip.  After hybridization, the arrays were washed several times and stained with 
streptavidin-Cy3.  After the staining, the arrays went through a final wash and were left 
to dry.  The arrays were scanned on the Illumina BeadArray Reader using Illumina 
BeadScan image data acquisition software.  
 
Microarray data analysis  
     Data were quantile normalized without background subtraction using Illumina 
BeadStudio software.  1,342 unique probes that were found to hybridize to transcript 
sequences containing a strain-specific polymorphism or indel (insertion/deletion) were 
excluded from further gene expression-related analyses.  All the different variations that 
occurred between AKR and DBA/2 (SNPs and indels) were obtained from sequencing 
data generated from the Mouse Genomes Project: http://www.sanger.ac.uk/resources/ 
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mouse/genomes/.  A catalog (in pileup format) was used to identify the probes 
hybridizing to regions containing the strain specific structural differences.    
     Nonparametric t-test analysis were performed to identify the genes whose expression 
levels changed significantly between the two strains at basal level (unloaded) or after 
cholesterol loading in each strain. The False Discovery Rate (FDR) Q-value estimates 
were calculated using QVALUE software (http://www.genomics.princeton.edu/storeylab/ 
qvalue/index.html) 20.  Only the genes with an unadjusted t-test p-value < 0.01 were 
further analyzed and reported.  Fold change was calculated as the ratio between average 
expression level in DBA/2 versus average expression level in AKR macrophages for each 
transcript (average signal DBA)/ average signal AKR).  
     A nested analysis of variance (ANOVA) was performed when more than two groups 
were compared, such as in identifying the genes whose expression levels changed due to 
cholesterol loading with strain background difference as covariant (interaction).  Data 
were log2 transformed prior to the analysis that was performed using R package, version 
2.11.0.  
      Gene ontology, biological networks, as well as canonical functions and pathways 
were evaluated with DAVID Annotation Tool website (http://david.abcc.ncifcrf.gov) 21, 
22. 
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RESULTS 
Hierarchical cluster analysis 
     To asses the performance of both arrays prior to any other statistical analysis we 
compared signal intensities of the replicates and performed hierarchical sample clustering 
analysis on quantile normalized data using Illumina BeadStudio sofware.  As visualized 
in Figure 4.3, the samples clustered nicely and clearly by strain and cholesterol loading 
status.  
 
 
Strain differences in BMM transcriptome 
     We used microarray analysis to identify the differences in expression level of 
transcripts in bone marrow macrophages of the atherosclerosis resistant AKR strain and 
the atherosclerosis susceptible DBA/2 strain.  10,003 probe IDs were called present 
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Figure 4.3: Hierarchical clustering analysis of 16 samples included in the 
study.  Four replicates each for control and AcLDL cholesterol loaded 
macrophages from AKR and DBA/2 strains were used (L, loaded; UnL, unloaded 
samples). 
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(Illumina detection p-value ≤0.05) in four or more samples  and these were utilized in 
subsequent analyses.  2,725 (~27.2%) of the transcripts were identified as differentially 
expressed between AKR and DBA/2 strains at an unadjusted nonparametric t-test p-value 
<0.01.  We estimated the false discovery rate (FDR) at p<0.01 to be 1.19%, meaning that 
32 of the 2,725 regulated transcripts may be false positives.  To correct for multiple 
testing, we applied the Bonferroni test and found that 61 transcripts met the significance 
threshold of adjusted P-value < 0.05 (Appendix 4A).  Of these 61 transcripts, 40 (65.6%) 
were expressed higher in DBA/2 strain compared to 21 (34.4%) transcripts which were 
expressed higher in AKR bone marrow macrophages (Appendix 4A).  Expression levels 
of 37 (~61%) differentially expressed transcripts (Bonferroni adjusted p-value < 0.05) 
changed by 2-fold or more between the two strains (Table 4.1).    
     The transcript with the most significant p-value overall encoded for interleukin 11 
receptor alpha chain 2 (Il11ra2) which was expressed 3.0-fold higher in DBA/2 when 
compared to AKR macrophages.  Neutrophil cytosolic factor 2 (Ncf2), which encodes for 
a cytosolic subunit of NADPH oxidase complex, had the highest fold change between the 
two strains, with 68-fold higher expression in DBA/2 versus AKR macrophages (Table 
4.1), encodes for.  Other significantly regulated transcripts that were highly expressed in 
DBA/2 versus AKR macrophages include stabilin 2 (Stab2, fold change 10.9), 
AA881470 (expressed sequence tag with a fold change of 9.1) ATPase, Ca++ transporting 
protein (Atp2a3, fold change of 6.5), and ATP-binding cassette, sub-family B, member 4 
(Abcb4, fold change of 5.3) (Table 4.1).    
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Table 4.1: List of differentially expressed transcripts between AKR and DBA/2 unloaded 
macrophages with Bonferroni adjusted p-values < 0.05 and 2-or more fold change.  
Probe_ID 
 
 
Symbol 
 
 
Bonferroni 
adjusted 
P-values 
Log2 Fold 
Change 
DBA/AKR 
Definition 
 
 
ILMN_2619594 Il11ra2 3.41E-05 1.56 Interleukin 11 receptor, alpha chain 2 
ILMN_2631663 BC022687 9.78E-05 -1.77 cDNA sequence BC022687 (BC022687) 
ILMN_2610737 Iap 1.18E-04 1.56 Intracisternal A particles 
ILMN_1242902 Rapgef5 2.79E-04 1.44 Rap guanine nucleotide exchange factor 5 
ILMN_1221584 Crym 3.29E-04 1.71 Crystallin, mu  
ILMN_1229957 Il11ra1 5.14E-04 1.76 Interleukin 11 receptor, alpha chain 1  
ILMN_1244799 Usp39 6.85E-04 1.40 Ubiquitin specific peptidase 39  
ILMN_1256171 BC026370 7.45E-04 1.36 Transmembrane protein 63b 
ILMN_1245678 Abhd1 2.09E-03 -1.47 Abhydrolase domain containing 1 
ILMN_2758199 Sdh1 2.10E-03 -1.33 Sorbitol dehydrogenase  
ILMN_2775360 Mapkapk3 2.21E-03 1.30 Mitogen-activated protein kinase-activated protein kinase 3 
ILMN_2760800 Cxcl14 3.02E-03 1.16 Chemokine (C-X-C motif) ligand 14 
ILMN_2667020 Ryk 3.61E-03 -1.02 Receptor-like tyrosine kinase 
ILMN_2648742 Abcb4 4.71E-03 2.41 ATP-binding cassette, sub-family B (MDR/TAP), member 4 
ILMN_2688236 Atp2a3 5.01E-03 2.70 ATPase, Ca++ transporting, ubiquitous  
ILMN_2523170 Treml1 5.36E-03 1.24 Triggering receptor expressed on myeloid cells-like 1 
ILMN_2633063 Ttc39b 5.51E-03 1.54 Tetratricopeptide repeat domain 39B 
ILMN_2680827 Il7r 6.29E-03 2.10 Interleukin 7 receptor  
ILMN_2737368 Stab2 7.84E-03 3.45 Stabilin 2  
ILMN_1236574 Cenpa 8.55E-03 1.31 Centromere protein A 
ILMN_1222196 2310007A19Rik 9.42E-03 1.21 RIKEN cDNA 2310007A19Rik 
ILMN_1224736 Zmiz1 1.03E-02 1.13 Zinc finger, MIZ-type containing 1 
ILMN_2600190 Gjb4 1.07E-02 -1.16 Gap junction protein, beta 4 
ILMN_2680038 1200013B22Rik 1.09E-02 1.06 NUAK family, SNF1-like kinase, 2  
ILMN_1213662 Tm4sf5 1.21E-02 1.60 Transmembrane 4 superfamily member 5  
ILMN_2605630 AA881470 1.36E-02 3.19 EST AA881470 (AA881470), variant 2 
ILMN_2747923 Slc40a1 1.51E-02 2.09 Solute carrier family 40(iron-regulated transporter) member 1 
ILMN_2731407 Gdf3 1.56E-02 -1.92 Growth differentiation factor 3 
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Probe_ID 
 
 
Symbol 
 
 
Bonferroni 
adjusted 
P-values 
Log2 Fold 
Change 
DBA/AKR 
Definition 
 
 
ILMN_2774430 Ncf2 2.28E-02 6.09 Neutrophil cytosolic factor 2  
ILMN_1232183 Mgmt 2.64E-02 -1.54 O-6-methylguanine-DNA methyltransferase 
ILMN_1216809 Igh-6 2.68E-02 1.54 Immunoglobulin heavy chain 6 (heavy chain of IgM) 
ILMN_2619620 C1qb 2.73E-02 -1.30 Complement component 1, q subcomponent, beta polypeptide 
ILMN_2621649 Gpr160 3.54E-02 -1.20 G protein-coupled receptor 160 
ILMN_2677859 Insl6 3.55E-02 1.79 Insulin-like 6 (Insl6) 
ILMN_2683486 Dennd4a 4.14E-02 1.08 DENN/MADD domain containing 4A 
ILMN_2622374 Ndn 4.33E-02 1.07 Necdin 
ILMN_1239221 2310016C08Rik 4.85E-02 1.10 RIKEN cDNA 2310016C08 gene  
 
     Upon relaxing the p-value criterion, there were 225 significantly regulated transcripts 
(unadjusted p-value < 0.01) whose expression changed by 2-fold or more between the 
two strains, 135 of which were expressed higher in DBA/2 and 90 transcripts expressed 
higher in AKR.  Of the 135 significant transcripts that were expressed higher in DBA/2 
macrophages, H2-D1 and H2-Q6 (histocompatibility 2, D region locus 1 and Q region 
locus 6) had the first and the third highest fold change (211 and 49-fold respectively) 
(Appendix 4B).  Among the 90 differentially regulated transcripts that were expressed 
higher in AKR bone marrow macrophages, chemokine (C_C motif) ligand 5 (Ccl5) and 
glycoprotein transmembrane nmb (Gpnmb) were the transcripts with the highest fold 
change, 23 and 13-fold respectively (Appendix 4B).   
     To identify the biological mechanisms, pathways and functions most relevant to the 
genes that differ in expression between AKR and DBA/2 bone marrow macrophages, the 
differentially expressed transcripts (p < 0.001) were subjected to Gene Ontology and 
Pathway Analysis (David Annotation Tool).  The pathways and their respective genes 
were identified based on the KEGG pathway database and detailed information is 
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provided in Appendix 4C.  The top significant pathway identified was "Toll-like receptor 
signaling pathway" (p-value = 3.9E-04).  16 transcripts that are differentially expressed 
between DBA/2 and AKR strains were involved in this pathway (Appendix 4C).  The 
following pathways (together with their respective number of differentially expressed 
transcripts involved) were the most significantly represented canonical pathways: 
chemokine signaling pathway (23 genes, p-value = 5.3E-04), systemic lupus 
erythematosus (16 genes, p-value = 6.0E-04), NOD-like receptor signaling pathway (11 
genes, p-value = 2.2E-03), cytokine-cytokine receptor interaction (26 genes, p-value = 
2.5E-03), fructose and mannose metabolism (8 transcripts, p-value = 4.1E-03), and focal 
adhesion (21 genes, 7.8E-03). 
 
Cholesterol loading-strain interaction 
     To detect the strain differences in genes and mechanisms of response to cholesterol 
loading, M-CSF differentiated macrophages were incubated for 24 hours in the presence 
or absence of acetylated LDL.  Transcripts expression levels were measured; however, to 
reduce the noise only the probe IDs for transcripts that were called expressed in eight or 
more samples from 16 totals were further analyzed.  9,711 probe IDs were called present 
(Illumina detection p-value ≤0.05).  Based on the nature of our data which consist of one 
measurable variable that is each transcript’s expression level and two nominal variables 
(strain and cholesterol loading) we performed a Nested Analysis of Variance (Nested 
ANOVA) as the statistical test to identify the transcripts whose expression changed 
significantly due to cholesterol loading using background strain as an interactive 
covariate.  This allows detection of transcripts that are regulated either similarly or 
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differently in the two strains; for example, a transcript that is up regulated in AKR and 
down regulated in DBA/2.  Nested ANOVA is an extension of one way ANOVA, but 
applicable when groups are subdivided into subgroups.  It assumes that observations 
within each group are normally distributed and have equal variances.   
     The histogram of P-value distributions revealed a significant effect of strain and 
cholesterol loading on the gene expression profile (Figure 4.4) in macrophages.  Also, as 
demonstrated by ANOVA P-value frequency distributions, there were many genes whose 
expression was regulated by cholesterol loading in a strain-specific fashion (cholesterol 
loading-strain interaction).  We identified 2,553 cholesterol loading and strain interacting 
transcripts with unadjusted ANOVA p-value <0.01.   
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Figure 4.4: Histogram of P-value frequency distribution for strain effect is shown in red bars 
(calculated by nonparametric t-test for 8 unloaded samples).  P-value frequency distribution for the 
AcLDL loading effect with strain as covariate is shown in blue bars (calculated by Nested ANOVA). 
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     False discovery rate at the p-value <0.01 cut-off was estimated to be 1.56%, meaning 
that about 40 transcripts are expected to be false positives.  We applied the Bonferroni 
test to correct for multiple testing and found that 277 transcripts passed the strict criterion 
of Bonferroni-adjusted p-value < 0.05 (a complete list of transcripts is provided in 
Appendix 4D).  Because some transcripts had more than one probe on the array, these 
277 transcripts represent 265 unique genes.  Expression of 118 transcripts among 277 
most significantly regulated ones after cholesterol loading (Bonferroni adjusted p-value < 
0.05) changed by a 2-fold or higher in AKR versus 14 transcripts in DBA/2 macrophages 
(Appendix 4D).  The top 50 transcripts (with the most significant P-values) that 
responded significantly differently to the cholesterol loading in AKR and DBA/2 
macrophages after cholesterol loading are shown in Table 4.2.   
 
Table 4.2: List of the 50 most significant differentially regulated transcripts with the 
strain-interaction effect after cholesterol loading.  The transcripts with 2-or more fold 
change are shown in bold.   
Probe_ID 
 
 
Symbol 
 
 
Bonferroni 
adjusted P-
values 
Fold 
Change 
AKR#  
Fold 
Change 
DBA/2# 
Definition  
 
ILMN_2774888 Tgfbi 2.62E-08 0.4 1.0 Transforming growth factor, beta induced 
ILMN_3160659 Dok2 3.68E-07 0.5 1.3 Docking protein 2 
ILMN_2689138 2310044G17Rik 9.51E-07 2.6 1.2 RIKEN cDNA 2310044G17 gene 
ILMN_1257949 Ccnd1 2.00E-06 0.6 1.5 Cyclin D1 
ILMN_2761472 
 
Lrpap1 
 
3.22E-06 
 
1.7 
 
1.0 
 
Low density lipoprotein receptor-related 
protein associated protein 1 
ILMN_2742152 
 
Gadd45a 
 
3.49E-06 
 
3.6 
 
1.3 
 
Growth arrest and DNA-damage-inducible 45 
alpha  
ILMN_2663249 Slamf9 6.10E-06 0.2 1.1 SLAM family member 9 
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Probe_ID 
 
 
Symbol 
 
 
Bonferroni 
adjusted P-
values 
Fold 
Change 
AKR#  
Fold 
Change 
DBA/2# 
Definition  
 
ILMN_1244291 
 
Gja1 
 
8.11E-06 
 
0.2 
 
0.9 
 
Gap junction membrane channel protein alpha 
1 
ILMN_2606144 Cd300lf 8.51E-06 3.0 1.1 CD300 antigen like family member F 
ILMN_1241610 Adrb2 8.85E-06 0.4 0.8 Adrenergic receptor, beta 2  
ILMN_1252851 Zfp661 1.42E-05 0.6 1.6 Zinc finger protein 661 
ILMN_1255341 Atf5 1.62E-05 2.3 0.9 Activating transcription factor 5  
ILMN_2719036 B130052G07Rik 1.71E-05 3.1 1.4 Vasohibin 2  
ILMN_3161489 Acaca 1.91E-05 0.7 1.2 Acetyl-Coenzyme A carboxylase alpha 
ILMN_2617468 1810008K03Rik 1.92E-05 7.6 1.2 ChaC, cation transport regulator-like 1 
ILMN_2519673 Vwf 1.96E-05 3.9 0.9 Von Willebrand factor homolog 
ILMN_1225528 Trib3 2.24E-05 6.1 1.2 Tribbles homolog 3 (Drosophila) 
ILMN_2735350 Gdf15 2.62E-05 3.2 1.0 Growth differentiation factor 15 
ILMN_2715500 Dner 3.47E-05 0.7 2.5 Delta/notch-like EGF-related receptor 
ILMN_1230489 AA407930 3.51E-05 1.6 1.0 Zinc finger, AN1-type domain 2A 
ILMN_1250438 Mlp 3.53E-05 0.5 1.4 MARCKS-like 1 
ILMN_1252283 Tulp4 5.86E-05 2.1 1.2 Tubby like protein 4 
ILMN_2643513 Asns 5.97E-05 3.8 1.4 Asparagine synthetase  
ILMN_2681965 Ctsc 6.50E-05 0.5 0.9 Cathepsin C  
ILMN_2760800 Cxcl14 6.89E-05 1.0 3.3 Chemokine (C-X-C motif) ligand 14 
ILMN_2667384 Slc6a9 7.20E-05 2.8 1.0 Solute carrier family 6, member 9 
ILMN_2680827 Il7r 7.87E-05 4.4 1.2 Interleukin 7 receptor  
ILMN_2710705 Sqstm1 8.77E-05 2.1 0.9 Sequestosome 1 
ILMN_2644375 Hyal1 9.26E-05 4.8 1.6 Hyaluronoglucosaminidase 1 
ILMN_2751304 Ell 9.89E-05 1.7 1.0 Elongation factor RNA polymerase II 
ILMN_2610944 Fpr1 1.01E-04 0.2 0.8 Formyl peptide receptor 1 
ILMN_1225204 
 
2510004L01Rik 
 
1.03E-04 
 
1.2 
 
0.5 
 
Radical S-adenosyl methionine domain 
containing 2 
ILMN_1239221 2310016C08Rik 1.06E-04 1.9 0.7 RIKEN cDNA 2310016C08 gene  
ILMN_1246139 Cldn11 1.31E-04 2.5 0.8 Claudin 11 
ILMN_1258988 Igfbp4 1.38E-04 0.4 0.8 Insulin-like growth factor binding protein 4 
ILMN_2620583 Pacs2 1.41E-04 1.7 1.0 Phosphofurin acidic cluster sorting protein 2 
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Probe_ID 
 
 
Symbol 
 
 
Bonferroni 
adjusted P-
values 
Fold 
Change 
AKR#  
Fold 
Change 
DBA/2# 
Definition  
 
ILMN_2640346 
 
P2ry13 
 
1.51E-04 
 
0.1 
 
0.5 
 
Purinergic receptor P2Y, G-protein coupled 
13  
ILMN_2663130 
 
P2ry6 
 
1.57E-04 
 
0.4 
 
0.8 
 
Pyrimidinergic receptor P2Y, G-protein 
coupled, 6 
ILMN_1260456 
 
Hsd3b7 
 
1.58E-04 
 
2.2 
 
1.3 
 
Hydroxy-delta-5-steroid dehydrogenase, 3 
beta- and steroid delta-isomerase 7 
ILMN_1229082 Klhl21 1.58E-04 1.8 0.9 Kelch-like 21 (Drosophila) 
ILMN_2626722 
 
Ssb4 
 
1.66E-04 
 
4.3 
 
1.3 
 
SplA/ryanodine receptor domain and SOCS 
box containing 4  
ILMN_2610737 Iap 1.74E-04 1.4 0.7 Intracisternal A particles-discontinued record 
ILMN_1229718 
 
Ms4a6c 
 
1.78E-04 
 
0.2 
 
0.6 
 
Membrane-spanning 4-domains, subfamily A, 
member 6C 
ILMN_1253972 Irak3 1.80E-04 0.4 1.1 Interleukin-1 receptor-associated kinase 3  
ILMN_2695199 Siat10 1.87E-04 0.3 0.7 
ST3 beta-galactoside alpha-2,3-
sialyltransferase 6 
ILMN_2621148 Kif3a 1.92E-04 2.3 0.8 Kinesin family member 3A 
ILMN_1249640 Neurl 2.08E-04 0.3 0.9 Neuralized homolog 1A (Drosophila) 
ILMN_2714796 Coro1a 2.12E-04 0.5 0.9 Coronin, actin binding protein 1A 
ILMN_2589651 Anpep 2.27E-04 2.7 1.5 Alanyl (membrane) aminopeptidase  
ILMN_1213483 B430214A04Rik 2.34E-04 1.5 1.0 Folliculin  
# represents the ratio between average expression values for each transcript after cholesterol loading (AKR 
loaded/AKR unloaded; DBA loaded/DBA unloaded) 
 
     The transcript with the highest ANOVA p-value (2.62E-08) encodes for beta induced 
transforming growth factor (Tgfbi) whose expression was down regulated significantly in 
AKR macrophages by 62% but remained unchanged in DBA/2 strain (Figure 4.5A) after 
cholesterol loading.  Other examples of transcripts that were found to be differentially 
regulated between AKR and DBA/2 macrophages include Gpnmb transcript, which was 
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up regulated only in AKR macrophages after cholesterol loading, ATP-binding cassette, 
sub-family G member 1 (Abcg1) transcript, whose expression was up regulated after 
cholesterol loading by 1.7 fold in AKR and 1.4 fold in DBA/2 macrophages, while Cd14 
transcript expression was down regulated in AKR and up regulated in DBA/2 
macrophages (Figure 4.5B, C and D).   
 
     Gene ontology analysis of the 277 significantly regulated transcripts (Bonferroni 
adjusted p-value <0.05) revealed that the list of transcripts which responded differently to 
cholesterol loading between the two strains was enriched for genes involved in 
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Figure 4.5: Examples of differentially regulated transcripts by cholesterol loading between AKR 
and DBA/2 macrophages (mean ± SD, n=4 per group).  Tgfbi expression (shown in upper left corner) 
represents the transcripts with the highest significant ANOVA p-value.  Other differentially regulated 
transcripts include B) Gpnmb, C) Abcg1 and, D) Cd14 gene expression. 
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chemotaxis (p-value = 1.4E-04) represented by Cmtm7, Rac2, S100A8, Ccl4, Cxcl13, 
Coro1a, Fpr1, Fpr2 and Itgam genes.  Also, genes involved in immune response were 
significantly represented (p-value = 2.1E-04), including among others: Clec4e, Clec5a, 
Cd14, Cd300lf, Fcgr1, Ccl4, Cxcl13, Cxcl14, Gradd45g, H2-Ab1 Il7R, C1qc, C1qb, etc.  
     55 out of 277 submitted for the gene ontology analysis were either located in the 
plasma membrane or involved in plasma-membrane related functions, such as hydrogen 
ion ATPase transporter (ATP6v1c1), cell surface markers (Cd14, Cd52, Cd274 and 
Cd300lf), several G-coupled protein receptors, members of the solute carrier protein 
family, low density lipoprotein receptor related protein (Lrpap1), lymphocyte antigen 6 
complex (Ly6a), and many others of distinct functions.  Other GO terms included 
“phosphoprotein” (the most significantly enriched GO term with 126 genes, P-value 
9.3E-08), “early endosome” (p-value = 6.0E-04), “endoplasmatic reticulum unfolded 
protein response” (p-value = 1.6E-04) and “receptor mediated endocytosis” (p-value = 
2.9E-03).     
     Pathway analysis was conducted with a larger set of transcripts (ANOVA p-value 
<0.001) and we found that our list of significantly differentially regulated transcripts in 
response to cholesterol loading was enriched for several distinct biological pathways.  
The top pathway identified was KEGG’s “lysosome pathway” (p-value <2.3E-06) which 
included 25 differentially regulated transcripts.  The following pathways (together with 
their respective number of differentially expressed transcripts involved and enrichment p-
values) were the most significantly represented canonical pathways: cell cycle (23 genes, 
8.4E-05), renal cell carcinoma/MAPK signaling (14 genes, 1.1E-03), DNA replication (9 
genes, 2.6E-03), gap junction (15 genes, 2.8E-03), endocytosis (25 genes, 8.7E-3), p53 
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signaling pathway (13 genes, 3.1E-3), and leukocyte transendothelial migration (17 
genes, 9.8E-3).   
     As mentioned above the top canonical pathway identified was “Lysosome” pathway.  
Twenty-five differentially regulated genes between the AKR and DBA/2 strains in 
response to cholesterol loading were involved in this pathway (Table 4.3).  Many of them 
were genes encoding for lysosomal enzymes:  proteases including different cathepsins 
(CtsA, CtsB, CtsC, CtsH, CtsK and CtsZ) and the peptidase napsin (Napsa); two 
glycosidases (Hyal1 and Naglu); palmitoyl-protein thioesterases (Ppt1 and Ppt2); other 
major and minor lysosomal membrane proteins (Lamp, Ctns, Slc17a5, Laptm4a and 
Cln5), adapter-related protein complex subunits delta and mu (Ap3d1 and Ap3m2) and 
several ATPase transporters (Atp2a2, Atp2a3, Atp9b, Atp6v0b and Atp6v1c1).  A 
detailed list of significantly regulated transcripts involved in this pathway is given in 
Table 4.3, including the respective % changes in each strain calculated as: (average signal 
loaded – average signal control)/average signal control.  Negative values mean that the 
transcripts were down regulated after cholesterol loading.  About 60% of 25 transcripts 
were up regulated after cholesterol loading in both strains; however the magnitude of 
change is much higher in AKR than DBA/2 macrophages.  
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Table 4.3: List of significantly regulated transcripts involved in the “Lysosome” pathway 
Probe_ID 
 
Symbol 
 
% Change 
in AKR 
% Change 
in DBA/2 
Definition 
 
ILMN_1243149   Atp6v0b 40.8 11.5 ATPase, H+ transporting, lysosomal V0 subunit B   
ILMN_3162570 
  
Gnptab 
 
50.1 
 
8.4 
 
N-acetylglucosamine-1-phosphate transferase, alpha and beta 
subunits  
ILMN_2746456 
 
Tcirg1 
 
138.9 
 
16.2 
 
T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 
protein A3  
ILMN_2624740  Ap3d1 36.9 -4.3 Adaptor-related protein complex 3, delta 1 subunit  
ILMN_3162495  Ap3m2 -18.8 13.2 Adaptor-related protein complex 3, mu 2 subunit  
ILMN_2599667  Ap4m1 -16.6 3.6 Adaptor-related protein complex AP-4, mu 1  
ILMN_2652058  Ap4s1 -26.3 -2.3 Adaptor-related protein complex AP-4, sigma 1  
ILMN_2721503  Naglu 60.6 4.2 Alpha-N-acetylglucosaminidase (Sanfilippo disease IIIB)  
ILMN_1213617  Ctsa 11.3 -30.6 Cathepsin A  
ILMN_2638941  Ctsb 89.8 8.3 Cathepsin B  
ILMN_2681965 Ctsc -55.0 -7.7 Cathepsin C  
ILMN_2775154  Ctsh -24.2 -4.3 Cathepsin H  
ILMN_2711163  Ctsk 145.6 32.1 Cathepsin K  
ILMN_2632785  Ctsz 39.9 12.3 Cathepsin Z  
ILMN_2639290  Cln5 47.9 19.7 Ceroid-lipofuscinosis, neuronal 5  
ILMN_2653284  Ctns 37.2 -7.7 Cystinosis, nephropathic  
ILMN_1227459 
 
Gga2 
 
57.4 
 
23.1 
 
Golgi associated, gamma adaptin ear containing, ARF binding 
protein 2  
ILMN_2644375  Hyal1 378.0 56.6 Hyaluronoglucosaminidase 1  
ILMN_2589275  Igf2r 159.4 52.8 Insulin-like growth factor 2 receptor  
ILMN_1217454  Lamp2 -29.3 -1.2 Lysosomal-associated membrane protein 2  
ILMN_1254173  Laptm4a -41.3 -19.1 Lysosomal-associated protein transmembrane 4A  
ILMN_2657867  Napsa -31.5 -9.2 Napsin A aspartic peptidase  
ILMN_2736168  Ppt1 -40.0 -17.4 Palmitoyl-protein thioesterase 1  
ILMN_2775331  Ppt2 -20.1 3.2 Palmitoyl-protein thioesterase 2  
ILMN_1216788  Slc17a5 48.1 -4.8 Solute carrier family 17 (anion/sugar transporter), member 5 
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Identification of new candidate genes for Ath24 QTL 
     Plasma cholesterol level is a major risk factor for development of atherosclerosis and 
elucidation of mechanisms that control its biosynthesis, modification and/or storage is 
very important.  In previous chapters we explained in details how one can integrate 
genetics and genomics methods to identify plausible candidate genes for complex 
diseases.  We searched to identify genes, whose expression was significantly 
differentially regulated in atherosclerosis resistant strain AKR versus atherosclerosis 
susceptible strain DBA/2 when loaded with cholesterol, which reside within Ath24 QTL 
interval.  49 transcripts were identified, many of which have functions that are not well 
characterized; however, 3 of these transcripts/genes stood out as potential candidates for 
Ath24 QTL based on their known functions.  The first candidate is the gene that encodes 
for arachidonate 5-lipoxygenase activating protein (Alox5ap, ANOVA p-value = 1.09E-
05) which is located at the distal end of chromosome 5 (~150 Mb).  Its expression was 
down regulated by 37% in AKR macrophages and only 4% in DBA/2 strain after 
cholesterol loading (Figure 4.6A).  It is involved in leukotriene synthesis, molecules that 
have been implicated in the inflammatory response.  
     The second candidate is a gene that encodes for high mobility group box 1 protein 
(Hmgb1, ANOVA p-value = 4.23E-03), whose expression was down regulated by 21% in 
AKR and up regulated by ~22% in DBA/2 macrophages after cholesterol loading (Figure 
4.6B).  The gene is located on chromosome 5 at 149.85 Mb.  It has been shown that 
Hmgb1, a nuclear DNA binding protein, can be secreted outside the cells and acts as a 
proinflammatory cytokine in the extracellular environment by binding to Tlr2 and Tlr4 23.   
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     The third candidate is P450 (cytochrome) oxidoreductase gene (Por, ANOVA p-value 
= 6.38E-04), located at ~136.1 Mb on chromosome 5.  It encodes for an endoplasmatic 
reticulum oxidoreductase that functions as an electron donor for the microsomal 
cytochrome P450 enzymes (Cyps) which otherwise remain catalytically inactive 24.  Its 
transcript expression was highly up regulated in AKR macrophages by 82% compared to 
an 18% increase in expression level in DBA/2 macrophages (Figure 4.6C).   
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Figure 4.6: Expression of three new Ath24 QTL candidate transcripts (mean ± SD, n=4 per group): A) 
Alox5ap, B) Hmgb1 and C) Por transcript. 
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DISCUSSION 
     Experiments performed in our laboratory revealed that atherosclerosis resistant AKR 
and atherosclerosis susceptible DBA/2 strain bone marrow-derived macrophages react 
differently to cholesterol loading with acetylated LDL.  The aim of this study was to 
investigate how the transcriptome of atherosclerosis resistant AKR and atherosclerosis 
susceptible DBA/2 macrophages would respond to cholesterol loading and identify 
possible genes and pathways/mechanisms that could explain the observed physiological 
differences.  Also, we sought to identify potential candidate genes for the previously 
identified Ath24 QTL.  For this purpose we cultured bone marrow monocytes from both 
strains which were differentiated into macrophages in the presence of macrophage colony 
stimulating factor (MCSF).  The cells were incubated in the presence or absence of Ac-
LDL for 24 hours to induce foam cell formation prior to transcriptome analysis.     
 
Genes that affect cholesterol influx, cell cholesterol metabolism and cholesterol 
efflux  
    Cholesterol influx: As previously mentioned, cholesterol loading of macrophages was 
associated with a significantly higher level of total cholesterol in DBA/2 compared to 
AKR macrophages.  The uptake of modified lipoproteins is thought to be central to foam 
cell formation.  Modified LDL is mainly taken inside the cells by scavenger receptors, 
mainly class A (SR-A) and class B receptors (SR-B).  We observed that the transcript 
encoding for Cd14 antigen, a membrane glycoprotein that promotes expression of 
scavenger receptors, was significantly differentially regulated after cholesterol loading.  
The Cd14 transcript was down regulated in atherosclerosis resistant AKR macrophages 
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by 32%, but up regulated in atherosclerosis susceptible DBA/2 macrophages by 20%.  By 
stimulating LDL uptake through activation of scavenger receptors it could induce 
macrophages to accumulate excess cholesterol leading to foam cell formation.  The 
observation that its expression was down regulated in AKR macrophages suggests that 
this down regulation might act as an atherosclerosis protective mechanism and might 
provide an explanation for the significantly lower levels of total cholesterol accumulated 
in AKR compared to DBA/2 macrophages.  Our data showed that expression level of the 
transcript encoding Scarb1 (SR-B1) receptor was down regulated by 36% in AKR and by 
23% in DBA/2 macrophages.  Meanwhile, Cd68 a class D scavenger receptor (known as 
macrosialin in mice) was found to respond differently to cholesterol loading.  Its 
transcript was up regulated by cholesterol loading by 49% in AKR and by 10% in DBA/2 
macrophages.  However, none of the findings related to scavenger receptors could 
explain for the difference in cholesterol uptake between the strains other than Scarb1 
which although down regulated in both strains maintains slightly higher expression levels 
in DBA/2 than AKR macrophages after cholesterol loading.  We could not detect any 
differences in the SR-A receptor(s) mainly because of the poor hybridization of the probe 
with its transcript (undetected in all 16 samples).  Other receptors or receptor-related 
proteins that showed significantly different responses to cholesterol loading between the 
two strains were low density lipoprotein receptor-related protein associated protein 1 
(Lrpap1) and low density lipoprotein-related protein 12 (Lrp12), both up regulated in 
AKR strain (the later only slightly up regulated in DBA/2).     
     Cholesterol metabolism: Once inside the cells, cholesterol is subjected to enzymatic 
modifications and is transported through different intracellular compartments.  Of the 
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genes involved in these processes the transcript that encodes for cholesterol 25-
hydroxylase (Ch25h) was significantly differentially regulated between the two strains.  
Although its transcript was expressed 2.5-fold higher in unloaded macrophages of AKR 
strain compared to DBA/2, the opposite was observed after cholesterol loading as its 
expression was reduced by 82% in AKR macrophages and 36% in DBA/2 strain 
macrophages.  This enzyme catalyzes the enzymatic reaction that generates 25-
hydroxycholesterol, a partial agonist of the nuclear receptors of LXR α and β, which 
regulate cholesterol efflux via ABCA1 and apoE induction and fatty acid synthesis by 
controlling the expression of sterol regulatory element binding protein-1c (SREBP-1c) 5, 
6.   
     Another important gene involved in cholesterol metabolism and foam cell formation 
that was found to be differentially regulated after cholesterol loading encodes for acyl-
coenzyme A: cholesterol acyltransferase (Soat1, also known as ACAT).  Its expression in 
unloaded macrophages differed significantly between the two strains (expressed about 
3.7-fold higher in DBA/2 strain); however, after cholesterol loading the difference in 
expression between the two strains increased to 5-fold as Soat1 was down regulated by 
18% in AKR and up regulated by 10% in DBA/2 macrophages.  The difference could, at 
least partially, explain the presence of significantly higher cholesterol esters found in the 
DBA/2 macrophages after cholesterol loading when compared to AKR strain.     
     Cholesterol efflux: Cholesterol efflux from macrophage foam cells to HDL cholesterol 
is one of the main important mechanisms in protecting against atherosclerosis 
development.  ATP-binding cassette transporters play a key role in this process; and, 
Abca1 and Abcg1 are the main transporters for cholesterol efflux in macrophages 7-9, 11, 
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12.  Combined deficiency of Abca1 and Abcg1 has been shown to lead to severe defects 
in cholesterol efflux to HDL and accumulation of cholesteryl esters in macrophages 10.  
Experiments in our lab have demonstrated that AKR macrophages efflux more 
cholesterol.  While there was no major difference in Abca1 expression between the two 
strains, we observed a significant difference in Abcg1 expression between AKR and 
DBA/2 macrophages in response to cholesterol loading.  The gene was robustly 
expressed in macrophages of both strains and its expression was found to be significantly 
more up regulated in AKR than DBA/2 macrophages (68% in AKR versus 39% in 
DBA/2).  These differences in expression of Abcg1 may account for the difference 
observed in cholesterol efflux between AKR and DBA/2 macrophages.  
 
Candidate genes for Ath24 QTL 
     Among the genes that responded significantly differently to cholesterol loading in 
AKR and DBA/2 macrophages we identified three candidate genes for Ath24 QTL, 
Alox5ap, Hmgb1 and Por.  Of these three candidate genes, Alox5ap had the most 
significant p-value (7.04E-03).  We found that the expression of Alox5ap was reduced by 
37% in AKR versus 4% in DBA/2 macrophages.  Arachidonate 5-lipoxygenase activating 
protein (Apox5ap), together with 5-lipoxygenase (Alox5 also known as 5-LO), is involved 
in the synthesis of leukotriene B4 (Ltb4) from arachidonic acid.  Ltb4 acts as a 
chemoattractant that has the ability to promote chemotaxis and adhesion of molecules and 
is considered as one of the most potent ones produced in atherosclerotic lesions.  
Lipoxygeneases have been demonstrated to be important in foam cell formation and 
development of atherosclerosis 14, 25.  5-LO was identified as the mouse atherosclerosis 
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modifier gene for an atherosclerosis resistance locus on chromosome 6.  Mehrabian et al., 
found that mice with reduced levels of 5-LO had a dramatic decrease in aortic lesion 
development 26.   Furthermore, common human variation in the ALOX5AP gene has been 
shown to be associated with risk for MI and stroke, highlighting the role of this pathway 
in atherosclerotic diseases 27.  When combined with previous studies, our finding that 
Alox5ap transcript was significantly down regulated in the atherosclerosis resistant AKR 
macrophages after cholesterol loading suggests that this gene as an attractive candidate 
responsible for Ath24 QTL. 
     The second candidate is a gene that encodes for high mobility group box 1 protein 
(Hmgb1), whose expression was down regulated by 21% in AKR and up regulated by 
~22% in DBA/2 macrophages after cholesterol loading.  The Hmgb1 gene encodes a 
nuclear DNA binding protein that has been implicated in atherosclerosis.  It has been 
shown that HMGB1 protein can be released from dead cells and regulate inflammatory 
responses by binding to TLR2 and TLR4 23.  A second study found that the nuclear form 
of HMGB1 binds to the SREBP-1 and -2, and enhances their DNA binding 28 implying 
that HMGB1 might be potentially involved in regulation of genes involved in cholesterol 
homeostasis.  Due to its potential role in inflammation and cholesterol metabolism 
Hmgb1 represents another alternate candidate for the Ath24 QTL. 
     The third alternative candidate for the Ath24 QTL is the cytochrome P450 
oxidoreductase gene (Por) that encodes an endoplasmatic reticulum oxidoreductase.  Its 
mRNA level was highly up regulated by cholesterol loading by 82% in AKR compared to 
a modest 18% increase in DBA/2 macrophages.  One study has demonstrated that hepatic 
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disruption of Por gene is accompanied by changes in lipid transporters, an increase in 
lipid uptake, and repression of cholesterol efflux 29. 
     Also, we sought to examine the effect (if any) that cholesterol loading would have on 
the expression of Pan3 gene, our top candidate for Ath24 QTL.  However, this was not 
possible as no probes hybridizing with its transcript were present in the Illumina 
microarray chip (its original discovery was made using Affymetrix microarrays).  
 
Other genes/transcripts of interest identified from cholesterol loading-strain 
interaction  
     The transcript with the best p-value for strain-cholesterol loading interaction was the 
gene coding for transforming growth factor beta induced (Tgfbi).  Tgfbi expression is 
induced by transforming growth factor beta and its protein acts as a ligand that binds to 
several integrins, thus playing a diverse role in cell adhesion, migration proliferation and 
differentiation 30.  It is one of the extracellular matrix (ECM) components, and it has also 
been found in blood and accumulated in inflammatory sites, including atherosclerotic 
human lesions.  A recent study reported that the TGFBI protein is involved in activation 
of platelets and likely to promote thrombosis 31.  In our study Tgfbi transcript expression 
was reduced by 62% in AKR, but did not change in DBA/2 macrophages.  It would be 
very useful to investigate and identify the receptor(s) it might bind to in macrophages and 
the consequent events which are likely to affect the response of macrophages to 
cholesterol loading, as our data suggest.   
     An additional atherosclerosis protective advantage of cholesterol efflux to HDL is that 
it leads to the suppression of inflammatory cytokines 10.  Abca1 and Abcg1 deficient mice 
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are characterized by an increased inflammatory response and accumulated inflammatory 
macrophage foam cells in various tissues.  It has been demonstrated that the mechanism 
involves CD14 protein and it was associated with the enhancement of MyD88/NF-кB 
pathway through Toll-like receptors 3, 10.  Activation of NF-кB leads to expression of 
inflammatory genes.  In line with this model we observed that the transcript encoding for 
CD14 antigen, was significantly differentially regulated after cholesterol loading 
(explained above).  Also, expression of transcripts encoding for downstream signaling 
molecules involved in this pathway such as toll-like receptors 2 and 6, Myd88 (myeloid 
differentiation primary response gene 88) and Irak3 (interleukin-1 receptor-associated 
kinase 3) were significantly differentially affected as well.   Expression of Tlr2 transcript 
was down regulated by 62% in AKR and by 44% in DBA/2 macrophages; Tlr6 transcript 
expression was down regulated by 16% in AKR and up regulated by 3% in DBA/2; 
MyD88 transcript expression was down regulated by 33% in AKR versus 12% in DBA/2 
macrophages; and, Irak3 transcript expression was down regulated by 59% in AKR and 
up regulated by 8% in DBA/2.  Overall these findings suggest that inflammatory response 
as well is affected significantly differently in both strains and more specifically MyD88-
NF-кB pathway was suppressed at a higher degree in AKR than DBA/2 macrophages.  
This might be reflected in the different spectrum of cytokine/chemokine molecules 
produced in macrophages of both strains with Ccl3 and Ccl4 being up regulated in AKR 
and down regulated in DBA/2; and, Ccl6, Ccl9, Ccl12, Cxcl13 and Cxcl14 (the later 
expressed in DBA/2 only) being down regulated in atherosclerosis resistant AKR strain 
and up regulated in atherosclerosis susceptible DBA/2 macrophages.  The interplay of 
different cytokines and chemokines in affecting atherosclerosis warrants further 
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investigation. Furthermore, it would be informative to investigate the role of Cd14 in 
atherosclerosis and the mechanism(s) that control/regulates its expression in response to 
cholesterol loading. 
     Our findings provide further support to the hypothesis that the uptake of modified 
lipoproteins by scavenger receptors might be central to foam cell formation and also 
represent one of the major activation events stimulating the pro- or anti-inflammatory 
response of macrophages recruited to aortic lesions.  In addition to changes in various 
cytokines/chemokines expression pattern, 4 C-type lectins were differently affected by 
cholesterol loading in AKR versus DBA/2 macrophages, Clec5a, Clec4a1, Clec4a3 and 
Clec4e.  These proteins play a role in inflammatory response; however, they exhibit also 
a diverse range of other functions including cell-cell adhesion, immune response to 
pathogens and apoptosis. 
     An interesting finding was the differentially regulated expression of Trib3 gene 
(tribbles homolog 3) which was found to be highly up regulated in AKR after cholesterol 
loading versus DBA/2 macrophages (increased expression in AKR about 6.1-fold  
compared to 1.2-fold in DBA/2).  TRIB3 protein acts as negative regulator of NF-кB as it 
inhibits the phosphorylation p65 RELA (an NF-кB subunit).  It also interacts with other 
signaling cascade proteins such as AKT1 and AKT2, Map kinases Map2K1 and 
Map2K7.  A widely accepted hypothesis is that several signaling cascades that regulate 
macrophage activation, lipid metabolism and inflammatory programs are initiated when 
these cells are loaded with cholesterol 3.  Because of the Trib3 known role as a negative 
regulator NF-кB, interactions with other signaling pathway molecules, and based on its 
expression pattern exhibited under cholesterol loading it would be worth studying the role 
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of this gene and its effect on atherosclerosis.  Recently SNPs near TRIB1 gene, a member 
of the same gene family as Trib3, were found to be associated with blood triglyceride 
levels in a GWAS study in human subjects 32.  
 
Strain differences in unloaded BMM transcriptome  
     Significant differences in expression level of several transcripts were observed 
between AKR and DBA/2 unloaded macrophages, 61 of which passed a very 
conservative Bonferroni p-value cut-off of smaller than 0.05 threshold for multiple 
testing correction.  The transcript with the best p-value encodes for interleukin 11 
receptor alpha chain 2, a type-I cytokine receptor whose function has not been well 
described yet.  Another significantly differentially expressed transcript between the two 
strains is the gene encoding for neutrophil cytosolic factor 2 (Ncf2), also known as 
p67phox which is a 67-kDa subunit of the NADPH oxidase complex.  The NADPH 
enzymatic complex is involved in the production of superoxide, a highly reactive oxygen 
species (ROS).  Recent studies have demonstrated that mice deficient in components of 
the NADPH oxidase complex (such as p47phox) develop significantly smaller aortic 
lesions 33; and also, treatment with testosterone played a significant role in prevention of 
atherosclerosis by decreasing the production of superoxide anion (~40%) achieved 
mainly by inhibiting the expression of NADPH oxidase cytosolic subunits p67phox and 
p47phox 34.  It is possible that Ncf2, which was found to be expressed 68 times higher in 
DBA/2 strain compared to AKR, plays a crucial role in the development of 
atherosclerosis and large aortic lesions in DBA/2 mice and could at least partially explain 
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for the phenotypic difference (~10 times larger lesions in DBA/2 when compared to 
AKR) between the two strains.   
      Another gene that demonstrated a significant difference in expression level between 
the two strains and a large fold change is stabilin2 (Stab2), a transmembrane receptor 
protein that is believed to function as scavenger receptor.  The transcript was expressed 
11- fold higher in DBA/2 compared to AKR macrophages.      
 
     In conclusion, the study was very helpful in understanding the genes, pathways and 
mechanisms involved that could explain for the phenotypic differences observed in 
cholesterol influx, cholesterol metabolism and cholesterol efflux between AKR and 
DBA/2 macrophages.  Major contributions of this study include the identification of three 
alternate candidate genes for Ath24 QTL and generation of several new hypothesis to test 
the candidate as well as of other interesting genes discussed here for their role in 
atherosclerosis.       
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CHAPTER V 
CHANGES IN WHOLE BLOOD GENE EXPRESSION IN OBESE SUBJECTS WITH 
TYPE 2 DIABETES FOLLOWING BARIATRIC SURGERY 
 
 
ABSTRACT 
     A pilot study was performed in order to investigate the effects of bariatric surgery on 
whole blood gene expression profiles in obese subjects with type 2 diabetes.  Whole 
blood from eleven obese subjects with type 2 diabetes was collected in PAXgene tubes 
prior to and 6-12 months after bariatric surgery.  Overall, bariatric surgery resulted in 
significant reduction of BMI, fasting plasma glucose, fasting plasma insulin, and 
normalization of glycosylated hemoglobin A1C levels.  The expression levels of 204 
transcripts, representing 200 unique genes, were significantly altered after bariatric 
surgery.  Among the significantly regulated genes were GGT1, CAMP, DEFA1, LCN2, 
TP53, PDSS1, OLR1, CNTNAP5, DHCR24, HHAT and SARDH, which have been 
previously implicated in lipid metabolism, obesity and/or type 2 diabetes.  The changes in 
expression of seven transcripts, WDR35, FLF45244, DHCR24, TIGD7, TOPBP1, 
TSHZ1, and FAM8A1 were strongly correlated with the changes in body weight, fasting 
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plasma glucose and HbA1C content.  The top pathway associated with gene expression 
changes after bariatric surgery was lipid metabolism, small molecule biochemistry and 
gene expression.  Two antimicrobial peptides were among the transcripts with the largest 
changes in gene expression after bariatric surgery.  These preliminary data suggest that 
whole blood expression levels of specific transcripts may be useful as biomarkers 
associated with susceptibility for type 2 diabetes and/or therapeutic response. 
 
Keywords: bariatric surgery, obesity, type 2 diabetes, mRNA expression profiling, 
genomics 
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INTRODUCTION 
     The prevalence of obesity and type 2 diabetes has increased dramatically in the past 
decades accompanied by an array of secondary health issues 1.  Both obesity and diabetes 
are features of the metabolic syndrome, which increases ones risk for cardiovascular 
diseases.  Obesity is a key factor contributing to the development of type 2 diabetes; and, 
weight loss is associated with improvements in glucose homeostasis.  Bariatric surgery 
represents one of the most efficacious methods for the treatment of obesity and type 2 
diabetes and, often leads to normalization of hyperglycemia and insulin resistance prior 
to significant weight loss 2, 3.  Furthermore, bariatric surgery results in sustained weight 
loss and resolution of type 2 diabetes in a majority of patients with a higher success rate 
compared to that obtained through diet/lifestyle changes and pharmacotherapy 4. 
     The goal of the present pilot study was to examine changes in gene expression in 
obese subjects with type 2 diabetes after bariatric surgery, which resulted in weight loss 
and a reduction in hyperglycemia.  We chose to observe gene expression changes in 
whole blood, as this tissue may reflect a systemic response to altered metabolism, and it 
is the easiest tissue to obtain for serial sampling in a clinical setting.  In 11 subjects 
studied before and after surgery, we found 200 unique genes whose expression was 
significantly altered, many of which have been previously implicated in obesity and/or 
type 2 diabetes. 
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MATERIALS AND METHODS 
Study design 
      The complete clinical characteristics of subjects that participated in this study are 
given Appendix 5A.  The study was conducted in accordance with the appropriate 
clinical and experimental ethical guidelines and was approved by the Cleveland Clinic 
Institutional Review Board.  Informed consent was obtained by the subjects before their 
participation.  Eleven obese subjects with type 2 diabetes, (5 females and 6 males), with 
an average age at enrollment 50.5 ± 11.9 (mean ± SD) were studied.  Roux-en-Y gastric 
bypass surgery (RYGB) was performed on seven subjects, (3 females and 4 males), while 
4 subjects underwent Sleeve Gastrectomy (SG).  None of the women were taking 
hormonal therapy, no subjects used steroid medications, and none were smokers. The 
distribution of oral diabetes medications prior to surgery was: 9/11 metformin; 2/11 
pioglitazone; and 4/11 sulfonylureas.  Diabetes medications were discontinued by 6 
weeks after surgery.  Following a 10-12 hour overnight fast, peripheral blood was drawn 
for clinical laboratory tests and transcriptome analysis 2 weeks prior to and 6-12 months 
after intervention.  All medications were withheld at least 24 hours prior to blood draw on 
both occasions.  
 
Isolation of total RNA and hybridization 
     Whole blood samples from each subject were collected in PAXgene Blood RNA tubes 
(BD, Franklin Lakes, NJ).  Total RNA was isolated using PAXgene Blood RNA Kit 
(Qiagen, Valencia, CA).  An aliquot of total RNA for each sample was amplified and 
biotin labeled using Ovation RNA amplification System V2 (NuGEN, San Carlos, CA).  
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Purified labeled cDNA was hybridized to HumanWG–6 v2 Expression BeadChip 
microarrays (Illumina, San Diego, CA) at 48oC.  
 
Microarray Data Analysis  
     Data were quantile normalized without background subtraction using Illumina 
BeadStudio software.  To reduce the chip-to-chip variability the control (pre-surgery) and 
post-surgery samples for each patient were put on the same microarray chip.  A two-
tailed paired t-test analysis was performed to identify the genes whose expression levels 
changed significantly after the surgery.  Only the genes with an unadjusted paired t-test 
p-value < 0.01 were further analyzed and reported.  To correct for multiple testing the 
False Discovery Rate (FDR) Q-value estimates were calculated using QVALUE software 
(http://www.genomics.princeton.edu/storeylab/qvalue/index.html) 5, 6.  Changes in 
expression level of each transcript and changes in the clinical values were calculated as 
(value post – value pre)/value pre, and the mean for all subjects was expressed as percent 
change.  Gene ontology, biological networks, and canonical pathways were evaluated 
with Ingenuity Pathway Analysis software (www.ingenuity.com) and the DAVID 
Annotation Tool website (http://david.abcc.ncifcrf.gov) 7, 8.  The microarray dataset from 
this study is available through the Gene Expression Omnibus server, accession number 
GSE19790. 
 
Real-Time quantitative PCR (qPCR) 
     To validate the microarray findings, the expression of selected gene transcripts was 
assessed by qPCR, relative to the endogenous control gene, beta actin (ACTB) using pre-
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designed TaqMan gene expression assays (Applied Biosystems, Foster City, CA).  Mean 
fold changes for each sample were calculated using the 2-∆∆ cycle threshold method, as 
previously described 9.  
 
Protein expression and clinical assays 
     Human plasma levels of lipocalin 2 were determined using a rapid ELISA kit 
(BioPorto Diagnostics, Gentofte, Denmark) following the manufacturer’s protocol.  
Serum gamma-glutamyltransferase 1 activity and all other clinical values were 
determined by standard clinical assays performed by the Cleveland Clinic Pathology and 
Laboratory Medicine Institute.  Gamma-glutamyltransferase activity must be measured in 
serum, which was only available for six pairs of samples. 
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RESULTS 
Clinical and Metabolic Effects of Bariatric Surgery 
     The diabetes related clinical characteristics of the subjects before and after surgery are 
presented in Table 5.1 and the complete clinical data for each subject are presented in 
Appendix 5A.  Overall, bariatric surgery had a positive impact on weight loss and 
resolution of hyperglycemia for every subject included in this study, leading to 
significant decreases of 22% in mean weight (p=9.1x10-7), 21.0% in mean BMI 
(p=9.9x10-7), 42% in fasting plasma glucose (p=8.6x10-4), 26% in mean HbA1C content 
(p=5.9x10-4), and 80% in fasting plasma insulin (p=0.042).  Other significant changes 
include a 12% decrease in white blood cell count (p=0.016), a 31% decrease in mean 
VLDL-cholesterol (p=0.036), a 54% decrease in alanine aminotransferase (p=7.5x10-4), a 
7% decrease in % neutrophils (p= 0.01), and a 14% increase in percent lymphocytes 
(p=0.007).  Although this pilot study was not designed or powered to compare the two 
types of surgery, we observed that the seven subjects who underwent RYGB surgery 
were more responsive in weight loss and resolution of type 2 diabetes than the four SG 
surgery subjects, with larger percent decreases in BMI (24% and 18% decreases for 
RYGB and SG, respectively, p=0.016), fasting plasma glucose (45% and 28%, 
respectively, p=0.086), and HbA1C (30% and16%, respectively, p=0.064).  Post surgery, 
all seven of the RYGB subjects and only one of four SG subjects met the criterion for 
normal fasting plasma glucose of <100 mg/dL (p = 0.0072 by chi square test).
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Table 5.1: Diabetes related clinical characteristics of subjects involved in the study  
Clinical Characteristic Pre-surgerya Post-surgerya % Change P- valueb % Change 
RYGB 
% Change 
SG 
P-valuec 
Weight (kg) 140.7 ± 35.1 110.4 ± 29.9 -21.5 9.08E-07 -24 -18 0.033 
BMI (kg/m2) 47.1 ± 11.6 37.2 ± 10.0 -21.0 9.90E-07 -24 -17 0.016 
Fasting plasma glucose (mg/dL) 170 ± 54.2 97.8 ± 26.5 -42.5 8.57E-04 -45 -28 0.086 
Fasting plasma insulin (µIU/ml)d 32.2 ± 35.4 6.6 ± 4.8 -79.5 4.25E-02 -79 -53 0.135 
HbA1C (%) 7.9 ± 1.5 5.9 ± 0.6 -26.3 5.87E-04 -30 -16 0.064 
 
a, Data are means ± SD for 11 subjects pre- and post surgery. 
b, Unadjusted paired T-test comparing pre- vs. post surgery.  
c, T-test comparing % change by RYBG vs. SG. 
d, Data only available for 9 subjects before and after surgery. 
BMI, Body mass index 
HbA1C, glycosylated hemoglobin A1C 
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Gene expression profiling 
     17,115 probe IDs were called present (Illumina detection p-value ≤0.05) in 10 or more 
of the 22 total samples and these were utilized in subsequent analyses.  Due to the small 
number of subjects, we were not powered to compare the effects of the two types of 
surgery on gene expression, thus all subjects were pooled for our analyses.  204 (~1.7%) 
of the transcripts were identified as differentially expressed due to the bariatric surgery at 
a p-value <0.01 (Appendix 5B).  Because some transcripts had more than one probe on 
the array, these 204 transcripts represent 200 unique genes.  To correct for multiple 
testing, we estimated the false discovery rate (FDR) at p<0.01 to be 0.52, meaning that 
107 of the 204 regulated transcripts may be false positives.  Of the 204 differentially 
expressed transcripts, 115 (56%) were down regulated and 89 (44%) were up regulated.  
None of the 204 transcripts had a >2- fold change, and only 17 (8.3%) were altered by 
more than 25%, with 8 being down regulated and 9 up regulated (Table 5.2). 
The transcript with the most significant p-value overall encoded for gamma-
glutamyltransferase 1 (GGT1); and, although its expression was only reduced by 10% 
post-surgery, this change was very consistent in all subjects.  The transcript with the third 
most significant p-value overall encoded for cathelicidin antimicrobial peptide (CAMP), 
which was reduced by 41% post surgery.  The microarray contained three probes that 
align to both alpha defensin 1 (DEFA1) and alpha defensin 3 (DEFA3), which ranked 
first, third and fourth of those genes with the largest percent change in gene expression 
(45 to 46% down regulated, Table 5.2), demonstrating internal consistency in this 
finding.  Thus, two separate antimicrobial peptides (CAMP and DEFA1/A3) were 
relatively highly down regulated.  Other transcripts that were relatively highly down 
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regulated include lipocalin 2 (LCN2) and carcinoembryonic antigen-related cell adhesion 
molecule 8 (CEACAM8), with 46% and 45% reductions post-surgery, respectively 
(Table 5.2).  
 
Table 5.2: Differentially expressed transcripts with >25% change in expression 
following bariatric surgery.  
PROBE_ID GENE Symbol P-valuea % Change DEFINITION 
 
ILMN_1679357 DEFA1/DEFA3 1.08E-03 -46% Defensin, alpha 1/ definsin alpha 3. 
ILMN_1692223 LCN2 4.37E-03 -46% Lipocalin 2 (oncogene 24p3). 
ILMN_1725661 DEFA1/DEFA3 1.16E-03 -45% Defensin, alpha 1/ defensin alpha 3 
ILMN_1693262 DEFA1/DEFA3 1.65E-03 -45% Defensin, alpha 1/ defensin alpha 3 
ILMN_1806056 
 
CEACAM8 
 
3.73E-03 
 
-45% 
 
Carcinoembryonic antigen-related cell adhesion 
molecule 8. 
ILMN_1688580 CAMP 1.76E-04 -41% Cathelicidin antimicrobial peptide. 
ILMN_1723035 OLR1 8.09E-03 -37% Oxidized low density lipoprotein (lectin-like) receptor 1. 
ILMN_1762713 C19ORF59 6.53E-03 -29% Chromosome 19 open reading frame 59. 
ILMN_1690546 
 
PPP3CC 
 
6.21E-03 
 
26% 
 
Protein phosphatase 3  catalytic subunit, gamma 
isoform. 
ILMN_1805271 ZNF721 6.81E-03 26% Zinc finger protein 721. 
ILMN_1813400 CBR4 8.96E-03 26% Carbonyl reductase 4. 
ILMN_1702858 ADHFE1 3.78E-03 27% Alcohol dehydrogenase, iron containing, 1. 
ILMN_1748476 NOP5/NOP58 2.49E-03 28% Nucleolar protein NOP5/NOP58. 
ILMN_1661940 CAMTA1 4.40E-03 28% Calmodulin binding transcription activator 1. 
ILMN_1656111 MYLIP 3.83E-03 29% Myosin regulatory light chain interacting protein. 
ILMN_1797893 PFAAP5 5.93E-03 31% Phosphonoformate immuno-associated protein 5. 
ILMN_1679045 SBDS 6.03E-03 39% Shwachman-Bodian-Diamond syndrome. 
 
a, Paired T-test pre- and post-surgery 
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Quantitative Real-Time PCR (qPCR) 
     To confirm the microarray data we performed quantitative real-time PCR for four 
selected transcripts: three highly regulated ones, DEFA1, CAMP, CEACAM8; and one 
non-regulated transcript related to obesity, ADIPOR1.  Paired t-test p-values for the 
effect of bariatric surgery on transcript expression levels were found to be consistent with 
the microarray data; and, the percent changes after surgery were similar or greater than 
the percent changes detected by microarray (Table 5.3).  The expression levels of these 
four transcripts were compared between the microarray and qPCR data for the 22 (pre 
and post-surgery) samples using linear regression analysis; and, each transcript had a 
very strong positive correlation (R values ranged from 0.75 to 0.88).   
 
Table 5.3: qPCR validation of microarray results for select transcripts 
 
Gene/Transcript 
Symbol 
Array vs. qPCR 
Correlation (R)a 
qPCR Paired T-Test  
P-valueb 
Array Paired T-Test  
P-valueb 
qPCR 
% Change 
Array 
% Change 
DEFA1 0.88 2.99E-03 1.08E-03 -64% -46% 
CAMP 0.75 1.01E-03 1.76E-04 -43% -41% 
CEACAM8 0.86 1.08E-02 3.73E-03 -57% -45% 
ADIPOR1 0.88 7.95E-02 9.13E-02 -35% -22% 
 
a, P-values of linear regression analysis are all significant (p<0.05). 
b,  Two-tailed paired t-test based on comparing transcript levels pre- vs. post- surgery.   
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Plasma protein assays 
     To determine whether the protein levels follow the same expression pattern as their 
transcripts we measured the activity/levels of two serum proteins, gamma-
glutamyltransferase and lipocalin 2.  Serum gamma-glutamyltransferase activity was 
reduced in the post-surgery samples by an average of 38% (p=0.05, paired t-test), 
consistent with the change observed for GGT1 mRNA levels in whole blood.  Plasma 
levels of lipocalin 2 were determined in 8 subjects pre and post surgery, and its levels 
were significantly increased after the surgery by an average of 34% (p=0.008), which is 
opposite to the whole blood LCN2 mRNA levels that were significantly decreased.  This 
discrepancy may be due to the majority of plasma lipocalin 2 being synthesized in tissues 
other than blood such as adipocytes and liver 10, 11. 
 
Pathway and correlation analyses 
     To identify the biological mechanisms, pathways and functions most relevant to the 
genes of interest, the differentially expressed transcripts (p <0.01) were subjected to 
Ingenuity Pathway Analysis.  The top scoring network identified was "lipid metabolism, 
small molecule biochemistry and gene expression" (Figure 5.1).  Of the 23 transcripts 
involved in the network, 16 were down regulated and seven were up regulated.  The 
following pathways (together with their respective genes) were the most significantly 
represented canonical pathways: myc-mediated apoptosis signaling (FAS↑, SHC1↓ and 
TP53↓), and fatty acid metabolism (ADHFE1↑, CPT1A↓, CYP51A1↓ and SLC27A6↓). 
     Linear regression analysis was performed in order to identify changes in transcript 
expression that were best correlated with changes in weight, FPG, HbA1C, and WBC 
155 
 
count, using an arbitrary R2 cutoff of ≥0.25.  We found t hat 20 (9.8%) of these 
 
differentially regulated transcripts were highly correlated with changes in weight 
(Appendix 5C).  Of these 20 transcripts, 12 were found to be inversely correlated and 8 
were positively correlated with weight change.  The transcript for prenyl (decaprenyl) 
 
Figure 5.1: Lipid Metabolism, Small Molecule Biochemistry, Gene Expression Network.  The 
straight lines represent direct relationships and the dotted lines represent indirect relationships. Up 
regulated and down-regulated genes that meet the P-value cutoff of <0.01 are shown in red and 
green respectively, with color intensity related to the fold change in expression.  Symbols used in 
the figure represent: trapezoid, transporter; circle, other; concentric circles, complex/group; dotted 
square, growth factor; vertical rhombus, enzyme; horizontal rhombus, peptidase; horizontal oval, 
transcription regulation; vertical oval, transmembrane receptor. 
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diphosphate synthase subunit 1 (PDSS1) was best correlated with weight change (R=-
0.80).  GO analysis revealed two related GO terms that were significantly represented, 
cholesterol biosynthetic process (p=1.23E-04) and sterol biosynthetic process (p=2.21E-
04, Appendix 5D). 
     Thirty-five (17.2%) transcripts were highly correlated with changes in FPG.  More 
transcripts were inversely correlated than positively correlated (23 versus 12).  The 
transcript best correlated with changes in FPG was HHAT (R=-0.79), which encodes the 
hedgehog acyltransferase enzyme.  Thirty-two (15.7%) transcripts were strongly 
correlated with changes in HbA1C levels, of which 23 were inversely and 9 transcripts 
were positively correlated (Appendix 5C).  The transcript best correlated with changes in 
HbA1C content (R=-0.75) encodes for the WD repeat 35 protein (WDR35).  We looked 
for transcripts that were correlated to more than one of these clinical traits, and we found 
many that were highly correlated with two or more traits, and seven that were highly 
correlated with all three traits (Figure 5.2).  These seven transcripts were WDR35, 
FLJ45244, DHCR24, TIGD7, TOPBP1, TSHZ1 and FAM8A1 (Appendix 5C).   
     Twenty-seven (13.24%) transcripts were strongly correlated with changes in WBC 
count, with 16 inversely and 11 positively correlated.  Two of our top three differentially 
expressed transcripts, GGT1 and CAMP, were highly and positively correlated with 
changes in WBC count (R= 0.63 and 0.56, respectively, Appendix 5C).   
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Figure 5.2: Venn diagram representing the number of transcripts that were highly correlated 
with percent changes in weight loss, fasting plasma glucose and HbA1c content.  Seven 
transcripts were highly correlated with changes in the three clinical characteristics. 
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DISCUSSION 
     This pilot study was designed to examine the clinical and biochemical changes 
induced by bariatric surgery and their association with changes in whole blood gene 
expression in obese subjects with type 2 diabetes. This is the first study that we are aware 
of comparing the whole blood transcriptome in subjects before and after bariatric surgery. 
Our pilot study identified many transcripts whose expression levels in whole blood were 
significantly changed after bariatric surgery, some of which were previously reported to 
be implicated in obesity and/or type 2 diabetes.   
     In the present study, we found that bariatric surgery led to significantly decreased 
levels of serum alanine aminotransferase (ALT) (54% decrease), plasma VLDL-
cholesterol, and serum gamma-glutamyltransferase (GGT) activity.  Given previously 
reported association of elevated serum VLDL, ALT and GGT levels with hepatic 
steatosis in obese and type 2 diabetes subjects, and the positive effects of bariatric 
surgery to reverse hepatic steatosis and the levels of these markers 12, their decreased 
levels in our study likely reflect the reduction of hepatic fat and improvement in liver 
function following bariatric surgery.  We found a decrease in whole blood GGT1 mRNA 
levels, the transcript with the most significant p-value in our study. Since the liver is 
thought to be the major source of serum GGT activity 13, this result implies that the liver 
and blood levels of GGT1 mRNA may be coordinately regulated.  Thus, our observed 
decrease in whole blood GGT1 mRNA levels along with decreased FPG levels after 
bariatric surgery in the current study are consistent with these prior studies that showed 
increased serum GGT activity in those at most risk for type 2 diabetes. 
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     A variety of acute-phase proteins are increased in subjects with obesity and type 2 
diabetes 14; while, several acute phase reactant proteins have been shown to decline 
following bariatric surgery 15. We found that the mRNA levels of two antimicrobial 
peptides, cathelicidin antimicrobial peptide (CAMP) and alpha defensin 1/3 
(DEFA1/DEFA3), were significantly decreased after bariatric surgery.  In two prior 
studies, plasma levels of alpha defensins were found to be decreased by 55 to 60% in 
women after bariatric surgery, and their levels were correlated with changes in plasma 
triglyceride levels and pathology based measures of liver steatosis and inflammation 16,17.  
Thus, our finding of decreased DEFA1/DEFA3 mRNA levels after bariatric surgery 
agrees with prior protein based assays. 
     Lipocalin 2 (LCN2) is another gene whose expression was significantly (46%) 
decreased after surgery.  LCN2 has been classified as an adipokine that increases 
expression of PPARγ and adiponectin in 3T3-L1 adipocytes, and suppresses LPS-induced 
macrophage cytokine production 18.  Lcn2 mRNA is increased in the liver and adipose 
tissue of db/db  vs. wild type mice; and, lipocalin 2 protein levels are higher in obese vs. 
lean humans 19.  Furthermore, plasma lipocalin 2 levels are positively correlated with 
BMI, adiposity, hyperglycemia, and insulin resistance 19.  Lipocalin 2 has also been 
implicated in innate immunity, as Lcn2-deficient mice are more susceptible to bacterial 
infection 19.  Although blood LCN2 mRNA was decreased after surgery in our study, we 
found that plasma lipocalin 2 levels increased after surgery, which may be attributed to 
increased secretion from another tissue source. Although our observed effects of surgery 
on plasma lipocalin 2 levels are not concordant with the prior correlations, we are not 
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aware of any other studies measuring plasma lipocalin 2 before and after bariatric 
surgery. 
     Tumor protein p53 (TP53) is another transcript that we identified that was down 
regulated after bariatric surgery.  A recent study has reported that adipose tissue p53 
plays a crucial role in the regulation of insulin resistance 20.  Increased expression of p53 
was found to be associated with an increased production of proinflammatory cytokines 
that led to insulin resistance, while decreased expression had the opposite effect on 
proinflamatory cytokines and was associated with improved insulin resistance in mice 
with type 2 diabetes-like disease.  Thus, our finding of decreased whole blood p53 
mRNA after bariatric surgery, weight loss, and remission of type 2 diabetes is consistent 
with this prior study. 
     The lectin-like low density lipoprotein receptor 1 (OLR1) gene, also known as LOX1, 
encodes for a protein that can be proteolytically cleaved and released as soluble form in 
serum.  Whole blood OLR1 mRNA levels were significantly decreased by 37% after 
bariatric surgery in our study, consistent with a previous study reporting that the serum 
levels of the sLOX1 protein is higher in type 2 diabetes patients than in controls 21.  
     Human genome wide association studies have identified many SNPs associated with 
type 2 diabetes.  Four genes with common SNPs that were previously identified to be 
associated with type 2 diabetes 22-24 are found in our list of 204 transcripts whose 
expression was altered after bariatric surgery.  Surgery induced changes in expression of 
all four of these genes were found to be highly correlated with surgery induced changes 
in HbA1C content.  These four genes are: contactin associated protein-like 5 (CNTNAP5, 
decreased after surgery), 24-dehydrocholesterol reductase (DHCR24, decreased), 
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hedgehog acyltransferase (HHAT, increased), and sarcosine dehydrogenase (SARDH, 
decreased).  The finding that two distinct methods, genetic association with type 2 
diabetes and transcriptome profiling after bariatric surgery, yield four identical gene hits 
highlights a potential for gene environmental interactions playing an important role for 
these specific genes and their influence on glucose homeostasis. 
     DHCR24 was one of seven genes whose change in expression level after bariatric 
surgery was also positively and highly correlated with changes in the three examined 
clinical phenotypes: HbA1C content, weight, and FPG.  DHCR24 gene encodes an 
enzyme participating in sterol biosynthesis; however, it also has another activity, it binds 
to p53 and protects it from degradation leading to cellular defense against oxidative stress 
25, 26.  DHCR24 is upregulated in endothelial cells by exposure to HDL, and the HDL 
mediated lowering of NF-kB and VCAM expression is dependent upon DHCR24 
expression 27.  The decrease in expression of both DHCR24 and p53 in whole blood after 
surgery reinforce the concept that surgically induced weight loss and remission of type 2 
diabetes may alter WBC p53 pathways; however, the role of DHCR24 in WBC 
metabolism and inflammation is not known. 
     Our study used whole blood rather than isolated peripheral mononuclear cells to avoid 
gene expression changes due to variable handling times during processing 28, in addition 
to capturing changes in more cell types.  Adipose tissue would be an attractive tissue to 
analyze in regard to changes in gene expression following bariatric surgery, since a 
higher proportion of adipose transcripts than whole blood transcripts are correlated with 
BMI in a population study 29.  However, blood is simpler to obtain, particularly for serial 
sampling; and, genetic cis effects on gene expression are mostly conserved between 
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adipose tissue and whole blood 29.  Furthermore, white blood cell expression profiling has 
been shown to be useful for screening of diseases of non-blood tissues, such as colorectal 
cancer 30.  In a prior preliminary study, whole blood transcriptome profiling was used to 
compare six obese and four lean subjects, yielding a set of transcripts that were 
differentially expressed 31; although only 18 genes were presented and the complete list 
of regulated transcripts was not reported.  One potential complication of the use of whole 
blood for transcriptome analysis is that the abundant globin mRNA can interfere with 
subsequent analyses.  There are several ways to counter this issue, and we chose NuGen 
Ovation RNA amplification kit to eliminate this problem, as it has been shown to be the 
most efficient method and yields increased sensitivity 32. 
     The present study had several limitations. The small sample size led to a high FDR 
and prevented the analysis of differential transcriptome responses to the RYGB and SG 
surgeries.  The paired t-test analysis with each subjects' pre and post surgery whole blood 
RNA placed on the same Illumina BeadChip controlled for chip to chip variation; but, 
this design also precluded the use of multiple logistic regression to correct for covariates 
such as gender and surgery type.  Overall, we did not observe large fold effects on 
transcript levels, but variations of 10% to 60% can have meaningful physiological 
consequences.   
     In conclusion, our pilot study identified many genes whose expression was markedly 
altered in whole blood following bariatric surgery, some of which are related to 
inflammation and lipid metabolism.  We identified seven genes whose expression 
changes were correlated with changes in HbA1C content, weight, and FPG.  Thus, whole 
blood expression levels of these and potentially other transcripts identified in this study 
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may be useful as biomarkers indicative of type 2 diabetes susceptibility, as well as 
response to various therapeutic regimens.  In addition, this type of study may illuminate 
new targets and pathways for intervention. 
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CHAPTER VI 
GENERAL CONCLUSIONS 
 
 
     A gender specific atherosclerosis QTL (Ath24) was identified in an intercross between 
atherosclerosis resistant AKR and atherosclerosis susceptible DBA/2 strain prior to my 
involvement in the research studies presented in this dissertation.  Furthermore, Pan3 
gene was identified as the top candidate gene for this locus by using an integrated 
genetic-genomic approach.  At the time I started working on this research project the goal 
was twofold: to validate Ath24 QTL as a locus harboring gene(s) that affect 
atherosclerosis and, to confirm or exclude Pan3 as the gene responsible for the Ath24 
QTL.    
     To achieve the first goal, we generated congenic mice for the Ath24 QTL on the AKR 
and DBA/2 Apoe-/- parental strains, performed progeny testing by brother-sister mating, 
and quantified aortic root lesion area.  A high number of different recombinants 
generated within the interval, mainly due to its length (~35 Mb) and the presence of 
recombination hotspots, presented challenges which took a considerable amount of time 
to troubleshoot.  Furthermore, the fact that AKR strain is a challenging breeder made it 
168 
 
difficult to carrying out the project at a fast pace.  The atherosclerosis assays are still 
ongoing; however, at this time we have not been able to validate the Ath24 QTL interval 
on either of the parental strains background.  One of the reasons might be that the inbred 
genetic background of the congenic strain is quite different from the mixed genetic 
background of the F2 cohort that was used to identify the QTL, therefore important gene-
gene interactions might have been eliminated.  To overcome this problem we are 
currently following another strategy, which instead of using congenic mice and testing 
the phenotype on the inbred background of either parental strain, uses interval specific 
congenic strains on the F1 background.  This approach was designed to restore genetic 
interactions and consequently the desired phenotype modified by the responsible modifier 
gene.      
     The second goal was to: 1) identify any structural or splice variant differences 
between the AKR and DBA/2 Pan3 allele; and, 2) test whether lower expression levels of 
Pan3 transcript would be associated with smaller aortic lesions, a result that could also 
explain the positive association/correlation that was previously observed between Pan3 
gene and the aortic root lesion size.   
     Regarding splice variants, we identified three new alternatively spliced variants for the 
Pan3 gene in bone marrow macrophages.  These alternatively spliced Pan3 transcripts 
differed from the canonical Pan3 transcript at the 3’ends which correspond to the C-
terminus for those transcripts that were theoretically translatable into proteins.  However, 
these novel splice variants were found in both AKR and DBA/2 strains. We think that it 
would be informative to determine the expression levels of these splice variants in the 
two strains.  Also, it would be useful to search for their presence and/or the presence of 
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other possible alternatively spliced variants in tissues such as endothelial cells and liver 
which are known to be implicated in atherosclerosis.    
     Additionally, we identified two strain specific novel SNPs located upstream of the 
Pan3 gene, positioned in predicted transcription factor binding sites for Runx1 (activator) 
and CTCF (which is a context dependent activator or repressor).  We are not sure whether 
the SNPs are functional but it may be informative to study whether they regulate the 
expression of Pan3 and/or other nearby genes.    
     To study the effect of Pan3 gene deficiency on atherosclerosis, we generated a 
knockout mouse model.  We were unable to study the effect of Pan3 total deficiency on 
atherosclerosis as Pan3 knockout (-/-) mice were not viable.  Thus, we studied the effect 
of Pan3 partial deficiency on atherosclerosis.  Although, we observed a 64% reduction in 
Pan3 gene expression level in bone marrow macrophage of female hemizygous (-/+) mice 
when compared to Pan3 wild type (+/+) mice, we did not observe a significant difference 
in aortic lesion size in Pan3 hemizygous versus wild type mice.   
     Real-time PCR quantification of Pan3 transcript revealed that female F2 mice with 
larger aortic lesions have a higher expression of the Pan3 gene when compared with 
female F2 samples characterized by smaller aortic lesions, however, the expression of 
Pan3 gene in the parental strains was unexpectedly found to be the same between AKR 
and DBA/2 Apoe-/-.  Taking all these findings together we hypothesized that it is possible 
that we may not observe an effect of the Pan3 gene partial deficiency when bred onto a 
inbred parental background because important gene-gene interactions have been 
eliminated.  Therefore, we decided to adopt the F1 background strategy for studying the 
effect of Pan3 gene expression on atherosclerosis and these studies are ongoing.   
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     At the moment we remain unsure whether Pan3 is the responsible gene for Ath24 
QTL; however, if Pan3 gene is excluded as the responsible gene we have been able to 
identify Flt3, Alox5ap, Hmgb1 and Por as alternate candidate genes for the locus which 
might be further studied for their role on atherosclerosis.  
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Appendix 2A: The genomic sequence and the position of rs13462610 SNP used to 
design a custom TaqMan genotyping assay.  The polymorphic SNP for AKR and DBA/2 
inbred strains (shown in bold) represents a coding synonymous mutation, located at 
152.45 Mb [exon 4 of replication factor C (activator 1) 3 (Rcf3)] gene. 
 
Part Number 4332077 
Rs13462610, Chr5 
  
AGTAAGAACAAACTGCTGTAAGGACACAATGTTTTTAGTGGTGGTACAATTTAAATTTGCTACTGAGCCTA
AAAGATCTCAAGTTTCAAGGTTCCTACTTGTAATTAGATATTACTAGTTTCAGCAAAACACAAACAGAAGA
AAGCAAACTTCCTGATAGTGTTCACGTAATAACAGATTAAGAGTGAGGGTGCAATACTTGGTGAGTGTTTA
CATCCATGTGACCATCATTCTGGTGTCGTGTAGTGATGCGGGGAACAGCGACCGAGTTGTAATTCAGGAGA
TGCTGAAGACAGTGGC[A/C]CAGTCACAACAACTTGAAACCAGCTCACAAAGAGACTTCAAAGGTGAGGG
GCTTTCTGTGAGGCTGGGGACCATCAGTGCTTTTACATTGGAGTACAAATGAATGCGTGCTGTGCAAGGTT
GCACCCACCCTTAATCTGAGTGCCCGGGAGGCAGAGACAGGAGGATCTCTGAAAGTTCCAAGCCAGCCTGT
TTTATAGAGTGAGCTCTAGGGCAGCCAGGCCTGCATGTAGAGGCCTGTCAGAAAAAAAAAAAAAGAAAAAA
GACATATGAATGGAAGCCCTGGTCTCTGCTCATGGTG 
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APPENDIX 3A: The table presents the sequences and detailed characteristics of primers used for genotyping of Pan3 gene coding 
sequence in AKR and DBA/2 strains, as well as information on the expected amplification products. 
 
 
Rank 
 
Primer name 
 
Primer 
length  
 
Primer sequence 
 
Primer 
Tm$ (in 
oC) 
 
Product ID 
 
Expected 
product  
Length 
 
Optimal 
annealing 
Tm (in oC) 
 
Product GC 
content 
 
Sequenced 
(YES/NO) 
1a Exon 1-fragment 1 F* 20-mer 5’ TCCAGAAGAGGGCGTCAGAT 3’ 53.6  
Exon 1-fragment 1 
 
557 bp 
 
55.2 
 
45.1% 
 
NO 1b Exon 1-fragment 1 R# 20-mer 5’ TTGGGGAGTGGGGAGAGTGT 3’ 55.5 
2a Exon 1-fragment 2 F 20-mer 5’ ACTCTCCCCACTCCCCAACA 3’ 55.5  
Exon 1-fragment 2 
 
550 bp 
 
55.1 
 
42.7% 
 
YES 2b Exon 1-fragment 2 R 23-mer 5’ TGAACCGCAGTGAAGTGAAAAAT 3’ 55.4 
3a Exon 1-fragment 3 F 19-mer 5’ GTCAGGCTGCCACGATTCC 3’ 55.2  
Exon 1-fragment 3 
 
522 bp 
 
55.6 
 
44.8% 
 
YES 3b Exon 1-fragment 3 R 24-mer 5’ CTCCGCCACCCCTCTAGCCTTTGT 3’ 64.3 
4a Exon 1-fragment 4 F 24-mer 5’ AGGGTTCTGGCTCCATCTTTTGAC 3’ 58.6  
Exon 1-fragment 4 
 
562 bp 
 
61.4 
 
61.6% 
 
YES 4b Exon 1-fragment 4 R 24-mer 5’ GAGGGAGCCGCCGGTTTGTTTTTA 3’ 64.7 
5a Exon 1-fragment 5 F 17-mer 5’ GAGGGCTCGGGCTGAAG 3’ 52.8  
Exon 1-fragment 5 
 
453 bp 
 
63.1 
 
74% 
 
YES 5b Exon 1-fragment 5 R 16-mer 5’ CGGGCGGGCGGGTTGG 3’ 64.8 
6a Exon 1-fragment 6 F 18-mer 5’ CCGCCCGCCCGCCCTTCC 3’ 70.0  
Exon 1-fragment 6 
 
620 bp 
 
70.0 
 
79% 
 
YES 6b Exon 1-fragment 6 R 23-mer 5’ GCACCAACCCCGCACCGCACCAC 3’ 72.3 
7a Exon 2 F 18-mer 5’ GATTATGGGACTCTGAAA 3’ 38.3  
Exon 2 
 
281 bp 
 
48.7 
 
41.3% 
 
YES 7b Exon 2 R 17-mer 5’ CTGCCCTCCCCAACCTC 3’ 52.3 
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8a Exon 3 F 23-mer 5’ ACCTGGCCTAGTCTGTCTTTCTG 3’  53.4  
Exon 3  
 
248 bp 
 
50.3 
 
37.5% 
 
YES 8b Exon 3 R 24-mer 5’ TTTTCTAATTAATACCTGCTCACA 3’ 48.1 
9a Exon 4 F 17-mer 5’ CATTGGGCTGCTGTTGA 3’ 47.7  
Exon 4 
 
242 bp 
 
52.1 
 
44.6% 
 
YES 9b Exon 4 R 19-mer 5’ CCCACTGAGGAAAATGTTG 3’ 47.5 
10a Exon 5 F 18-mer 5’ TAACCTCTCCGAATAAGT 3’ 38.0  
Exon 5 
 
457 bp 
 
48.7 
 
39.4% 
 
YES 10b Exon 5 R 15-mer 5’ CCCTGGCAACACAAG 3’ 41.1 
11a Exon 6 F  24-mer 5’ GTTTGCATTTATTTTCCAGTTTTT 3’ 51.1  
Exon 6 
 
400 bp 
 
54.6 
 
49.8% 
 
YES 11b Exon 6 R 20-mer 5’ GGGGGTGACCTCATTAGTTA 3’ 48.1 
12a Exon 7 F 20-mer 5’ TTAACTATACCAAAATCACT 3’ 36.0  
Exon 7 
 
322 bp 
 
48.2 
 
41.3% 
 
YES 12b Exon 7 R 20-mer 5’ CCACTTGCTTAGGAGACTGC 3’ 49.1 
13a Exon 8 F 19-mer 5’ TAGGTATAATGGGAAATCT 3’ 37.9  
Exon 8 
 
185 bp 
 
46.6 
 
37.3% 
 
YES 13b Exon 8 R 17-mer 5’ CGCCTGCCTTGCCTGAG 3’ 55.0 
14a Exon 9 F 21-mer 5’ TGGGGTTTGACAGTGGGTAGT 3’ 53.2  
Exon 9 
 
416 bp 
 
53.2 
 
40.4% 
 
YES 14b Exon 9 R 23-mer 5’ TAATCTTCAAATGGGGACAAAAA 3’ 52.4 
15a Exon 10 F 23-mer 5’ AATACTTTACAGCCAACATAGAC 3’ 44.9  
Exon 10  
 
298 bp 
 
49.2 
 
38.3% 
 
YES 15b Exon 10 R 21-mer 5’ TTACAAAGAAACAGAAACACA 3’ 42.7 
16a Exon 11 F 23-mer 5’ GAGCCTTGTAAGTACCCAGTCCT 3’  52.6  
Exon 11 
 
241 bp 
 
54.7 
 
48.1% 
 
YES 16b Exon 11 R 24-mer 5’ GTCAAAAGCATGCATCAAAACAGT 3’ 55.0 
17a Exon 12 F 19-mer 5’ CTCTAATAGTGTGAAACCT 3’ 34.9  
Exon 12 
 
316 bp 
 
49.1 
 
45.6% 
 
YES 17b Exon 12 R 19-mer 5’ CACTAAAGAAAAATGACAA 3’ 37.2 
18a Exon 13 F 18-mer 5’ TTTGTGGGTGGGGAGGAT 3’ 52.0  
Exon 13 
 
220 bp 
 
50.0  
 
33.6% 
 
YES 18b Exon 13 R 23-mer 5’ AAAACCAAAATAAGCAGCCATAC 3’ 51.6 
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19a Exon 14 F 20-mer 5’ AAGTTATGTTTATTTTCTCA 3’  36.2  
Exon 14 
 
262 bp 
 
37.8 
 
40.5% 
 
YES 19b Exon 14 R 20-mer 5’ AATAACTGCTTGTGTCTGCT 3’ 44.0 
20a Exon 15 F 21-mer 5’ TTATTAACCCTTGCTGACCAT 3’  48.5  
Exon 15 
 
278 bp 
 
51.7 
 
44.6% 
 
YES 20b Exon 15 R 23-mer 5’ CTAAACTACTGCCTACTGTGAAC 3’ 45.2 
21a Exon 16 F 20-mer 5’ CTCAGTTCATATTCAGTTAG 3’ 35.8  
Exon 16 
 
199 bp 
 
46.2 
 
37.7% 
 
YES 21b Exon 16 R 19-mer 5’ TAGTTCGCTCATTCCTTAC 3’ 41.8 
22a Exon 17 F 18-mer 5’ TAATTAACTGGGGAAGAT 3’ 38.1  
Exon 17 
 
287 bp 
 
48.5 
 
41.5% 
 
YES 22b Exon 17 R 20-mer 5’ ACACAGACATAGTAAGAACC 3’ 37.4 
23a Exon 18 F 23-mer 5’ ATTATAGTATTTCATTCATCATC 3’ 39.9  
Exon 18 
 
319 bp 
 
49.3 
 
41.1% 
 
YES 23b Exon 18 R 21-mer 5’ GAGGACAGTTCAGCCGTAGTG 3’ 51.4 
24a Exon 19-fragment 1 F 24-mer 5’ AGATATGAATTTCCGTTTGTTGAT 3’ 50.9  
Exon 19-fragment 1 
 
651 bp 
 
53.6 
 
42.1% 
 
YES 24b Exon 19-fragment 1 R 22-mer 5’ AGCACCGGGAAGGAGATGAAGT 3’  57.8 
25a Exon 19-fragment 2 F 18-mer 5’ CCTGTAGGGTCGGTCATC 3’ 46.8  
Exon 19-fragment 2 
 
407 bp 
 
52.1 
 
42.5% 
 
YES 25b Exon 19-fragment 2 R 19-mer 5’ GCAAATTTCAAGGCAGAGA 3’ 47.8 
26a Exon 19-fragment 3 F 21-mer 5’ GTGGGGATTTGGAGGTCAGGA 3’ 57.3  
Exon 19-fragment 3 
 
624 bp 
 
53.2 
 
35.3% 
 
YES 26b Exon 19-fragment 3 R 22-mer 5’ CCAGGCCCCCAAAACTAAAATA 3’ 56.1 
27a Exon 19-fragment 4 F 22-mer 5’ ATTTATAAGCGGGCTGGAGATT 3’  53.1  
Exon 19-fragment 4 
 
491 bp 
 
52.5 
 
39.3% 
 
YES 27b Exon 19-fragment 4 R 22-mer 5’ AAAAAGCAAAGCAAAACAAAAC 3’ 50.5 
28a Exon 19-fragment 5 F 17-mer 5’ CAGCCAGAAAACAGTCG 3’  43.6  
Exon 19-fragment 5 
 
693 bp 
 
49.4 
 
36.1% 
 
YES 28b Exon 19-fragment 5 R 19-mer 5’ TTCACCCAAAATACATAGG 3’ 42.3 
Tm$, temperature; F*, Forward primer; R#, Reverse primer; bp, base pairs 
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APPENDIX 3B: The table presents the sequences and detailed characteristics of primers used for amplification of exons from Pan3 
cDNA.  
 
Rank 
 
Primer name 
 
Primer sequence 
 
Expected 
product  
Length 
 
Optimal 
annealing Tm 
(in oC) 
 
Product GC content 
1a AltSpl Exons 1-3 forward 5’-GATGGCCCGCGGGTGGCGATTCC-3’  
271 bp 
 
60.4oC 
 
49.1% 1b AltSpl Exons 1-3 reverse 5’-TCTGGGAGATGTTGAGGGCACCGAAGTCAT-3’ 
2a AltSpl Exons 3-5 forward  5’-CCGGGAATGGATGGAGGTG-3’  
449 bp 
 
56.9oC 
 
47.9% 2b AltSpl Exons 3-5 reverse 5’-TTGGGGGAATGGAGAGGGGAAGAT-3’ 
3a AltSpl Exons 5-7 forward 5’-TCGGTGCCCTCAACATCTCC-3’  
592 bp 
 
57.6oC 
 
49.5% 3b AltSpl Exons 5-7 reverse 5’-GCTGGCATATCTGCTTGGTCAAT-3’ 
4a AltSpl Exons 7-9 forward 5’-GGGGGACGACTTACTTCTATACAGATA-3’  
371 bp 
 
55.2oC 
 
45.3% 4b AltSpl Exons 7-9 reverse 5’-CCTCCGAAGGCAATATGGCAGAT-3’ 
5a AltSpl Exons 9-11 forward 5’-TCCGACAGGAGCTGATCAACAGAC-3’  
423 bp 
 
56.1oC 
 
43.3% 5b AltSpl Exons 9-11 reverse 5’-CATCAGAATTCGGGTCGTTAAAGTGTC-3’ 
6a AltSpl Exons 11-13 forward 5’-AAATATTGTAACTCTGCGTGAAG-3  
410 bp 
 
53oC 
 
44.4% 6b AltSpl Exons 11-13 reverse 5’-GGTACTGAGCCATTAATGCCAAAGGAT-3’ 
177 
 
7a AltSpl Exons 13-15 forward 5’-AGGTTTGGCCTGTAGAGTAATGGAC-3  
463 bp 
 
54.4oC 
 
40.6% 7b AltSpl Exons 13-15 reverse 5’-TCCCAATTTTGCTAGAAGCCTAAA-3’ 
8a AltSpl Exons 15-17 forward 5’-GGCTTTGGCTTGCAACTCTTTG-3’  
413 bp 
 
56.1oC 
 
44.8% 8b AltSpl Exons 15-17 reverse 5’-TGAGGTCGATCCAGGGAGCAC-3’ 
9a AltSpl Exons 17-19 forward 5’-GGAGGTTCAAAATGGAAGACTGTTTAG-3’  
485 bp 
 
56oC 
 
44.9% 9b AltSpl Exons 17-19 reverse 5’-TTAGGCCTTCAGCACAATTTCATTTT-3’ 
Tm$, temperature; F*, Forward primer; R#, Reverse primer; bp, base pairs 
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Appendix 3C: The primers and probes for the Mus musculus Pan3 custom TaqMan gene 
expression assay designed to quantify Pan3 transcript expression at exons 2-3 junction. 
 
Cleveland Clinic Foundation  
Part number: 4331348 
 
Product Type: Custom Taqman(R) Gene Expression Assay Service 
Assay Mix Concentration: 20x  
Assay ID: AI7ZZNC         
 
Forward Primer Seq. TTGGAAGCCCTGTAGAAACAAAGT 
Reverse Primer Seq. GGCTTGGCACTGTCATTTAGAAG 
Reporter 1 Sequence: CTTGATGCAGAGAATGAC 
Reporter 1 Dye: FAM 
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Appendix 3D: Table represents the list of SNPs (genotyped from different sources) that were found to be different between Mus 
musculus Pan3 gene AKR and DBA/2 alleles, including 5,000 base pairs on each side, upstream and downstream the Pan3 genomic 
sequence coordinates (148,242,465 ÷ 148,360,072).  SNPs data were downloaded from Mouse Phenome Database 
(http://www.jax.org/phenome). 
 
Mbp 
location 
(Build 37) 
 Chr. 5 
 
NCBI 
Gene 
Annotation 
  
dbSNP 
128 
SNP 
Annotation 
 
AKR 
  
DBA/2 
 
dbSNP (Rs) 
 
Observed 
 
Source 
 
148.261443 Pan3 intron 1 I A G Rs32385875 A/G (Celera2,Perlegen2) 
148.261770 Pan3 intron 1 I A G Rs32385878 A/G (Broad1,Celera2,Perlegen2) 
148.285849 Pan3 intron 4 I G A Rs6349247 A/G (Celera2,GNF2,Perlegen2,WICGR3) 
148.286206 Pan3 intron 4 I A C Rs29681007 A/C (Broad1,Broad2,CGD2,Celera2,Perlegen2) 
148.289271 Pan3 intron 4 I T C Rs29542678 C/T (Celera2,Perlegen2) 
148.289673 Pan3 intron 4 I A T Rs32389811 A/T (Celera2,Perlegen2) 
148.290056 Pan3 intron 4 I G A Rs32390585 A/G (CGD2,Celera2,Perlegen2) 
148.291740 Pan3 intron 4 I C G Rs32390589 C/G (Celera2,Perlegen2) 
148.292081 Pan3 intron 4 I T A Rs32383854 A/T (Celera2,Perlegen2) 
148.297602 Pan3 intron 4 I T A Rs29528199 A/T (Celera2,Perlegen2) 
148.299117 Pan3 intron 4 I A G Rs29823197 A/G (Celera2,Perlegen2) 
148.300164 Pan3 intron 5 I T C Rs32384887 C/T (Celera2,Perlegen2) 
148.301196 Pan3 intron 5 I C T Rs29533191 C/T (Celera2,Perlegen2) 
148.301465 Pan3 intron 5 I A G Rs29551095 A/G (CGD2,Celera2,Perlegen2) 
148.302185 Pan3 intron 5 I T C Rs29508505 C/T (CGD2,Celera2,Perlegen2) 
148.302567 Pan3 intron 5 I C A Rs32386474 A/C (Celera2,Perlegen2) 
148.314277 Pan3 intron 5 I G A Rs29781644 A/G (Broad1,Broad2,CGD2,Celera2,Perlegen2) 
148.315870 Pan3 intron 5 I C G Rs32387380 C/G (Celera2,Perlegen2) 
148.321802 Pan3 intron 5 I G C Rs32388993 C/G (Perlegen2)  
148.328035 Pan3 intron 5 I G A Rs32390490 A/G (Broad1,CGD2,Celera2,Perlegen2) 
148.328654 Pan3 intron 5 I C A Rs32384664 A/C (Celera2,Perlegen2) 
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148.330600 Pan3 intron 5 I G C Rs29577726 C/G (Celera2,Perlegen2) 
148.331677 Pan3 intron 6 I C A Rs32385428 A/C (Celera2,Perlegen2) 
148.332846 Pan3 intron 6 I A C Rs32386005 A/C (Perlegen2) 
148.332857 Pan3 intron 6 I T C Rs29545406 C/T (Broad1,Broad2,Celera2) 
148.333498 Pan3 exon 7 *Cs   D246 T C Rs32386009 C/T (Celera2,Perlegen2) 
148.333956 Pan3 intron 7 I A G Rs29765605 A/G (Celera2,Perlegen2) 
148.334112 Pan3 intron 7 I C T Rs32386765 C/T (Celera2,Perlegen2) 
148.339921 Pan3 intron 11 I A G Rs32389473 A/G (CGD2,Perlegen2) 
148.342519 Pan3 intron 12 I C A Rs29682472 A/C (Celera2,Perlegen2) 
148.343078 Pan3 intron 13 I C T Rs32391044 C/T (Celera2,Perlegen2) 
148.343217 Pan3 intron 13 I G A Rs32391045 A/G (Celera2,Perlegen2) 
148.343234 Pan3 intron 13 I C T Rs29525584 C/T (Celera2,Perlegen2) 
148.343521 Pan3 intron 13 I G A Rs32391046 A/G (CGD2,Celera2,Perlegen2) 
148.344661 Pan3 intron 13 I C A Rs32391050 A/C (Celera2,Perlegen2) 
148.345598 Pan3 intron 13 I G A Rs29721674 A/G (Celera2,Perlegen2) 
148.345668 Pan3 intron 13 I A T Rs32391051 A/T (Perlegen2) 
148.345733 Pan3 intron 13 I A G rs32391053 A/G (Perlegen2) 
148.349297 Pan3 intron 14 I T C rs32384566 C/T (Perlegen2)  
148.350022 Pan3 intron 14 I A G rs29618999 A/G (Celera2,Perlegen2) 
148.351689 Pan3 intron 16 I T C rs29561707 C/T (Celera2,Perlegen2) 
148.351853 Pan3 intron 16 I ? C rs29628792 C/G (CGD2,Celera2,Perlegen2) 
148.352568 Pan3 intron 16 I C T rs32384573 C/T (Perlegen2) 
148.352699 Pan3 intron 16 I C T rs32385538 C/T (Perlegen2) 
148.353287 Pan3 intron 16 I A G rs29775265 A/G (Celera2,Perlegen2) 
148.354475 Pan3 intron 16 I T A rs32386257 A/T (Perlegen2) 
148.354596 Pan3 intron 16 I A G rs32386259 A/G (Perlegen2) 
 148.354692 Pan3 exon 17 Cs   L610 T C rs32386260 C/T (Perlegen2) 
148.355460 Pan3 intron 17 I G A rs29530120 A/G (Celera2,Perlegen2) 
148.357782 Pan3 intron 18 I A G rs32387906 A/G (Perlegen2) 
148.360714     T C rs32387909 C/T (Perlegen2) 
148.360838     C T rs29530164 C/T (CGD2,Celera2,Perlegen2) 
148.361189     A C rs32387911 A/C (Perlegen2) 
148.361206     C T rs32387912 C/T (Celera2,Perlegen2) 
148.363984     C A rs32388911 A/C (Perlegen2) 
148.364112     T C rs32388912 C/T (Perlegen2) 
 
*Cs, coding synonymous mutation; D, aspartic acid; L. leucine.  
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Appendix 3E: Canonical and newly identified Pan3 transcripts’ sequences and their 
respective predicted protein’s amino acids content.  The alternatively spiced transcripts 
were detected in BMM of AKR and DBA/2 strains.    
 
Canonical Pan3 mRNA sequence (NM_028291.2) 
 
TTTCCTCCGGGAGCGCTCCCGGGCGGGGGAGCGGGGCCGCCCGCGGGGCC 
CAAGAAGCCGGAGCTGGGCGTCCCGGGGGCGGCGACCGCGGGCGGCGGAC 
TCGATGGCCCGCGGGTGGCGATTCCGGGAATGGATGGAGGTGCTTTAACT 
GATGCGAGTCTCACAGAGTCCTATTTCAGCACCAGCTTTATTGGAGTCAA 
TGGATTTGGAAGCCCTGTAGAAACAAAGTATCCCTTGATGCAGAGAATGA 
CTAGTAGTAGCAGCTCCCCAAGCCTTCTAAATGACAGTGCCAAGCCATAC 
ACAGGCCACGATCTTCTGACTTCATCTGCTTCATCCTTGTTTAATGACTT 
CGGTGCCCTCAACATCTCCCAGAGAAGGAAGACACCAAATCCTACTGCAA 
GCGAATTTATACCTAAAGGAGGATCAACCTCCAGGCTGAGTAACGTGTCC 
CAGTCAAATATGTCTGCCTTCTCTCAAGTTTTCTCTCACCCATCCATGGG 
AAGTCCTGCTACTGCTGGATTAGCACCAGGAATGTCACTGTCTGCTGGAT 
CTTCCCCTCTCCATTCCCCCAAAATTACTCCACACACCTCTCCTGCTCCT 
AGAAGAAGAAGCCACACTCCAAACCCAGCAAGTTTCATGGTGCCGCCTAG 
TGCCTCCACTCCTGCCAATAACCCTGCTCCTCAGCCTCCGTCCTCTGGTC 
AGGTGATCCAGAAGGAGACTGTCGGGGGGACGACTTACTTCTATACAGAT 
ACAACCCCAGCACCTTTGACTGGAATGGTATTTCCAAACTATCATATTTA 
TCCTCCAACCGCACCTCATGTTGCTTATATGCAACCAAAAGCAAATGCAC 
CTTCCTTCTTCATGGCCGACGAGCTCCGACAGGAGCTGATCAACAGACAT 
TTAATAACGATGGCTCAAATTGACCAAGCAGATATGCCAGCAGTCCCCAC 
AGAAGTTGACAGCTACCATAGCCTGTTCCCTCTAGAACCACTGCCACCTC 
CCAACCGGATACAGAAATCAAGTAATTTTGGATATATCACGTCTTGCTAC 
AAAGCTGTAAATAGCAAAGATGATCTGCCATATTGCCTTCGGAGGATACA 
TGGTTTTCGTCTTGTTAACACAAAGTGCATGGTGTTGGTTGATATGTGGA 
AAAAAATTCAGCACTCAAATATTGTAACTCTGCGTGAAGTGTTTACCACT 
AAAGCATTTGCCGAGCCTTCTCTGGTGTTCGCCTATGATTTCCATGCTGG 
AGGAGAAACTATGATGAGCAGACACTTTAACGACCCGAATTCTGATGCCT 
ACTTCACAAAGAGGAAGTGGGGCCAGCACGATGGACCACTGCCCAGGCAG 
CATGCTGGATTGTTACCAGAGTCTCTCATCTGGGCATACATTGTACAGCT 
GAGTTCTGCTCTGCGGACCATTCATACAGCAGGTTTGGCCTGTAGAGTAA 
TGGACCCAACGAAGATTCTGATAACCAGCAAAACAAGGTTACGAGTAAAT 
TGTGTAGGAGTCTTTGATGTTTTAACATTTGATAACAGTCAAAATAATAA 
TCCTTTGGCATTAATGGCTCAGTACCAGCAAGCAGATCTGATATCATTAG 
GAAAAGTTGTGTTGGCTTTGGCTTGCAACTCTTTGGCAGGAATTCAGCGA 
GAAAATTTACAGAAAGCCATGGAATTGGTGACAATCAACTACTCCTCTGA 
CCTGAAGAACCTCATCTTGTACTTGTTGACTGACCAAAACAGGATGCGGA 
GTGTGAATGACATCATGCCCATGATTGGTGCTCGGTTTTACACTCAATTG 
GATGCTGCTCAAATGAGAAATGATGTTATCGAGGAAGACCTTGCTAAGGA 
GGTTCAAAATGGAAGACTGTTTAGGCTTCTAGCAAAATTGGGAACAATCA 
ACGAGAGGCCGGAGTTTCAGAAGGATCCAACCTGGTCAGAGACTGGAGAC 
AGATACCTGTTGAAACTCTTTAGAGATCATCTTTTTCATCAGGTGACAGA 
AGCAGGTGCTCCCTGGATCGACCTCAGTCACATCATTTCTTGTCTTAACA 
AGCTAGATGCTGGTGTGCCAGAAAAAATCAGCCTGATTTCCAGAGACGAG 
AAGAGCGTGCTGGTGGTGACATACAGTGACCTAAAACGCTGCTTTGAAAA 
TACCTTTCAAGAACTGATTGCGGCTGCAAATGGTAACGATCGGAACAGTA 
ACTGAAGGAGCAGGCGCTGCTCTTCTCCAGGTTCATCTAGAGGCTTCTTC 
AAAGAGGCGTCTGTCTGCCAGTCACATACACTTATCTTGACGTAATTTTT 
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AATAGCAAAATGAAATTGTGCTGAAGGCCTAAAAGTGGAGGAGTTATATT 
ACCTTAGGGTCTTTCCAGTTTATTTGTTTTTTGTTTTTTTTTTTGTTTTT 
GTTTTTTGTTTTTTGTCTTTGAACTACAGCTTTATAATGGTACTTTACAC 
TGGATAGACTCAGACACTGTCGAGGAGGTGAGCTGAGCACAGCAGTGGCC 
TGATGCTTTGCGGCCTGACTCTGGAGGGACACTTTTCTGCTGTGCCTTTG 
CACTCACTGCTTAACCCAAAGGAACAGGACTTTTGATAAAACTCACCCTG 
TAGGGTCGGTCATCTGAGAAGGCCATTTCAAAAGTTGGAGTTTTCCTCCA 
TGGAACTTACTATTTGGACATGCAGTTGTCGCCAAACTCAAGTATTGTGG 
GATTTGTGGTCACTTCGATACTGAAGACTGCCAAATACATTGGGATTTTC 
TCTTAAACAGCCGCCATGAAGACTTCATCTCCTTCCCGGTGCTGTGTGTT 
GAGCGCGCACTGGGTGTGCACCCCATACCTGGGAAGAAATGTGGGGATTT 
GGAGGTCAGGACAGACTCCAAGCACTTGCAACTGATGTTACTGTCTTCAT 
TTTTAACAAGTATGCGTATTTGTATATTTCAGAGAAGTTTTTAACATTTC 
TCTGTCCACTTTTTATAAGCTTTAAAATGATTTTTCTCTGCCTTGAAATT 
TGCATCAAGAAAAAGCACCTCTCTTCACTGAAAGCTTTGAGGACTAGAGA 
CACACTTCCCATGTCTAACAAGCACGTCTGTATCTGAGAGCGCTAGCATC 
AGTTGTTAATGAGAAAATCAATTACTGCATTTGATCTGGATGGATTTTAG 
AAGAACATAATGTTCAATATTCCAAGGATAATGAACATTTGCCACCATGA 
TGTTCCTTGTGTTTAAAGGGAACGAGAACTTTCGGTGTACCACGCAGAAG 
TCTTTATCATTAGCTCATGTATTTGAGGAAGAGCAGCTGTCTTTTTATAT 
GTTTTTTGACAAATCATATTGTAATTCTTTTGTACAAAAAAGAACTACTT 
GTATTCTAGAAGAAATATGAAATGCTTAATTTATAAGCGGGCTGGAGATT 
TTTTTCCAATATTGTTTTCTTTGAAAATGAAAGGGGATCATCTATTTTAG 
TTTTGGGGGCCTGGGAACTTTTTGAAAATTTTCATTTGTGGACCAATGTT 
ATGTGAATGCTAAGGAAGGGCAGGGGTAACATAGGGCTTGGACCTCTAGT 
CCTGCATAGACCAGCAAACTCCCCTCTGCAAGGCAGGTTCACATCACAAC 
CCCGAGTGTCTGCATCAGAAATGCTAGTCTGCTTCCGCCCCAGCAACCTC 
AGGACTTGGGTTGGGTATAAAAGGTAGTCAGCTGAAAGTACCTAAGTAAA 
TAGTGTCAGCCAGAAAACAGTCGGTGTCAGGTGATACGTATTTTTTAGCT 
TTGTTTTATATTTATTTTTCATTTCATTTTCATTGGGAATGGTTTTCAAA 
AGAACTCTTGAGTTCTGCTTTGATGGGTTTCTTTTTTTTTTTTTTCTGTT 
TTGTTTTGCTTTGCTTTTTTTTTTTTTTTTTTTTTTTTCTGGGAGCCCTC 
TTTTCCACAGTGTAAACCCATATAGAAGGTTGTCTGAAAGTTACTATTTA 
GTGCATAGGAAGAGTTTAATATCTGAGAGTATCGAATGAAGGATGTGAAC 
TCATCATAACTTCCTGTTATGACAGACACAACACGGAAAGGACAACCCTT 
GAAATCATGTCGCGTCGCTCACTTCAGCAGTGTACCCATCTCCAGTCCTG 
TTAGTGTATTCACTTCACTGCAGATACCTTTGAGGGTGCCCTTGTGTTCT 
GCTTTGACCTTGGTTCTGTCATTGGATAGCAACATTGTCTCTAGAAAGCA 
CCAGTACGTTTAAGTTCTAATGTCACAATCCCAGTACCTGTTGCTCATCT 
TTAACCCTGTTTTCAGTCTCTACGTGTATAGCAGTATTTTTTAATAAAGA 
ATTGCAGAAATAA 
 
Canonical Pan3 protein sequence (NP_082567) 
 
  1 mdggaltdas ltesyfstsf igvngfgspv etkyplmqrm tssssspsll ndsakpytgh 
 61 dlltssassl fndfgalnis qrrktpnpta sefipkggst srlsnvsqsn msafsqvfsh 
121 psmgspatag lapgmslsag ssplhspkit phtspaprrr shtpnpasfm vppsastpan 
181 npapqppssg qviqketvgg ttyfytdttp apltgmvfpn yhiypptaph vaymqpkana 
241 psffmadelr qelinrhlit maqidqadmp avptevdsyh slfpleplpp pnriqkssnf 
301 gyitscykav nskddlpycl rrihgfrlvn tkcmvlvdmw kkiqhsnivt lrevfttkaf 
361 aepslvfayd fhaggetmms rhfndpnsda yftkrkwgqh dgplprqhag llpesliway 
421 ivqlssalrt ihtaglacrv mdptkilits ktrlrvncvg vfdvltfdns qnnnplalma 
481 qyqqadlisl gkvvlalacn slagiqrenl qkamelvtin yssdlknlil ylltdqnrmr 
541 svndimpmig arfytqldaa qmrndvieed lakevqngrl frllaklgti nerpefqkdp 
601 twsetgdryl lklfrdhlfh qvteagapwi dlshiiscln kldagvpeki slisrdeksv 
661 lvvtysdlkr cfentfqeli aaangndrns n 
 
183 
 
RNA sequence of the Pan3 gene alternatively spliced variant 1.  The transcript retains 
a few bases from intron 14 which are shown in bold. 
 
TTTCCTCCGGGAGCGCTCCCGGGCGGGGGAGCGGGGCCGCCCGCGGGGCC 
CAAGAAGCCGGAGCTGGGCGTCCCGGGGGCGGCGACCGCGGGCGGCGGAC 
TCGATGGCCCGCGGGTGGCGATTCCGGGAATGGATGGAGGTGCTTTAACT 
GATGCGAGTCTCACAGAGTCCTATTTCAGCACCAGCTTTATTGGAGTCAA 
TGGATTTGGAAGCCCTGTAGAAACAAAGTATCCCTTGATGCAGAGAATGA 
CTAGTAGTAGCAGCTCCCCAAGCCTTCTAAATGACAGTGCCAAGCCATAC 
ACAGGCCACGATCTTCTGACTTCATCTGCTTCATCCTTGTTTAATGACTT 
CGGTGCCCTCAACATCTCCCAGAGAAGGAAGACACCAAATCCTACTGCAA 
GCGAATTTATACCTAAAGGAGGATCAACCTCCAGGCTGAGTAACGTGTCC 
CAGTCAAATATGTCTGCCTTCTCTCAAGTTTTCTCTCACCCATCCATGGG 
AAGTCCTGCTACTGCTGGATTAGCACCAGGAATGTCACTGTCTGCTGGAT 
CTTCCCCTCTCCATTCCCCCAAAATTACTCCACACACCTCTCCTGCTCCT 
AGAAGAAGAAGCCACACTCCAAACCCAGCAAGTTTCATGGTGCCGCCTAG 
TGCCTCCACTCCTGCCAATAACCCTGCTCCTCAGCCTCCGTCCTCTGGTC 
AGGTGATCCAGAAGGAGACTGTCGGGGGGACGACTTACTTCTATACAGAT 
ACAACCCCAGCACCTTTGACTGGAATGGTATTTCCAAACTATCATATTTA 
TCCTCCAACCGCACCTCATGTTGCTTATATGCAACCAAAAGCAAATGCAC 
CTTCCTTCTTCATGGCCGACGAGCTCCGACAGGAGCTGATCAACAGACAT 
TTAATAACGATGGCTCAAATTGACCAAGCAGATATGCCAGCAGTCCCCAC 
AGAAGTTGACAGCTACCATAGCCTGTTCCCTCTAGAACCACTGCCACCTC 
CCAACCGGATACAGAAATCAAGTAATTTTGGATATATCACGTCTTGCTAC 
AAAGCTGTAAATAGCAAAGATGATCTGCCATATTGCCTTCGGAGGATACA 
TGGTTTTCGTCTTGTTAACACAAAGTGCATGGTGTTGGTTGATATGTGGA 
AAAAAATTCAGCACTCAAATATTGTAACTCTGCGTGAAGTGTTTACCACT 
AAAGCATTTGCCGAGCCTTCTCTGGTGTTCGCCTATGATTTCCATGCTGG 
AGGAGAAACTATGATGAGCAGACACTTTAACGACCCGAATTCTGATGCCT 
ACTTCACAAAGAGGAAGTGGGGCCAGCACGATGGACCACTGCCCAGGCAG 
CATGCTGGATTGTTACCAGAGTCTCTCATCTGGGCATACATTGTACAGCT 
GAGTTCTGCTCTGCGGACCATTCATACAGCAGGTTTGGCCTGTAGAGTAA 
TGGACCCAACGAAGATTCTGATAACCAGCAAAACAAGGTTACGAGTAAAT 
TGTGTAGGAGTCTTTGATGTTTTAACATTTGATAACAGTCAAAATAATAA 
TCCTTTGGCATTAATGGCTCAGTACCAGCAAGCAGATCTGATATCATTAG 
GAAAAGTTGTGTTGGCTTTGGCTTGCAACTCTTTGGCAGGAATTCAGCGA 
GAAAATTTACAGAAAGCCATGGAATTGGTGACAATCAACTACTCCTCTGA 
CCTGAAGAACCTCATCTTcttccagtgaacctttctgctctttctgtgta 
gccctggatgatccagtttctttttggaccagccctggggtaGTACTTGT 
TGACTGACCAAAACAGGATGCGGAGTGTGAATGACATCATGCCCATGATT 
GGTGCTCGGTTTTACACTCAATTGGATGCTGCTCAAATGAGAAATGATGT 
TATCGAGGAAGACCTTGCTAAGGAGGTTCAAAATGGAAGACTGTTTAGGC 
TTCTAGCAAAATTGGGAACAATCAACGAGAGGCCGGAGTTTCAGAAGGAT 
CCAACCTGGTCAGAGACTGGAGACAGATACCTGTTGAAACTCTTTAGAGA 
TCATCTTTTTCATCAGGTGACAGAAGCAGGTGCTCCCTGGATCGACCTCA 
GTCACATCATTTCTTGTCTTAACAAGCTAGATGCTGGTGTGCCAGAAAAA 
ATCAGCCTGATTTCCAGAGACGAGAAGAGCGTGCTGGTGGTGACATACAG 
TGACCTAAAACGCTGCTTTGAAAATACCTTTCAAGAACTGATTGCGGCTG 
CAAATGGTAACGATCGGAACAGTAACTGAAGGAGCAGGCGCTGCTCTTCT 
CCAGGTTCATCTAGAGGCTTCTTCAAAGAGGCGTCTGTCTGCCAGTCACA 
TACACTTATCTTGACGTAATTTTTAATAGCAAAATGAAATTGTGCTGAAG 
GCCTAAAAGTGGAGGAGTTATATTACCTTAGGGTCTTTCCAGTTTATTTG 
TTTTTTGTTTTTTTTTTTGTTTTTGTTTTTTGTTTTTTGTCTTTGAACTA 
CAGCTTTATAATGGTACTTTACACTGGATAGACTCAGACACTGTCGAGGA 
GGTGAGCTGAGCACAGCAGTGGCCTGATGCTTTGCGGCCTGACTCTGGAG 
GGACACTTTTCTGCTGTGCCTTTGCACTCACTGCTTAACCCAAAGGAACA 
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GGACTTTTGATAAAACTCACCCTGTAGGGTCGGTCATCTGAGAAGGCCAT 
TTCAAAAGTTGGAGTTTTCCTCCATGGAACTTACTATTTGGACATGCAGT 
TGTCGCCAAACTCAAGTATTGTGGGATTTGTGGTCACTTCGATACTGAAG 
ACTGCCAAATACATTGGGATTTTCTCTTAAACAGCCGCCATGAAGACTTC 
ATCTCCTTCCCGGTGCTGTGTGTTGAGCGCGCACTGGGTGTGCACCCCAT 
ACCTGGGAAGAAATGTGGGGATTTGGAGGTCAGGACAGACTCCAAGCACT 
TGCAACTGATGTTACTGTCTTCATTTTTAACAAGTATGCGTATTTGTATA 
TTTCAGAGAAGTTTTTAACATTTCTCTGTCCACTTTTTATAAGCTTTAAA 
ATGATTTTTCTCTGCCTTGAAATTTGCATCAAGAAAAAGCACCTCTCTTC 
ACTGAAAGCTTTGAGGACTAGAGACACACTTCCCATGTCTAACAAGCACG 
TCTGTATCTGAGAGCGCTAGCATCAGTTGTTAATGAGAAAATCAATTACT 
GCATTTGATCTGGATGGATTTTAGAAGAACATAATGTTCAATATTCCAAG 
GATAATGAACATTTGCCACCATGATGTTCCTTGTGTTTAAAGGGAACGAG 
AACTTTCGGTGTACCACGCAGAAGTCTTTATCATTAGCTCATGTATTTGA 
GGAAGAGCAGCTGTCTTTTTATATGTTTTTTGACAAATCATATTGTAATT 
CTTTTGTACAAAAAAGAACTACTTGTATTCTAGAAGAAATATGAAATGCT 
TAATTTATAAGCGGGCTGGAGATTTTTTTCCAATATTGTTTTCTTTGAAA 
ATGAAAGGGGATCATCTATTTTAGTTTTGGGGGCCTGGGAACTTTTTGAA 
AATTTTCATTTGTGGACCAATGTTATGTGAATGCTAAGGAAGGGCAGGGG 
TAACATAGGGCTTGGACCTCTAGTCCTGCATAGACCAGCAAACTCCCCTC 
TGCAAGGCAGGTTCACATCACAACCCCGAGTGTCTGCATCAGAAATGCTA 
GTCTGCTTCCGCCCCAGCAACCTCAGGACTTGGGTTGGGTATAAAAGGTA 
GTCAGCTGAAAGTACCTAAGTAAATAGTGTCAGCCAGAAAACAGTCGGTG 
TCAGGTGATACGTATTTTTTAGCTTTGTTTTATATTTATTTTTCATTTCA 
TTTTCATTGGGAATGGTTTTCAAAAGAACTCTTGAGTTCTGCTTTGATGG 
GTTTCTTTTTTTTTTTTTTCTGTTTTGTTTTGCTTTGCTTTTTTTTTTTT 
TTTTTTTTTTTTCTGGGAGCCCTCTTTTCCACAGTGTAAACCCATATAGA 
AGGTTGTCTGAAAGTTACTATTTAGTGCATAGGAAGAGTTTAATATCTGA 
GAGTATCGAATGAAGGATGTGAACTCATCATAACTTCCTGTTATGACAGA 
CACAACACGGAAAGGACAACCCTTGAAATCATGTCGCGTCGCTCACTTCA 
GCAGTGTACCCATCTCCAGTCCTGTTAGTGTATTCACTTCACTGCAGATA 
CCTTTGAGGGTGCCCTTGTGTTCTGCTTTGACCTTGGTTCTGTCATTGGA 
TAGCAACATTGTCTCTAGAAAGCACCAGTACGTTTAAGTTCTAATGTCAC 
AATCCCAGTACCTGTTGCTCATCTTTAACCCTGTTTTCAGTCTCTACGTG 
TATAGCAGTATTTTTTAATAAAGAATTGCAGAAATAA 
 
Predicted protein sequence for the Pan3 alternatively spliced variant 1 
 
  1 mdggaltdas ltesyfstsf igvngfgspv etkyplmqrm tssssspsll ndsakpytgh 
 61 dlltssassl fndfgalnis qrrktpnpta sefipkggst srlsnvsqsn msafsqvfsh 
121 psmgspatag lapgmslsag ssplhspkit phtspaprrr shtpnpasfm vppsastpan 
181 npapqppssg qviqketvgg ttyfytdttp apltgmvfpn yhiypptaph vaymqpkana 
241 psffmadelr qelinrhlit maqidqadmp avptevdsyh slfpleplpp pnriqkssnf 
301 gyitscykav nskddlpycl rrihgfrlvn tkcmvlvdmw kkiqhsnivt lrevfttkaf 
361 aepslvfayd fhaggetmms rhfndpnsda yftkrkwgqh dgplprqhag llpesliway 
421 ivqlssalrt ihtaglacrv mdptkilits ktrlrvncvg vfdvltfdns qnnnplalma 
481 qyqqadlisl gkvvlalacn slagiqrenl qkamelvtin yssdlknlif fq 
 
 
RNA sequence of the Pan3 gene alternatively spliced variant 2.  The transcript retains 
the intron 18 which is shown in bold. 
 
TTTCCTCCGGGAGCGCTCCCGGGCGGGGGAGCGGGGCCGCCCGCGGGGCC 
CAAGAAGCCGGAGCTGGGCGTCCCGGGGGCGGCGACCGCGGGCGGCGGAC 
TCGATGGCCCGCGGGTGGCGATTCCGGGAATGGATGGAGGTGCTTTAACT 
GATGCGAGTCTCACAGAGTCCTATTTCAGCACCAGCTTTATTGGAGTCAA 
185 
 
TGGATTTGGAAGCCCTGTAGAAACAAAGTATCCCTTGATGCAGAGAATGA 
CTAGTAGTAGCAGCTCCCCAAGCCTTCTAAATGACAGTGCCAAGCCATAC 
ACAGGCCACGATCTTCTGACTTCATCTGCTTCATCCTTGTTTAATGACTT 
CGGTGCCCTCAACATCTCCCAGAGAAGGAAGACACCAAATCCTACTGCAA 
GCGAATTTATACCTAAAGGAGGATCAACCTCCAGGCTGAGTAACGTGTCC 
CAGTCAAATATGTCTGCCTTCTCTCAAGTTTTCTCTCACCCATCCATGGG 
AAGTCCTGCTACTGCTGGATTAGCACCAGGAATGTCACTGTCTGCTGGAT 
CTTCCCCTCTCCATTCCCCCAAAATTACTCCACACACCTCTCCTGCTCCT 
AGAAGAAGAAGCCACACTCCAAACCCAGCAAGTTTCATGGTGCCGCCTAG 
TGCCTCCACTCCTGCCAATAACCCTGCTCCTCAGCCTCCGTCCTCTGGTC 
AGGTGATCCAGAAGGAGACTGTCGGGGGGACGACTTACTTCTATACAGAT 
ACAACCCCAGCACCTTTGACTGGAATGGTATTTCCAAACTATCATATTTA 
TCCTCCAACCGCACCTCATGTTGCTTATATGCAACCAAAAGCAAATGCAC 
CTTCCTTCTTCATGGCCGACGAGCTCCGACAGGAGCTGATCAACAGACAT 
TTAATAACGATGGCTCAAATTGACCAAGCAGATATGCCAGCAGTCCCCAC 
AGAAGTTGACAGCTACCATAGCCTGTTCCCTCTAGAACCACTGCCACCTC 
CCAACCGGATACAGAAATCAAGTAATTTTGGATATATCACGTCTTGCTAC 
AAAGCTGTAAATAGCAAAGATGATCTGCCATATTGCCTTCGGAGGATACA 
TGGTTTTCGTCTTGTTAACACAAAGTGCATGGTGTTGGTTGATATGTGGA 
AAAAAATTCAGCACTCAAATATTGTAACTCTGCGTGAAGTGTTTACCACT 
AAAGCATTTGCCGAGCCTTCTCTGGTGTTCGCCTATGATTTCCATGCTGG 
AGGAGAAACTATGATGAGCAGACACTTTAACGACCCGAATTCTGATGCCT 
ACTTCACAAAGAGGAAGTGGGGCCAGCACGATGGACCACTGCCCAGGCAG 
CATGCTGGATTGTTACCAGAGTCTCTCATCTGGGCATACATTGTACAGCT 
GAGTTCTGCTCTGCGGACCATTCATACAGCAGGTTTGGCCTGTAGAGTAA 
TGGACCCAACGAAGATTCTGATAACCAGCAAAACAAGGTTACGAGTAAAT 
TGTGTAGGAGTCTTTGATGTTTTAACATTTGATAACAGTCAAAATAATAA 
TCCTTTGGCATTAATGGCTCAGTACCAGCAAGCAGATCTGATATCATTAG 
GAAAAGTTGTGTTGGCTTTGGCTTGCAACTCTTTGGCAGGAATTCAGCGA 
GAAAATTTACAGAAAGCCATGGAATTGGTGACAATCAACTACTCCTCTGA 
CCTGAAGAACCTCATCTTGTACTTGTTGACTGACCAAAACAGGATGCGGA 
GTGTGAATGACATCATGCCCATGATTGGTGCTCGGTTTTACACTCAATTG 
GATGCTGCTCAAATGAGAAATGATGTTATCGAGGAAGACCTTGCTAAGGA 
GGTTCAAAATGGAAGACTGTTTAGGCTTCTAGCAAAATTGGGAACAATCA 
ACGAGAGGCCGGAGTTTCAGAAGGATCCAACCTGGTCAGAGACTGGAGAC 
AGATACCTGTTGAAACTCTTTAGAGATCATCTTTTTCATCAGGTGACAGA 
AGCAGGTGCTCCCTGGATCGACCTCAGTCACATCATTTCTTGTCTTAACA 
AGCTAGATGCTGGTGTGCCAGAAAAAATCAGCCTGATTTCCAGAGACGAG 
AAGAGCGTGCTGGTGGTGACATACAGTGACCTAAAACGCTGCTTTGAAAA 
TACCTTTCAAGAACTGATTGCGGCTGCAAATGgtcagttgtagtatttgc 
Taaaaatgttgagagggcatggtgaaggaccaagcctctagccagtttgc 
Actacggctgaactgtcctccatctcctgccaccagggggaggagcagga 
Aggagcgaagcttctcacacgtgggtctaacaggtgcactgttacttgag 
Aggaagactgtctcactttgtgcgcactctggctgcctcaggcctccgag 
Gaatttgtgcagactcaggtcaccttcggtgaatgacgcgcctgcttacg 
Gttttccacttgtgtatgcactaattgtcattttttaaagacttttttcc 
Tgatctttgacctcttgccacattgtatacttactaagggaactatttgc 
Aaggacattgggaaacaaagggggcagctgttcgccactgagagatgcag 
Aatttgctcttgggggatgggccaggtcagtacattagttcatagaaatg 
Ccgtgtagtgcatagtccttatgagtattgtgtgcaagctccacatgcca 
Cccactgttagctcaagttgaggcttgtattgtgtttaagaacacgcaga 
Gagaaatatcattgagctgtcagatatgaatttccgtttgttgatttaaa 
tccttttccagGTAACGATCGGAACAGTAACTGAAGGAGCAGGCGCTGCT 
CTTCTCCAGGTTCATCTAGAGGCTTCTTCAAAGAGGCGTCTGTCTGCCAG 
TCACATACACTTATCTTGACGTAATTTTTAATAGCAAAATGAAATTGTGC 
TGAAGGCCTAAAAGTGGAGGAGTTATATTACCTTAGGGTCTTTCCAGTTT 
ATTTGTTTTTTGTTTTTTTTTTTGTTTTTGTTTTTTGTTTTTTGTCTTTG 
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AACTACAGCTTTATAATGGTACTTTACACTGGATAGACTCAGACACTGTC 
GAGGAGGTGAGCTGAGCACAGCAGTGGCCTGATGCTTTGCGGCCTGACTC 
TGGAGGGACACTTTTCTGCTGTGCCTTTGCACTCACTGCTTAACCCAAAG 
GAACAGGACTTTTGATAAAACTCACCCTGTAGGGTCGGTCATCTGAGAAG 
GCCATTTCAAAAGTTGGAGTTTTCCTCCATGGAACTTACTATTTGGACAT 
GCAGTTGTCGCCAAACTCAAGTATTGTGGGATTTGTGGTCACTTCGATAC 
TGAAGACTGCCAAATACATTGGGATTTTCTCTTAAACAGCCGCCATGAAG 
ACTTCATCTCCTTCCCGGTGCTGTGTGTTGAGCGCGCACTGGGTGTGCAC 
CCCATACCTGGGAAGAAATGTGGGGATTTGGAGGTCAGGACAGACTCCAA 
GCACTTGCAACTGATGTTACTGTCTTCATTTTTAACAAGTATGCGTATTT 
GTATATTTCAGAGAAGTTTTTAACATTTCTCTGTCCACTTTTTATAAGCT 
TTAAAATGATTTTTCTCTGCCTTGAAATTTGCATCAAGAAAAAGCACCTC 
TCTTCACTGAAAGCTTTGAGGACTAGAGACACACTTCCCATGTCTAACAA 
GCACGTCTGTATCTGAGAGCGCTAGCATCAGTTGTTAATGAGAAAATCAA 
TTACTGCATTTGATCTGGATGGATTTTAGAAGAACATAATGTTCAATATT 
CCAAGGATAATGAACATTTGCCACCATGATGTTCCTTGTGTTTAAAGGGA 
ACGAGAACTTTCGGTGTACCACGCAGAAGTCTTTATCATTAGCTCATGTA 
TTTGAGGAAGAGCAGCTGTCTTTTTATATGTTTTTTGACAAATCATATTG 
TAATTCTTTTGTACAAAAAAGAACTACTTGTATTCTAGAAGAAATATGAA 
ATGCTTAATTTATAAGCGGGCTGGAGATTTTTTTCCAATATTGTTTTCTT 
TGAAAATGAAAGGGGATCATCTATTTTAGTTTTGGGGGCCTGGGAACTTT 
TTGAAAATTTTCATTTGTGGACCAATGTTATGTGAATGCTAAGGAAGGGC 
AGGGGTAACATAGGGCTTGGACCTCTAGTCCTGCATAGACCAGCAAACTC 
CCCTCTGCAAGGCAGGTTCACATCACAACCCCGAGTGTCTGCATCAGAAA 
TGCTAGTCTGCTTCCGCCCCAGCAACCTCAGGACTTGGGTTGGGTATAAA 
AGGTAGTCAGCTGAAAGTACCTAAGTAAATAGTGTCAGCCAGAAAACAGT 
CGGTGTCAGGTGATACGTATTTTTTAGCTTTGTTTTATATTTATTTTTCA 
TTTCATTTTCATTGGGAATGGTTTTCAAAAGAACTCTTGAGTTCTGCTTT 
GATGGGTTTCTTTTTTTTTTTTTTCTGTTTTGTTTTGCTTTGCTTTTTTT 
TTTTTTTTTTTTTTTTTCTGGGAGCCCTCTTTTCCACAGTGTAAACCCAT 
ATAGAAGGTTGTCTGAAAGTTACTATTTAGTGCATAGGAAGAGTTTAATA 
TCTGAGAGTATCGAATGAAGGATGTGAACTCATCATAACTTCCTGTTATG 
ACAGACACAACACGGAAAGGACAACCCTTGAAATCATGTCGCGTCGCTCA 
CTTCAGCAGTGTACCCATCTCCAGTCCTGTTAGTGTATTCACTTCACTGC 
AGATACCTTTGAGGGTGCCCTTGTGTTCTGCTTTGACCTTGGTTCTGTCA 
TTGGATAGCAACATTGTCTCTAGAAAGCACCAGTACGTTTAAGTTCTAAT 
GTCACAATCCCAGTACCTGTTGCTCATCTTTAACCCTGTTTTCAGTCTCT 
ACGTGTATAGCAGTATTTTTTAATAAAGAATTGCAGAAATAAA 
 
Predicted protein sequence for the Pan3 alternatively spliced variant 2 
 
  1 mdggaltdas ltesyfstsf igvngfgspv etkyplmqrm tssssspsll ndsakpytgh 
 61 dlltssassl fndfgalnis qrrktpnpta sefipkggst srlsnvsqsn msafsqvfsh 
121 psmgspatag lapgmslsag ssplhspkit phtspaprrr shtpnpasfm vppsastpan 
181 npapqppssg qviqketvgg ttyfytdttp apltgmvfpn yhiypptaph vaymqpkana 
241 psffmadelr qelinrhlit maqidqadmp avptevdsyh slfpleplpp pnriqkssnf 
301 gyitscykav nskddlpycl rrihgfrlvn tkcmvlvdmw kkiqhsnivt lrevfttkaf 
361 aepslvfayd fhaggetmms rhfndpnsda yftkrkwgqh dgplprqhag llpesliway 
421 ivqlssalrt ihtaglacrv mdptkilits ktrlrvncvg vfdvltfdns qnnnplalma 
481 qyqqadlisl gkvvlalacn slagiqrenl qkamelvtin yssdlknlil ylltdqnrmr 
541 svndimpmig arfytqldaa qmrndvieed lakevqngrl frllaklgti nerpefqkdp 
601 twsetgdryl lklfrdhlfh qvteagapwi dlshiiscln kldagvpeki slisrdeksv 
661 lvvtysdlkr cfentfqeli aaangql 
 
RNA sequence of the Pan3 gene alternatively spliced variant 3.  The transcript skips 
most of the exon 19, retaining only a few base pairs at the end which are shown in bold. 
187 
 
 
TTTCCTCCGGGAGCGCTCCCGGGCGGGGGAGCGGGGCCGCCCGCGGGGCC 
CAAGAAGCCGGAGCTGGGCGTCCCGGGGGCGGCGACCGCGGGCGGCGGAC 
TCGATGGCCCGCGGGTGGCGATTCCGGGAATGGATGGAGGTGCTTTAACT 
GATGCGAGTCTCACAGAGTCCTATTTCAGCACCAGCTTTATTGGAGTCAA 
TGGATTTGGAAGCCCTGTAGAAACAAAGTATCCCTTGATGCAGAGAATGA 
CTAGTAGTAGCAGCTCCCCAAGCCTTCTAAATGACAGTGCCAAGCCATAC 
ACAGGCCACGATCTTCTGACTTCATCTGCTTCATCCTTGTTTAATGACTT 
CGGTGCCCTCAACATCTCCCAGAGAAGGAAGACACCAAATCCTACTGCAA 
GCGAATTTATACCTAAAGGAGGATCAACCTCCAGGCTGAGTAACGTGTCC 
CAGTCAAATATGTCTGCCTTCTCTCAAGTTTTCTCTCACCCATCCATGGG 
AAGTCCTGCTACTGCTGGATTAGCACCAGGAATGTCACTGTCTGCTGGAT 
CTTCCCCTCTCCATTCCCCCAAAATTACTCCACACACCTCTCCTGCTCCT 
AGAAGAAGAAGCCACACTCCAAACCCAGCAAGTTTCATGGTGCCGCCTAG 
TGCCTCCACTCCTGCCAATAACCCTGCTCCTCAGCCTCCGTCCTCTGGTC 
AGGTGATCCAGAAGGAGACTGTCGGGGGGACGACTTACTTCTATACAGAT 
ACAACCCCAGCACCTTTGACTGGAATGGTATTTCCAAACTATCATATTTA 
TCCTCCAACCGCACCTCATGTTGCTTATATGCAACCAAAAGCAAATGCAC 
CTTCCTTCTTCATGGCCGACGAGCTCCGACAGGAGCTGATCAACAGACAT 
TTAATAACGATGGCTCAAATTGACCAAGCAGATATGCCAGCAGTCCCCAC 
AGAAGTTGACAGCTACCATAGCCTGTTCCCTCTAGAACCACTGCCACCTC 
CCAACCGGATACAGAAATCAAGTAATTTTGGATATATCACGTCTTGCTAC 
AAAGCTGTAAATAGCAAAGATGATCTGCCATATTGCCTTCGGAGGATACA 
TGGTTTTCGTCTTGTTAACACAAAGTGCATGGTGTTGGTTGATATGTGGA 
AAAAAATTCAGCACTCAAATATTGTAACTCTGCGTGAAGTGTTTACCACT 
AAAGCATTTGCCGAGCCTTCTCTGGTGTTCGCCTATGATTTCCATGCTGG 
AGGAGAAACTATGATGAGCAGACACTTTAACGACCCGAATTCTGATGCCT 
ACTTCACAAAGAGGAAGTGGGGCCAGCACGATGGACCACTGCCCAGGCAG 
CATGCTGGATTGTTACCAGAGTCTCTCATCTGGGCATACATTGTACAGCT 
GAGTTCTGCTCTGCGGACCATTCATACAGCAGGTTTGGCCTGTAGAGTAA 
TGGACCCAACGAAGATTCTGATAACCAGCAAAACAAGGTTACGAGTAAAT 
TGTGTAGGAGTCTTTGATGTTTTAACATTTGATAACAGTCAAAATAATAA 
TCCTTTGGCATTAATGGCTCAGTACCAGCAAGCAGATCTGATATCATTAG 
GAAAAGTTGTGTTGGCTTTGGCTTGCAACTCTTTGGCAGGAATTCAGCGA 
GAAAATTTACAGAAAGCCATGGAATTGGTGACAATCAACTACTCCTCTGA 
CCTGAAGAACCTCATCTTGTACTTGTTGACTGACCAAAACAGGATGCGGA 
GTGTGAATGACATCATGCCCATGATTGGTGCTCGGTTTTACACTCAATTG 
GATGCTGCTCAAATGAGAAATGATGTTATCGAGGAAGACCTTGCTAAGGA 
GGTTCAAAATGGAAGACTGTTTAGGCTTCTAGCAAAATTGGGAACAATCA 
ACGAGAGGCCGGAGTTTCAGAAGGATCCAACCTGGTCAGAGACTGGAGAC 
AGATACCTGTTGAAACTCTTTAGAGATCATCTTTTTCATCAGGTGACAGA 
AGCAGGTGCTCCCTGGATCGACCTCAGTCACATCATTTCTTGTCTTAACA 
AGCTAGATGCTGGTGTGCCAGAAAAAATCAGCCTGATTTCCAGAGACGAG 
AAGAGCGTGCTGGTGGTGACATACAGTGACCTAAAACGCTGCTTTGAAAA 
TACCTTTCAAGAACTGATTGCGGCTGCAAATGGACACAACACGGAAAGGA 
CAACCCTTGAAATCATGTCGCGTCGCTCACTTCAGCAGTGTACCCATCTC 
CAGTCCTGTTAGTGTATTCACTTCACTGCAGATACCTTTGAGGGTGCCCT 
TGTGTTCTGCTTTGACCTTGGTTCTGTCATTGGATAGCAACATTGTCTCT 
AGAAAGCACCAGTACGTTTAAGTTCTAATGTCACAATCCCAGTACCTGTT 
GCTCATCTTTAACCCTGTTTTCAGTCTCTACGTGTATAGCAGTATTTTTT 
AATAAAGAATTGCAGAAATAAA 
 
 
Predicted protein sequence for the Pan3 alternatively spliced variant 3 
 
  1 mdggaltdas ltesyfstsf igvngfgspv etkyplmqrm tssssspsll ndsakpytgh 
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 61 dlltssassl fndfgalnis qrrktpnpta sefipkggst srlsnvsqsn msafsqvfsh 
121 psmgspatag lapgmslsag ssplhspkit phtspaprrr shtpnpasfm vppsastpan 
181 npapqppssg qviqketvgg ttyfytdttp apltgmvfpn yhiypptaph vaymqpkana 
241 psffmadelr qelinrhlit maqidqadmp avptevdsyh slfpleplpp pnriqkssnf 
301 gyitscykav nskddlpycl rrihgfrlvn tkcmvlvdmw kkiqhsnivt lrevfttkaf 
361 aepslvfayd fhaggetmms rhfndpnsda yftkrkwgqh dgplprqhag llpesliway 
421 ivqlssalrt ihtaglacrv mdptkilits ktrlrvncvg vfdvltfdns qnnnplalma 
481 qyqqadlisl gkvvlalacn slagiqrenl qkamelvtin yssdlknlil ylltdqnrmr 
541 svndimpmig arfytqldaa qmrndvieed lakevqngrl frllaklgti nerpefqkdp 
601 twsetgdryl lklfrdhlfh qvteagapwi dlshiiscln kldagvpeki slisrdeksv 
661 lvvtysdlkr cfentfqeli aaandttrkg qplkscrvah fscvpisspv svftslqipl 
721 rvplcsaltl vlsldsnivs rkhqyv 
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Appendix 4A: List of significantly differentially expressed transcripts between unloaded AKR and DBA/2 macrophages.  Transcripts 
with Bonferroni adjusted t-test p-value < 0.05 with their respective gene symbol, definition and log2 fold change are presented.  Those 
with a 2- or more fold change are shown in bold. 
P-value 
Rank 
Probe_ID 
 
 
Symbol 
 
 
Nonparametric 
T-test 
P-values 
Bonferroni 
 
 
Log2 Fold 
Change 
DBA/AKR 
 
Definition 
 
 
1 ILMN_2619594 Il11ra2 3.41E-09 3.41E-05 1.56 Interleukin 11 receptor, alpha chain 2 
2 ILMN_2631663 BC022687 9.78E-09 9.78E-05 -1.77 cDNA sequence  
3 ILMN_2610737 Iap 1.18E-08 1.18E-04 1.56 Intracisternal A particles 
4 ILMN_2710774 Mon2 1.62E-08 1.62E-04 0.59 MON2 homolog (yeast) 
5 ILMN_1242902 Rapgef5 2.79E-08 2.79E-04 1.44 Rap guanine nucleotide exchange factor 5 
6 ILMN_1221584 Crym 3.29E-08 3.29E-04 1.71 Crystallin, mu  
7 ILMN_1229957 Il11ra1 5.14E-08 5.14E-04 1.76 Interleukin 11 receptor, alpha chain 1 
8 ILMN_1244799 Usp39 6.85E-08 6.85E-04 1.40 Ubiquitin specific peptidase 39 
9 ILMN_1256171 BC026370 7.44E-08 7.45E-04 1.36 Transmembrane protein 63b 
10 ILMN_1244134 Lrp4 8.26E-08 8.26E-04 -0.95 Low density lipoprotein receptor-related protein 4  
11 ILMN_2631771 Cenpb 8.37E-08 8.37E-04 -0.58 Centromere protein B 
12 ILMN_1245678 Abhd1 2.09E-07 2.09E-03 -1.47 Abhydrolase domain containing 1  
13 ILMN_2758199 Sdh1 2.10E-07 2.10E-03 -1.33 Sorbitol dehydrogenase  
14 ILMN_2771033 Mfge8 2.11E-07 2.12E-03 0.77 Milk fat globule-EGF factor 8 protein 
15 ILMN_2775360 Mapkapk3 2.21E-07 2.21E-03 1.30 Mitogen-activated protein kinase-activated protein kinase 3 
16 ILMN_2729097 Fbxl20 2.47E-07 2.47E-03 0.75 F-box and leucine-rich repeat protein 20 
17 ILMN_2760800 Cxcl14 3.02E-07 3.02E-03 1.16 Chemokine (C-X-C motif) ligand 14 
18 ILMN_2667020 Ryk 3.60E-07 3.61E-03 -1.02 Receptor-like tyrosine kinase 
19 ILMN_1253637 AA959742 4.17E-07 4.17E-03 -0.86 Leucine rich repeat containing 59  
20 
ILMN_2648742 Abcb4 4.71E-07 4.71E-03 2.41 
ATP-binding cassette, sub-family B (MDR/TAP), member 
4 
21 ILMN_2705097 Deadc1 4.77E-07 4.77E-03 -0.97 Adenosine deaminase, tRNA-specific 2, TAD2 homolog 
22 ILMN_2688236 Atp2a3 5.00E-07 5.01E-03 2.70 ATPase, Ca++ transporting, ubiquitous  
23 ILMN_2523170 Treml1 5.36E-07 5.36E-03 1.24 Triggering receptor expressed on myeloid cells-like 1 
24 ILMN_2633063 Ttc39b 5.51E-07 5.51E-03 1.54 Tetratricopeptide repeat domain 39B 
25 ILMN_2680827 Il7r 6.29E-07 6.29E-03 2.10 Interleukin 7 receptor  
26 ILMN_1224117 Uhrf2 7.06E-07 7.06E-03 0.64 Ubiquitin-like, containing PHD and RING finger domains 2 
27 ILMN_1214090 H47 7.30E-07 7.30E-03 -0.68 Histocompatibility 47 
28 ILMN_2737368 Stab2 7.83E-07 7.84E-03 3.45 Stabilin 2  
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29 ILMN_2702061 4930542G03Rik 7.87E-07 7.88E-03 -0.62 Tubulin, beta 2c  
30 ILMN_2724449 Il3ra 8.07E-07 8.07E-03 0.84 Interleukin 3 receptor, alpha chain  
31 ILMN_1240857 Cox7a1 8.08E-07 8.09E-03 -0.89 Cytochrome c oxidase, subunit VIIa 1 
32 ILMN_1236574 Cenpa 8.55E-07 8.55E-03 1.31 Centromere protein A 
33 ILMN_1222196 2310007A19Rik 9.42E-07 9.42E-03 1.21 RIKEN cDNA 2310007A19Rik 
34 ILMN_1224736 Zmiz1 1.03E-06 1.03E-02 1.13 Zinc finger, MIZ-type containing 1 
35 ILMN_2600190 Gjb4 1.07E-06 1.07E-02 -1.16 Gap junction protein, beta 4 
36 ILMN_2680038 1200013B22Rik 1.09E-06 1.09E-02 1.06 NUAK family, SNF1-like kinase, 2 
37 ILMN_1213662 Tm4sf5 1.21E-06 1.21E-02 1.60 Transmembrane 4 superfamily member 5  
38 ILMN_2605630 AA881470 1.36E-06 1.36E-02 3.19 EST AA881470, transcript variant 2 
39 
ILMN_2747923 Slc40a1 1.51E-06 1.51E-02 2.09 
Solute carrier family 40 (iron-regulated transporter), 
member 1 
40 ILMN_2731407 Gdf3 1.56E-06 1.56E-02 -1.92 Growth differentiation factor 3 
41 ILMN_3161489 Acaca 1.59E-06 1.59E-02 -0.52 Acetyl-Coenzyme A carboxylase alpha  
42 ILMN_1254547 Nr4a2 1.82E-06 1.82E-02 0.61 Nuclear receptor subfamily 4, group A, member 2 
43 ILMN_1259463 D1Ertd161e 2.08E-06 2.08E-02 0.60 Ankyrin repeat and zinc finger domain containing 1 
44 ILMN_2774430 Ncf2 2.28E-06 2.28E-02 6.09 Neutrophil cytosolic factor 2  
45 
ILMN_2724643 D1Wsu40e 2.45E-06 2.45E-02 -0.50 
IMP4, U3 small nucleolar ribonucleoprotein, homolog 
(yeast) 
46 ILMN_2667815 2010002H18Rik 2.51E-06 2.51E-02 0.72 Isoleucine-tRNA synthetase 2, mitochondrial  
47 ILMN_1232183 Mgmt 2.64E-06 2.64E-02 -1.54 O-6-methylguanine-DNA methyltransferase 
48 ILMN_1216809 Igh-6 2.68E-06 2.68E-02 1.54 Immunoglobulin heavy chain 6 (heavy chain of IgM) 
49 
ILMN_2750926 Ss18l1 2.70E-06 2.70E-02 0.76 
Synovial sarcoma translocation gene on chromosome 18-
like 1 
50 
ILMN_2619620 C1qb 2.73E-06 2.73E-02 -1.30 
Complement component 1, q subcomponent, beta 
polypeptide 
51 ILMN_2615901 Ptk2 2.76E-06 2.76E-02 -0.57 PTK2 protein tyrosine kinase 2  
52 ILMN_2727318 Pgp 3.05E-06 3.05E-02 -0.32 Phosphoglycolate phosphatase 
53 ILMN_1227658 Thg1l 3.18E-06 3.18E-02 0.95 tRNA-histidine guanylyltransferase 1-like (S. cerevisiae) 
54 ILMN_2733179 Aldh2 3.31E-06 3.32E-02 0.98 Aldehyde dehydrogenase 2, mitochondrial 
55 ILMN_2621649 Gpr160 3.54E-06 3.54E-02 -1.20 G protein-coupled receptor 160 
56 ILMN_2677859 Insl6 3.55E-06 3.55E-02 1.79 Insulin-like 6  
57 ILMN_2683486 Dennd4a 4.14E-06 4.14E-02 1.08 DENN/MADD domain containing 4A 
58 ILMN_2622374 Ndn 4.33E-06 4.33E-02 1.07 Necdin 
59 ILMN_1241171 Anxa3 4.52E-06 4.52E-02 -0.50 Annexin A3  
60 ILMN_1239397 Hk2 4.76E-06 4.76E-02 0.64 Hexokinase 2 
61 ILMN_1239221 2310016C08Rik 4.84E-06 4.85E-02 1.10 RIKEN cDNA 2310016C08 gene  
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Appendix 4B: List of significantly differentially expressed transcripts with a 2- or more fold change between unloaded AKR and 
DBA/2 macrophages.  Transcripts with nonparametric t-test p-value < 0.01 with their respective gene symbol, definition and log2 fold 
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1 ILMN_1258338 H2-D1 3.47E-05 3.47E-01 211.29 7.72 Histocompatibility 2, D region locus 1 
2 ILMN_2774430 Ncf2 2.28E-06 2.28E-02 68.04 6.09 Neutrophil cytosolic factor 2  
3 ILMN_2495447 H2-Q6 1.97E-04 1.97E+00 49.41 5.63 Histocompatibility 2, Q region locus 6 
4 ILMN_2455850 Tm7sf1 9.75E-06 9.75E-02 18.45 4.21 G protein-coupled receptor 137B 
5 ILMN_1256699 Sfi1 4.39E-05 4.39E-01 12.86 3.69 Sfi1 homolog, spindle assembly associated (yeast) 
6 ILMN_2502731 Villp 9.24E-06 9.24E-02 12.72 3.67 Villin-like 
7 ILMN_2737368 Stab2 7.83E-07 7.84E-03 10.95 3.45 Stabilin 2  
8 ILMN_2639155 2510048K03Rik 2.79E-05 2.79E-01 10.02 3.32 Prolylcarboxypeptidase (angiotensinase C) 
9 ILMN_1259100 Pilrb 1.37E-04 1.37E+00 9.83 3.30 Paired immunoglobin-like type 2 receptor beta 1 
10 ILMN_2605630 AA881470 1.36E-06 1.36E-02 9.14 3.19 EST AA881470 (AA881470), transcript variant 2 
11 ILMN_2675337 H2-Q6 1.66E-03 1.66E+01 8.99 3.17 Histocompatibility 2, Q region locus 6 
12 ILMN_2688236 Atp2a3 5.00E-07 5.01E-03 6.48 2.70 ATPase, Ca++ transporting, ubiquitous 
13 ILMN_1227555 Il1b 1.10E-03 1.10E+01 5.54 2.47 Interleukin 1 beta 
14 ILMN_1251748 Pscdbp 1.74E-04 1.74E+00 5.53 2.47 Cytohesin 1 interacting protein 
15 ILMN_2648742 Abcb4 4.71E-07 4.71E-03 5.32 2.41 ATP-binding cassette, sub-family B, member 4  
16 ILMN_2754170 H2-Q7 1.05E-05 1.05E-01 4.96 2.31 Histocompatibility 2, Q region locus 7 
17 ILMN_2728134 Ism1 1.23E-03 1.23E+01 4.88 2.29 Isthmin 1 homolog (zebrafish) 
18 ILMN_1234720 4930565N07Rik 2.49E-05 2.49E-01 4.59 2.20 RIKEN cDNA C130026I21 gene 
19 ILMN_1260218 Sfi1 9.62E-04 9.62E+00 4.32 2.11 Sfi1 homolog, spindle assembly associated (yeast) 
20 ILMN_2680827 Il7r 6.29E-07 6.29E-03 4.29 2.10 Interleukin 7 receptor 
21 ILMN_2747923 Slc40a1 1.51E-06 1.51E-02 4.26 2.09 Solute carrier family 40, member 1 
22 ILMN_2631206 Fblim1 4.59E-04 4.59E+00 4.10 2.03 Filamin binding LIM protein 1 
23 ILMN_2775154 Ctsh 3.78E-05 3.79E-01 4.05 2.02 Cathepsin H 
24 ILMN_1236009 Camk2b 3.13E-03 3.13E+01 4.00 2.00 Calcium/calmodulin-dependent protein kinase II, beta 
25 ILMN_2692960 1300013B24Rik 1.35E-04 1.35E+00 3.99 2.00 ERO1-like beta (S. cerevisiae) (Ero1lb) 
26 ILMN_2662317 5830482F20Rik 2.35E-04 2.35E+00 3.86 1.95 RIKEN cDNA 5830482F20 gene  
27 ILMN_1248510 Soat1 1.82E-04 1.82E+00 3.66 1.87 Sterol O-acyltransferase 1 
192 
 
Fold 
change 
RANK 
Probe_ID 
 
 
 
Symbol 
 
 
 
Nonparametric 
T-test 
P-values 
 
Bonferroni 
 
 
 
Fold 
Change  
DBA/AKR 
 
Log2 Fold 
Change 
DBA/AKR 
 
Definition 
 
 
 
28 ILMN_2656021 Osbpl3 1.12E-04 1.12E+00 3.52 1.82 Oxysterol binding protein-like 3 
29 ILMN_2677859 Insl6 3.55E-06 3.55E-02 3.45 1.79 Insulin-like 6 
30 ILMN_1229957 Il11ra1 5.14E-08 5.14E-04 3.39 1.76 Interleukin 11 receptor, alpha chain 1 
31 ILMN_2450096 Zfp30 1.36E-05 1.36E-01 3.37 1.75 Zinc finger protein 30  
32 ILMN_2744657 Igh-6 7.72E-04 7.72E+00 3.36 1.75 Immunoglobulin heavy chain 6 (heavy chain of IgM) 
33 ILMN_2684371 Igk-C 2.57E-04 2.57E+00 3.32 1.73 Immunoglobulin kappa chain, constant region 
34 ILMN_2747959 Dcn 1.62E-03 1.62E+01 3.32 1.73 Decorin 
35 ILMN_1221584 Crym 3.29E-08 3.29E-04 3.27 1.71 Crystallin, mu 
36 ILMN_3162925 LOC620078 1.10E-03 1.10E+01 3.26 1.71 SP140 nuclear body protein family member  
37 ILMN_1249691 Mlycd 3.78E-04 3.79E+00 3.26 1.70 Malonyl-CoA decarboxylase 
38 ILMN_2606667 Ddx6 1.54E-03 1.54E+01 3.25 1.70 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 
39 ILMN_2602837 Akr1e1 1.36E-03 1.36E+01 3.18 1.67 Aldo-keto reductase family 1, member E1 
40 ILMN_2450879 C330046E03 2.15E-04 2.15E+00 3.14 1.65 Hypothetical protein C330046E03 
41 ILMN_2731989 Ext1 2.64E-03 2.64E+01 3.09 1.63 Exostoses (multiple) 1 
42 ILMN_3160369 Nos3as 1.69E-05 1.69E-01 3.04 1.61 ATG9 autophagy related 9 homolog B (S. cerevisiae)  
43 ILMN_2777769 H2-DMa 9.76E-06 9.76E-02 3.04 1.60  
44 ILMN_1213662 Tm4sf5 1.21E-06 1.21E-02 3.03 1.60 Transmembrane 4 superfamily member 5  
45 ILMN_1229256 Bzrap1 8.51E-06 8.51E-02 2.97 1.57 Benzodiazapine receptor associated protein 1 
46 ILMN_2619594 Il11ra2 3.41E-09 3.41E-05 2.96 1.56  
47 ILMN_1228775 BC003331 1.19E-04 1.19E+00 2.95 1.56  
48 ILMN_1254717 AI929863 1.47E-04 1.47E+00 2.95 1.56  
49 ILMN_2610737 Iap 1.18E-08 1.18E-04 2.94 1.56  
50 ILMN_2727980 AA415817 1.26E-04 1.26E+00 2.92 1.55  
51 ILMN_1245079 Adssl1 7.58E-06 7.58E-02 2.91 1.54 Adenylosuccinate synthetase like 1 
52 ILMN_2633063 9130422G05Rik 5.51E-07 5.51E-03 2.90 1.54  
53 ILMN_1216809 Igh-6 2.68E-06 2.68E-02 2.90 1.54  
54 ILMN_2694153 Ddef1 2.61E-05 2.61E-01 2.78 1.47  
55 ILMN_1243928 Npy 3.32E-04 3.33E+00 2.75 1.46 Neuropeptide Y 
56 ILMN_2649101 Ncf2 1.28E-05 1.28E-01 2.73 1.45 Neutrophil cytosolic factor 2 
57 ILMN_1242902 Rapgef5 2.79E-08 2.79E-04 2.71 1.44  
58 ILMN_1258283 Ltb 1.59E-04 1.59E+00 2.64 1.40 Lymphotoxin B 
59 ILMN_1255047 C80638 1.74E-03 1.74E+01 2.64 1.40  
60 ILMN_1244799 Usp39 6.85E-08 6.85E-04 2.64 1.40 Ubiquitin specific peptidase 39  
61 ILMN_1240264 Usp2 4.74E-03 4.75E+01 2.62 1.39  
62 ILMN_1242391 Tmem8 5.53E-06 5.53E-02 2.61 1.38 Transmembrane protein 8  
63 ILMN_1233146 Rasgrf1 7.09E-05 7.09E-01 2.60 1.38  
64 ILMN_2693934 4833444G19Rik 2.67E-05 2.67E-01 2.60 1.38  
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65 ILMN_2717716 Rapgef5 3.09E-04 3.09E+00 2.57 1.36  
66 ILMN_1256171 BC026370 7.44E-08 7.45E-04 2.56 1.36 Transmembrane protein 63b  
67 ILMN_1247894 Snrpn 5.23E-05 5.23E-01 2.55 1.35  
68 ILMN_2589640 Ednrb 4.22E-03 4.22E+01 2.55 1.35 Endothelin receptor type B 
69 ILMN_1250922 AA415817 3.87E-04 3.87E+00 2.52 1.33  
70 ILMN_2606162 Pdlim4 1.08E-03 1.08E+01 2.50 1.32 PDZ and LIM domain 4 
71 ILMN_1236574 Cenpa 8.55E-07 8.55E-03 2.49 1.31  
72 ILMN_2748879 4833414E09Rik 1.05E-03 1.05E+01 2.48 1.31  
73 ILMN_2775360 Mapkapk3 2.21E-07 2.21E-03 2.47 1.30  
74 ILMN_2690556 C730049P21 1.40E-03 1.40E+01 2.45 1.29  
75 ILMN_2674602 Rapgef5 3.50E-05 3.50E-01 2.45 1.29  
76 ILMN_2704562 Igk-C 1.07E-03 1.07E+01 2.43 1.28  
77 ILMN_1238167 Pop4 3.46E-03 3.46E+01 2.42 1.27  
78 ILMN_1246992 A630042L21Rik 2.30E-04 2.30E+00 2.41 1.27 RIKEN cDNA A630042L21 gene 
79 ILMN_1257446 Nfkbib 1.21E-04 1.21E+00 2.41 1.27  
80 ILMN_2627566 Capn5 1.91E-04 1.91E+00 2.40 1.26  
81 ILMN_2702406 Pim1 1.11E-03 1.11E+01 2.39 1.26 Proviral integration site 1 
82 ILMN_2642969 Centb1 9.10E-04 9.10E+00 2.39 1.26  
83 ILMN_1252481 Fosl2 1.19E-03 1.19E+01 2.39 1.25 Fos-like antigen 2 
84 ILMN_1245129 Ifitm1 2.49E-04 2.49E+00 2.38 1.25 Interferon induced transmembrane protein 1 
85 ILMN_1229318 Pdk1 9.58E-06 9.58E-02 2.37 1.25  
86 ILMN_2523170 Treml1 5.36E-07 5.36E-03 2.37 1.24  
87 ILMN_1231552 C530043K16Rik 6.19E-04 6.19E+00 2.32 1.21  
88 ILMN_1234456 0610037D15Rik 1.67E-03 1.67E+01 2.31 1.21 RIKEN cDNA 0610037D15 gene 
89 ILMN_1222196 2310007A19Rik 9.42E-07 9.42E-03 2.31 1.21  
90 ILMN_2492201 Txnl4 1.20E-03 1.20E+01 2.31 1.21  
91 ILMN_2644764 Hp 1.45E-03 1.45E+01 2.29 1.20 Haptoglobin 
92 ILMN_2515599 Vldlr 4.03E-04 4.04E+00 2.29 1.19 Very low density lipoprotein receptor 
93 ILMN_2778289 Cxcl2 1.09E-04 1.09E+00 2.29 1.19  
94 ILMN_1254655 Casp4 2.12E-03 2.12E+01 2.26 1.18 Caspase 4, apoptosis-related cysteine peptidase 
95 ILMN_2591502 A130052D22 2.50E-04 2.50E+00 2.26 1.18  
96 ILMN_2661407 1500016H10Rik 1.04E-04 1.04E+00 2.24 1.17  
97 ILMN_2760800 Cxcl14 3.02E-07 3.02E-03 2.23 1.16  
98 ILMN_2663230 Slco3a1 2.70E-03 2.70E+01 2.22 1.15  
99 ILMN_2763679 Sipa1l1 3.93E-05 3.93E-01 2.22 1.15  
100 ILMN_2447464 Ucp1 7.63E-04 7.63E+00 2.19 1.13 Uncoupling protein 1 (mitochondrial, proton carrier)  
101 ILMN_1224736 BC065120 1.03E-06 1.03E-02 2.19 1.13  
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102 ILMN_1216764 Ier3 4.49E-04 4.50E+00 2.19 1.13  
103 ILMN_2668510 Hp 2.06E-03 2.06E+01 2.18 1.13 Haptoglobin 
104 ILMN_2687797 Cryab 2.07E-05 2.07E-01 2.18 1.12 Crystallin, alpha B 
105 ILMN_2679937 Pbxip1 2.93E-04 2.93E+00 2.17 1.12  
106 ILMN_2634083 Cdkn1a 5.38E-06 5.38E-02 2.16 1.11 Cyclin-dependent kinase inhibitor 1A (P21)  
107 ILMN_1214871 Cdkn1a 1.31E-04 1.31E+00 2.16 1.11 Cyclin-dependent kinase inhibitor 1A (P21) 
108 ILMN_1247811 Ass1 5.47E-04 5.47E+00 2.15 1.10 Argininosuccinate synthetase 1 
109 ILMN_2640766 Ifitm1 2.92E-05 2.92E-01 2.15 1.10 Interferon induced transmembrane protein 1 
110 ILMN_1239221 2310016C08Rik 4.84E-06 4.85E-02 2.14 1.10 RIKEN cDNA 2310016C08 gene 
111 ILMN_2635784 Gpc1 1.99E-04 1.99E+00 2.14 1.10  
112 ILMN_1220121 Kif23 1.61E-05 1.61E-01 2.13 1.09  
113 ILMN_1235969 Gnl2 2.37E-05 2.37E-01 2.12 1.09  
114 ILMN_2610609 1810054D07Rik 8.15E-06 8.15E-02 2.12 1.09  
115 ILMN_2683486 AI115600 4.14E-06 4.14E-02 2.12 1.08  
116 ILMN_3160218 Amica1 3.33E-05 3.33E-01 2.10 1.07 Adhesion molecule, interacts with CXADR antigen 1 
117 ILMN_2622374 Ndn 4.33E-06 4.33E-02 2.10 1.07  
118 
 
ILMN_1242677 
 
Galnt2 
 
5.05E-06 
 
5.05E-02 
 
2.09 
 
1.06 
 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 2 
119 ILMN_1246614 BC066107 3.97E-04 3.97E+00 2.09 1.06 cDNA sequence BC066107 
120 ILMN_2680038 1200013B22Rik 1.09E-06 1.09E-02 2.08 1.06 NUAK family, SNF1-like kinase, 2 
121 ILMN_1226325 Cnnm2 7.61E-05 7.61E-01 2.08 1.06  
122 ILMN_2716116 Cias1 1.33E-03 1.33E+01 2.08 1.05  
123 ILMN_2778279 Fosb 2.69E-05 2.69E-01 2.07 1.05  
124 ILMN_2619408 Atf3 3.52E-05 3.52E-01 2.05 1.04 Activating transcription factor 3  
125 ILMN_2519673 Vwf 1.41E-04 1.41E+00 2.05 1.03  
126 ILMN_1240445 Stard4 2.03E-03 2.03E+01 2.04 1.03  
127 ILMN_2737685 Mmp13 4.16E-04 4.16E+00 2.04 1.03 Matrix metallopeptidase 13 
128 
 
ILMN_2514439 
 
Ugt1a6 
 
2.13E-03 
 
2.13E+01 
 
2.04 
 
1.03 
 
UDP glucuronosyltransferase 1 family, polypeptide 
A6A  
129 ILMN_1219908 Tmem8 1.28E-03 1.28E+01 2.04 1.03 Transmembrane protein 8 
130 ILMN_2632665 Cav1 4.35E-04 4.35E+00 2.04 1.03 Caveolin, caveolae protein 1 
131 ILMN_2751603 Phxr4 2.74E-03 2.74E+01 2.03 1.02  
132 ILMN_1248714 Daf1 2.88E-04 2.88E+00 2.03 1.02  
133 ILMN_2685291 A2bp1 8.17E-06 8.17E-02 2.02 1.02  
134 ILMN_2699665 1810029C22Rik 5.27E-03 5.27E+01 2.01 1.01  
135 ILMN_1245389 scl0001356.1_58 2.31E-04 2.31E+00 2.00 1.00  
136 ILMN_2608052 Smox 7.64E-05 7.64E-01 0.50 -1.01 Spermine oxidase  
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137 ILMN_1247404 B230312I18Rik 2.17E-03 2.17E+01 0.50 -1.01  
138 ILMN_1230518 Prps1 1.87E-05 1.87E-01 0.50 -1.01 Phosphoribosyl pyrophosphate synthetase 1 
139 ILMN_3160837 Hoxb7 1.24E-05 1.24E-01 0.49 -1.02 Homeo box B7 
140 ILMN_2768228 Cox7a2l 7.57E-06 7.58E-02 0.49 -1.02  
141 ILMN_2670935 Rasgrp3 2.23E-03 2.23E+01 0.49 -1.02 RAS, guanyl releasing protein 3  
142 ILMN_1251018 Fxyd2 2.38E-03 2.39E+01 0.49 -1.02  
143 ILMN_2667020 Ryk 3.60E-07 3.61E-03 0.49 -1.02  
144 ILMN_2419185 Tuft1 7.24E-05 7.24E-01 0.49 -1.03  
145 ILMN_2679664 D1Ertd251e 1.97E-04 1.97E+00 0.49 -1.03 Transcriptional adaptor 1 (HFI1 homolog, yeast) like 
146 ILMN_1220609 Ltb4r1 3.27E-04 3.27E+00 0.49 -1.04 Leukotriene B4 receptor 1 
147 ILMN_1237993 Nasp 1.53E-05 1.53E-01 0.48 -1.05  
148 
 
ILMN_2644719 
 
Hmgn3 
 
4.17E-03 
 
4.17E+01 
 
0.48 
 
-1.05 
 
High mobility group nucleosomal binding domain 3, 
variant 2, 
149 ILMN_1216813 2310003L22Rik 8.82E-06 8.82E-02 0.48 -1.06 RIKEN cDNA 2310003L22 gene  
150 ILMN_2661289 Csprs 5.40E-06 5.40E-02 0.48 -1.06 Component of Sp100-rs 
151 ILMN_2771766 Ccl12 1.91E-05 1.91E-01 0.48 -1.06  
152 ILMN_2750725 F630022B06Rik 2.54E-03 2.54E+01 0.48 -1.07 Phosphatidylinositol glycan anchor biosynthesisclass Z  
153 ILMN_2640346 P2ry13 4.76E-03 4.76E+01 0.48 -1.07 Purinergic receptor P2Y, G-protein coupled 13 
154 ILMN_2596917 Nck2 2.71E-03 2.71E+01 0.47 -1.08 Noncatalytic region of tyrosine kinase adaptor protein2 
155 ILMN_2711075 Mmp9 5.08E-03 5.09E+01 0.47 -1.09 Musculus matrix metallopeptidase 9 
156 ILMN_2590950 Agtrap 1.28E-03 1.28E+01 0.47 -1.09  
157 ILMN_1231851 Enpp1 1.69E-04 1.69E+00 0.47 -1.09 Ectonucleotide pyrophosphatase/phosphodiesterase 1 
158 ILMN_1215092 Slp 2.46E-03 2.46E+01 0.47 -1.10  
159 ILMN_2633069 Mela 2.77E-03 2.77E+01 0.46 -1.11  
160 ILMN_1249378 Bhlhb2 1.13E-03 1.13E+01 0.46 -1.12 Basic helix-loop-helix domain containing, class B2 
161 ILMN_1252851 2810405K07Rik 7.42E-04 7.43E+00 0.46 -1.13  
162 ILMN_1249386 Erdr1 5.76E-04 5.76E+00 0.46 -1.13 Erythroid differentiation regulator 1 
163 ILMN_3161805 Ccl12 4.71E-05 4.72E-01 0.46 -1.13  
164 ILMN_2728038 Arhgap24 3.20E-04 3.20E+00 0.45 -1.14 Rho GTPase activating protein 24, transcript variant 2 
165 ILMN_2492170 Tnfsf13 2.55E-04 2.55E+00 0.45 -1.14  
166 ILMN_2661299 Pmp22 1.98E-05 1.98E-01 0.45 -1.14  
167 ILMN_3163535 Zfp277 1.12E-03 1.12E+01 0.45 -1.15 Zinc finger protein 277, transcript variant 2 
168 ILMN_2600190 Gjb4 1.07E-06 1.07E-02 0.45 -1.16  
169 ILMN_1236906 D11Ertd497e 3.05E-04 3.05E+00 0.45 -1.16 DNA segment, Chr 11, ERATO Doi 497, expressed  
170 ILMN_2606404 St18 1.78E-03 1.78E+01 0.45 -1.16 Suppression of tumorigenicity 18  
171 ILMN_2753356 Snapc5 2.19E-03 2.19E+01 0.44 -1.17  
172 ILMN_2621649 Gpr160 3.54E-06 3.54E-02 0.44 -1.20  
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173 ILMN_1256328 Tjp2 1.54E-04 1.54E+00 0.44 -1.20  
174 ILMN_2419138 Vcl 2.02E-04 2.02E+00 0.43 -1.21  
175 
 
ILMN_2517041 
 
Uhrf1 
 
6.39E-04 
 
6.39E+00 
 
0.42 
 
-1.23 
 
Ubiquitin-like, containing PHD and RING finger 
domains, 1  
176 ILMN_1233376 AW548124 2.92E-05 2.92E-01 0.42 -1.25  
177 ILMN_2702303 Ch25h 1.85E-03 1.85E+01 0.41 -1.30 Cholesterol 25-hydroxylase 
178 ILMN_2760020 Cxcl13 3.10E-03 3.10E+01 0.41 -1.30  
179 ILMN_1217097 Cables1 8.21E-04 8.21E+00 0.41 -1.30 Cdk5 and Abl enzyme substrate 1  
180 
 
ILMN_2619620 
 
C1qb 
 
2.73E-06 
 
2.73E-02 
 
0.41 
 
-1.30 
 
Complement component 1, q subcomponent, beta 
polypeptide  
181 ILMN_2431257 2510022D24Rik 4.85E-03 4.85E+01 0.40 -1.32  
182 ILMN_2758199 Sdh1 2.10E-07 2.10E-03 0.40 -1.33 Sorbitol dehydrogenase 
183 ILMN_2589865 Cd28 4.81E-03 4.81E+01 0.40 -1.34 CD28 antigen 
184 ILMN_2672772 Abhd1 3.93E-04 3.93E+00 0.39 -1.37 Abhydrolase domain containing 1 
185 ILMN_2730784 Gps2 2.08E-04 2.08E+00 0.39 -1.37  
186 ILMN_2776728 2610305D13Rik 4.68E-03 4.69E+01 0.38 -1.39  
187 ILMN_2718217 2310057H16Rik 2.33E-04 2.33E+00 0.38 -1.40 Tubulin, beta 6 
188 ILMN_2665266 H2-T10 5.98E-05 5.98E-01 0.38 -1.40  
189 ILMN_1258920 2210012G02Rik 1.50E-03 1.50E+01 0.38 -1.41  
190 ILMN_1226642 2210012G02Rik 3.58E-04 3.58E+00 0.36 -1.46  
191 ILMN_1245678 Abhd1 2.09E-07 2.09E-03 0.36 -1.47 Abhydrolase domain containing 1 
192 ILMN_2612895 C2 8.45E-06 8.45E-02 0.36 -1.49 Complement component 2 (within H-2S) 
193 ILMN_2653881 0610009K11Rik 2.33E-04 2.33E+00 0.35 -1.50 RIKEN cDNA 0610009K11 gene 
194 ILMN_1257631 Apobec1 4.77E-04 4.77E+00 0.35 -1.52  
195 ILMN_1232183 Mgmt 2.64E-06 2.64E-02 0.34 -1.54  
196 ILMN_2602462 Snx5 3.58E-03 3.58E+01 0.34 -1.56 Sorting nexin 5 
197 ILMN_2688287 Prss22 1.76E-03 1.76E+01 0.33 -1.59 Protease, serine, 22 
198 ILMN_2684316 P2ry1 1.09E-04 1.09E+00 0.33 -1.59 Purinergic receptor P2Y, G-protein coupled 1 
199 ILMN_1246153 Erdr1 1.77E-03 1.77E+01 0.33 -1.62 Erythroid differentiation regulator 1 
200 ILMN_2616328 Fxyd2 1.83E-03 1.83E+01 0.33 -1.62  
201 ILMN_2657019 Rab17 3.99E-05 4.00E-01 0.32 -1.65 RAB17, member RAS oncogene family 
202 ILMN_2589164 H2-DMb2 2.07E-04 2.07E+00 0.32 -1.66  
203 ILMN_1253614 E2f2 1.91E-04 1.91E+00 0.31 -1.67 E2F transcription factor 2  
204 ILMN_2725020 Ccr5 9.85E-03 9.85E+01 0.31 -1.68 Chemokine (C-C motif) receptor 5 
205 ILMN_2648669 Gpnmb 7.77E-06 7.78E-02 0.30 -1.74 Glycoprotein (transmembrane) nmb 
206 ILMN_2771176 Ccl7 9.49E-04 9.50E+00 0.30 -1.76  
207 ILMN_2631663 BC022687 9.78E-09 9.78E-05 0.29 -1.77 cDNA sequence BC022687 (BC022687) 
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208 ILMN_1236908 Tlr1 4.52E-05 4.52E-01 0.29 -1.77 Toll-like receptor 1 
209 ILMN_1220732 Scn1b 8.14E-05 8.15E-01 0.28 -1.81 Sodium channel, voltage-gated, type I, beta 
210 ILMN_2671667 Scn1b 3.26E-04 3.26E+00 0.27 -1.89 Sodium channel, voltage-gated, type I, beta 
211 ILMN_1254631 AI481316 8.34E-04 8.34E+00 0.27 -1.89  
212 ILMN_2657867 Napsa 5.07E-05 5.07E-01 0.27 -1.91 Napsin A aspartic peptidase 
213 ILMN_2731407 Gdf3 1.56E-06 1.56E-02 0.26 -1.92  
214 ILMN_2706101 Snx5 9.52E-04 9.52E+00 0.21 -2.28 Sorting nexin 5  
215 ILMN_2722488 Thumpd1 5.19E-06 5.19E-02 0.19 -2.43 THUMP domain containing 1 
216 ILMN_2774882 1110005F07Rik 7.61E-04 7.62E+00 0.16 -2.66  
217 ILMN_2669361 2310009E04Rik 4.76E-05 4.76E-01 0.15 -2.74  
218 ILMN_1241298 Hal 1.69E-04 1.69E+00 0.14 -2.81 Histidine ammonia lyase 
219 ILMN_1259610 6030411F23Rik 1.37E-04 1.37E+00 0.14 -2.86 CD276 antigen 
220 ILMN_1236420 Gpnmb 5.49E-05 5.49E-01 0.13 -3.00 Glycoprotein (transmembrane) nmb 
221 ILMN_2775030 Folr2 1.39E-03 1.39E+01 0.10 -3.27  
222 ILMN_2777337 Psmb6 5.02E-05 5.02E-01 0.08 -3.65  
223 ILMN_2614655 Gpnmb 2.52E-04 2.52E+00 0.08 -3.72 Glycoprotein (transmembrane) nmb 
224 ILMN_1247744 Gpnmb 1.60E-04 1.60E+00 0.08 -3.74 lycoprotein (transmembrane) nmb 
225 ILMN_1231814 Ccl5 2.93E-04 2.93E+00 0.04 -4.53 Chemokine (C-C motif) ligand 5 
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Appendix 4C: Table shows the pathways identified by gene ontology and functional analyses (DAVID) that were overrepresented (P-
value < 0.01) in our list of significantly differentially expressed transcripts between AKR and DBA/2 unloaded macrophages.  
 
Pathway 
 
Pathway P-value 
 
Genes/Probe_ID 
 
Definition 
 
Toll-like receptor signaling pathway 3.90E-04 ILMN_2742075 CD14 antigen 
  ILMN_2743244  CD86 antigen 
  ILMN_1223126  Fas (TNFRSF6)-associated via death domain 
  ILMN_2646625  Jun oncogene  
  ILMN_1253919  Chemokine (C-C motif) ligand 3  
  ILMN_1223257  Chemokine (C-C motif) ligand 4 
  ILMN_1231814  Chemokine (C-C motif) ligand 5  
  ILMN_2621752  Interferon regulatory factor 5 
  ILMN_2661579  Mitogen-activated protein kinase 3  
  ILMN_2753492  Receptor (TNFRSF)-interacting serine-threonine kinase 1 
  ILMN_2655721  Signal transducer and activator of transcription 1 
  ILMN_1229720  Toll interacting protein  
  ILMN_1236908  Toll-like receptor 1  
  ILMN_2733733  Toll-like receptor 2  
  ILMN_3162337  Toll-like receptor 6  
    ILMN_1245354  Toll-like receptor 7 
Chemokine signaling pathway 5.30E-04 ILMN_2615901   PTK2 protein tyrosine kinase 2   
  ILMN_3163572  adenylate cyclase 7  
  
ILMN_2771766, 
ILMN_3161805  
chemokine (C-C motif) ligand 12; similar to monocyte chemoattractant 
protein-5  
  ILMN_1245710  chemokine (C-C motif) ligand 2 
  ILMN_1253919  chemokine (C-C motif) ligand 3  
  ILMN_1223257  chemokine (C-C motif) ligand 4  
  ILMN_1231814  chemokine (C-C motif) ligand 5  
  ILMN_2771176  chemokine (C-C motif) ligand 7  
  ILMN_1238886  chemokine (C-C motif) ligand 8  
  ILMN_2776603  chemokine (C-C motif) ligand 9  
  ILMN_2685392  chemokine (C-C motif) receptor 5  
  ILMN_2763243  chemokine (C-X-C motif) ligand 1  
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Genes/Probe_ID 
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ILMN_2659427, 
ILMN_2760800  chemokine (C-X-C motif) ligand 14   
  ILMN_2593888  glycogen synthase kinase 3 beta  
  ILMN_2733852  guanine nucleotide binding protein (G protein), beta 1  
  ILMN_1257446  
nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, beta  
  ILMN_1229458  protein kinase C, beta  
  ILMN_1219914  
ras homolog gene family, member A; similar to aplysia ras-related 
homolog A2; predicted gene 12844  
  ILMN_2655721  signal transducer and activator of transcription 1  
  ILMN_2698046  similar to Stat3B; signal transducer and activator of transcription 3  
    ILMN_1224077  vav 1 oncogene 
Systemic lupus erithematosus 6.04E-04 ILMN_2743244   CD86 antigen   
  ILMN_2715840  complement component 1, q subcomponent, C chain  
  ILMN_2619620  complement component 1, q subcomponent, beta polypeptide  
  ILMN_2612895  complement component 2 (within H-2S)  
  ILMN_1230789  
complement component 3; similar to complement component C3 
prepropeptide, last  
  ILMN_2777769  histocompatibility 2, class II, locus DMa  
  ILMN_2589164  histocompatibility 2, class II, locus Mb2  
  ILMN_2730329  
histone cluster 1, H2ad; histone cluster 1, H2ae; histone cluster 1, 
H2ag; histone cluster 1, H2ah; histone cluster 1, H2ai; similar to 
histone 2a; histone cluster 1, H2an; histone cluster 1, H2ao; histone 
cluster 1, H2ac; histone cluster 1, H2ab  
    
  
ILMN_1242399, 
ILMN_1252995  
histone cluster 1, H2bg; histone cluster 1, H2be; histone cluster 2, 
H2bb; histone cluster 1, H2bc  
  ILMN_2698519  
histone cluster 1, H3i; histone cluster 1, H3h; histone cluster 1, H3g; 
predicted gene 12260; histone cluster 1, H3a  
  ILMN_1218380  histone cluster 2, H2ac  
  ILMN_2724358  
histone cluster 2, H3b; histone cluster 1, H3f; histone cluster 1, H3e; 
histone cluster 2, H3c1; histone cluster 1, H3d; histone cluster 1, H3c; 
histone cluster 1, H3b; histone cluster 2, H3c2; histone cluster 2, 
H2aa1; histone cluster 2, H2aa2 ILMN_2648292  
  ILMN_2646052  similar to Complement C4 precursor; complement component 4A  
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  ILMN_1257520  
similar to Hist1h2bj protein; histone cluster 1, H2bl; predicted gene, 
OTTMUSG00000013203; histone cluster 1, H2bj; histone cluster 1, 
H2bf; H2b histone family member; histone cluster 1, H2bn  
    ILMN_1225361  small nuclear ribonucleoprotein D1; predicted gene 14277 
NOD-like receptor signaling 
pathway 
2.20E-03 
 ILMN_1247592   caspase 1; hypothetical protein LOC100044207   
  
ILMN_2771766, 
ILMN_3161805  
chemokine (C-C motif) ligand 12; similar to monocyte chemoattractant 
protein-5  
  ILMN_1245710  Chemokine (C-C motif) ligand 2  
  ILMN_1231814  Chemokine (C-C motif) ligand 5  
  ILMN_2771176  Chemokine (C-C motif) ligand 7  
  ILMN_1238886  Chemokine (C-C motif) ligand 8  
  ILMN_2763243  Chemokine (C-X-C motif) ligand 1 
  ILMN_2778289  Chemokine (C-X-C motif) ligand 2  
  ILMN_2661579  mitogen-activated protein kinase 3  
  ILMN_1257446  
nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, beta  
    ILMN_2634970  receptor (TNFRSF)-interacting serine-threonine kinase 2 
Cytokine-cytokine receptor 
interaction 
2.50E-03 
 ILMN_1248328   activin A receptor, type II-like 1   
  
ILMN_2771766, 
ILMN_3161805  
chemokine (C-C motif) ligand 12; similar to monocyte chemoattractant 
protein-5  
  ILMN_1245710  chemokine (C-C motif) ligand 2  
  ILMN_1253919  chemokine (C-C motif) ligand 3  
  ILMN_1223257  chemokine (C-C motif) ligand 4  
  ILMN_1231814  chemokine (C-C motif) ligand 5  
  ILMN_2771176  chemokine (C-C motif) ligand 7  
  ILMN_1238886  chemokine (C-C motif) ligand 8  
  ILMN_2776603  chemokine (C-C motif) ligand 9  
  ILMN_2685392  chemokine (C-C motif) receptor 5  
  ILMN_2763243  chemokine (C-X-C motif) ligand 1  
  
ILMN_2659427, 
ILMN_2760800  chemokine (C-X-C motif) ligand 14  
  ILMN_2778289  chemokine (C-X-C motif) ligand 2  
  ILMN_2750047  colony stimulating factor 2 receptor, beta 2, low-affinity 
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ILMN_2688262 
  
colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-
macrophage)  
  ILMN_2514362  cytokine receptor-like factor 2  
  
ILMN_2619594, 
ILMN_1229957  interleukin 11 receptor, alpha chain 1 
  ILMN_2654028  interleukin 21 receptor  
  ILMN_2724449  interleukin 3 receptor, alpha chain  
  ILMN_2680827  interleukin 7 receptor  
  ILMN_1258283  lymphotoxin B  
  
ILMN_2760979, 
ILMN_1242086  transforming growth factor, beta receptor II  
  ILMN_2492170  
tumor necrosis factor (ligand) superfamily, member 12; tumor necrosis 
factor (ligand) superfamily, member 12-member 13; tumor necrosis 
factor (ligand) superfamily, member 13 
  ILMN_2464573  tumor necrosis factor receptor superfamily, member 21 
  ILMN_2484527  vascular endothelial growth factor A  
    ILMN_2486573  vascular endothelial growth factor C 
Fructose and manose metabolism  4.10E-03 ILMN_2731563   6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3   
  ILMN_2712668  
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 
ILMN_2766596  
  ILMN_3160137  aldolase C, fructose-bisphosphate  
  ILMN_1239397  hexokinase 2  
  ILMN_2698564  ketohexokinase  
  ILMN_2673233  phosphofructokinase, platelet 
    ILMN_2758199  sorbitol dehydrogenase 
Focal adhesion 7.80E-03 ILMN_2594857   3-phosphoinositide dependent protein kinase-1   
  ILMN_2646625  Jun oncogene  
  ILMN_2615901  PTK2 protein tyrosine kinase 2 
  ILMN_1233146  RAS protein-specific guanine nucleotide-releasing factor 1  
  ILMN_2519673  Von Willebrand factor homolog  
  
ILMN_2620030, 
ILMN_2683586  calpain 2 
  ILMN_2773395  cartilage oligomeric matrix protein  
  ILMN_2632665  caveolin 1, caveolae protein  
  ILMN_1257949  cyclin D1  
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  ILMN_2593888  glycogen synthase kinase 3 beta  
  ILMN_1227434  integrin beta 7  
  ILMN_2661579  mitogen-activated protein kinase 3  
  ILMN_1215465  p21 protein (Cdc42/Rac)-activated kinase 2  
  ILMN_2764580  parvin, gamma  
  ILMN_1229458  protein kinase C, beta  
  ILMN_2647628  protein phosphatase 1, catalytic subunit, beta isoform  
  ILMN_1219914  
ras homolog gene family, member A; similar to aplysia ras-related 
homolog A2; predicted gene 12844  
  ILMN_2484527  vascular endothelial growth factor A  
  ILMN_2486573  vascular endothelial growth factor C  
  ILMN_1224077  vav 1 oncogene  
  ILMN_2419138  Vinculin 
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Appendix 4D: List of significantly differentially expressed transcripts between AKR and DBA/2 macrophages in response to 
cholesterol loading.  Transcripts with Bonferroni adjusted ANOVA p-value < 0.05 with their respective gene symbol, definition and 
fold change in AKR and DBA/2 strains are presented.   
 
P-value 
Rank 
Probe_ID 
 
 
Symbol 
 
 
Nested 
ANOVA 
P-values 
Bonferroni 
 
 
AKR Loaded/ 
AKRUnloaded 
 
DBALoaded/ 
DBAUnloaded 
 
Definition 
 
 
1 ILMN_2774888 Tgfbi 2.70E-12 2.62E-08 0.4 1.0 Transforming growth factor, beta-induced 
2 ILMN_3160659 Dok2 3.79E-11 3.68E-07 0.5 1.3  
3 ILMN_2689138 2310044G17Rik 9.80E-11 9.51E-07 2.6 1.2  
4 ILMN_1257949 Ccnd1 2.06E-10 2.00E-06 0.6 1.5  
5 ILMN_2761472 Lrpap1 3.32E-10 3.22E-06 1.7 1.0  
6 ILMN_2742152 Gadd45a 3.59E-10 3.49E-06 3.6 1.3 Growth arrest and DNA-damage-inducible 45 alpha 
7 ILMN_2663249 Slamf9 6.28E-10 6.10E-06 0.2 1.1 SLAM family member 9 (Slamf9) 
8 ILMN_1244291 Gja1 8.35E-10 8.11E-06 0.2 0.9 Gap junction membrane channel protein alpha 1 
9 ILMN_2606144 F730004D16Rik 8.77E-10 8.51E-06 3.0 1.1  
10 ILMN_1241610 Adrb2 9.11E-10 8.85E-06 0.4 0.8 Adrenergic receptor, beta 2  
11 ILMN_1252851 2810405K07Rik 1.46E-09 1.42E-05 0.6 1.6  
12 ILMN_1255341 Atf5 1.67E-09 1.62E-05 2.3 0.9 Activating transcription factor 5  
13 ILMN_2719036 B130052G07Rik 1.77E-09 1.71E-05 3.1 1.4 Vasohibin 2  
14 ILMN_3161489 Acaca 1.97E-09 1.91E-05 0.7 1.2 Acetyl-Coenzyme A carboxylase alpha  
15 ILMN_2617468 1810008K03Rik 1.97E-09 1.92E-05 7.6 1.2 ChaC, cation transport regulator-like 1 (E. coli)  
16 ILMN_2519673 Vwf 2.02E-09 1.96E-05 3.9 0.9  
17 ILMN_1225528 Trib3 2.30E-09 2.24E-05 6.1 1.2  
18 ILMN_2735350 Gdf15 2.70E-09 2.62E-05 3.2 1.0 Growth differentiation factor 15  
19 ILMN_2715500 Dner 3.57E-09 3.47E-05 0.7 2.5 Delta/notch-like EGF-related receptor 
20 ILMN_1230489 AA407930 3.62E-09 3.51E-05 1.6 1.0 Zinc finger, AN1-type domain 2A  
21 ILMN_1250438 Mlp 3.64E-09 3.53E-05 0.5 1.4  
22 ILMN_1252283 Tulp4 6.04E-09 5.86E-05 2.1 1.2 Tubby like protein 4  
23 ILMN_2643513 Asns 6.15E-09 5.97E-05 3.8 1.4 Asparagine synthetase 
24 ILMN_2681965 Ctsc 6.69E-09 6.50E-05 0.5 0.9 Cathepsin C  
25 ILMN_2760800 Cxcl14 7.09E-09 6.89E-05 1.0 3.3  
26 ILMN_2667384 Slc6a9 7.41E-09 7.20E-05 2.8 1.0  
27 ILMN_2680827 Il7r 8.11E-09 7.87E-05 4.4 1.2 Interleukin 7 receptor 
28 ILMN_2710705 Sqstm1 9.03E-09 8.77E-05 2.1 0.9  
29 ILMN_2644375 Hyal1 9.53E-09 9.26E-05 4.8 1.6 Hyaluronoglucosaminidase 1 
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30 ILMN_2751304 Ell 1.02E-08 9.89E-05 1.7 1.0  
31 ILMN_2610944 Fpr1 1.04E-08 1.01E-04 0.2 0.8  
32 ILMN_1225204 2510004L01Rik 1.06E-08 1.03E-04 1.2 0.5 Radical S-adenosyl methionine domain containing 2  
33 ILMN_1239221 2310016C08Rik 1.10E-08 1.06E-04 1.9 0.7 RIKEN cDNA 2310016C08 gene  
34 ILMN_1246139 Cldn11 1.35E-08 1.31E-04 2.5 0.8  
35 ILMN_1258988 Igfbp4 1.42E-08 1.38E-04 0.4 0.8  
36 ILMN_2620583 6720425G15Rik 1.45E-08 1.41E-04 1.7 1.0  
37 ILMN_2640346 P2ry13 1.56E-08 1.51E-04 0.1 0.5 Purinergic receptor P2Y, G-protein coupled 13  
38 ILMN_2663130 P2ry6 1.61E-08 1.57E-04 0.4 0.8  
39 ILMN_1260456 Hsd3b7 1.62E-08 1.58E-04 2.2 1.3  
40 ILMN_1229082 1810045K06Rik 1.63E-08 1.58E-04 1.8 0.9  
41 ILMN_2626722 
 
Ssb4  
 
1.71E-08 
 
1.66E-04 
 
4.3 
 
1.3 
 
SplA/ryanodine receptor domain and SOCS box 
containing 4  
42 ILMN_2610737 Iap 1.79E-08 1.74E-04 1.4 0.7  
43 ILMN_1229718 Ms4a6c 1.84E-08 1.78E-04 0.2 0.6  
44 ILMN_1253972 Irak3 1.85E-08 1.80E-04 0.4 1.1 Interleukin-1 receptor-associated kinase 3 
45 ILMN_2695199 Siat10 1.93E-08 1.87E-04 0.3 0.7  
46 ILMN_2621148 Kif3a 1.97E-08 1.92E-04 2.3 0.8  
47 ILMN_1249640 Neurl 2.14E-08 2.08E-04 0.3 0.9  
48 ILMN_2714796 Coro1a 2.19E-08 2.12E-04 0.5 0.9 Coronin, actin binding protein 1A  
49 ILMN_2589651 Anpep 2.34E-08 2.27E-04 2.7 1.5 Alanyl (membrane) aminopeptidase  
50 ILMN_1213483 B430214A04Rik 2.41E-08 2.34E-04 1.5 1.0 Folliculin  
51 ILMN_2631161 Fcrl3 2.43E-08 2.36E-04 0.5 0.7 Fc fragment of IgG, low affinity IIIa, receptor  
52 ILMN_2602846 9530020G05Rik 2.73E-08 2.66E-04 1.8 1.0  
53 ILMN_1238557 Ccrk 3.05E-08 2.96E-04 1.8 1.1 Cell cycle related kinase  
54 ILMN_2674575 Mmd 3.05E-08 2.96E-04 0.5 1.1 Monocyte to macrophage differentiation-associated  
55 ILMN_2602938 Smpdl3b 3.32E-08 3.23E-04 0.6 1.1  
56 ILMN_2605212 Slc6a8 3.36E-08 3.26E-04 3.5 1.6 Solute carrier family 6, member 8  
57 ILMN_1226800 Pdcd1lg1 3.52E-08 3.42E-04 1.6 0.8 CD274 antigen  
58 ILMN_1254031 Bteb1 3.62E-08 3.51E-04 2.3 0.9 Kruppel-like factor 9  
59 ILMN_1230062 Cpeb1 3.92E-08 3.80E-04 2.1 1.1 Cytoplasmic polyadenylation element binding protein  
60 ILMN_1243928 Npy 3.95E-08 3.84E-04 4.3 2.1 Neuropeptide Y  
61 ILMN_2646625 Jun 4.34E-08 4.22E-04 2.1 0.9 Jun oncogene  
62 ILMN_1230708 BC049354 4.35E-08 4.22E-04 0.3 0.9  
63 ILMN_2711948 Slc7a5 4.44E-08 4.31E-04 2.0 1.1 Solute carrier family 7 member 5  
64 ILMN_2609056 Eif2c2 4.47E-08 4.35E-04 2.4 1.2  
65 ILMN_3162394 LOC629605 4.89E-08 4.75E-04 0.7 1.2 Hypothetical protein LOC629605  
66 ILMN_3161013 Hk3 4.98E-08 4.83E-04 3.5 1.7 Hexokinase 3  
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67 ILMN_1239075 Igfbp4 5.38E-08 5.22E-04 0.4 0.9  
68 ILMN_2654074 Sesn1 5.94E-08 5.77E-04 0.3 0.8  
69 ILMN_2627733 1200006F02Rik 6.40E-08 6.22E-04 0.3 0.6  
70 ILMN_1242457 Fpr-rs2 6.73E-08 6.54E-04 0.3 0.8  
71 ILMN_2763002 Eno2 6.90E-08 6.70E-04 4.9 1.5 Enolase 2, gamma neuronal  
72 ILMN_2721357 Lhfpl2 7.14E-08 6.93E-04 2.5 1.1 Lipoma HMGIC fusion partner-like 2  
73 ILMN_1247753 Ppap2b 8.06E-08 7.83E-04 3.0 1.1  
74 ILMN_1244896 Pim3 8.32E-08 8.08E-04 0.8 0.4  
75 ILMN_2642681 Atf4 8.64E-08 8.39E-04 1.9 1.1  
76 ILMN_2630993 Ppap2b 8.70E-08 8.45E-04 6.5 2.0  
77 ILMN_1256142 Marcks 8.84E-08 8.58E-04 0.5 0.9  
78 ILMN_2727663 Tgfbi 8.84E-08 8.58E-04 0.4 0.9  
79 ILMN_1236420 Gpnmb 9.41E-08 9.14E-04 2.7 1.1 Glycoprotein (transmembrane) nmb  
80 ILMN_2611767 
 
Gprc5b 
 
1.00E-07 
 
9.76E-04 
 
2.8 
 
0.9 
 
G protein-coupled receptor, family C, group 5, 
member B  
81 ILMN_1243741 Rora 1.02E-07 9.88E-04 1.9 1.0 RAR-related orphan receptor alpha  
82 ILMN_1258394 Aars 1.10E-07 1.07E-03 1.8 1.2  
83 ILMN_2517041 
 
Uhrf1 
 
1.13E-07 
 
1.10E-03 
 
0.4 
 
1.5 
 
Ubiquitin-like, containing PHD and RING finger 
domains, 1  
84 ILMN_1248811 Ctla2b 1.14E-07 1.11E-03 0.4 1.2  
85 ILMN_2677409 Hrmt1l2 1.14E-07 1.11E-03 0.9 1.3  
86 ILMN_2719803 AI586015 1.30E-07 1.26E-03 0.3 1.0 Expressed sequence AI586015  
87 ILMN_1252202 Tnfaip3 1.44E-07 1.40E-03 2.6 1.1 Tumor necrosis factor, alpha-induced protein 3  
88 ILMN_1255473 0610040B21Rik 1.45E-07 1.41E-03 0.8 1.2  
89 ILMN_2703738 Lrp12 1.46E-07 1.42E-03 2.8 1.3 Low density lipoprotein-related protein 12  
90 ILMN_2635801 2310079N02Rik 1.48E-07 1.43E-03 0.6 1.0 RIKEN cDNA 2310079N02 gene  
91 ILMN_2446496 Upp1 1.59E-07 1.54E-03 1.0 2.7 Uridine phosphorylase 1  
92 ILMN_2702061 4930542G03Rik 1.67E-07 1.63E-03 1.0 1.5 Tubulin, beta 2c  
93 ILMN_1241298 Hal 1.69E-07 1.64E-03 1.9 1.0 Histidine ammonia lyase  
94 ILMN_2621752 Irf5 1.70E-07 1.65E-03 0.9 1.3 Interferon regulatory factor 5  
95 ILMN_2682928 Rai14 1.80E-07 1.75E-03 3.3 1.9 Retinoic acid induced 14  
96 ILMN_1237114 9930117H01Rik 1.80E-07 1.75E-03 2.5 1.0 Transmembrane protein 154  
97 ILMN_1232183 Mgmt 1.98E-07 1.93E-03 0.6 1.2  
98 ILMN_2601471 Ccnd1 1.99E-07 1.93E-03 0.6 1.5  
99 ILMN_2654028 Il21r 2.02E-07 1.96E-03 0.6 1.2 Interleukin 21 receptor 
100 ILMN_2702303 Ch25h 2.06E-07 2.00E-03 0.2 0.6 Cholesterol 25-hydroxylase  
101 ILMN_2474858 Tnfaip2 2.06E-07 2.00E-03 2.0 0.8 Tumor necrosis factor, alpha-induced protein 2  
102 ILMN_2633758 BC004728 2.10E-07 2.04E-03 0.3 0.7  
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103 ILMN_1250195 Ndrg1 2.17E-07 2.11E-03 2.0 0.9  
104 ILMN_2523170 Treml1 2.26E-07 2.19E-03 2.3 1.0  
105 ILMN_3163360 
 
Elk3 
 
2.28E-07 
 
2.22E-03 
 
0.7 
 
1.2 
 
ELK3, member of ETS oncogene family, transcript 
variant 2, 
106 ILMN_2646167 Ndrl 2.46E-07 2.39E-03 1.9 0.9  
107 ILMN_2652909 Ddit3 2.54E-07 2.47E-03 2.1 1.0 DNA-damage inducible transcript 3 
108 ILMN_2622671 Acsl1 2.59E-07 2.51E-03 1.9 1.1  
109 ILMN_2666312 BC025833 2.65E-07 2.58E-03 2.5 1.3  
110 ILMN_2620924 Ddb1 2.68E-07 2.60E-03 1.5 1.0 Damage specific DNA binding protein 1  
111 ILMN_2689401 Mcoln2 2.68E-07 2.60E-03 1.1 0.8  
112 ILMN_1220697 Notch4 2.78E-07 2.70E-03 1.2 2.7  
113 ILMN_2776850 Gas7 2.86E-07 2.78E-03 0.6 0.9 Growth arrest specific 7  
114 ILMN_1225673 Ccnd1 2.98E-07 2.89E-03 0.6 1.6  
115 ILMN_2756474 6530401C20Rik 3.40E-07 3.30E-03 1.9 1.0  
116 ILMN_1212938 Aif1 3.43E-07 3.33E-03 0.3 0.8 Allograft inflammatory factor 1  
117 ILMN_1225146 Gig1 3.46E-07 3.36E-03 1.6 0.8 Zinc finger protein 704  
118 ILMN_2727687 Numb 3.57E-07 3.46E-03 1.7 1.0  
119 ILMN_2746456 
 
Tcirg1 
 
3.67E-07 
 
3.56E-03 
 
2.4 
 
1.2 
 
T-cell, immune regulator 1,ATPase, H+ 
transportinglysosomalV0 proteinA3  
120 ILMN_1228165 4933431N12Rik 3.83E-07 3.72E-03 2.0 1.1 TBC1 domain family, member 9  
121 ILMN_1228233 Gstm1 3.95E-07 3.84E-03 1.3 0.8  
122 ILMN_2503052 Tnnc1 3.98E-07 3.86E-03 0.6 0.9 Troponin C, cardiac/slow skeletal  
123 ILMN_1224635 Fkbp11 4.13E-07 4.01E-03 1.8 1.1  
124 ILMN_1259180 Dscr1 4.15E-07 4.03E-03 1.6 1.1  
125 ILMN_2598877 Slc7a8 4.21E-07 4.09E-03 0.8 1.3 Solute carrier family 7 member 8  
126 ILMN_1214167 Commd10 4.26E-07 4.14E-03 0.9 1.4  
127 ILMN_1254692 Ms4a6b 4.53E-07 4.40E-03 0.3 0.8  
128 ILMN_1213616 Mcm7 4.59E-07 4.45E-03 0.6 1.1  
129 ILMN_2667805 Ak1 4.60E-07 4.46E-03 0.9 1.7  
130 ILMN_2777972 BC003324 4.67E-07 4.54E-03 1.8 1.0  
131 ILMN_2752933 Tec 4.80E-07 4.67E-03 1.4 1.0  
132 ILMN_2693991 Gpr65 4.89E-07 4.75E-03 0.3 0.6 G-protein coupled receptor 65  
133 ILMN_2473562 Wbscr5 4.93E-07 4.78E-03 2.6 1.4  
134 ILMN_2703023 Fcho1 4.99E-07 4.85E-03 2.3 1.1 FCH domain only 1  
135 ILMN_2705578 4732481H14Rik 5.06E-07 4.91E-03 1.8 1.0  
136 ILMN_3161652 Clec4a3 5.11E-07 4.96E-03 0.2 0.4 C-type lectin domain family 4, member a3  
137 ILMN_2656645 AA536743 5.22E-07 5.07E-03 1.4 0.9  
138 ILMN_2479124 Tnfrsf26 5.23E-07 5.07E-03 1.8 1.0  
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139 ILMN_2419185 Tuft1 5.25E-07 5.10E-03 1.6 1.0  
140 ILMN_2706765 1500041B16Rik 5.30E-07 5.14E-03 2.3 0.9  
141 ILMN_2712075 Lcn2 5.36E-07 5.21E-03 0.7 1.3 Lipocalin 2  
142 ILMN_2769669 Snx2 5.38E-07 5.22E-03 0.6 1.1  
143 ILMN_2677876 Arhgap4 5.55E-07 5.39E-03 0.5 0.9 Rho GTPase activating protein 4  
144 ILMN_2673668 Mylc2b 5.64E-07 5.47E-03 0.8 1.2 Myosin light chain, regulatory B  
145 ILMN_2698930 Ptpn18 5.72E-07 5.55E-03 0.6 0.9  
146 ILMN_2742849 Mcm5 5.86E-07 5.69E-03 0.5 1.2  
147 ILMN_2747060 Coro1a 6.19E-07 6.01E-03 0.4 0.9 Coronin, actin binding protein 1A  
148 ILMN_2765513 Kif3a 6.25E-07 6.07E-03 2.1 0.8  
149 ILMN_2757391 Gamt 6.51E-07 6.32E-03 0.8 1.3 Guanidinoacetate methyltransferase  
150 ILMN_2744890 Gadd45g 6.57E-07 6.38E-03 1.8 0.9 Growth arrest and DNA-damage-inducible 45 gamma  
151 ILMN_1224458 Flrt2 6.58E-07 6.39E-03 3.5 1.5 Fibronectin leucine rich transmembrane protein 2  
152 ILMN_1244775 2810037C03Rik 6.77E-07 6.57E-03 0.7 1.0 GINS complex subunit 4 (Sld5 homolog)  
153 ILMN_2733793 Coro1a 6.85E-07 6.66E-03 0.4 0.7 Coronin, actin binding protein 1A  
154 ILMN_2628757 Ehd1 7.04E-07 6.84E-03 0.5 1.0 EH-domain containing 1  
155 ILMN_2659427 Cxcl14 7.14E-07 6.93E-03 1.1 3.3  
156 ILMN_2702069 Padi2 7.29E-07 7.08E-03 2.1 1.3 Peptidyl arginine deiminase, type II  
157 ILMN_2655510 Rps6ka2 7.47E-07 7.26E-03 2.2 1.3  
158 ILMN_2421220 Wdr9 7.70E-07 7.48E-03 1.5 0.9  
159 ILMN_1223257 Ccl4 7.70E-07 7.48E-03 1.5 0.5  
160 ILMN_1242047 Drr1 8.07E-07 7.83E-03 1.6 0.9  
161 ILMN_2710905 S100a8 8.10E-07 7.86E-03 1.2 4.5  
162 ILMN_2663604 Fignl1 8.29E-07 8.05E-03 0.6 1.2 Fidgetin-like 1  
163 ILMN_2652518 2410024A21Rik 8.42E-07 8.18E-03 1.5 1.0  
164 ILMN_1220230 Hbp1 8.56E-07 8.31E-03 1.3 0.9  
165 ILMN_2516349 Vamp4 8.65E-07 8.40E-03 1.7 0.9 Vesicle-associated membrane protein 4  
166 ILMN_2715558 Arhgap17 8.77E-07 8.52E-03 1.3 0.8 Rho GTPase activating protein 17  
167 ILMN_2473755 Vps18 8.86E-07 8.61E-03 2.0 1.2 Vacuolar protein sorting 18 (yeast)  
168 ILMN_1228020 1500010G04Rik 9.04E-07 8.78E-03 1.1 0.7  
169 ILMN_1250952 1700001C14Rik 9.05E-07 8.78E-03 1.7 1.0  
170 ILMN_3161278 LOC621954 9.05E-07 8.79E-03 0.7 1.4  
171 ILMN_2595519 Lig1 9.05E-07 8.79E-03 0.8 1.3 Ligase I, DNA, ATP-dependent  
172 ILMN_1216335 BC003236 9.09E-07 8.82E-03 0.6 0.9  
173 ILMN_2607675 H2-Ab1 9.10E-07 8.83E-03 0.2 0.4  
174 ILMN_1232076 Rragd 9.50E-07 9.22E-03 2.2 1.3  
175 ILMN_2466601 Wdr7 9.76E-07 9.47E-03 1.8 1.2  
176 ILMN_2493175 Tst 1.07E-06 1.04E-02 1.8 0.9 Thiosulfate sulfurtransferase, mitochondrial  
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177 ILMN_1214634 Aqp9 1.13E-06 1.10E-02 1.7 0.9 Aquaporin 9  
178 ILMN_1215030 2900024D24Rik 1.15E-06 1.12E-02 0.4 0.7 Membrane-associated ring finger (C3HC4) 1  
179 ILMN_2639572 Ntsr1 1.17E-06 1.14E-02 0.7 1.2 Neurotensin receptor 1  
180 
 
ILMN_2737959 
 
Plekhm1 
 
1.18E-06 
 
1.15E-02 
 
1.7 
 
1.1 
 
Pleckstrin homology domain containing, family M 
member 1  
181 ILMN_2654241 Psen2 1.20E-06 1.17E-02 1.5 1.0 Presenilin 2  
182 ILMN_1255416 Ly6a 1.21E-06 1.18E-02 0.2 0.4 Lymphocyte antigen 6 complex, locus A  
183 ILMN_2695047 BC027342 1.24E-06 1.21E-02 1.5 1.0  
184 ILMN_1233008 Dhx30 1.25E-06 1.21E-02 1.3 1.0 DEAH (Asp-Glu-Ala-His) box polypeptide 30  
185 
 
ILMN_2648409 
 
Cklfsf7 
 
1.26E-06 
 
1.23E-02 
 
0.7 
 
1.1 
 
CKLF-like MARVEL transmembrane domain 
containing 7  
186 ILMN_1222543 Ugt1a9 1.26E-06 1.23E-02 0.6 0.9  
187 ILMN_1244414 Sec61a2 1.28E-06 1.24E-02 1.6 1.0  
188 ILMN_2714648 BC062650 1.36E-06 1.32E-02 2.3 1.0  
189 ILMN_2773012 Hbp1 1.40E-06 1.36E-02 1.4 0.9  
190 ILMN_2744164 Tenc1 1.43E-06 1.38E-02 0.8 1.2  
191 ILMN_2696017 Itgam 1.43E-06 1.39E-02 0.7 1.4 Integrin alpha M  
192 ILMN_2603570 Obrgrp 1.45E-06 1.41E-02 0.7 1.0  
193 ILMN_1216972 Clecsf9 1.45E-06 1.41E-02 1.6 0.8  
194 ILMN_1237323 Lman2l 1.48E-06 1.44E-02 0.8 1.1  
195 ILMN_2684279 9530090G24Rik 1.55E-06 1.51E-02 1.4 1.0  
196 ILMN_1218247 2410003B16Rik 1.56E-06 1.52E-02 0.9 1.2  
197 ILMN_2516699 Ubb 1.56E-06 1.52E-02 1.1 1.0  
198 ILMN_1238838 Dtx3 1.60E-06 1.55E-02 2.1 1.1  
199 ILMN_1230395 Tmem24 1.63E-06 1.58E-02 1.7 1.1  
200 ILMN_2503715 Ttc7b 1.64E-06 1.59E-02 1.9 1.4  
201 ILMN_2716085 Pex6 1.68E-06 1.63E-02 1.2 0.9 Peroxisomal biogenesis factor 6  
202 ILMN_2742075 Cd14 1.71E-06 1.66E-02 0.7 1.2  
203 ILMN_1218104 5630401D24Rik 1.75E-06 1.70E-02 1.4 1.0 RIKEN cDNA 5630401D24 gene  
204 ILMN_1249514 Large 1.77E-06 1.72E-02 1.9 1.0 Like-glycosyltransferase  
205 ILMN_1244918 Rhov 1.80E-06 1.74E-02 3.0 1.4 Ras homolog gene family, member V  
206 ILMN_2731908 6330405H19 1.87E-06 1.82E-02 2.0 1.2  
207 ILMN_1237132 AW549877 1.88E-06 1.83E-02 1.3 0.7  
208 ILMN_2618396 Pter 1.91E-06 1.85E-02 0.9 1.5  
209 ILMN_1248347 4921501M20Rik 1.94E-06 1.88E-02 0.5 0.9 Nfat activating molecule with ITAM motif 1  
210 ILMN_1231552 C530043K16Rik 1.94E-06 1.89E-02 3.6 1.2  
211 ILMN_1229523 Fcgr1 1.98E-06 1.92E-02 0.6 1.1 Fc receptor, IgG, high affinity I  
212 ILMN_2683486 AI115600 2.10E-06 2.04E-02 1.3 0.8  
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213 ILMN_2600678 Rac2 2.11E-06 2.04E-02 0.6 1.1  
214 ILMN_1239535 Plekhm2 2.14E-06 2.08E-02 2.0 1.2  
215 ILMN_1250574 Nup43 2.20E-06 2.14E-02 0.8 1.1 Nucleoporin 43 
216 ILMN_2732465 Mef2c 2.26E-06 2.19E-02 0.4 0.8  
217 ILMN_2755585 Avpi1 2.28E-06 2.21E-02 0.6 0.9 Arginine vasopressin-induced 1 
218 ILMN_1213809 Gpr18 2.30E-06 2.23E-02 0.2 0.7 G protein-coupled receptor 18 
219 ILMN_1228568 Irf2bp1 2.30E-06 2.24E-02 1.3 1.0 Interferon regulatory factor 2 binding protein 1 
220 ILMN_1254516 Ntan1 2.33E-06 2.26E-02 0.7 1.0  
221 ILMN_1215639 Commd1 2.33E-06 2.26E-02 0.8 1.1  
222 ILMN_2756667 Cbr2 2.35E-06 2.28E-02 0.4 0.7 Carbonyl reductase 2  
223 ILMN_1228777 0610008A10Rik 2.35E-06 2.28E-02 1.9 0.8  
224 ILMN_2599719 1110028E10Rik 2.56E-06 2.48E-02 1.5 1.0  
225 ILMN_2627627 Dab2 2.66E-06 2.58E-02 0.6 1.0  
226 ILMN_1234693 4933421G18Rik 2.72E-06 2.64E-02 1.6 0.9  
227 ILMN_1249378 Bhlhb2 2.78E-06 2.69E-02 2.8 1.5 Basic helix-loop-helix domain containing, class B2 
228 ILMN_2607769 5830446M03Rik 2.84E-06 2.76E-02 0.7 1.1 ISY1 splicing factor homolog (S. cerevisiae) 
229 ILMN_1258820 2610510D13Rik 2.87E-06 2.79E-02 0.8 1.5  
230 ILMN_2718217 2310057H16Rik 2.88E-06 2.79E-02 1.2 2.3 Tubulin, beta 6  
231 ILMN_2690556 C730049P21 2.90E-06 2.82E-02 1.8 0.9  
232 ILMN_2722769 5830472M02Rik 2.94E-06 2.85E-02 0.5 0.9  
233 ILMN_2641514 Taf12 2.98E-06 2.90E-02 0.7 1.1  
234 ILMN_2722938 Myd116 3.00E-06 2.91E-02 1.8 0.8 Myeloid differentiation primary response gene 116 
235 
 
ILMN_2643876 
 
Tcirg1 
 
3.02E-06 
 
2.93E-02 
 
2.1 
 
0.9 
 
T-cell, immune regulator 1,ATPase, H+ 
transportinglysosomalV0protein A3 
236 ILMN_2669793 Ccnd1 3.11E-06 3.02E-02 0.6 1.7  
237 
 
ILMN_1226936 
 
Ugt1a6 
 
3.16E-06 
 
3.07E-02 
 
0.5 
 
0.8 
 
UDP glucuronosyltransferase 1 family, polypeptide 
A6A  
238 ILMN_1226143 Rabgef1 3.20E-06 3.11E-02 1.5 1.0 RAB guanine nucleotide exchange factor (GEF) 1 
239 ILMN_1249547 Zfp292 3.27E-06 3.18E-02 1.6 0.9  
240 ILMN_2608719 Clecsf5 3.34E-06 3.24E-02 0.6 1.1  
241 ILMN_2771754 Fh1 3.51E-06 3.41E-02 0.3 0.7  
242 ILMN_2760977 Impact 3.52E-06 3.42E-02 1.4 0.7  
243 ILMN_2735744 9030416H16Rik 3.68E-06 3.57E-02 1.6 1.0  
244 ILMN_2715840 C1qg 3.72E-06 3.62E-02 0.5 0.8  
245 ILMN_2701815 Plxna2 3.74E-06 3.64E-02 2.6 1.3  
246 ILMN_1229400 Cog3 3.75E-06 3.64E-02 1.7 1.0  
247 ILMN_1227459 Gga2 3.87E-06 3.76E-02 1.6 1.2  
248 ILMN_1233129 Zfp297 3.92E-06 3.80E-02 1.3 1.0 Zinc finger and BTB domain containing 22  
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AKR Loaded/ 
AKRUnloaded 
 
DBALoaded/ 
DBAUnloaded 
 
Definition 
 
 
249 ILMN_1224117 Uhrf2 3.99E-06 3.88E-02 1.5 1.1  
250 ILMN_1234672 2610007K22Rik 4.03E-06 3.91E-02 1.5 1.0  
251 ILMN_2776075 Atp6v1c1 4.06E-06 3.94E-02 1.8 1.2 ATPase, H+ transporting, lysosomal V1 subunit C1 
252 ILMN_2486573 Vegfc 4.12E-06 4.00E-02 1.3 1.9  
253 ILMN_1239430 Mrc1 4.13E-06 4.01E-02 0.4 0.7 Mannose receptor, C type 1 
254 ILMN_2684205 4930431B09Rik 4.13E-06 4.01E-02 1.9 1.0  
255 ILMN_1216265 Sdccag33 4.18E-06 4.06E-02 1.9 1.0  
256 ILMN_1214762 Sgk3 4.23E-06 4.11E-02 0.7 1.0  
257 ILMN_2600113 Gtpbp2 4.26E-06 4.14E-02 1.6 1.0 GTP binding protein 2 
258 ILMN_2493052 Zfyve26 4.27E-06 4.15E-02 1.7 1.1  
259 
 
ILMN_2619620 
 
C1qb 
 
4.35E-06 
 
4.22E-02 
 
0.5 
 
0.9 
 
Complement component 1, q subcomponent, beta 
polypeptide  
260 ILMN_2658208 2410195B05Rik 4.36E-06 4.23E-02 1.6 1.2 SET domain containing (lysine methyltransferase) 8  
261 ILMN_2760020 Cxcl13 4.45E-06 4.33E-02 0.2 0.8  
262 ILMN_2666917 Nktr 4.52E-06 4.39E-02 1.7 1.0  
263 ILMN_2609813 Chi3l1 4.53E-06 4.40E-02 0.7 1.0 Chitinase 3-like 1  
264 ILMN_1230162 Fem1b 4.53E-06 4.40E-02 1.6 1.1 Feminization 1 homolog b (C. elegans) 
265 ILMN_2748879 4833414E09Rik 4.56E-06 4.43E-02 2.6 1.2  
266 ILMN_2662322 Ebi3 4.61E-06 4.47E-02 0.4 0.7  
267 ILMN_1222256 Gpsm3 4.62E-06 4.48E-02 0.7 1.0  
268 ILMN_2507331 Xylt1 4.68E-06 4.55E-02 1.9 0.9  
269 ILMN_2623867 Ostm1 4.73E-06 4.60E-02 1.3 1.0 Osteopetrosis associated transmembrane protein 1  
270 ILMN_1226666 Cnn2 4.78E-06 4.64E-02 0.6 1.1  
271 ILMN_2682173 2600014M03Rik 4.80E-06 4.66E-02 1.2 0.8  
272 ILMN_1258880 Rbm5 4.84E-06 4.70E-02 1.5 0.8 RNA binding motif protein 5  
273 ILMN_1236368 D730049H07Rik 4.88E-06 4.74E-02 0.6 1.0  
274 ILMN_2729783 Ahrr 4.93E-06 4.79E-02 0.3 0.5  
275 ILMN_2589768 Htr2b 5.03E-06 4.88E-02 2.2 1.3  
276 ILMN_1251171 Cd52 5.12E-06 4.97E-02 0.4 1.1  
277 ILMN_2648664 Cap1 5.13E-06 4.98E-02 0.8 1.2 CAP, adenylate cyclase-associated protein 1 (yeast)  
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Appendix 5A: Clinical data measured in 11 subjects that participated in the study before undergoing bariatric surgery (RYGB, Roux-
en-Y Gastric Bypass; SG, Sleeve Gastrectomy). Clinical characteristics that were found to change significantly after bariatric surgery 
are shown in bold (paired t-test p-value < 0.05). 
Pre-surgery             
Subject ID 1 2 3 4 5 6 7 8 9 10 11 Mean SD 
Type of Surgery RYGB RYGB RYGB RYGB RYGB RYGB RYGB SG SG SG SG   
Age (years) 43 47 50 71 42 44 51 67 61 50 30 50.5 11.9 
Gender (F/M) M F F M M M F F M F M F= 5 M= 6 
Ht (m) 1.80 1.65 1.72 1.77 1.79 1.76 1.73 1.55 1.83 1.66 1.77 1.7 0.1 
Weight (kg) 180.5 180.2 112.7 115.8 145.5 108.0 93.2 123.5 158.0 128.9 201.3 140.7 35.1 
Body Mass Index (kg/m2) 55.71 66.19 38.01 37.05 45.41 35.06 31.14 51.40 47.23 46.78 64.25 47.1 11.6 
Fasting Plasma Glucose (mg/dL) 122 127 205 118 108 220 270 221 176 180 123 170.0 54.2 
HbA1C 6.2 6.5 8.9 6.4 8.3 10.4 10.3 7.5 8.4 7.4 7.1 7.9 1.5 
Fasting Plasma Insulin (µIU/mL) 17.3 - 17.1 13.3 32.7 24.4 24.6 8.9 124.5 27.4 - 32.2 35.4 
Systolic Blood Pressure (mmHg) 110 109 138 142 132 145 137 126 115 101 154 128.1 17.2 
Diastolic Blood Pressure (mmHg) 68 68 97 73 72 91 88 64 73 66 79 76.3 11.1 
Total Cholesterol (mg/dL 209 185 189 76 114 283 187 212 152 201 149 177.9 54.7 
Triglycerides 80 384 275 84 105 1375 171 88 298 124 120 282.2 376.5 
High Density Lipoprotein (mg/dL) 28 33 38 27 35 26 44 47 39 41 36 35.8 6.9 
Low Density Lipoprotein (mg/dL) 155 75 96 32 58 - 109 147 53 135 89 94.9 41.7 
Very-Low-Density Lipoprotein (mg/dL) 16 77 55 17 21 - 34 18 60 25 24 34.7 21.6 
Aspartate transaminase (IU/L) 22 25 19 29 57 - - 34 15 21 26 27.6 12.4 
Alanine transaminase (U/L) 26 25 29 25 84 - - 22 42 31 40 36.0 19.3 
Albumin/creatinine ratio (mg/mmol) 17 11 176 5 5 248 49 6 7 62 5 53.7 82.2 
Thyroid Stimulating Hormone (µIU/mL) 13.48 4.43 0.83 1.06 2.00 2.93 5.46 1.92 1.24 1.30 3.54 3.5 3.6 
White Blood Cells (x 103/µL) 7.22 7.70 6.52 3.98 6.60 5.00 8.46 7.19 4.78 6.06 8.68 6.6 1.5 
Red Blood Cells (x 106/µL) 5.03 4.32 4.92 4.30 5.13 4.55 5.04 4.51 4.41 4.59 4.70 4.7 0.3 
Hemoglobin (g/dL) 14.3 12.7 13.4 13.2 14.4 13.6 14.1 13.5 14.0 12.9 13.5 13.6 0.6 
Hematocrit (%) 42.9 38.4 41.6 37.5 43.2 39.9 42.2 41.3 42.5 39.6 41.3 40.9 1.9 
RDW-CV (%) 13.0 14.1 13.1 13.4 13.1 12.9 13.5 13.6 13.1 13.3 13.3 13.3 0.3 
Platelets (x 103/µL) 261 229 314 114 252 191 330 314 209 229 268 246.5 62.8 
Percentage of Neutrophils 57.2 65.2 51.1 46.0 61.2 - 46.4 77.8 58.0 66.4 61.4 59.1 9.7 
Absolute Neutrophils 4.13 5.02 3.33 1.83 4.04 - 3.77 5.59 2.77 4.02 5.34 4.0 1.2 
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Pre-surgery             
Subject ID 1 2 3 4 5 6 7 8 9 10 11 Mean  SD 
Percentage of Lymphocytes 30.2 26.0 39.6 42.2 28.3 - 45.9 16.6 29.9 25.1 28.0 31.2 8.9 
Absolute Lymphocytes 2.18 2.00 2.58 1.68 1.87 - 3.73 1.19 1.43 1.52 2.43 2.1 0.7 
Percentage of Monocytes 7.1 6.4 5.4 8.5 7.9 - 6.2 3.8 8.8 5.8 7.4 6.7 1.5 
Absolute Monocytes 0.51 0.49 0.35 0.34 0.52 - 0.50 0.27 0.42 0.35 0.64 0.4 0.1 
Percentage of Eosinophils 5.1 2.1 3.1 2.8 1.8 - 1.1 1.1 2.9 2.5 2.5 2.5 1.2 
Absolute Eosinophils 0.37 0.16 0.20 0.11 0.12 - 0.09 0.08 0.14 0.15 0.22 0.2 0.1 
Percentage of Basophils 0.4 0.3 0.8 0.5 0.8 - 0.4 0.7 0.4 0.2 0.6 0.5 0.2 
Absolute Basophils 0.03 0.02 0.05 0.02 0.05 - 0.03 0.05 0.02 0.01 0.05 0.0 0.0 
25-hydroxy vitamin D (ng/mL) 24 25 30 9 29 18 24 19 25 28 16 23.1 6.3 
 
 
Clinical data measured in 11 subjects that participated in the study 6-12 months after bariatric surgery  
 
 
Post - surgery              
Subject ID 1 2 3 4 5 6 7 8 9 10 11 Mean SD 
% 
Change 
Paired T-
TEST 
Ht (m) 1.80 1.65 1.70 1.78 1.81 1.75 1.72 1.52 1.82 1.66 1.77 1.7 0.1 -0.3 3.20E-01 
Weight (kg) 126.2 140.6 87.5 90.9 119.2 78.0 68.8 102.1 133.4 100.1 168.0 110.4 29.9 -21.5 9.08E-07 
Body Mass Index (kg/m2) 38.95 51.64 30.28 28.69 36.38 25.62 23.26 44.19 40.27 36.33 53.62 37.2 10.0 -21.0 9.90E-07 
Fasting Plasma Glucose (mg/dL) 77 81 88 82 80 77 91 153 139 117 91 97.8 26.5 -42.5 8.57E-04 
HbA1C 5.5 5.3 5.5 4.8 5.7 6.4 5.6 7 6.4 6.3 5.9 5.9 0.6 -26.3 5.87E-04 
Fasting Plasma Insulin (µIU/mL) 2.7 - 3.7 5.6 2.5 2.4 6.7 7.6 16.6 11.7 - 6.6 4.8 -79.5 4.25E-02 
Systolic Blood Pressure (mmHg) 144 132 144 122 145 149 140 148 138 157 136 141.4 9.4 10.4 7.35E-02 
Diastolic Blood Pressure (mmHg) 83 72 90 62 82 86 88 69 74 84 97 80.6 10.3 5.7 1.79E-01 
Total Cholesterol (mg/dL 159 169 171 115 101 159 182 177 125 160 178 154.2 27.7 -13.3 9.69E-02 
Triglycerides 88 159 163 79 73 89 119 76 226 84 116 115.6 48.5 -59.0 1.74E-01 
High Density Lipoprotein (mg/dL) 43 37 40 35 35 38 67 41 38 39 39 41.1 8.9 14.7 6.73E-02 
Low Density Lipoprotein (mg/dL) 98 100 98 64 51 - 91 121 42 104 116 88.5 27.0 -6.7 4.97E-01 
Very-Low-Density Lipoprotein (mg/dL) 18 32 33 16 15 - 24 15 45 17 23 23.8 10.0 -31.4 3.59E-02 
Aspartate transaminase (IU/L) 20 36 19 25 34 - - 14 17 16 11 21.3 8.7 -22.6 1.29E-01 
Alanine transaminase (U/L) 19 16 11 16 49 - - 10 10 10 9 16.7 12.6 -53.7 7.48E-04 
Albumin/creatinine ratio (mg/mmol) 7 39 33 6 5 45 8 14 8 43 - 20.8 17.0 -61.3 1.45E-01 
Thyroid Stimulating Hormone (µIU/mL) 34.46 2.39 0.61 1.27 1.32 6.24 2.16 1.57 1.08 1.19 2.78 5.0 9.9 44.2 4.61E-01 
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Post - surgery              
Subject ID 1 2 3 4 5 6 7 8 9 10 11 Mean SD 
% 
Change 
Paired T-
TEST 
White Blood Cells (x 103/µL) 6.60 5.28 6.08 4.03 5.96 4.37 6.73 7.49 5.11 4.32 7.74 5.8 1.3 -11.7 1.60E-02 
Red Blood Cells (x 106/µL) 4.77 4.6 4.86 4.37 4.97 4.03 4.37 4.15 4.01 4.44 5.29 4.5 0.4 -3.2 2.03E-01 
Hemoglobin (g/dL) 13.8 13.3 13.2 13.3 14.0 12.0 13.2 12.5 12.9 12.2 15.1 13.2 0.9 -2.7 1.95E-01 
Hematocrit (%) 40.6 41.9 42.0 38.6 43.4 36.0 39.8 37.8 37.7 39.4 46.9 40.4 3.1 -1.4 5.67E-01 
RDW-CV (%) 14.5 13.5 15.4 13.7 13.5 12.8 12.4 13.8 12.7 13.5 13.1 13.5 0.9 1.7 4.47E-01 
Platelets (x 103/µL) 316 206 271 111 224 224 281 260 191 208 235 229.7 54.2 -6.8 1.31E-01 
Percentage of Neutrophils 54.2 59.1 51.7 46.2 58.1 - 35.9 69.8 55.0 62.8 - 54.8 9.7 -7.3 9.82E-03 
Absolute Neutrophils 3.58 3.12 3.14 1.86 3.46 - 2.36 5.23 2.81 2.71 - 3.1 0.9 -21.2 1.68E-02 
Percentage of Lymphocytes 31.8 28.0 39.6 42.7 32.4 - 55.9 24.0 34.8 30.3 - 35.5 9.5 13.9 7.07E-03 
Absolute Lymphocytes 2.10 1.48 2.41 1.72 1.93 - 3.68 1.80 1.78 1.31 - 2.0 0.7 -1.8 9.76E-01 
Percentage of Monocytes 8.2 8.3 6.4 6.7 6.5 - 6.8 4.7 8.0 4.2 - 6.6 1.5 -1.3 9.81E-01 
Absolute Monocytes 0.54 0.44 0.39 0.27 0.39 - 0.45 0.35 0.41 0.18 - 0.4 0.1 -13.4 2.12E-01 
Percentage of Eosinophils 5.3 4.0 1.5 3.7 2.7 - 0.8 0.8 1.8 2.5 - 2.6 1.5 2.7 8.57E-01 
Absolute Eosinophils 0.35 0.21 0.09 0.15 0.16 - 0.05 0.06 0.09 0.11 - 0.1 0.1 -14.0 3.66E-01 
Percentage of Basophils 0.5 0.6 0.8 0.7 0.3 - 0.6 0.7 0.4 0.2 - 0.5 0.2 4.6 6.74E-01 
Absolute Basophils 0.03 0.03 0.05 0.03 0.02 - 0.04 0.05 0.02 0.01 - 0.0 0.0 -5.7 1.00E+00 
25-hydroxy vitamin D (ng/mL) 20 22 31 15 31 32 34 21 25 28 19 25.3 6.3 9.4 1.52E-01 
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Appendix 5B: List of significantly differentially expressed (paired t-test p-value < 0.01) transcripts IDs with their respective gene 
symbol, definition and percent change after bariatric surgery.  The genes discussed in the manuscript are shown in bold. 
 
P-value 
RANK PROBE_ID GENE Symbol Paired T-Test % Change DEFINITION 
1 ILMN_1652604 GGT1 6.35E-05 -10% Gamma-glutamyltransferase 1, transcript variant 4. 
2 ILMN_1736238 GNMT 9.49E-05 -7% Glycine N-methyltransferase. 
3 ILMN_1688580 CAMP 1.76E-04 -41% Cathelicidin antimicrobial peptide. 
4 ILMN_1682312 CYBB 2.24E-04 -13% Cytochrome b-245, beta polypeptide (chronic granulomatous disease). 
5 ILMN_1768399 ARFIP1 3.64E-04 -9% ADP-ribosylation factor interacting protein 1 (arfaptin 1), transcript variant 1. 
6 ILMN_1781028 ZMYM5 4.18E-04 20% Zinc finger, MYM-type 5, transcript variant 1. 
7 ILMN_1727740 SYNCRIP 4.59E-04 20% Synaptotagmin binding, cytoplasmic RNA interacting protein. 
8 ILMN_1797682 INSL3 4.81E-04 -13% Insulin-like 3 (Leydig cell). 
9 ILMN_1714987 TRIM54 5.04E-04 -18% Tripartite motif-containing 54, transcript variant 1. 
10 ILMN_1675413 ENPP7 5.06E-04 -11% Ectonucleotide pyrophosphatase/phosphodiesterase 7. 
11 ILMN_1813091 ARL1 5.84E-04 9% ADP-ribosylation factor-like 1. 
12 ILMN_1748384 BOC 6.02E-04 15% Boc homolog (mouse). 
13 ILMN_1759017 ZNF333 6.44E-04 15% Zinc finger protein 333. 
14 ILMN_1912287 HS.133181 7.69E-04 -11% BX093329 Soares_parathyroid_tumor_NbHPA   cDNA clone IMAGp998A124183 
15 ILMN_1775570 FLJ44635 8.33E-04 -9% TPT1-like protein. 
16 ILMN_1656371 TRPA1 9.35E-04 -10% Transient receptor potential cation channel, subfamily A, member 1. 
17 ILMN_1689294 LOC85390 9.46E-04 16% RNA, small nucleolar on chromosome 11. 
18 ILMN_1911981 HS.197709 9.90E-04 22% AGENCOURT_8291102 Lupski_sympathetic_trunk   cDNA clone IMAGE:6194146 5. 
19 ILMN_1679357 DEFA1/DEFA3 1.08E-03 -46% Defensin, alpha 1/Defensin, alpha 3. 
20 ILMN_1804631 CNBP 1.11E-03 13% CCHC-type zinc finger, nucleic acid binding protein. 
21 ILMN_1725661 DEFA1/DEFA3 1.16E-03 -45% Defensin, alpha 1/Defensin, alpha 3. 
22 ILMN_1815777 NBPF12 1.16E-03 -11% PREDICTED: neuroblastoma breakpoint family, member 12. 
23 ILMN_1687567 CUTL1 1.25E-03 -10% Cut-like 1, CCAAT displacement protein (Drosophila), transcript variant 1. 
24 ILMN_1672246 OR4C15 1.30E-03 -11% Olfactory receptor, family 4, subfamily C, member 15. 
25 ILMN_1893704 HS.541159 1.31E-03 14% 7n45b12.x1 NCI_CGAP_Lu24   cDNA clone IMAGE:3567335 3. 
26 ILMN_1833316 HS.112596 1.33E-03 -8% BX344991   PLACENTA COT 25-NORMALIZED   cDNA clone CS0DI054YO01 5-PRIME. 
27 ILMN_1651544 HDAC8 1.37E-03 13% Histone deacetylase 8. 
28 ILMN_1869810 HS.578254 1.43E-03 -10% EST98688 Thyroid cDNA 5 end. 
29 ILMN_1896265 HS.582507 1.44E-03 -10% CR747973 NCI_CGAP_GC6   cDNA clone IMAGp971B0892 ; IMAGE:2244480 5. 
30 ILMN_1690614 MYO9A 1.47E-03 8% Myosin IXA. 
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P-value 
RANK PROBE_ID GENE Symbol Paired T-Test % Change DEFINITION 
31 ILMN_1751393 ZNF684 1.50E-03 11% Zinc finger protein 684. 
32 ILMN_1890125 HS.323889 1.50E-03 13% yd20d08.s1 Soares fetal liver spleen 1NFLS cDNA clone IMAGE:108783 3. 
33 ILMN_1786319 MME 1.54E-03 -11% Membrane metallo-endopeptidase, transcript variant 1bis. 
34 ILMN_1772124 ATRN 1.56E-03 15% Attractin (ATRN), transcript variant 1. 
35 ILMN_1812701 C4ORF33 1.56E-03 24% Chromosome 4 open reading frame 33, transcript variant 2. 
36 ILMN_1869645 HS.148758 1.61E-03 -11% BX095745 Soares_NFL_T_GBC_S1   cDNA clone IMAGp998L204518. 
37 ILMN_1898520 HS.542384 1.63E-03 -10% xg67h08.x1 NCI_CGAP_Ut4   cDNA clone IMAGE:2633439 3. 
38 ILMN_1693262 DEFA1/DEFA3 1.65E-03 -45% Defensin, alpha 1/Defensin, alpha 3. 
39 ILMN_1808132 FAS 1.69E-03 13% Fas (TNF receptor superfamily, member 6), transcript variant 3. 
40 ILMN_1703324 PDSS1 1.73E-03 -5% Prenyl (decaprenyl) diphosphate synthase, subunit 1. 
41 ILMN_1821269 HS.541504 1.74E-03 -6% DB075041 TESTI4   cDNA clone TESTI4018801 5. 
42 ILMN_1769633 CTSO 1.96E-03 9% Cathepsin O. 
43 ILMN_1800721 VPS13A 1.96E-03 11% Vacuolar protein sorting 13 homolog A (S. cerevisiae), transcript variant D. 
44 ILMN_1802867 RNASE3 1.97E-03 -21% Ribonuclease, RNase A family, 3 (eosinophil cationic protein). 
45 ILMN_1654542 C5ORF21 2.00E-03 9% Chromosome 5 open reading frame 21. 
46 ILMN_1904282 HS.484967 2.02E-03 10% Full-length cDNA clone CS0DI042YD07 of Placenta Cot 25-normalized (human) 
47 ILMN_1704973 SARDH 2.03E-03 -7% Sarcosine dehydrogenase. 
48 ILMN_1877317 HS.561625 2.13E-03 12% UI-H-BW0-aim-a-09-0-UI.s1 NCI_CGAP_Sub6   cDNA clone IMAGE:2729752 3. 
49 ILMN_1652407 ZMYND8 2.13E-03 16% Zinc finger, MYND-type containing 8, transcript variant 1. 
50 ILMN_1788363 MLH1 2.17E-03 15% MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli). 
51 ILMN_1900247 HS.147149 2.21E-03 -7% BX118294 Soares_testis_NHT   cDNA clone IMAGp998H024404. 
52 ILMN_1655796 MARCH3 2.25E-03 -15% PREDICTED: membrane-associated ring finger (C3HC4) 3. 
53 ILMN_1651664 SDHALP1 2.26E-03 -8% Succinate dehydrogenase complex, subunit A, flavoprotein pseudogene 1 on chromosome 3. 
54 ILMN_1693055 ZDHHC3 2.32E-03 -13% Zinc finger, DHHC-type containing 3. 
55 ILMN_1720732 ZMAT4 2.35E-03 -10% Zinc finger, matrin type 4. 
56 ILMN_1847128 HS.564497 2.38E-03 -8% im45h10.x1 HR85 islet   cDNA clone IMAGE:6038251 3. 
57 ILMN_1703858 C7ORF24 2.45E-03 11% Chromosome 7 open reading frame 24. 
58 ILMN_1768743 FIP1L1 2.48E-03 9% FIP1 like 1 (S. cerevisiae). 
59 ILMN_1748476 NOP5/NOP58 2.49E-03 28% Nucleolar protein NOP5/NOP58. 
60 ILMN_1693998 SNX1 2.49E-03 24% Sorting nexin 1, transcript variant 3. 
61 ILMN_1726901 KLC1 2.50E-03 15% Kinesin light chain 1, transcript variant 1. 
62 ILMN_1797576 PLEKHA3 2.54E-03 13% Pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 3. 
63 ILMN_1684346 TNFAIP8L1 2.57E-03 -11% Tumor necrosis factor, alpha-induced protein 8-like 1. 
64 
 
ILMN_1667176 
 
LOC653539 
 
2.66E-03 
 
13% 
 
PREDICTED:   similar to amyotrophic lateral sclerosis 2 (juvenile) chromosome region, 
candidate 16, transcript variant 5. 
65 ILMN_1681260 LOC643272 2.72E-03 -15% PREDICTED:   hypothetical protein LOC643272. 
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66 ILMN_1754772 LOC650698 2.73E-03 -7% PREDICTED:   similar to SH3/ankyrin domain gene 2 isoform a. 
67 ILMN_1729175 FBXO3 2.82E-03 13% F-box protein 3, transcript variant 2. 
68 ILMN_1742109 DNAJC19 2.94E-03 18% DnaJ (Hsp40) homolog, subfamily C, member 19. 
69 ILMN_1740217 HACE1 2.95E-03 -9% HECT domain and ankyrin repeat containing, E3 ubiquitin protein ligase 1. 
70 
 
ILMN_1687589 
 
CPT1A 
 
2.96E-03 
 
-7% 
 
Carnitine palmitoyltransferase 1A (liver), nuclear gene encoding mitochondrial protein, 
transcript variant 1. 
71 ILMN_1789535 DHDDS 3.02E-03 8% Dehydrodolichyl diphosphate synthase, transcript variant 2. 
72 ILMN_1812578 LOC645636 3.24E-03 -8% PREDICTED:   similar to AIP1. 
73 ILMN_1666024 LOC642503 3.30E-03 -9% PREDICTED:   hypothetical protein LOC642503. 
74 ILMN_1726426 PHF2 3.31E-03 -7% PHD finger protein 2. 
75 ILMN_1699644 MARCH3 3.33E-03 -18% PREDICTED:   membrane-associated ring finger (C3HC4) 3. 
76 ILMN_1694483 GPR50 3.38E-03 -9% G protein-coupled receptor 50. 
77 ILMN_1675543 PRM1 3.40E-03 -6% Protamine 1. 
78 ILMN_1661486 DMRTC1 3.47E-03 -13% DMRT-like family C1. 
79 ILMN_1821473 HS.135282 3.49E-03 19% cDNA FLJ11554 fis, clone HEMBA1003037 
80 ILMN_1727526 KIAA1407 3.51E-03 14% KIAA1407. 
81 ILMN_1901720 HS.540860 3.54E-03 -7% zw86b02.s1 Soares_total_fetus_Nb2HF8_9w   cDNA clone IMAGE:783819 3. 
82 ILMN_1726134 CBX5 3.60E-03 -8% Chromobox homolog 5 (HP1 alpha homolog, Drosophila). 
83 ILMN_1672108 LOC388161 3.67E-03 -6% PREDICTED:   LOC388161, misc RNA. 
84 ILMN_1676905 TIGD7 3.67E-03 19% Tigger transposable element derived 7. 
85 ILMN_1806056 CEACAM8 3.73E-03 -45% Carcinoembryonic antigen-related cell adhesion molecule 8. 
86 ILMN_1702858 ADHFE1 3.78E-03 27% Alcohol dehydrogenase, iron containing, 1. 
87 ILMN_1742073 ADCY1 3.82E-03 -6% Adenylate cyclase 1 (brain). 
88 ILMN_1656111 MYLIP 3.83E-03 29% Myosin regulatory light chain interacting protein. 
89 ILMN_1689378 CCRN4L 3.95E-03 -14% CCR4 carbon catabolite repression 4-like (S. cerevisiae). 
90 ILMN_1810424 HRH4 3.98E-03 -14% Histamine receptor H4. 
91 ILMN_1656118 ZBTB7A 4.09E-03 -12% Zinc finger and BTB domain containing 7A. 
92 ILMN_1785266 OFD1 4.12E-03 19% Oral-facial-digital syndrome 1. 
93 ILMN_1802185 CICE 4.16E-03 -13% PREDICTED:   cell death-inducing CIDE-like effector pseudogene, transcript variant 2 
94 ILMN_1814009 LOC283157 4.21E-03 8% PREDICTED:   hypothetical LOC283157. 
95 ILMN_1851742 HS.580430 4.22E-03 -10% qy47a08.x1 NCI_CGAP_Brn23   cDNA clone IMAGE:2015126 3. 
96 ILMN_1911874 HS.253554 4.28E-03 -8% nad32f12.x1 NCI_CGAP_Lu24   cDNA clone IMAGE:3367438 3. 
97 ILMN_1848556 HS.125695 4.33E-03 -10% kdef14 Soares_NFL_T_GBC_S1   cDNA clone IMAGE:2349594. 
98 ILMN_1692223 LCN2 4.37E-03 -46% Lipocalin 2 (oncogene 24p3). 
99 ILMN_1700518 HMGN4 4.38E-03 8% High mobility group nucleosomal binding domain 4. 
100 ILMN_1661940 CAMTA1 4.40E-03 28% Calmodulin binding transcription activator 1. 
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101 ILMN_1815407 USP16 4.49E-03 23% Ubiquitin specific peptidase 16, transcript variant 2. 
102 ILMN_1724634 LOC645550 4.64E-03 14% PREDICTED:   hypothetical protein LOC645550. 
103 ILMN_1702783 LOC652595 4.66E-03 10% PREDICTED:   similar to U2 small nuclear ribonucleoprotein A (U2 snRNP-A). 
104 ILMN_1660585 C15ORF40 4.67E-03 10% Chromosome 15 open reading frame 40. 
105 ILMN_1804337 LOC653234 4.69E-03 9% PREDICTED:   similar to centaurin, gamma-like family, member 1. 
106 ILMN_1844299 HS.574590 4.72E-03 -17% DA728582 NT2RM2   cDNA clone NT2RM2002174 5. 
107 ILMN_1820198 HS.576440 4.73E-03 -13% DB341807 TESTI4   cDNA clone TESTI4048130 3. 
108 ILMN_1837167 HS.575696 4.76E-03 -16% HESC3_16_C05.g1_A036 Human embryonic stem cells   cDNA clone IMAGE:7476876 5. 
109 ILMN_1857150 HS.578899 4.79E-03 12% SM016252 Placenta 3 EST   cDNA clone ID_16252 3'. 
110 ILMN_1797666 SLC27A6 4.85E-03 -11% Solute carrier family 27 (fatty acid transporter), member 6, transcript variant 2. 
111 ILMN_1718354 INTS7 4.97E-03 14% Integrator complex subunit 7. 
112 ILMN_1695719 EIF2C2 4.99E-03 -16% Eukaryotic translation initiation factor 2C, 2. 
113 ILMN_1684929 TOPBP1 5.06E-03 16% Topoisomerase (DNA) II binding protein 1. 
114 ILMN_1767000 SRGAP2 5.09E-03 -8% SLIT-ROBO Rho GTPase activating protein 2, transcript variant 2. 
115 ILMN_1786564 LOC497256 5.12E-03 -11% PREDICTED:   hypothetical LOC497256, misc RNA. 
116 ILMN_1675055 C1ORF166 5.14E-03 -8% Chromosome 1 open reading frame 166. 
117 ILMN_1774971 FAM8A1 5.29E-03 20% Family with sequence similarity 8, member A1. 
118 ILMN_1754976 LOC647269 5.40E-03 -9% PREDICTED:   similar to Metalloproteinase inhibitor 4 precursor (TIMP-4) 
119 ILMN_1888435 FAM39DP 5.47E-03 -16% Family with sequence similarity 39, member D pseudogene on chromosome 15. 
120 ILMN_1738246 OR10A7 5.53E-03 -12% Olfactory receptor, family 10, subfamily A, member 7. 
121 ILMN_1857743 HS.569496 5.55E-03 -5% tt04g12.x1 NCI_CGAP_GC6   cDNA clone IMAGE:2239846 3 similar to contains element 
122 ILMN_1724240 LBR 5.69E-03 8% Lamin B receptor, transcript variant 2. 
123 ILMN_1718907 TSHZ1 5.73E-03 24% Teashirt zinc finger homeobox 1. 
124 ILMN_1910972 HS.561924 5.82E-03 -14% UI-E-EJ0-ahg-e-04-0-UI.s1 UI-E-EJ0   cDNA clone UI-E-EJ0-ahg-e-04-0-UI 3. 
125 ILMN_1700307 FLJ38969 5.84E-03 19% PREDICTED:   hypothetical protein FLJ38969. 
126 ILMN_1831119 HS.578507 5.91E-03 -10% 17000424188250 GRN_ES   cDNA 5. 
127 ILMN_1797893 PFAAP5 5.93E-03 31% Phosphonoformate immuno-associated protein 5. 
128 ILMN_1662318 CCDC59 5.99E-03 21% Coiled-coil domain containing 59. 
129 ILMN_1742608 SMOX 6.03E-03 -9% Spermine oxidase, transcript variant 4. 
130 ILMN_1679045 SBDS 6.03E-03 39% Shwachman-Bodian-Diamond syndrome. 
131 ILMN_1654493 LOC649169 6.04E-03 -4% PREDICTED: similar to WD-repeat protein 74, transcript variant 1. 
132 ILMN_1779356 TP53 6.10E-03 -7% Tumor protein p53 (Li-Fraumeni syndrome). 
133 ILMN_1738976 OR2A20P 6.13E-03 13% Olfactory receptor, family 2, subfamily A, member 20 pseudogene on chromosome 7. 
134 ILMN_1690546 PPP3CC 6.21E-03 26% Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform. 
135 ILMN_1664718 CYP51A1 6.34E-03 -9% Cytochrome P450, family 51, subfamily A, polypeptide 1. 
136 ILMN_1730986 MALT1 6.36E-03 22% Mucosa associated lymphoid tissue lymphoma translocation gene 1, transcript variant 1. 
218 
 
P-value 
RANK PROBE_ID GENE Symbol Paired T-Test % Change DEFINITION 
137 ILMN_1689234 LOC643836 6.39E-03 13% PREDICTED:   similar to Zinc finger protein 62 homolog (Zfp-62) (ZT3). 
138 ILMN_1693853 HHAT 6.40E-03 14% Hedgehog acyltransferase. 
139 ILMN_1762713 C19ORF59 6.53E-03 -29% Chromosome 19 open reading frame 59. 
140 ILMN_1859007 HS.541685 6.56E-03 -11% wf40a08.x1 Soares_NFL_T_GBC_S1   cDNA clone IMAGE:2358038 3  
141 ILMN_1805216 GPC6 6.76E-03 -9% Glypican 6. 
142 ILMN_1727674 FOXD4L2 6.77E-03 -11% Forkhead box D4-like 2. 
143 ILMN_1805271 ZNF721 6.81E-03 26% Zinc finger protein 721. 
144 ILMN_1652120 ZNF302 6.86E-03 9% Zinc finger protein 302, transcript variant 2. 
145 ILMN_1740258 KRTAP20-2 6.98E-03 -7% Keratin associated protein 20-2. 
146 ILMN_1652409 SPATA7 7.06E-03 12% Spermatogenesis associated 7, transcript variant 2. 
147 ILMN_1777449 IFT74 7.13E-03 12% Intraflagellar transport 74 homolog (Chlamydomonas), transcript variant 2. 
148 ILMN_1820761 HS.106801 7.13E-03 -11% qi02a09.x1 Soares_NFL_T_GBC_S1   cDNA clone IMAGE:1855288 3. 
149 ILMN_1819255 HS.428820 7.18E-03 -9% UI-H-CO0-asj-h-04-0-UI.s1 NCI_CGAP_Sub9   cDNA clone UI-H-CO0-asj-h-04-0-UI 3. 
150 ILMN_1751793 PCNXL2 7.40E-03 9% Pecanex-like 2 (Drosophila), transcript variant 1. 
151 ILMN_1764619 FLJ45244 7.41E-03 11% FLJ45244 protein. 
152 ILMN_1819332 HS.583211 7.43E-03 -12% UI-H-CO0-atb-h-04-0-UI.s1 NCI_CGAP_Sub9   cDNA clone UI-H-CO0-atb-h-04-0-UI 3. 
153 ILMN_1698560 C19ORF6 7.46E-03 17% Chromosome 19 open reading frame 6, transcript variant 1. 
154 ILMN_1806576 LOC651137 7.48E-03 -11% PREDICTED:   similar to T-complex protein 10A homolog, transcript variant 2. 
155 ILMN_1821485 HS.555706 7.49E-03 -12% NISC_gg04f02.x1 NCI_CGAP_Kid11   cDNA clone IMAGE:3253395 3. 
156 ILMN_1747119 FBXO46 7.58E-03 -11% PREDICTED:   F-box protein 46, transcript variant 5. 
157 ILMN_1684694 ANK1 7.59E-03 -8% Ankyrin 1, erythrocytic, transcript variant 5. 
158 ILMN_1898058 HS.566297 7.59E-03 -9% zr42c11.s1 Soares_NhHMPu_S1   cDNA clone IMAGE:666068 3. 
159 ILMN_1764207 P15RS 7.61E-03 15% Hypothetical protein FLJ10656. 
160 ILMN_1819989 HS.574405 7.78E-03 -15% cDNA: FLJ21635 fis, clone COL08233, highly similar to AF131819  clone 24838  
161 ILMN_1720850 BAZ2B 7.81E-03 10% Bromodomain adjacent to zinc finger domain, 2B. 
162 ILMN_1711089 DNAJA5 7.92E-03 7% DnaJ homology subfamily A member 5, transcript variant 1. 
163 ILMN_1792682 MCTP2 7.93E-03 -9% Multiple C2 domains, transmembrane 2. 
164 ILMN_1775744 MRPS16 7.95E-03 -9% Mitochondrial ribosomal protein S16, nuclear gene encoding mitochondrial protein. 
165 ILMN_1723035 OLR1 8.09E-03 -37% Oxidized low density lipoprotein (lectin-like) receptor 1. 
166 ILMN_1800855 PPTC7 8.13E-03 12% PTC7 protein phosphatase homolog (S. cerevisiae). 
167 ILMN_1710394 CNTNAP5 8.14E-03 -9% Contactin associated protein-like 5. 
168 ILMN_1759475 TAS2R39 8.15E-03 -9% Taste receptor, type 2, member 39. 
169 ILMN_1697412 RHBG 8.16E-03 -13% Rh family, B glycoprotein. 
170 ILMN_1737819 C7ORF16 8.16E-03 -9% Chromosome 7 open reading frame 16. 
171 ILMN_1889178 HS.157581 8.19E-03 -8% tf70b04.x5 NCI_CGAP_Brn23   cDNA clone IMAGE:2104591 3. 
172 ILMN_1877890 HS.551244 8.20E-03 -8% xs34e11.x1 NCI_CGAP_Kid11   cDNA clone IMAGE:2771564 3. 
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173 ILMN_1725510 DHCR24 8.21E-03 -18% 24-dehydrocholesterol reductase. 
174 ILMN_1789266 CCDC25 8.28E-03 16% Coiled-coil domain containing 25. 
175 ILMN_1682487 GPR133 8.29E-03 -7% G protein-coupled receptor 133. 
176 ILMN_1678150 OR6S1 8.31E-03 -10% Olfactory receptor, family 6, subfamily S, member 1. 
177 ILMN_1814007 LOC441488 8.43E-03 -17% PREDICTED:   similar to Transcription factor Dp-1, transcript variant 2. 
178 ILMN_1891009 HS.567064 8.53E-03 -14% xd96c08.x1 Soares_NFL_T_GBC_S1   cDNA clone IMAGE:2605454 3  
179 ILMN_1770454 AGRN 8.58E-03 -9% Agrin. 
180 ILMN_1903750 HS.544238 8.64E-03 -8% Human clone H8 Cri-du-chat critical region mRNA, partial sequence 
181 ILMN_1741712 MS4A4A 8.67E-03 -15% Membrane-spanning 4-domains, subfamily A, member 4, transcript variant 1. 
182 ILMN_1889426 HS.554342 8.68E-03 -8% cong2.P5.a4 conorm   cDNA 3. 
183 ILMN_1658044 LOC648814 8.70E-03 14% PREDICTED:   hypothetical protein LOC648814. 
184 ILMN_1691418 CDRT4 8.78E-03 20% CMT1A duplicated region transcript 4. 
185 ILMN_1721022 SHC1 8.79E-03 -6% SHC (Src homology 2 domain containing) transforming protein 1, transcript variant 2. 
186 ILMN_1687484 ZFX 8.84E-03 16% Zinc finger protein, X-linked. 
187 ILMN_1731168 MBD1 8.84E-03 -8% Methyl-CpG binding domain protein 1, transcript variant 1. 
188 ILMN_1812281 ARG1 8.85E-03 -11% Arginase, liver. 
189 ILMN_1777725 LSM14B 8.88E-03 9% LSM14B, SCD6 homolog B (S. cerevisiae). 
190 ILMN_1798032 TRIM24 8.92E-03 15% Tripartite motif-containing 24, transcript variant 2. 
191 ILMN_1813400 CBR4 8.96E-03 26% Carbonyl reductase 4. 
192 ILMN_1678775 CLEC2D 9.05E-03 19% C-type lectin domain family 2, member D, transcript variant 1. 
193 ILMN_1724825 PCBP2 9.05E-03 -8% Poly(rC) binding protein 2, transcript variant 3. 
194 ILMN_1888658 HS.130260 9.11E-03 16% qk02b10.x1 NCI_CGAP_Kid3   cDNA clone IMAGE:1867771 3. 
195 ILMN_1734553 LOC653234 9.27E-03 9% PREDICTED:   similar to centaurin, gamma-like family, member 1. 
196 ILMN_1751214 STARD3NL 9.31E-03 15% STARD3 N-terminal like. 
197 ILMN_1707780 C6ORF165 9.51E-03 -11% Chromosome 6 open reading frame 165, transcript variant 2. 
198 ILMN_1670878 YTHDC1 9.55E-03 12% YTH domain containing 1, transcript variant 1. 
199 ILMN_1749253 TUBD1 9.58E-03 13% Tubulin, delta 1. 
200 ILMN_1755769 MFSD8 9.73E-03 14% Major facilitator superfamily domain containing 8. 
201 ILMN_1789879 WDR35 9.87E-03 15% WD repeat domain 35, transcript variant 1. 
202 ILMN_1871496 HS.213049 9.88E-03 -13% we11f11.x1 NCI_CGAP_Lu24   cDNA clone IMAGE:2340813 3. 
203 ILMN_1687951 LOC653480 9.98E-03 -12% PREDICTED:   similar to transmembrane protein 23. 
204 ILMN_1808305 RTCD1 9.99E-03 15% RNA terminal phosphate cyclase domain 1. 
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< 0.01) transcripts IDs that are correlated to at least one of the following four clinical 
characteristics: weight, FPG, HbA1C or WBC, with an R2 > 0.25. Values with R2 ≥ 0.25 
are shown in bold. 
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Weight FPG HbA1c WBC 
 
R 
 
R square 
 
R 
 
R square 
 
R 
 
R square 
 
R 
 
R square 
ILMN_1652604 GGT1 0.12 0.01 -0.24 0.06 -0.35 0.12 0.63 0.39 
ILMN_1688580 CAMP 0.57 0.32 0.59 0.35 0.31 0.10 0.56 0.31 
ILMN_1682312 CYBB 0.50 0.25 0.65 0.42 0.37 0.14 0.13 0.02 
ILMN_1797682 INSL3 0.14 0.02 0.34 0.12 0.52 0.27 -0.02 0.00 
ILMN_1748384 BOC 0.06 0.00 0.02 0.00 0.34 0.12 -0.62 0.38 
ILMN_1679357 DEFA1/DEFA3 0.36 0.13 0.56 0.31 0.46 0.21 0.38 0.14 
ILMN_1703324 PDSS1 -0.80 0.63 -0.32 0.11 0.00 0.00 -0.05 0.00 
ILMN_1804631 CNBP -0.53 0.29 -0.61 0.37 -0.33 0.11 -0.06 0.00 
ILMN_1833316 HS.112596 0.38 0.15 0.56 0.31 0.22 0.05 0.09 0.01 
ILMN_1651544 HDAC8 -0.50 0.25 -0.65 0.43 -0.48 0.23 -0.47 0.22 
ILMN_1751393 ZNF684 -0.08 0.01 -0.50 0.25 -0.66 0.43 0.40 0.16 
ILMN_1769633 CTSO 0.21 0.04 0.37 0.13 0.36 0.13 0.76 0.58 
ILMN_1904282 HS.484967 -0.06 0.00 -0.30 0.09 -0.66 0.44 0.07 0.00 
ILMN_1704973 SARDH 0.05 0.00 0.26 0.07 0.58 0.33 -0.14 0.02 
ILMN_1652407 ZMYND8 -0.26 0.07 -0.59 0.35 -0.54 0.29 -0.77 0.59 
ILMN_1900247 HS.147149 -0.28 0.08 0.39 0.15 0.52 0.27 0.34 0.11 
ILMN_1651664 SDHALP1 -0.51 0.26 0.01 0.00 0.20 0.04 -0.25 0.06 
ILMN_1703858 C7ORF24 -0.34 0.12 -0.62 0.39 -0.61 0.37 -0.54 0.30 
ILMN_1768743 FIP1L1 -0.43 0.19 -0.54 0.29 -0.34 0.11 -0.64 0.41 
ILMN_1684346 TNFAIP8L1 -0.22 0.05 -0.58 0.33 -0.53 0.28 -0.44 0.20 
ILMN_1754772 LOC650698 -0.51 0.26 0.05 0.00 0.37 0.13 -0.14 0.02 
ILMN_1729175 FBXO3 -0.56 0.31 -0.42 0.18 -0.32 0.10 -0.25 0.06 
ILMN_1812578 LOC645636 -0.28 0.08 -0.04 0.00 0.31 0.10 -0.76 0.58 
ILMN_1666024 LOC642503 0.43 0.19 0.68 0.47 0.41 0.17 0.32 0.10 
ILMN_1699644 MARCH3 -0.01 0.00 0.46 0.21 0.60 0.36 -0.27 0.08 
ILMN_1694483 GPR50 -0.01 0.00 -0.58 0.34 -0.74 0.55 -0.14 0.02 
ILMN_1672108 LOC388161 0.29 0.09 0.63 0.39 0.19 0.04 0.15 0.02 
ILMN_1676905 TIGD7 -0.52 0.27 -0.67 0.45 -0.64 0.41 -0.20 0.04 
ILMN_1702858 ADHFE1 -0.20 0.04 -0.33 0.11 -0.12 0.01 -0.78 0.61 
ILMN_1656111 MYLIP -0.45 0.20 -0.56 0.32 -0.61 0.37 0.11 0.01 
ILMN_1689378 CCRN4L 0.57 0.33 0.66 0.43 0.24 0.06 0.36 0.13 
ILMN_1814009 LOC283157 -0.12 0.01 0.32 0.10 0.30 0.09 0.50 0.25 
ILMN_1911874 HS.253554 -0.10 0.01 0.12 0.02 -0.08 0.01 0.63 0.40 
ILMN_1848556 HS.125695 -0.37 0.14 -0.25 0.06 -0.28 0.08 -0.53 0.28 
ILMN_1661940 CAMTA1 -0.36 0.13 -0.50 0.25 -0.52 0.27 -0.44 0.20 
ILMN_1724634 LOC645550 0.15 0.02 0.16 0.03 0.22 0.05 -0.56 0.31 
ILMN_1820198 HS.576440 -0.02 0.00 0.02 0.00 0.25 0.06 -0.76 0.58 
ILMN_1718354 INTS7 -0.34 0.12 -0.58 0.33 -0.67 0.45 -0.03 0.00 
ILMN_1684929 TOPBP1 -0.55 0.30 -0.62 0.38 -0.58 0.34 -0.11 0.01 
ILMN_1774971 FAM8A1 -0.77 0.60 -0.65 0.42 -0.50 0.25 -0.12 0.01 
ILMN_1738246 OR10A7 -0.29 0.09 -0.42 0.17 -0.52 0.27 -0.18 0.03 
ILMN_1724240 LBR -0.46 0.21 -0.57 0.32 -0.45 0.20 0.32 0.10 
ILMN_1718907 TSHZ1 -0.55 0.30 -0.74 0.55 -0.52 0.27 -0.42 0.18 
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ILMN_1662318 CCDC59 -0.41 0.16 -0.58 0.33 -0.29 0.08 -0.34 0.11 
ILMN_1779356 TP53 0.29 0.09 0.07 0.01 -0.14 0.02 0.81 0.66 
ILMN_1664718 CYP51A1 -0.54 0.29 -0.14 0.02 0.08 0.01 -0.60 0.36 
ILMN_1693853 HHAT -0.48 0.23 -0.79 0.62 -0.55 0.30 -0.64 0.41 
ILMN_1762713 C19ORF59 0.18 0.03 0.39 0.15 0.32 0.11 0.80 0.64 
ILMN_1805271 ZNF721 -0.35 0.12 -0.58 0.33 -0.30 0.09 -0.28 0.08 
ILMN_1652409 SPATA7 -0.58 0.33 -0.44 0.19 -0.32 0.10 -0.27 0.07 
ILMN_1819255 HS.428820 0.39 0.15 0.50 0.25 0.38 0.14 0.09 0.01 
ILMN_1751793 PCNXL2 0.01 0.00 0.30 0.09 0.53 0.29 -0.47 0.23 
ILMN_1764619 FLJ45244 0.68 0.46 0.77 0.60 0.73 0.53 0.33 0.11 
ILMN_1698560 C19ORF6 0.70 0.49 0.35 0.13 0.22 0.05 0.15 0.02 
ILMN_1806576 LOC651137 -0.18 0.03 -0.17 0.03 0.30 0.09 -0.50 0.25 
ILMN_1821485 HS.555706 -0.03 0.00 -0.28 0.08 -0.53 0.28 0.34 0.12 
ILMN_1747119 FBXO46 0.53 0.28 0.21 0.04 -0.13 0.02 0.12 0.02 
ILMN_1898058 HS.566297 -0.19 0.04 0.17 0.03 0.35 0.12 -0.58 0.34 
ILMN_1819989 HS.574405 0.56 0.32 0.44 0.19 0.17 0.03 0.09 0.01 
ILMN_1711089 DNAJA5 -0.22 0.05 -0.59 0.35 -0.34 0.11 0.26 0.07 
ILMN_1775744 MRPS16 0.16 0.02 -0.07 0.00 -0.03 0.00 -0.62 0.38 
ILMN_1710394 CNTNAP5 0.05 0.00 0.26 0.07 0.52 0.27 -0.39 0.15 
ILMN_1889178 HS.157581 -0.12 0.01 -0.28 0.08 -0.20 0.04 0.51 0.26 
ILMN_1725510 DHCR24 0.62 0.39 0.62 0.39 0.59 0.35 0.31 0.09 
ILMN_1889426 HS.554342 0.76 0.58 0.62 0.39 0.20 0.04 0.59 0.35 
ILMN_1721022 SHC1 0.14 0.02 -0.23 0.05 -0.51 0.27 -0.35 0.12 
ILMN_1687484 ZFX -0.42 0.17 -0.54 0.29 -0.53 0.28 -0.21 0.05 
ILMN_1812281 ARG1 0.03 0.00 0.26 0.07 0.17 0.03 0.69 0.47 
ILMN_1777725 LSM14B -0.21 0.04 -0.17 0.03 -0.53 0.28 0.06 0.00 
ILMN_1798032 TRIM24 -0.32 0.10 -0.39 0.15 -0.57 0.32 0.12 0.01 
ILMN_1813400 CBR4 -0.47 0.22 -0.66 0.44 -0.74 0.54 -0.23 0.05 
ILMN_1751214 STARD3NL -0.11 0.01 -0.38 0.14 -0.50 0.25 0.25 0.06 
ILMN_1707780 C6ORF165 -0.10 0.01 0.23 0.05 0.62 0.38 -0.18 0.03 
ILMN_1789879 WDR35 -0.53 0.28 -0.62 0.39 -0.75 0.56 -0.25 0.06 
ILMN_1871496 HS.213049 0.35 0.12 0.44 0.19 0.46 0.21 0.55 0.30 
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Appendix 5D: Table shows the gene ontology (GO) terms and pathways identified by gene ontology and functional analyses 
(DAVID) that were overrepresented (P-value < 0.01) in our list of 204 significantly differentially expressed transcripts after bariatric 
surgery. GO terms discussed in the manuscripts are shown in bold.  
20 Transcripts were found to be best correlated with weight changes, only 18 were recognized and included in gene ontology analysis.   
     
Term Resource and ID Term Name Count % of genes involved/total genes P-Value 
GO:0006695 Cholesterol biosynthetic process 3 17.65% 1.23E-04 
GO:0016126 Sterol biosynthetic process 3 17.65% 2.12E-04 
GO:0008610 Lipid biosynthetic process 4 23.53% 6.41E-04 
GO:0008203 Cholesterol metabolic process 3 17.65% 1.06E-03 
GO:0006694 Steroid biosynthetic process 3 17.65% 1.29E-03 
GO:0016125 Sterol metabolic process 3 17.65% 1.39E-03 
KEGG_PATHWAY Biosynthesis of steroids 2 11.76% 5.70E-03 
GO:0008202 Steroid metabolic process 3 17.65% 6.22E-03 
GO:0044255 Cellular lipid metabolic process 4 23.53% 6.46E-03 
     
35 Transcripts were found to be best correlated with fasting plasma glucose changes, only 32 were recognized and included in gene ontology analysis. 
     
Term Resource and ID Term Name Count % of genes involved/total genes     P-Value 
GO:0006139 Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 14 43.75% 6.47E-04 
GO:0016070 RNA metabolic process 12 37.50% 8.27E-04 
GO:0005634 Nucleus 15 46.88% 9.00E-04 
GO:0010467 Gene expression 13 40.62% 1.14E-03 
GO:0006350 Transcription 11 34.38% 1.46E-03 
GO:0043283 Biopolymer metabolic process 15 46.88% 2.98E-03 
GO:0006351 Transcription, DNA-dependent 10 31.25% 3.45E-03 
GO:0032774 RNA biosynthetic process 10 31.25% 3.47E-03 
GO:0003677 DNA binding 9 28.12% 4.64E-03 
GO:0045449 Regulation of transcription 10 31.25% 4.67E-03 
GO:0003676 Nucleic acid binding 11 34.38% 4.93E-03 
GO:0019219 Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 10 31.25% 5.47E-03 
SP_PIR_KEYWORDS Nucleus 12 37.50% 5.76E-03 
GO:0010468 Regulation of gene expression 10 31.25% 7.06E-03 
223 
 
Term Resource and ID Term Name Count   % of genes involved/total genes      P-Value 
SP_PIR_KEYWORDS DNA-binding 8 25.00% 7.15E-03 
SP_PIR_KEYWORDS Transcription regulation 8 25.00% 7.28E-03 
SP_PIR_KEYWORDS Transcription 8 25.00% 7.96E-03 
GO:0031323 Regulation of cellular metabolic process 10 31.25% 9.25E-03 
 
 
